sulfasalazine has been researched along with Arthritis, Rheumatoid in 859 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
Arthritis, Rheumatoid: A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.
| Excerpt | Relevance | Reference |
|---|---|---|
| "One hundred and fifty patients with rheumatoid arthritis were given sulfasalazine in a daily dosage of 2 g during an open-label, multicenter, six-month trial." | 10.17 | [Sulfasalazine in the treatment of rheumatoid arthritis. A multicenter open study of 150 patients during 6 months]. ( , 1992) |
| "To compare efficacy and safety of two different combination csDMARD therapy in Methotrexate-failed Rheumatoid arthritis patients." | 9.51 | Comparison between leflunomide and sulfasalazine based triple therapy in methotrexate refractory rheumatoid arthritis: an open-label, non-inferiority randomized controlled trial. ( Belani, PJ; Kavadichanda, CG; Negi, VS, 2022) |
| "Although it is common for rheumatologists to initiate biologic agents after failure of methotrexate monotherapy in rheumatoid arthritis (RA), ample data support the initial use of combinations of conventional therapies in this clinical scenario." | 9.24 | Rheumatoid Arthritis Treatment After Methotrexate: The Durability of Triple Therapy Versus Etanercept. ( Brophy, M; Lew, R; Mikuls, T; O'Dell, J; Peper, SM; Rybin, D; Wu, H, 2017) |
| "In early, methotrexate-refractory rheumatoid arthritis, a treatment strategy commencing with addition of infliximab, as compared to sulfasalazine+hydroxychloroquine, was not cost-effective over 21 months at willingness to pay levels generally considered acceptable." | 9.20 | Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial. ( Bratt, J; Eriksson, JK; Ernestam, S; Geborek, P; Karlsson, JA; Neovius, M; Petersson, IF; van Vollenhoven, RF, 2015) |
| "5 mg/week, sulfasalazine 2 g/day, with initial prednisolone 60 mg/day) after 26 weeks in patients with early active rheumatoid arthritis (RA)." | 9.20 | Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial. ( Boers, M; den Uyl, D; Kerstens, P; Lems, WF; Nurmohamed, M; ter Wee, MM; van Schaardenburg, D; Voskuyl, AE, 2015) |
| "Treatment with initial high-dose prednisolone and a combination of methotrexate (MTX) and sulfasalazine (SSZ) according to the COBRA regimen (Dutch acronym for combinatietherapie bij reumatoide artritis, 'combination therapy for rheumatoid arthritis'), has repeatedly been demonstrated to be very effective in early rheumatoid arthritis (RA)." | 9.20 | Initial high-dose prednisolone combination therapy using COBRA and COBRA-light in early rheumatoid arthritis. ( Boers, M; Lems, WF; Rasch, LA; van Tuyl, LH, 2015) |
| " High-risk patients (n=290) were randomised to 1/3 treatment strategies: combination therapy for early rheumatoid arthritis (COBRA) Classic (methotrexate (MTX)+ sulfasalazine+60 mg prednisone tapered to 7." | 9.20 | Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. ( Corluy, L; De Brabanter, G; De Cock, D; Durnez, A; Geens, E; Geusens, P; Joly, J; Joos, R; Langenaken, C; Lenaerts, J; Meyfroidt, S; Raeman, F; Ravelingien, I; Remans, J; Sileghem, A; Taelman, V; Van der Elst, K; Van Essche, E; Vander Cruyssen, B; Vandevyvere, K; Vanhoof, J; Verschueren, P; Westhovens, R, 2015) |
| "To study changes in lipid profiles at 24 weeks among patients with early rheumatoid arthritis (RA) participating in the Treatment of Early RA (TEAR) trial and randomized to receive methotrexate (MTX) plus etanercept, triple therapy (MTX plus sulfasalazine plus hydroxychloroquine), or aggressively titrated MTX monotherapy." | 9.17 | Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial. ( Bathon, JM; Bridges, SL; Charles-Schoeman, C; Chen, L; Cofield, SS; Curtis, JR; Dell'Italia, LJ; Moreland, LW; Navarro-Millán, I; O'Dell, JR; Paulus, HE; Yang, S, 2013) |
| "In the Treatment of Early Rheumatoid Arthritis (TEAR) trial, 755 participants with early, poor-prognosis RA were randomized to receive MTX monotherapy or combination therapy (MTX plus etanercept or MTX plus sulfasalazine plus hydroxychloroquine)." | 9.17 | Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial. ( Bridges, SL; Cofield, SS; Curtis, JR; Mikuls, TR; Moreland, LW; O'Dell, JR; Ranganath, VK, 2013) |
| "We conducted a 48-week, double-blind, noninferiority trial in which we randomly assigned 353 participants with rheumatoid arthritis who had active disease despite methotrexate therapy to a triple regimen of disease-modifying antirheumatic drugs (methotrexate, sulfasalazine, and hydroxychloroquine) or etanercept plus methotrexate." | 9.17 | Therapies for active rheumatoid arthritis after methotrexate failure. ( Ahluwalia, V; Anis, AH; Brophy, M; Cannella, AC; Keystone, E; Kunkel, G; Leatherman, S; Lew, RA; Mikuls, TR; O'Dell, JR; Phibbs, CS; Taylor, TH; Warren, SR, 2013) |
| "To compare EuroQol 5-Dimensions (EQ-5D) utility and quality-adjusted life-years (QALYs) in patients with early, methotrexate (MTX) refractory rheumatoid arthritis (RA), randomised to addition of infliximab (IFX) or sulfasalazine and hydroxychloroquine (SSZ+HCQ)." | 9.17 | Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial. ( Bratt, J; Ernestam, S; Geborek, P; Karlsson, JA; Neovius, M; Nilsson, JÅ; Petersson, IF; van Vollenhoven, RF, 2013) |
| "Analysis of the Swedish Farmacotherapy (Swefot) trial at 12 months showed that the addition of an anti-tumour-necrosis-factor agent gave an improved clinical outcome compared with the addition of conventional disease-modifying antirheumatic drugs in patients with methotrexate-refractory early rheumatoid arthritis." | 9.16 | Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. ( Albertsson, K; Bratt, J; Chatzidionysiou, K; Ernestam, S; Forslind, K; Geborek, P; Petersson, IF; van Vollenhoven, RF, 2012) |
| "The study participants included patients with early RA (<3 years in duration) enrolled in the Treatment of Early Aggressive Rheumatoid Arthritis study, a randomized, blinded, placebo-controlled clinical trial comparing early intensive therapy (MTX + etanercept or MTX + hydroxychloroquine + sulfasalazine triple therapy) versus initial treatment with MTX with step-up to MTX + etanercept or to triple therapy if the disease was still active at 24 weeks." | 9.16 | Serum cotinine as a biomarker of tobacco exposure and the association with treatment response in early rheumatoid arthritis. ( Bridges, SL; Cofield, SS; Curtis, JR; Maska, LB; Mikuls, TR; Moreland, LW; O'Dell, JR; Sayles, HR, 2012) |
| "The aim of the present study was to measure the changes in serum selenium, zinc, and copper in patients being treated for rheumatoid arthritis." | 9.15 | Effects of different medical treatments on serum copper, selenium and zinc levels in patients with rheumatoid arthritis. ( Bulut, V; Çolak, M; Flores-Arce, MF; Nazıroğlu, M; Önal, S, 2011) |
| "In this trial, we investigated the safety and efficacy of tacrolimus used in addition to standard antirheumatic drugs in patients with rheumatoid arthritis." | 9.15 | Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDs--a multicenter, double-blind, parallel-group trial. ( Kawai, S; Miyasaka, N; Takeuchi, T; Tanaka, Y; Yamamoto, K, 2011) |
| "To determine the efficacy and safety of etanercept and etanercept plus sulfasalazine versus sulfasalazine in patients with rheumatoid arthritis (RA) despite sulfasalazine therapy." | 9.14 | Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study. ( Codreanu, C; Combe, B; Fatenejad, S; Fiocco, U; Gaubitz, M; Geusens, PP; Khandker, R; Kvien, TK; Pavelka, K; Sambrook, PN; Singh, A; Smolen, JS; Wajdula, J, 2009) |
| "Bucillamine (Buc), developed in Japan, is a disease-modifying antirheumatic drug (DMARD) which has been used to treat numerous patients with rheumatoid arthritis (RA) in Japan and Korea with favorable results." | 9.14 | A comparative study of the effects of bucillamine and salazosulfapyridine in the treatment of rheumatoid arthritis. ( Abe, M; Kinoshita, M; Nakajima, M; Ohara, H; Ueda, N, 2009) |
| " We enrolled patients with early rheumatoid arthritis (symptom duration <1 year) and administered methotrexate (up to 20 mg per week)." | 9.14 | Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. ( Akre, F; Bratt, J; Chatzidionysiou, A; Cöster, L; Dackhammar, C; Ernestam, S; Forslind, K; Geborek, P; Hellström, H; Ljung, L; Oding, R; Petersson, IF; Teleman, A; Theander, J; Thörner, A; van Vollenhoven, RF; Waltbrand, E; Wörnert, M; Zickert, A, 2009) |
| "To compare the benefits and side effects of TwHF extract with those of sulfasalazine for the treatment of active rheumatoid arthritis." | 9.14 | Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial. ( Costello, R; Csako, G; Fleischmann, R; Goldbach-Mansky, R; Kempf, P; Kivitz, A; Lipsky, PE; Olsen, N; Pham, TH; Pucino, F; Sherrer, Y; Silverfield, J; Snyder, C; Tao, X; van der Heijde, D; Wesley, R; Wilson, M, 2009) |
| "To carry out a pilot study to investigate the effect of short-term oral probiotic administration on the metabolism of sulfasalazine (SSZ) in patients with rheumatoid arthritis (RA) stabilized on SSZ." | 9.14 | The effects of an orally administered probiotic on sulfasalazine metabolism in individuals with rheumatoid arthritis: a preliminary study. ( Fawcett, JP; Highton, J; Lee, HJ; Orlovich, DA; Schmierer, D; Stebbings, S; Waller, RD, 2010) |
| "To compare efficacy and tolerability of combined therapy with methotrexate (MTX), sulfasalazine (SSZ) and hydroxychloroquine (HCQ) with MTX-monotherapy in patients with rheumatoid arthritis (RA)." | 9.13 | [Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis]. ( Bochkova, AG; Bunchuk, NV; Gubar', EE, 2008) |
| "To prospectively determine the efficacy and safety of etanercept in combination with sulfasalazine (SSZ), hydroxychloroquine (HCQ), and gold in the treatment of rheumatoid arthritis (RA)." | 9.12 | Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis. ( Blakely, K; Fernandez, A; Haire, C; Leff, R; O'Dell, JR; Palmer, W; Petersen, K; Schned, E, 2006) |
| "To compare the efficacy and safety of etanercept and sulfasalazine, alone and in combination, in patients with active rheumatoid arthritis despite sulfasalazine treatment." | 9.12 | Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison. ( Codreanu, C; Combe, B; Fatenejad, S; Fiocco, U; Gaubitz, M; Geusens, PP; Kvien, TK; Pavelka, K; Sambrook, PN; Smolen, JS; Wajdula, J, 2006) |
| "Bucillamine (Buc) is a disease-modifying antirheumatic drug (DMARD) developed in Japan, which has been used as one of the first-line DMARDs for the treatment of rheumatoid arthritis (RA) in Japan." | 9.12 | Efficacy profile of bucillamine in rheumatoid arthritis patients in a large observational cohort study, IORRA. ( Hara, M; Inoue, E; Iwatani, M; Kamatani, N; Nakajima, A; Nakamura, T; Tomatsu, T; Yamanaka, H, 2006) |
| "We conducted a 28-week, randomized, double-blind, parallel-group study of iguratimod in 376 Japanese patients with active rheumatoid arthritis to compare the efficacy and safety of the drug with those of placebo and salazosulfapyridine." | 9.12 | Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study. ( Abe, T; Hara, M; Hashimoto, H; Hoshi, K; Irimajiri, S; Matsui, N; Mizushima, Y; Nakano, S; Nobunaga, M; Sugawara, S; Yoshino, S, 2007) |
| "To determine the efficacy of subsequent disease modifying antirheumatic drug (DMARD) therapies after initial methotrexate (MTX) failure in patients with recent onset rheumatoid arthritis (RA), treated according to the DAS for 2 years." | 9.12 | Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score. ( Allaart, CF; Breedveld, FC; de Vries-Bouwstra, JK; Dijkmans, BA; Gerards, AH; Goekoop-Ruiterman, YP; Hazes, JM; Kerstens, PJ; van der Kooij, SM; van Groenendael, JH; van Zeben, D, 2007) |
| "To evaluate the effect of low dose oral prednisolone in early rheumatoid arthritis on disease activity over two years." | 9.11 | Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. ( Capell, HA; Hampson, R; Hunter, JA; Larkin, J; Madhok, R; Morrison, E; Poon, FW; Porter, D; Thomson, EA, 2004) |
| "To compare the efficacy of combination therapy with methotrexate (MTX) and hydroxychloroquine (HCQ), MTX and sulfasalazine (SSZ), and MTX, HCQ, and SSZ in patients with rheumatoid arthritis (RA)." | 9.10 | Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. ( Blakely, K; Churchill, M; Eckhoff, PJ; Felt, J; Fernandez, A; Hadley, S; Haire, C; Klassen, L; Leff, R; Mallek, J; Moore, G; O'Dell, JR; Palmer, W; Paulsen, G; Stoner, J; Waytz, P; Wees, S, 2002) |
| "The intent of this study was to assess the effect of low-dose methotrexate treatment on bone mineral density (BMD) in patients with early rheumatoid arthritis (RA)." | 9.10 | The effect of low-dose methotrexate on bone mineral density in patients with early rheumatoid arthritis. ( Armagan, O; Oner, C; Tascioglu, F, 2003) |
| "To determine the effects of treatment with sulfasalazine (SSZ) or the combination of methotrexate (MTX) and SSZ on serum matrix metalloproteinase 3 (MMP-3) levels in patients with early rheumatoid arthritis (RA)." | 9.10 | Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis. ( Limburg, PC; Posthumus, MD; van Leeuwen, MA; van Rijswijk, MH; Westra, J, 2002) |
| "To determine the effect of methotrexate (MTX) on bone mineral density (BMD) in rheumatoid arthritis (RA)." | 9.10 | Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density. ( Beresford, JN; Bhalla, AK; Compston, JE; Kounali, D; Minaur, NJ; Vedi, S, 2002) |
| "Phase II trials of leflunomide, an inhibitor of de-novo pyrimidine synthesis, have shown efficacy in rheumatoid arthritis." | 9.09 | Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. ( Kalden, JR; Kvien, TK; Larsen, A; Loew-Friedrich, I; Oed, C; Rosenburg, R; Rozman, B; Scott, DL; Smolen, JS, 1999) |
| "The aim of the study was to assess the efficacy of a new formulation of cyclosporin-A (CyA) and sulfasalazine (SASP) combination treatment in preventing disability and reducing inflammatory disease activity in patients with early rheumatoid arthritis, as well as to assess the tolerability, safety, and suitability for long-term treatment." | 9.09 | Cyclosporin and sulfasalazine combination in the treatment of early rheumatoid arthritis. ( Bálint, G; Hodinka, L; Molnár, E; Rojkovich, B; Szegedi, G; Szilágyi, M; Szocsik, K; Tamási, L; Varjú, T, 1999) |
| "To evaluate the efficacy and safety of additive triple disease modifying anti-rheumatic drug (DMARD) combination therapy of a low dose of sulfhydryl compounds ¿D-penicillamine, bucillamine or tiopronin¿, sulfasalazine (SSZ) and methotrexate (MTX) as a treatment for rheumatoid arthritis (RA) patients, we studied a total of 33 Japanese RA patients (6 males, 27 females)." | 9.09 | Additive triple DMARD combination therapy of a low dose of sulfhydryl compounds, sulfasalazine and methotrexate in the treatment of rheumatoid arthritis: a clinical trial. ( Hashimoto, K; Hisakawa, N; Ito, H; Matsumori, A; Nakatani, K; Nishiya, K; Tahara, K; Takatori, K, 1999) |
| "To determine whether a regimen of methotrexate, cyclosporin A, and corticosteroids introduced at onset in poor-prognosis rheumatoid arthritis (RA) can produce a significant improvement in outcome compared with standard monotherapy with sulfasalazine (SSZ)." | 9.09 | Treatment of poor-prognosis early rheumatoid arthritis. A randomized study of treatment with methotrexate, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone. ( Adebajo, A; Conaghan, PG; Emery, P; Gough, A; Green, MJ; Griffiths, B; Helliwell, P; Huston, G; Isaacs, J; Martin, M; McGonagle, D; Miles, S; Pease, C; Proudman, SM; Reece, RJ; Richardson, C; van der Heijde, DM; Veale, DJ; Wakefield, RJ, 2000) |
| "Radiographic disease progression with leflunomide and sulfasalazine treatment was assessed in rheumatoid arthritis patients in a double-blind trial that was placebo controlled for the first 6 months." | 9.09 | Slowing of disease progression in rheumatoid arthritis patients during long-term treatment with leflunomide or sulfasalazine. ( Kvien, TK; Larsen, A; Oed, C; Rau, R; Rosenburg, R; Rozman, B; Schattenkirchner, M; Scott, DL; Smolen, JS; Tikly, M; Westhovens, R, 2001) |
| "We previously reported that the new disease modifying antirheumatic drug leflunomide resulted in significant improvement in functional ability compared with placebo and sulfasalazine in a 6 month double blind, randomized, Phase III trial in rheumatoid arthritis (RA)." | 9.09 | Improved functional ability in patients with rheumatoid arthritis--longterm treatment with leflunomide versus sulfasalazine. European Leflunomide Study Group. ( Jones, P; Kalden, JR; Kvien, TK; Oed, C; Rosenburg, R; Rozman, B; Schattenkirchner, M; Scott, DL; Smolen, JS; Williams, BD; Williams, RB, 2001) |
| "358 patients with rheumatoid arthritis in a double blind trial were randomly allocated to receive either leflunomide 20 mg/day, placebo, or sulfasalazine 2 g/day." | 9.09 | Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. ( Kalden, JR; Kvien, TK; Larsen, A; Loew-Friedrich, I; Nash, P; Oed, C; Schattenkirchner, M; Scott, DL; Smolen, JS; van de Putte, LB, 2001) |
| "Data analysis from a randomized clinical trial with 155 rheumatoid arthritis (RA) patients; median age 50 yr, early and active disease (diagnosis < 2 yr); one group treated with a combination of sulphasalazine (SSZ; 2000 mg/day), methotrexate (MTX; 7." | 9.09 | Bone turnover, joint damage and bone mineral density in early rheumatoid arthritis treated with combination therapy including high-dose prednisolone. ( Boers, M; Geusens, P; Markusse, HM; te Koppele, JM; van der Laan, WH; van der Linden, S; Verhoeven, AC, 2001) |
| "Long term treatment of 190 cases of rheumatoid arthritis with either methotrexate or salazosulfapyridine was analyzed for their efficacy and adverse effects." | 9.08 | [Methotrexate and salazosulfapyridine in the long-term treatment of rheumatoid arthritis]. ( Ichikawa, Y; Kameda, H; Kawai, S; Matsuda, T; Shinozawa, T; Suzuki, Y; Yamada, H; Yoshida, T, 1995) |
| "In a recent study from our group, the combination of methotrexate and sulphasalazine (MTX + SASP) seemed superior to MTX alone in the treatment of rheumatoid arthritis (RA)." | 9.08 | Effect of methotrexate alone or in combination with sulphasalazine on the production and circulating concentrations of cytokines and their antagonists. Longitudinal evaluation in patients with rheumatoid arthritis. ( Barrera, P; Boerbooms, AM; Borm, GF; Haagsma, CJ; Van de Putte, LB; Van der Meer, JW; Van Riel, PL, 1995) |
| "In patients with rheumatoid arthritis, combination therapy with methotrexate, sulfasalazine, and hydroxychloroquine is more effective than either methotrexate alone or a combination of sulfasalazine, and hydroxychloroquine." | 9.08 | Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. ( Drymalski, W; Eckhoff, PJ; Erikson, N; Garwood, V; Haire, CE; Klassen, LW; Klein, H; Maloley, P; Moore, GF; O'Dell, JR; Palmer, W; Wees, S, 1996) |
| " The influence of sulphasalazine (SASP) on the pharmacokinetics of low dose methotrexate (MTX) and the relation between pharmacokinetic variables and clinical response was studied in 15 patients with active rheumatoid arthritis despite > 6 months of SASP treatment." | 9.08 | Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and relationship to clinical response. ( Haagsma, CJ; Russel, FG; Van de Putte, LB; Van Riel, PL; Vree, TB, 1996) |
| "To determine the safety and therapeutic potential of sulfasalazine (SSZ) in the treatment of a large cohort of patients with juvenile rheumatoid arthritis (JRA)." | 9.08 | Sulfasalazine therapy for juvenile rheumatoid arthritis. ( Imundo, LF; Jacobs, JC, 1996) |
| "To compare the efficacy of sulphasalazine, methotrexate, and the combination of both in patients with early rheumatoid arthritis (RA), not treated with disease-modifying anti-rheumatic drugs previously, we conducted a double-blind, double-dummy, controlled, clinical trial." | 9.08 | Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. ( de Jong, AJ; Haagsma, CJ; van de Putte, LB; van Riel, PL, 1997) |
| "Assessment of the cost-effectiveness and cost-utility of early intervention in rheumatoid arthritis (RA) patients, with combined step-down prednisolone, methotrexate and sulphasalazine, compared to sulphasalazine alone." | 9.08 | Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. COBRA Trial Group. Combinatietherapie Bij Reumat ( Bibo, JC; Boers, M; Engel, GL; van der Linden, S; Verhoeven, AC, 1998) |
| "To investigate the efficacy and tolerability of sulfasalazine (SSZ) in the treatment of early rheumatoid arthritis (RA)." | 9.07 | Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study. ( Hakola, M; Hannonen, P; Möttönen, T; Oka, M, 1993) |
| "To compare the effects of hydroxychloroquine and sulphasalazine alone and in combination in rheumatoid arthritis." | 9.07 | Hydroxychloroquine and sulphasalazine alone and in combination in rheumatoid arthritis: a randomised double blind trial. ( Egsmose, C; Faarvang, KL; Hansen, TM; Ingeman-Nielsen, M; Kryger, P; Pødenphant, J, 1993) |
| "One hundred and five patients with a diagnosis of early nonerosive rheumatoid arthritis (RA) were randomized to receive enteric coated sulfasalazine as Salazopyrin En-tabs or placebo for 6 months." | 9.07 | Sulfasalazine in early rheumatoid arthritis. The Australian Multicentre Clinical Trial Group. ( , 1992) |
| "Eighty-six patients with rheumatoid arthritis treated with sulfasalazine were followed for 5 years, or until treatment was discontinued." | 9.07 | Response to sulfasalazine in rheumatoid arthritis: life table analysis of a 5-year followup. ( Jones, E; Jones, JV; Woodbury, JF, 1991) |
| "Sulfasalazine (SLZ) is now a second-line treatment in rheumatoid arthritis (RA), as well as in psoriatic arthritis and ankylosing spondylitis." | 9.07 | [Sulfasalazine in rheumatoid arthritis]. ( Caspi, D; Fluser, D; Gedz, D; Horowitz, I; Rubinov, A; Scharf, Y; Segal, R; Shapira, D; Sukenik, S; Weinberger, A, 1991) |
| "An attempt was made to audit the clinical usefulness of sulphasalazine and penicillamine in patients with rheumatoid arthritis (RA) managed in a routine out-patient setting with assistance from general practitioners and to ascertain whether clinically significant differences can be shown between these two 'second-line' agents." | 9.06 | Degree and extent of response to sulphasalazine or penicillamine therapy for rheumatoid arthritis: results from a routine clinical environment over a two-year period. ( Capell, HA; Hunter, JA; Madhok, R; Marabani, M; Torley, H, 1990) |
| "Response to sulfasalazine was studied for 1 year in 45 patients with rheumatoid arthritis." | 9.06 | A one-year, open, prospective study of sulfasalazine in the treatment of rheumatoid arthritis: adverse reactions and clinical response in relation to laboratory variables, drug and metabolite serum levels, and acetylator status. ( Chalmers, IM; Hunter, T; Sitar, DS, 1990) |
| "The authors tested the therapeutic effectiveness and tolerance of the sulphonamide chemotherapeutic preparation sulfasalazine in 69 patients with active rheumatoid arthritis." | 9.06 | [Results of a clinical trial of sulfasalazine in rheumatoid arthritis]. ( Gatterová, J; Macek, J; Pelísková, Z; Trnavský, K, 1989) |
| "The effects of hydroxychloroquine and sulphasalazine on progression of joint damage shown by X-rays were compared in a double-blind, randomised trial in 60 patients with rheumatoid arthritis not previously treated with slow-acting antirheumatic drugs." | 9.06 | Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. ( Gribnau, FW; Nuver-Zwart, IH; vad de Putte, LB; van der Heijde, DM; van Riel, PL, 1989) |
| "Fifty-four patients with rheumatoid arthritis were randomized to either sulphasalazine or D-penicillamine in order to compare the short- and long-term efficacy of these two agents in the treatment of rheumatoid arthritis." | 9.06 | Sulphasalazine versus penicillamine in the treatment of rheumatoid arthritis. ( Breidahl, PD; Carroll, GJ; Tinsley, LM; Will, RK, 1989) |
| "In a double blind, single observer, 48 week study the effects of sulphasalazine (2 g daily) and hydroxychloroquine (400 mg daily months 0-6, thereafter 200 mg daily) were compared in 60 patients with definite or classical rheumatoid arthritis." | 9.06 | A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazine. ( Gribnau, FW; Nuver-Zwart, IH; van de Putte, LB; van Riel, PL, 1989) |
| "Sulfasalazine (SSZ), 3 gm daily, was compared with placebo for treatment of rheumatoid arthritis, in a 15-week randomized, parallel, double-blind trial." | 9.06 | Sulfasalazine in rheumatoid arthritis. A double-blind, placebo-controlled trial. ( Hepburn, B; Kaplan, SB; Lawson, JG; Pinals, RS, 1986) |
| "Twenty-six out-patients with active rheumatoid arthritis (RA) were randomly allocated to treatment with sulphasalazine (SASP) or D-penicillamine (DPA)." | 9.06 | Effects of sulphasalazine on faecal flora in patients with rheumatoid arthritis: a comparison with penicillamine. ( Cooke, EM; Neumann, VC; Shinebaum, R; Wright, V, 1987) |
| "One hundred eight-six patients with active rheumatoid arthritis were evaluated in a double-blind, randomized study that compared treatment with sulfasalazine (SSZ) (2 mg/day), gold sodium thiomalate (GST) (50 mg/week), and placebo (PBO)." | 9.06 | A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis. ( Clegg, DO; Dahl, SL; Luggen, ME; Michaels, RM; Oglesby, T; Schlegel, S; Ward, JR; Weisman, MH; Williams, HJ; Willkens, RF, 1988) |
| "Thirty-one patients with chronic active rheumatoid arthritis (RA) resistant to gold and/or penicillamine therapy, were treated with sulfasalazine, 2-3 g daily, in a 12-week open study." | 9.05 | Sulfasalazine in severe rheumatoid arthritis: a study to assess potential correlates of efficacy and toxicity. ( Chalmers, IM; Hunter, T; Martin, L; Sitar, DS, 1985) |
| "Pulsed methylprednisolone (PMP) has been shown to produce clinical improvement and reduction in the ESR and acute phase protein concentrations in patients with active rheumatoid arthritis and has been advocated for use either as an alternative to slow-acting antirheumatoid drugs (SAARDs) or in conjunction with SAARDs to accelerate the response to treatment." | 9.05 | Combination therapy with pulsed methylprednisolone in rheumatoid arthritis. ( Bird, H; Dixon, J; Hopkins, R; Neumann, V; Watkins, A; Wright, V, 1985) |
| "To evaluate the efficacy of the triple synthetic Disease Modifying Anti-Rheumatic Drugs (sDMARD) combination methotrexate, sulfasalazine and hydroxychloroquine versus a biologic DMARD (bDMARD) in the treatment of early rheumatoid arthritis." | 8.95 | Efficacy of triple association methotrexate, sulfasalazine and hydroxychloroquine in early treatment of rheumatoid arthritis with insufficient response to methotrexate: Meta-analysis of randomized controlled trials. ( Baillet, A; Bernard, AC; Clay, M; Gaudin, P; Mazouyès, A, 2017) |
| " We report a case in a 63-year-old woman who had been on sulfasalazine for 2 months to treat rheumatoid arthritis." | 8.82 | DRESS syndrome in a patient on sulfasalazine for rheumatoid arthritis. ( Ferraud, D; Michel, F; Navellou, JC; Toussirot, E; Wendling, D, 2005) |
| "Sulfasalazine (salazosulfapyridine) [Azulfidine, Salazopyrin] is a well established disease-modifying antirheumatic drug (DMARD) used in the treatment of patients with rheumatoid arthritis." | 8.82 | Sulfasalazine: a review of its use in the management of rheumatoid arthritis. ( Croom, KF; Plosker, GL, 2005) |
| "To estimate the short-term efficacy and toxicity of sulfasalazine for the treatment of rheumatoid arthritis (RA)." | 8.80 | Sulfasalazine for rheumatoid arthritis. ( Belseck, E; Shea, B; Suarez-Almazor, ME; Tugwell, P; Wells, G, 2000) |
| "I wished to review the pharmacology and current clinical experience with the combination of methotrexate and sulfasalazine as a management for rheumatoid arthritis." | 8.79 | Combination sulfasalazine and methotrexate in the management of rheumatoid arthritis. ( Shiroky, JB, 1996) |
| "We report the use of granulocyte-macrophage colony stimulating factor (GM-CSF) in a case of rheumatoid arthritis with sulfasalazine induced agranulocytosis, leading to a rapid bone marrow recovery within 7 days." | 8.78 | Sulfasalazine induced agranulocytosis treated with granulocyte-macrophage colony stimulating factor. ( de Wolf, JT; Hazenberg, BP; Kuipers, EJ; Vellenga, E, 1992) |
| "Methotrexate (MTX) is recommended as a first-line conventional synthetic disease-modifying antirheumatic drug (csDMARD) for treating rheumatoid arthritis (RA)." | 8.31 | Iguratimod versus salazosulfapyridine in rheumatoid arthritis patients with an inadequate response to methotrexate: Adjusted with propensity score matching. ( Fukuda, K; Funahashi, K; Hayashi, S; Itami, T; Kinoshita, K; Kuroda, R; Maeda, T; Matsubara, T; Matsumura, I; Nozaki, Y; Oribe, M; Tomita, D, 2023) |
| " Methotrexate (MTX), the anchor drug for RA treatment, is contraindicated during pregnancy." | 8.12 | Pregnancy outcomes in patients with rheumatoid arthritis who discontinue methotrexate treatment to conceive. ( Goto, Y; Kawahata, K; Kiyokawa, T; Nagafuchi, H; Ooka, S, 2022) |
| "Sulfasalazine has been widely used in treatment of rheumatoid arthritis and spondyloarthritis." | 8.12 | Adverse reaction profile of sulfasalazine and its persistence in chronic therapy of rheumatoid arthritis and spondyloarthritis: A multicentric observational study. ( David, R; Jayachandran, M; Koshy, V; Marwaha, V; Mithun, CB; Nair, AS; Padmanabhan, DS; Palatty, PL; Santhakumari, V; Singh, SK; Singhal, A; Suman, SK; Surendran, S; Tiwari, A; Yadav, P, 2022) |
| "To investigate the expression and roles of TAM (Tyro3/Axl/Mer) receptor tyrosine kinases (TK) in synovial fluid and synovial tissue of patients with rheumatoid arthritis (RA)." | 8.12 | Elevated expression of TAM receptor tyrosine kinase in synovial fluid and synovial tissue of rheumatoid arthritis. ( Bai, M; Hu, F; Su, Y; Xu, L; Xue, J; Yao, R; Zheng, L; Zhong, H; Zhu, H, 2022) |
| " Here, we describe a case of tubercular osteomyelitis in an old fused hip of a patient with RA who received prednisolone, salazosulfapyridine (SASP), and low-dose methotrexate (MTX)." | 7.96 | Tuberculosis osteomyelitis in an old fused hip; activated by prednisolone, salazosulfapyridine, and low-dose methotrexate therapy in a patient with rheumatoid arthritis. ( Fukushi, JI; Ishitani, EI; Katsuki, I; Matsubara, H; Okada, F; Sonoda, Y, 2020) |
| "To evaluate the prophylactic effect of sulfasalazine against Pneumocystis jirovecii pneumonia (PJP) among rheumatoid arthritis (RA) patients." | 7.91 | Prophylactic effect of sulfasalazine against Pneumocystis pneumonia in patients with rheumatoid arthritis: A nested case-control study. ( Gosho, M; Nishino, J; Nunokawa, T; Shimada, K; Sugii, S; Tohma, S; Wagatsuma, Y; Yokogawa, N, 2019) |
| "Combination treatments for patients with rheumatoid arthritis (RA) with an inadequate response to methotrexate (MTX) alone include the addition of a tumor necrosis factor inhibitor (TNFi) or the addition of sulfasalazine (SSZ) and hydroxychloroquine to MTX (triple therapy)." | 7.91 | Low Persistence Rates in Patients With Rheumatoid Arthritis Treated With Triple Therapy and Adverse Drug Events Associated With Sulfasalazine. ( Cannon, GW; Curtis, JR; Erhardt, DP; Mikuls, TR; Sauer, BC; Teng, CC, 2019) |
| "To investigate the effects of hydroxychloroquine, sulfasalazine and methotrexate on ischemic stroke in patients with rheumatoid arthritis (RA)." | 7.88 | Methotrexate might reduce ischemic stroke in patients with rheumatoid arthritis: a population-based retrospective cohort study. ( Chen, CH; Chen, CM; Chiou, JY; Leong, PY; Li, YC; Lin, LC; Tam, HW; Wang, YH; Wei, JC, 2018) |
| "For patients with rheumatoid arthritis (RA) who have an inadequate response to methotrexate (MTX), the relative effectiveness of the combination of conventional disease-modifying antirheumatic drugs (DMARD) compared with the combination of tumor necrosis factor (TNF) inhibitors and MTX, as second-line therapy, is uncertain." | 7.85 | Triple Oral Therapy Versus Antitumor Necrosis Factor Plus Methotrexate (MTX) in Patients with Rheumatoid Arthritis and Inadequate Response to MTX: A Systematic Literature Review. ( Combe, B; De Bandt, M; Lukas, C; Mary, J; Morel, J, 2017) |
| "To compare persistence and adherence to triple therapy with the nonbiologic disease-modifying antirheumatic drugs (DMARDs) methotrexate (MTX), hydroxychloroquine, and sulfasalazine, versus a tumor necrosis factor inhibitor (TNFi) plus MTX in patients with rheumatoid arthritis (RA)." | 7.85 | Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis. ( Cannon, GW; Curtis, JR; Harrison, DJ; Leng, J; Mikuls, TR; Sauer, BC; Tang, D; Teng, CC, 2017) |
| "Sulfasalazine has long been used for the treatment of rheumatoid arthritis and is often chosen as a first-line treatment." | 7.85 | Sulfasalazine induced immune thrombocytopenia in a patient with rheumatoid arthritis. ( Carlucci, F; Narayan, N; Rigby, S, 2017) |
| "Combination treatment with methotrexate, salazosulfapyridine and bucillamine as an alternative to treatment with TNF-inhibiting biologics in rheumatoid arthritis was investigated." | 7.83 | The usefulness of a new triple combination treatment utilizing methotrexate, salazosulfapyridine, and bucillamine in rheumatoid arthritis. ( Abe, C; Funahashi, K; Katayama, K; Kondo, M; Matsubara, T; Matsuno, H; Okada, M; Sagawa, A; Sakai, Y; Yamasaki, K, 2016) |
| "To develop a population model describing the disease activity (DAS28) time course in patients with early rheumatoid arthritis (RA) treated with triple disease-modifying anti-rheumatic drug (DMARD) therapy (methotrexate, sulfasalazine and hydroxychloroquine)." | 7.81 | A population model of early rheumatoid arthritis disease activity during treatment with methotrexate, sulfasalazine and hydroxychloroquine. ( Foster, DJ; Proudman, SM; Upton, RN; Wiese, MD; Wojciechowski, J, 2015) |
| "To estimate adherence and persistence with etanercept plus methotrexate (ETN-MTX) combination therapy and MTX, hydroxychloroquine, and sulfasalazine triple therapy at 1 year following treatment initiation in adults with rheumatoid arthritis (RA)." | 7.81 | Etanercept-Methotrexate Combination Therapy Initiators Have Greater Adherence and Persistence Than Triple Therapy Initiators With Rheumatoid Arthritis. ( Bonafede, M; Collier, DH; Harrison, DJ; Johnson, BH; Shah, N; Tang, DH, 2015) |
| "Although etanercept (ETN) is effective when used in monotherapy for the treatment of rheumatoid arthritis (RA), ETN/methotrexate (MTX) combination therapy is more efficacious." | 7.78 | Etanercept in combination with conventional disease-modifying antirheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis patients intolerant to methotrexate. ( Koyama, Y; Ohta, T; Shiraishi, H; Uchino, A, 2012) |
| "Despite the availability of several new agents for the treatment of rheumatoid arthritis (RA), sulfasalazine remains the mainstay because of both cost and experience with its use." | 7.75 | The effect of 677C>T and 1298A>C MTHFR polymorphisms on sulfasalazine treatment outcome in rheumatoid arthritis. ( Drozdzik, M; Dziedziejko, V; Gawronska-Szklarz, B; Gornik, W; Juzyszyn, Z; Kurzawski, M; Pawlik, A; Safranow, K, 2009) |
| "To study genetic polymorphisms in the folate pathway, a site of action of methotrexate (MTX) and sulfasalazine (SSZ), as predictors of efficacy of combination disease modifying antirheumatic drug (DMARD) regimens containing MTX and SSZ in early rheumatoid arthritis (RA)." | 7.74 | Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis. ( Cleland, LG; Gillis, D; Hissaria, P; James, HM; Lester, S; Proudman, SM; Somogyi, AA, 2008) |
| "To determine whether improvements in physical function and health related quality of life (HRQOL) are sustained over 2 years of blinded treatment with leflunomide (LEF), methotrexate (MTX), or sulfasalazine (SSZ) in patients with active rheumatoid arthritis (RA)." | 7.73 | Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. ( Cannon, GW; Crawford, B; Emery, P; Kalden, JR; Scott, DL; Smolen, JS; Strand, V; Tugwell, P, 2005) |
| "To study which factors are associated with longterm methotrexate (MTX) use in rheumatoid arthritis (RA)." | 7.72 | Longterm observational study of methotrexate use in a Dutch cohort of 1022 patients with rheumatoid arthritis. ( Bernelot Moens, HJ; Haagsma, CJ; Hoekstra, M; Kruijsen, MW; van de Laar, MA, 2003) |
| "To investigate whether interactions of sulfasalazine (SSZ) with reduced folate carrier (RFC), the dominant cell membrane transporter for natural folates and methotrexate (MTX), may limit the efficacy of combination therapy with MTX and SSZ in patients with rheumatoid arthritis." | 7.72 | Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications for combination therapies with methotrexate in rheumatoid arthritis. ( Assaraf, YG; Dijkmans, BA; Ifergan, I; Jansen, G; Lems, WF; Oerlemans, R; Scheper, RJ; van der Heijden, J, 2004) |
| "A severe systemic reaction to sulfasalazine developed in a 21-year old female with rheumatoid arthritis characterized by eosinophilia, granulomatous enteritis and myelotoxicity, cholestatic hepatitis, and seizures." | 7.71 | Is it Crohn's disease? A severe systemic granulomatous reaction to sulfasalazine in patient with rheumatoid arthritis. ( Fontana, RJ; Greenson, J; Haftel, HM; Quallich, LG, 2001) |
| "To compare the impact of leflunomide on resource utilization and costs relative to that of etanercept and infliximab among patients with rheumatoid arthritis (RA) in a managed care setting." | 7.71 | Impact of leflunomide versus biologic agents on the costs of care for rheumatoid arthritis in a managed care population. ( Doyle, J; Huse, DM; Ollendorf, DA; Peterson, AN, 2002) |
| "New treatment options for patients with methotrexate (MTX)-naive rheumatoid arthritis (RA) have become available." | 7.71 | A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis. ( Choi, HK; Kuntz, KM; Seeger, JD, 2002) |
| "In this study we report our two years experience of methotrexate (MTX) in the management of rheumatoid arthritis (RA) at the Aga Khan University Hospital, Karachi." | 7.70 | Methotrexate in rheumatoid arthritis: a 2 year experience at a university hospital in Pakistan. ( Ali, AA; Beg, JA; Hussain, MA; Iqbal, MP; Mehboobali, N; Rahbar, MH, 1998) |
| " We describe a patient with rheumatoid arthritis (RA) treated with methotrexate (MTX), sulfasalazine, and low dose corticosteroids, whose case was seriously complicated by the occurrence of acute febrile pancytopenia." | 7.70 | Pancytopenia secondary to hemophagocytic syndrome in rheumatoid arthritis treated with methotrexate and sulfasalazine. ( Albert, A; Cazenave, JP; Javier, RM; Kuntz, JL; Sibilia, J, 1998) |
| "We investigated the in vitro immunomodulatory effects of sulfasalazine on B cells in rheumatoid arthritis (RA)." | 7.69 | Effect of sulfasalazine on B cell hyperactivity in patients with rheumatoid arthritis. ( Akiyama, Y; Dohi, Y; Imai, F; Ishibashi, T; Suzuki, T; Tanaka, M, 1994) |
| "We describe the case of a 46-year-old woman with rheumatoid arthritis who developed a severe reaction to sulfasalazine, characterized by dysphasia, seizures, rash and the development of strongly positive pANCA (perinuclear antineutrophil cytoplasmic antibodies)." | 7.69 | Sulfasalazine induced seizures and dysphasia. ( Gordon, C; Heath, DA; Hill, ME; Situnayake, RD, 1994) |
| "We describe 2 cases of a lupus syndrome induced by sulfasalazine in rheumatoid arthritis." | 7.69 | Sulfasalazine induced lupus in rheumatoid arthritis. ( Andrieu, V; Caulier, M; Dromer, C; Fournie, B; Le Guennec, P, 1994) |
| "Patients with rheumatoid arthritis who did not respond sufficiently to auranofin therapy were divided into three groups to be continued on auranofin monotherapy (1), to be on combination therapy of auranofin and salazosulfapyridine (2) and to be given methotrexate concomitantly with auranofin (3), and clinical responses were compared in a prospective manner." | 7.69 | [Study on combined of auranofin, salazosulfapyridine and methotrexate in rheumatoid arthritis]. ( Akizuki, M; Fujii, T; Mimori, T; Suwa, A; Yosida, T, 1994) |
| "To analyze whether the intestinal mucosa in rheumatoid arthritis (RA) is immunologically abnormal and whether sulfasalazine (SSZ) possesses any local intestinal immunoregulatory effect." | 7.69 | Evidence of a local intestinal immunomodulatory effect of sulfasalazine in rheumatoid arthritis. ( Hafström, I; Kanerud, L; Scheynius, A, 1994) |
| "The aim of the study was to evaluate the effects of treatment with methotrexate, sulphasalazine and aurothiomalate on polymorphonuclear leucocytes (PMN) in rheumatoid arthritis (RA)." | 7.69 | Effects of methotrexate, sulphasalazine and aurothiomalate on polymorphonuclear leucocytes in rheumatoid arthritis. ( Anderson, PL; Jensen, MP; Møller, BK; Obel, N; Stengaard-Pedersen, K; Storgaard, M, 1996) |
| "In an attempt to estimate the frequency of folate deficiency and haemolysis in a group of 25 outpatients with arthritis treated with sulphasalazine (SASP), haematological measurements, including plasma total homocysteine (tHcy) which is a sensitive marker of folate deficiency, serum folate (S-folate), erythrocyte (RBC) folate, S-cobalamin and routine indices of haemolysis were performed." | 7.69 | Folate and homocysteine status and haemolysis in patients treated with sulphasalazine for arthritis. ( Ekelund, S; Krogh Jensen, M; Svendsen, L, 1996) |
| "Sulfasalazine is an efficient treatment for rheumatoid arthritis (RA), but its mode of action is not known." | 7.68 | Variation in the serum IgA concentration and the production of IgA in vitro in rheumatoid arthritis treated by sulfasalazine. ( Anaya, JM; Bologna, C; Jorgensen, C; Reme, T; Sany, J, 1993) |
| "In a retrospective analysis a total of 167 patients with rheumatoid arthritis (RA) who had been treated with the basic therapy formulas of methotrexate (MTX) or sulfasalazine (SUL) were evaluated with respect to therapeutical result and side effects after a period of 12 months." | 7.68 | [Basic therapy of rheumatoid arthritis. Comparison of methotrexate and sulfasalazine]. ( Keitel, R; Keitel, W; Pap, T, 1993) |
| "The interaction between sulphasalazine and cimetidine has been studied, a drug combination which is quite likely in view of the higher incidence of peptic ulceration in patients with RA." | 7.68 | Lack of interaction between sulphasalazine and cimetidine in patients with rheumatoid arthritis. ( Breckenridge, AM; Bucknall, RC; Coleman, MD; Galvani, D; Park, BK; Pirmohamed, M, 1993) |
| " In this report we present a patient with an erosive seropositive rheumatoid arthritis developing the clinical and serological features of systemic lupus erythematosus including the occurrence of double-stranded DNA antibodies under sulfasalazine treatment." | 7.68 | Drug-related lupus in a patient with rheumatoid arthritis under sulfasalazine treatment. ( Deicher, H; Hammer, M; Hartung, K; Mau, W; Schmidt, RE; Wildhagen, K; Zeidler, H, 1993) |
| "The pharmacokinetic disposition of sulfasalazine and its metabolites was studied in 8 young and 12 elderly patients with active rheumatoid arthritis." | 7.68 | The effect of age and acetylator phenotype on the pharmacokinetics of sulfasalazine in patients with rheumatoid arthritis. ( McDermott, BJ; Roberts, SD; Taggart, AJ, 1992) |
| "From the analysis of literature and first-hand data on methylprednisolone pulse-therapy for rheumatoid arthritis (RA) the conclusion is made that such therapy produces a rapid and pronounced though short-term effect on the disease activity." | 7.68 | [Clinical notes about methylprednisolone pulse-therapy in patients with rheumatoid arthritis]. ( Fomina, LL, 1991) |
| "A female patient with IgM RF seropositive rheumatoid arthritis according to criteria of the American Rheumatism Association was treated for 133 months with Penicillamine and for 17 months also with Sulfasalazine." | 7.68 | [Rheumatoid arthritis developing into systemic lupus erythematosus during long-term treatment with penicillamine and sulfasalazine]. ( Hrncír, Z; Pintérová, E; Rejchrt, S, 1991) |
| "A 56 year old woman with rheumatoid arthritis developed relapsing thrombocytopenia during successive treatments with aurothioglucose, sulphasalazine, and hydroxychloroquine." | 7.68 | Thrombocytopenia due to aurothioglucose, sulphasalazine, and hydroxychloroquine. ( Allebes, WA; Boerbooms, AM; van de Putte, LB; van Riel, PL; Wijnands, MJ, 1990) |
| "The outcome of attempts to continue treatment indefinitely with either gold, penicillamine, sulphasalazine, or dapsone was studied in 240 patients with rheumatoid arthritis (RA)." | 7.67 | Outcome of attempts to treat rheumatoid arthritis with gold, penicillamine, sulphasalazine, or dapsone. ( Grindulis, KA; McConkey, B, 1984) |
| "The long term efficacy and tolerability of sulphasalazine (SASP) in the treatment of 21 patients with active classical or definite rheumatoid arthritis (RA) were examined and compared with the effects of penicillamine in a similarly active group of RA patients." | 7.67 | The long term effects of sulphasalazine in the treatment of rheumatoid arthritis and a comparative study with penicillamine. ( Bacon, PA; Crockson, AP; Farr, M; Tunn, E, 1984) |
| "Four patients with rheumatoid arthritis received a combination of methotrexate and sulfasalazine for a mean of 24 months (range 20-28 months)." | 7.67 | Combination methotrexate and sulfasalazine in the management of rheumatoid arthritis: case observations. ( Neville, C; Shiroky, JB; Watts, CS, 1989) |
| "A patient with rheumatoid arthritis and collagenous colitis apparently responding to sulfasalazine and prednisolone enemas is reported." | 7.67 | Collagenous colitis: possible response to sulfasalazine and local steroid therapy. ( Farah, DA; Lee, FD; McLay, A; Mills, PR; Russell, RI, 1985) |
| "Thirty patients (22 women) with active rheumatoid arthritis participated in an open study of 6 months' treatment with either enteric-coated sulphasalazine (SASP) or SASP plus D-penicillamine (DPA)." | 7.67 | Sulphasalazine alone or in combination with D-penicillamine in rheumatoid arthritis. ( Astbury, C; Bird, HA; Dixon, JS; Hill, J; Taggart, AJ; Wright, V, 1987) |
| "A 55-year-old woman with rheumatoid arthritis in overlap with polymyositis received sulfasalazine for control of synovitis." | 7.67 | Cholestasis and fatal agranulocytosis complicating sulfasalazine therapy: case report and review of the literature. ( Mitrane, MP; Seibold, JR; Singh, A, 1986) |
| "Life-table analysis was applied to the records of 317 patients with rheumatoid arthritis (RA) treated with sulphasalazine (SAS), 201 treated with sodium aurothiomalate (gold), and 163 with penicillamine." | 7.67 | Long-term treatment of rheumatoid arthritis with sulphasalazine, gold, or penicillamine: a comparison using life-table methods. ( Grindulis, KA; McConkey, B; Situnayake, RD, 1987) |
| "Sulfasalazine is now an established 2nd line agent in the treatment of rheumatoid arthritis (RA) but its mode of action is unknown." | 7.67 | Sulfasalazine treatment and lymphocyte function in patients with rheumatoid arthritis. ( Bacon, PA; Farr, M; Salmon, M; Symmons, DP, 1988) |
| "Forty-two patients with active rheumatoid arthritis treated with hydroxychloroquine sulphate (400 mg day-1) for six months have been compared with patients treated with D-penicillamine (n = 14), aurothiomalate (n = 13), sulphasalazine (n = 15) and chloroquine (n = 17) to compare the changes in articular index, plasma viscosity and ESR." | 7.67 | How reliable is ESR as a measure of disease activity in rheumatoid arthritis treated with hydroxychloroquine? ( Bird, HA; Dixon, JS; Greenwood, M, 1988) |
| "Sulfasalazine was synthesized almost 50 years ago specifically to treat rheumatoid arthritis." | 7.67 | History of enteric coated sulfasalazine in rheumatoid arthritis. ( Pinals, RS, 1988) |
| "Cross-sectional and longitudinal studies have been carried out to determine the incidence and clinical significance of eosinophilia in patients taking penicillamine for rheumatoid arthritis." | 7.66 | Eosinophilia in D-penicillamine therapy. ( Scott, DL; Smith, DH; Zaphiropoulos, GC, 1983) |
| " Secondary outcomes will include the incremental cost per reducing 1 case of relapse; patient reported intolerance to the treatment; adverse events; change of mean disease activity measured by DAS28, clinical disease activity index (CDAI) and simplified disease activity index (SDAI); the proportion of modified Sharp score increase < 0." | 7.01 | The efficacy, safety and cost-effectiveness of hydroxychloroquine, sulfasalazine, methotrexate triple therapy in preventing relapse among patients with rheumatoid arthritis achieving clinical remission or low disease activity: the study protocol of a rand ( Ji, P; Wu, Y; Yan, X; Yang, L; Zhang, Z; Zhao, J; Zhou, W, 2021) |
| " Adverse events (AEs) were reported in 114/122 (93." | 6.87 | Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients. ( Harigai, M; Hsu, B; Kato, Y; Nakano, T; Takeuchi, T; Tamamura, R; Tanaka, Y; Ukyo, Y; Yamanaka, H, 2018) |
| "Nausea was the most frequent side effect: 32%, 23%, 49% in the SASP, MTX, and SASP + MTX groups respectively (p = 0." | 6.69 | Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. ( Cantagrel, A; Combe, B; Dougados, M; Goupille, P; Leirisalo-Repo, M; Meusser, S; Olive, P; Paimela, L; Peldan, K; Rau, R; Schattenkirchner, M; Zeidler, H, 1999) |
| "Nausea was the major side effect in the sulphasalazine treated group." | 6.65 | Comparison between penicillamine and sulphasalazine in rheumatoid arthritis: Leeds-Birmingham trial. ( Grindulis, KA; Hubball, S; McConkey, B; Neumann, VC; Wright, V, 1983) |
| "Early aggressive treatment of rheumatoid arthritis is associated with improved disease control, slower radiological progression and improved functional outcomes." | 6.44 | Combination therapy for rheumatoid arthritis: methotrexate and sulfasalazine together or with other DMARDs. ( Alcorn, N; Capell, H; Dale, J; Madhok, R, 2007) |
| "Sulfasalazine is an effective treatment for rheumatoid arthritis (RA), producing improvements in disease parameters similar to those seen with penicillamine, hydroxychloroquine or oral or parenteral gold in comparative clinical trials." | 6.39 | Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis. ( Faulds, D; Noble, S; Rains, CP, 1995) |
| "Collagenous colitis has been associated with rheumatoid arthritis in only a few cases." | 6.37 | Collagenous colitis and rheumatoid arthritis with response to sulfasalazine. A case report and review of the literature. ( Okon, E; Pollak, A; Stalnikowicz, R; Wengrower, D, 1987) |
| "One hundred and fifty patients with rheumatoid arthritis were given sulfasalazine in a daily dosage of 2 g during an open-label, multicenter, six-month trial." | 6.17 | [Sulfasalazine in the treatment of rheumatoid arthritis. A multicenter open study of 150 patients during 6 months]. ( , 1992) |
| "We performed 2 metaanalyses of placebo-controlled and comparative clinical trials to examine the relative efficacy and toxicity of methotrexate (MTX), injectable gold, D-penicillamine (DP), sulfasalazine (SSZ), auranofin (AUR), and antimalarial drugs, the second-line drugs most commonly used to treat rheumatoid arthritis (RA)." | 6.16 | The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. ( Anderson, JJ; Felson, DT; Meenan, RF, 1990) |
| "Sulfasalazine use was associated with a decreased PCP risk (adjusted IRR <0." | 5.91 | Efficacy of sulfasalazine for the prevention of Pneumocystis pneumonia in patients with rheumatoid arthritis: A multicentric self-controlled case series study. ( Chen, FY; Chinen, N; Kimura, M; Nunokawa, T; Setoguchi, K; Shimada, K; Sugihara, M; Tateishi, M, 2023) |
| "To compare efficacy and safety of two different combination csDMARD therapy in Methotrexate-failed Rheumatoid arthritis patients." | 5.51 | Comparison between leflunomide and sulfasalazine based triple therapy in methotrexate refractory rheumatoid arthritis: an open-label, non-inferiority randomized controlled trial. ( Belani, PJ; Kavadichanda, CG; Negi, VS, 2022) |
| "Prednisone use was associated with a significantly increased risk of mortality in patients with RA." | 5.43 | Prednisone Use and Risk of Mortality in Patients With Rheumatoid Arthritis: Moderation by Use of Disease-Modifying Antirheumatic Drugs. ( Chester Wasko, M; Dasgupta, A; Fries, JF; Ilse Sears, G; Ward, MM, 2016) |
| "The aim of this study was to evaluate the effect of treatment with methotrexate (MTX), by itself or combined with other non-biological disease-modifying antirheumatic drugs (DMARDs) (methotrexate, MTX with prednisolone, MTX with leflunomide, MTX with chloroquine, and MTX with sulfasalazine) on clinimetric outcomes in a retrospective cohort with a 6-month follow-up and under a Treat to Target (T2T) approach." | 5.42 | Treatment of rheumatoid arthritis with methotrexate alone and in combination with other conventional DMARDs using the T2T strategy. A cohort study. ( Castro, C; de la Hoz-Valle, J; Palomino, A; Sánchez, G; Santos-Moreno, PI; Villarreal, L, 2015) |
| "To compare the pain course between methotrexate (MTX)-refractory early rheumatoid arthritis (RA) patients randomized to infliximab (IFX) versus sulfasalazine (SSZ) plus hydroxychloroquine (HCQ)." | 5.41 | Pain Over Two Years After Start of Biologic Versus Conventional Combination Treatment in Early Rheumatoid Arthritis: Results From a Swedish Randomized Controlled Trial. ( Ernestam, S; Jöud, A; Lampa, J; Olofsson, T; Saevarsdottir, S; Schelin, MEC; van Vollenhoven, R; Wallman, JK, 2021) |
| " We collected clinical information, including patient background, treatment efficacy (evaluated using the DAS score), and adverse events observed." | 5.38 | Single-center, retrospective analysis of efficacy and safety of tacrolimus as a second-line DMARD in combination therapy and the risk factors contributing to adverse events in 115 patients with rheumatoid arthritis. ( Amano, H; Kageyama, M; Kempe, K; Kusaoi, M; Matsudaira, R; Matsushita, M; Morimoto, S; Nawata, M; Ogasawara, M; Onuma, S; Sekiya, F; Tada, K; Takasaki, Y; Tamura, N; Toyama, S; Yamaji, K, 2012) |
| "To assess the incidence and severity of disease modifying antirheumatic drug (DMARD)-induced adverse effects (AE) in patients with rheumatoid arthritis (RA) taking/not taking glucocorticoids (GC)." | 5.35 | Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs. ( Arnold, S; Baerwald, CG; Häntzschel, H; Malysheva, OA; Pierer, M; Wagner, U; Wahle, M, 2008) |
| "To evaluate the cost-effectiveness of treat-to-target strategies among recently diagnosed patients with rheumatoid arthritis (RA) using methotrexate (MTX) and a step-down glucocorticoid (GC) scheme (COBRA Slim) compared with (1) this combination with either sulphasalazine (COBRA Classic) or leflunomide (COBRA Avant-Garde) in high-risk patients and (2) MTX without GCs (Tight-Step-Up, TSU) in low-risk patients." | 5.34 | Two-year cost-effectiveness of different COBRA-like intensive remission induction schemes in early rheumatoid arthritis: a piggyback study on the pragmatic randomised controlled CareRA trial. ( Boonen, A; De Cock, D; Joly, J; Pazmino, S; Stouten, V; Van der Elst, K; Verschueren, P; Westhovens, R, 2020) |
| " The results highlight the efficacy and safety of active conventional treatment based on methotrexate combined with corticosteroids, with nominally better results for abatacept, in treatment naive early rheumatoid arthritis." | 5.34 | Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial. ( Baecklund, E; Bakland, G; Brodin, E; Cagnotto, G; Ellingsen, T; Faustini, F; Grondal, G; Grøn, KL; Gudbjornsson, B; Haavardsholm, EA; Heiberg, MS; Hendricks, O; Hetland, ML; Hultgård Ekwall, AK; Husmark, T; Hyldstrup, LH; Hørslev-Petersen, K; Just, SA; Kapetanovic, M; Krabbe, S; Lampa, J; Larsson, P; Laurberg, TB; Lend, K; Lindqvist, J; Ljoså, MA; Lorenzen, T; Nordström, D; Nurmohamed, M; Olsen, IC; Olsson, ÅR; Rizk, M; Rudin, A; Söderbergh, A; Sokka-Isler, T; Stevens, DJ; Tuompo, R; Twisk, J; Uhlig, T; Uhrenholt, L; van Vollenhoven, R; Vedder, D; Østergaard, M, 2020) |
| "Current dosing strategies should be re-evaluated, and coping strategies for common AEs should be investigated." | 5.32 | Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study. ( Aletaha, D; Eberl, G; Grisar, J; Kapral, T; Machold, KP; Smolen, JS; Stamm, T, 2003) |
| "Histopathologic diagnosis was bronchiolitis obliterans organizing pneumonia (BOOP)." | 5.32 | Bronchiolitis obliterans organizing pneumonia associated with sulfasalazine in a patient with rheumatoid arthritis. ( Apaydin, D; Aydin, O; Ozer, C; Ozgür, E; Sahin, G; Ulubaş, B, 2004) |
| "Treatment with sulfasalazine correlated positively with BMD at 3 of the 5 measured bone sites." | 5.31 | Bone mineral density in men with rheumatoid arthritis is associated with erosive disease and sulfasalazine treatment but not with sex hormones. ( Hafström, I; Tengstrand, B, 2002) |
| " We examine whether there was a correlation between diplotype configurations (combinations of 2 haplotypes for a subject) at the NAT2 gene and the adverse effects of SSZ used for the treatment of rheumatoid arthritis (RA)." | 5.31 | Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene. ( Kamatani, N; Kitamura, Y; Matsuda, Y; Nakajima, H; Saito, M; Saito, T; Tanaka, E; Taniguchi, A; Urano, W; Yamanaka, H, 2002) |
| " The average dosage of MTX used was calculated to be 590 mg." | 5.31 | [The effect of low dose methotrexate treatment on bone mineral density in patients with rheumatoid arthritis]. ( Kita, K; Sierakowski, S, 2002) |
| " There is no evidence that the dosage of drugs metabolized by the CYP3A4 isoenzyme needs to be adjusted for disease activity in RA." | 5.30 | Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. ( Beyeler, C; Bird, HA; Frey, BM, 1997) |
| " The proportion of adverse events was lowest in group 1 (14%) and highest in groups 3 and 4 (25%)." | 5.30 | Toxicity profile of dual methotrexate combinations with gold, hydroxychloroquine, sulphasalazine and minocycline in rheumatoid arthritis patients. ( Caspi, D; Elkayam, O; Segal, R; Yaron, M; Zhukovsky, G, 1997) |
| "Although it is common for rheumatologists to initiate biologic agents after failure of methotrexate monotherapy in rheumatoid arthritis (RA), ample data support the initial use of combinations of conventional therapies in this clinical scenario." | 5.24 | Rheumatoid Arthritis Treatment After Methotrexate: The Durability of Triple Therapy Versus Etanercept. ( Brophy, M; Lew, R; Mikuls, T; O'Dell, J; Peper, SM; Rybin, D; Wu, H, 2017) |
| "To compare long-term work loss in methotrexate-refractory early rheumatoid arthritis (RA) patients randomized to the addition of infliximab or conventional combination treatment." | 5.22 | Infliximab Versus Conventional Combination Treatment and Seven-Year Work Loss in Early Rheumatoid Arthritis: Results of a Randomized Swedish Trial. ( Eriksson, JK; Ernestam, S; Miller, H; Neovius, M; Petersson, IF; van Vollenhoven, RF; Vivar, N; Wallman, JK, 2016) |
| "In early, methotrexate-refractory rheumatoid arthritis, a treatment strategy commencing with addition of infliximab, as compared to sulfasalazine+hydroxychloroquine, was not cost-effective over 21 months at willingness to pay levels generally considered acceptable." | 5.20 | Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial. ( Bratt, J; Eriksson, JK; Ernestam, S; Geborek, P; Karlsson, JA; Neovius, M; Petersson, IF; van Vollenhoven, RF, 2015) |
| "5 mg/week, sulfasalazine 2 g/day, with initial prednisolone 60 mg/day) after 26 weeks in patients with early active rheumatoid arthritis (RA)." | 5.20 | Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial. ( Boers, M; den Uyl, D; Kerstens, P; Lems, WF; Nurmohamed, M; ter Wee, MM; van Schaardenburg, D; Voskuyl, AE, 2015) |
| "Treatment with initial high-dose prednisolone and a combination of methotrexate (MTX) and sulfasalazine (SSZ) according to the COBRA regimen (Dutch acronym for combinatietherapie bij reumatoide artritis, 'combination therapy for rheumatoid arthritis'), has repeatedly been demonstrated to be very effective in early rheumatoid arthritis (RA)." | 5.20 | Initial high-dose prednisolone combination therapy using COBRA and COBRA-light in early rheumatoid arthritis. ( Boers, M; Lems, WF; Rasch, LA; van Tuyl, LH, 2015) |
| " High-risk patients (n=290) were randomised to 1/3 treatment strategies: combination therapy for early rheumatoid arthritis (COBRA) Classic (methotrexate (MTX)+ sulfasalazine+60 mg prednisone tapered to 7." | 5.20 | Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. ( Corluy, L; De Brabanter, G; De Cock, D; Durnez, A; Geens, E; Geusens, P; Joly, J; Joos, R; Langenaken, C; Lenaerts, J; Meyfroidt, S; Raeman, F; Ravelingien, I; Remans, J; Sileghem, A; Taelman, V; Van der Elst, K; Van Essche, E; Vander Cruyssen, B; Vandevyvere, K; Vanhoof, J; Verschueren, P; Westhovens, R, 2015) |
| "Early, intensive treatment of rheumatoid arthritis (RA) with the combination of (initially high dose) prednisolone, methotrexate and sulfasalazine (COBRA therapy) considerably lowers disease activity and suppresses radiological progression, but is infrequently prescribed in daily practice." | 5.19 | A non-inferiority trial of an attenuated combination strategy ('COBRA-light') compared to the original COBRA strategy: clinical results after 26 weeks. ( Boers, M; den Uyl, D; Dijkmans, B; Kerstens, P; Lems, W; Nurmohamed, M; Raterman, H; ter Wee, M; van Dillen, N; van Schaardenburg, D; Voskuyl, A, 2014) |
| "610 patients with early rheumatoid arthritis (RA 2010 criteria) or undifferentiated arthritis (UA) started treatment with methotrexate (MTX) and a tapered high dose of prednisone." | 5.19 | A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study. ( Allaart, CF; Bijkerk, C; de Buck, MP; de Sonnaville, PB; Goekoop, RJ; Grillet, BA; Harbers, JB; Heimans, L; Huizinga, TW; Speyer, I; van Oosterhout, M; Visser, K; Wevers-de Boer, KV, 2014) |
| "To compare 1-year clinical efficacy of (1) initial triple disease-modifying antirheumatic drug therapy (iTDT) with initial methotrexate (MTX) monotherapy (iMM) and (2) different glucocorticoid (GC) bridging therapies: oral versus a single intramuscular injection in early rheumatoid arthritis." | 5.19 | Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial. ( de Jong, PH; de Sonnaville, PB; Gerards, AH; Han, HK; Hazes, JM; Huisman, M; Luime, JJ; van der Lubbe, PA; van Krugten, MV; van Schaeybroeck, B; van Zeben, D; Weel, AE, 2014) |
| "To study changes in lipid profiles at 24 weeks among patients with early rheumatoid arthritis (RA) participating in the Treatment of Early RA (TEAR) trial and randomized to receive methotrexate (MTX) plus etanercept, triple therapy (MTX plus sulfasalazine plus hydroxychloroquine), or aggressively titrated MTX monotherapy." | 5.17 | Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial. ( Bathon, JM; Bridges, SL; Charles-Schoeman, C; Chen, L; Cofield, SS; Curtis, JR; Dell'Italia, LJ; Moreland, LW; Navarro-Millán, I; O'Dell, JR; Paulus, HE; Yang, S, 2013) |
| "In the Treatment of Early Rheumatoid Arthritis (TEAR) trial, 755 participants with early, poor-prognosis RA were randomized to receive MTX monotherapy or combination therapy (MTX plus etanercept or MTX plus sulfasalazine plus hydroxychloroquine)." | 5.17 | Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial. ( Bridges, SL; Cofield, SS; Curtis, JR; Mikuls, TR; Moreland, LW; O'Dell, JR; Ranganath, VK, 2013) |
| "We conducted a 48-week, double-blind, noninferiority trial in which we randomly assigned 353 participants with rheumatoid arthritis who had active disease despite methotrexate therapy to a triple regimen of disease-modifying antirheumatic drugs (methotrexate, sulfasalazine, and hydroxychloroquine) or etanercept plus methotrexate." | 5.17 | Therapies for active rheumatoid arthritis after methotrexate failure. ( Ahluwalia, V; Anis, AH; Brophy, M; Cannella, AC; Keystone, E; Kunkel, G; Leatherman, S; Lew, RA; Mikuls, TR; O'Dell, JR; Phibbs, CS; Taylor, TH; Warren, SR, 2013) |
| "In this study, 610 patients with early rheumatoid arthritis (RA) or undifferentiated arthritis (UA) were treated with methotrexate (MTX) and tapered high dose of prednisone." | 5.17 | Health-related quality of life and functional ability in patients with early arthritis during remission steered treatment: results of the IMPROVED study. ( Allaart, CF; Goekoop-Ruiterman, YP; Grillet, BA; Harbers, JB; Heimans, L; Huizinga, TW; Koudijs, KK; Lard, LR; Steup-Beekman, GM; Visser, K; Wevers-de Boer, KV, 2013) |
| "Early treatment of patients with rheumatoid arthritis (RA) with combination treatment starting with methotrexate, sulfasalazine, hydroxychloroquine and prednisolone (FIN-RACo strategy) is superior to monotherapy." | 5.17 | Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study). ( Blåfield, H; Hannonen, PJ; Ilva, K; Julkunen, HA; Kaipiainen-Seppänen, O; Karjalainen, A; Kauppi, MJ; Kautiainen, H; Korpela, M; Laasonen, L; Leirisalo-Repo, M; Luosujärvi, R; Luukkainen, R; Moilanen, E; Möttönen, T; Paimela, L; Puolakka, K; Uutela, T, 2013) |
| "To compare EuroQol 5-Dimensions (EQ-5D) utility and quality-adjusted life-years (QALYs) in patients with early, methotrexate (MTX) refractory rheumatoid arthritis (RA), randomised to addition of infliximab (IFX) or sulfasalazine and hydroxychloroquine (SSZ+HCQ)." | 5.17 | Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial. ( Bratt, J; Ernestam, S; Geborek, P; Karlsson, JA; Neovius, M; Nilsson, JÅ; Petersson, IF; van Vollenhoven, RF, 2013) |
| "Analysis of the Swedish Farmacotherapy (Swefot) trial at 12 months showed that the addition of an anti-tumour-necrosis-factor agent gave an improved clinical outcome compared with the addition of conventional disease-modifying antirheumatic drugs in patients with methotrexate-refractory early rheumatoid arthritis." | 5.16 | Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. ( Albertsson, K; Bratt, J; Chatzidionysiou, K; Ernestam, S; Forslind, K; Geborek, P; Petersson, IF; van Vollenhoven, RF, 2012) |
| "The study participants included patients with early RA (<3 years in duration) enrolled in the Treatment of Early Aggressive Rheumatoid Arthritis study, a randomized, blinded, placebo-controlled clinical trial comparing early intensive therapy (MTX + etanercept or MTX + hydroxychloroquine + sulfasalazine triple therapy) versus initial treatment with MTX with step-up to MTX + etanercept or to triple therapy if the disease was still active at 24 weeks." | 5.16 | Serum cotinine as a biomarker of tobacco exposure and the association with treatment response in early rheumatoid arthritis. ( Bridges, SL; Cofield, SS; Curtis, JR; Maska, LB; Mikuls, TR; Moreland, LW; O'Dell, JR; Sayles, HR, 2012) |
| "The aim of the present study was to measure the changes in serum selenium, zinc, and copper in patients being treated for rheumatoid arthritis." | 5.15 | Effects of different medical treatments on serum copper, selenium and zinc levels in patients with rheumatoid arthritis. ( Bulut, V; Çolak, M; Flores-Arce, MF; Nazıroğlu, M; Önal, S, 2011) |
| "In this trial, we investigated the safety and efficacy of tacrolimus used in addition to standard antirheumatic drugs in patients with rheumatoid arthritis." | 5.15 | Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDs--a multicenter, double-blind, parallel-group trial. ( Kawai, S; Miyasaka, N; Takeuchi, T; Tanaka, Y; Yamamoto, K, 2011) |
| "Adults with a clinical diagnosis of rheumatoid arthritis or psoriatic arthritis who were referred to the nursing team for counselling about starting on methotrexate, sulfasalazine or leflunomide were included." | 5.14 | Providing patients with information about disease-modifying anti-rheumatic drugs: Individually or in groups? A pilot randomized controlled trial comparing adherence and satisfaction. ( Homer, D; Jobanputra, P; Nightingale, P, 2009) |
| "To determine the efficacy and safety of etanercept and etanercept plus sulfasalazine versus sulfasalazine in patients with rheumatoid arthritis (RA) despite sulfasalazine therapy." | 5.14 | Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study. ( Codreanu, C; Combe, B; Fatenejad, S; Fiocco, U; Gaubitz, M; Geusens, PP; Khandker, R; Kvien, TK; Pavelka, K; Sambrook, PN; Singh, A; Smolen, JS; Wajdula, J, 2009) |
| "A two-armed randomized trial of patients with early rheumatoid arthritis (RA) treated by either combination therapy (sulfasazaline, methotrextate, prednisolone) or monotherapy (sulfasazaline)." | 5.14 | Relapse-remission and remission-relapse switches in rheumatoid arthritis patients were modeled by random effects. ( Berkhof, J; Boers, M; Knol, DL; Rijmen, F; Twisk, JW; Uitdehaag, BJ, 2009) |
| "Bucillamine (Buc), developed in Japan, is a disease-modifying antirheumatic drug (DMARD) which has been used to treat numerous patients with rheumatoid arthritis (RA) in Japan and Korea with favorable results." | 5.14 | A comparative study of the effects of bucillamine and salazosulfapyridine in the treatment of rheumatoid arthritis. ( Abe, M; Kinoshita, M; Nakajima, M; Ohara, H; Ueda, N, 2009) |
| " We enrolled patients with early rheumatoid arthritis (symptom duration <1 year) and administered methotrexate (up to 20 mg per week)." | 5.14 | Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. ( Akre, F; Bratt, J; Chatzidionysiou, A; Cöster, L; Dackhammar, C; Ernestam, S; Forslind, K; Geborek, P; Hellström, H; Ljung, L; Oding, R; Petersson, IF; Teleman, A; Theander, J; Thörner, A; van Vollenhoven, RF; Waltbrand, E; Wörnert, M; Zickert, A, 2009) |
| "To compare the benefits and side effects of TwHF extract with those of sulfasalazine for the treatment of active rheumatoid arthritis." | 5.14 | Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial. ( Costello, R; Csako, G; Fleischmann, R; Goldbach-Mansky, R; Kempf, P; Kivitz, A; Lipsky, PE; Olsen, N; Pham, TH; Pucino, F; Sherrer, Y; Silverfield, J; Snyder, C; Tao, X; van der Heijde, D; Wesley, R; Wilson, M, 2009) |
| "To carry out a pilot study to investigate the effect of short-term oral probiotic administration on the metabolism of sulfasalazine (SSZ) in patients with rheumatoid arthritis (RA) stabilized on SSZ." | 5.14 | The effects of an orally administered probiotic on sulfasalazine metabolism in individuals with rheumatoid arthritis: a preliminary study. ( Fawcett, JP; Highton, J; Lee, HJ; Orlovich, DA; Schmierer, D; Stebbings, S; Waller, RD, 2010) |
| "To compare efficacy and tolerability of combined therapy with methotrexate (MTX), sulfasalazine (SSZ) and hydroxychloroquine (HCQ) with MTX-monotherapy in patients with rheumatoid arthritis (RA)." | 5.13 | [Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis]. ( Bochkova, AG; Bunchuk, NV; Gubar', EE, 2008) |
| "To prospectively determine the efficacy and safety of etanercept in combination with sulfasalazine (SSZ), hydroxychloroquine (HCQ), and gold in the treatment of rheumatoid arthritis (RA)." | 5.12 | Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis. ( Blakely, K; Fernandez, A; Haire, C; Leff, R; O'Dell, JR; Palmer, W; Petersen, K; Schned, E, 2006) |
| "To compare the efficacy and safety of etanercept and sulfasalazine, alone and in combination, in patients with active rheumatoid arthritis despite sulfasalazine treatment." | 5.12 | Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison. ( Codreanu, C; Combe, B; Fatenejad, S; Fiocco, U; Gaubitz, M; Geusens, PP; Kvien, TK; Pavelka, K; Sambrook, PN; Smolen, JS; Wajdula, J, 2006) |
| "Bucillamine (Buc) is a disease-modifying antirheumatic drug (DMARD) developed in Japan, which has been used as one of the first-line DMARDs for the treatment of rheumatoid arthritis (RA) in Japan." | 5.12 | Efficacy profile of bucillamine in rheumatoid arthritis patients in a large observational cohort study, IORRA. ( Hara, M; Inoue, E; Iwatani, M; Kamatani, N; Nakajima, A; Nakamura, T; Tomatsu, T; Yamanaka, H, 2006) |
| "We conducted a 28-week, randomized, double-blind, parallel-group study of iguratimod in 376 Japanese patients with active rheumatoid arthritis to compare the efficacy and safety of the drug with those of placebo and salazosulfapyridine." | 5.12 | Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study. ( Abe, T; Hara, M; Hashimoto, H; Hoshi, K; Irimajiri, S; Matsui, N; Mizushima, Y; Nakano, S; Nobunaga, M; Sugawara, S; Yoshino, S, 2007) |
| "To determine the efficacy of subsequent disease modifying antirheumatic drug (DMARD) therapies after initial methotrexate (MTX) failure in patients with recent onset rheumatoid arthritis (RA), treated according to the DAS for 2 years." | 5.12 | Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score. ( Allaart, CF; Breedveld, FC; de Vries-Bouwstra, JK; Dijkmans, BA; Gerards, AH; Goekoop-Ruiterman, YP; Hazes, JM; Kerstens, PJ; van der Kooij, SM; van Groenendael, JH; van Zeben, D, 2007) |
| "In the Finnish Rheumatoid Arthritis Combination Therapy trial, 195 patients with recent-onset RA were randomly assigned to receive either combination therapy with DMARDs (sulfasalazine, methotrexate, hydroxychloroquine) plus prednisolone or single therapy with a DMARD with or without prednisolone." | 5.11 | Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial. ( Blåfield, H; Hakala, M; Hannonen, P; Julkunen, H; Kautiainen, H; Korpela, M; Leirisalo-Repo, M; Luukkainen, R; Möttönen, T; Paimela, L; Puolakka, K; Vuori, K, 2004) |
| "Progression of radiographic damage and association of radiographic damage and genetic predisposition were compared in two cohorts, one treated according to the delayed treatment strategy (initial treatment with analgesics), the other treated according to the early treatment strategy (treatment with disease modifying antirheumatic drugs (DMARDs) chloroquine or sulfasalazine)." | 5.11 | Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis. ( Breedveld, FC; Hazes, JM; Huizinga, TW; Lard, LR; le Cessie, S; van Aken, J, 2004) |
| "To evaluate the effect of low dose oral prednisolone in early rheumatoid arthritis on disease activity over two years." | 5.11 | Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. ( Capell, HA; Hampson, R; Hunter, JA; Larkin, J; Madhok, R; Morrison, E; Poon, FW; Porter, D; Thomson, EA, 2004) |
| "In the Finnish Rheumatoid Arthritis Combination Therapy trial, 195 patients with recent-onset RA were randomized to receive either a combination of disease-modifying antirheumatic drugs (DMARDs) with prednisolone or a single DMARD with or without prednisolone for 2 years." | 5.11 | Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. ( Ahonen, J; Forsberg, S; Hakala, M; Hannonen, P; Järvinen, P; Kautiainen, H; Korpela, M; Leirisalo-Repo, M; Möttönen, T; Puolakka, K, 2005) |
| "To compare the efficacy of combination therapy with methotrexate (MTX) and hydroxychloroquine (HCQ), MTX and sulfasalazine (SSZ), and MTX, HCQ, and SSZ in patients with rheumatoid arthritis (RA)." | 5.10 | Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. ( Blakely, K; Churchill, M; Eckhoff, PJ; Felt, J; Fernandez, A; Hadley, S; Haire, C; Klassen, L; Leff, R; Mallek, J; Moore, G; O'Dell, JR; Palmer, W; Paulsen, G; Stoner, J; Waytz, P; Wees, S, 2002) |
| "To evaluate whether early combined therapy with methotrexate (MTX) and sulfasalazine (SSZ) during the first year in early rheumatoid arthritis (RA) induces long term beneficial effects, compared with monotherapy, when the further treatment strategy is a free choice." | 5.10 | Long term structural effects of combination therapy in patients with early rheumatoid arthritis: five year follow up of a prospective double blind controlled study. ( Cantagrel, A; Combe, B; Dougados, M; Goupille, P; Maillefert, JF, 2003) |
| "The intent of this study was to assess the effect of low-dose methotrexate treatment on bone mineral density (BMD) in patients with early rheumatoid arthritis (RA)." | 5.10 | The effect of low-dose methotrexate on bone mineral density in patients with early rheumatoid arthritis. ( Armagan, O; Oner, C; Tascioglu, F, 2003) |
| "The Combinatietherapie Bij Reumatoide Artritis (COBRA) trial demonstrated that step-down combination therapy with prednisolone, methotrexate, and sulfasalazine (SSZ) was superior to SSZ monotherapy for suppressing disease activity and radiologic progression of rheumatoid arthritis (RA)." | 5.10 | COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. ( Boers, M; Boonen, A; Dijkmans, BA; Jacobs, P; Landewé, RB; Markusse, HM; Peeters, AJ; van de Laar, MA; van Denderen, JC; van der Heijde, DM; van der Linden, S; Verhoeven, AC; Westedt, ML; Westhovens, R, 2002) |
| "In the FIN-RACo (FINnish Rheumatoid Arthritis Combination therapy) trial, 195 patients with recent-onset RA (median duration 6 months) were randomly assigned to receive either 1) a combination of DMARDs (sulfasalazine, methotrexate, hydroxychloroquine, and prednisolone) or 2) a single DMARD with or without prednisolone." | 5.10 | Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. ( Franzen, P; Gripenberg-Gahmberg, M; Hannonen, P; Helve, T; Ilonen, J; Kaipiainen-Seppänen, O; Kautiainen, H; Korpela, M; Koski, J; Laasonen, L; Leirisalo-Repo, M; Möttönen, T; Myllykangas-Luosujärvi, R; Nissilä, M, 2002) |
| "To determine the effects of treatment with sulfasalazine (SSZ) or the combination of methotrexate (MTX) and SSZ on serum matrix metalloproteinase 3 (MMP-3) levels in patients with early rheumatoid arthritis (RA)." | 5.10 | Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis. ( Limburg, PC; Posthumus, MD; van Leeuwen, MA; van Rijswijk, MH; Westra, J, 2002) |
| "To determine the effect of methotrexate (MTX) on bone mineral density (BMD) in rheumatoid arthritis (RA)." | 5.10 | Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density. ( Beresford, JN; Bhalla, AK; Compston, JE; Kounali, D; Minaur, NJ; Vedi, S, 2002) |
| "Phase II trials of leflunomide, an inhibitor of de-novo pyrimidine synthesis, have shown efficacy in rheumatoid arthritis." | 5.09 | Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. ( Kalden, JR; Kvien, TK; Larsen, A; Loew-Friedrich, I; Oed, C; Rosenburg, R; Rozman, B; Scott, DL; Smolen, JS, 1999) |
| "The aim of the study was to assess the efficacy of a new formulation of cyclosporin-A (CyA) and sulfasalazine (SASP) combination treatment in preventing disability and reducing inflammatory disease activity in patients with early rheumatoid arthritis, as well as to assess the tolerability, safety, and suitability for long-term treatment." | 5.09 | Cyclosporin and sulfasalazine combination in the treatment of early rheumatoid arthritis. ( Bálint, G; Hodinka, L; Molnár, E; Rojkovich, B; Szegedi, G; Szilágyi, M; Szocsik, K; Tamási, L; Varjú, T, 1999) |
| "To evaluate the efficacy and safety of additive triple disease modifying anti-rheumatic drug (DMARD) combination therapy of a low dose of sulfhydryl compounds ¿D-penicillamine, bucillamine or tiopronin¿, sulfasalazine (SSZ) and methotrexate (MTX) as a treatment for rheumatoid arthritis (RA) patients, we studied a total of 33 Japanese RA patients (6 males, 27 females)." | 5.09 | Additive triple DMARD combination therapy of a low dose of sulfhydryl compounds, sulfasalazine and methotrexate in the treatment of rheumatoid arthritis: a clinical trial. ( Hashimoto, K; Hisakawa, N; Ito, H; Matsumori, A; Nakatani, K; Nishiya, K; Tahara, K; Takatori, K, 1999) |
| "To determine whether a regimen of methotrexate, cyclosporin A, and corticosteroids introduced at onset in poor-prognosis rheumatoid arthritis (RA) can produce a significant improvement in outcome compared with standard monotherapy with sulfasalazine (SSZ)." | 5.09 | Treatment of poor-prognosis early rheumatoid arthritis. A randomized study of treatment with methotrexate, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone. ( Adebajo, A; Conaghan, PG; Emery, P; Gough, A; Green, MJ; Griffiths, B; Helliwell, P; Huston, G; Isaacs, J; Martin, M; McGonagle, D; Miles, S; Pease, C; Proudman, SM; Reece, RJ; Richardson, C; van der Heijde, DM; Veale, DJ; Wakefield, RJ, 2000) |
| "Radiographic disease progression with leflunomide and sulfasalazine treatment was assessed in rheumatoid arthritis patients in a double-blind trial that was placebo controlled for the first 6 months." | 5.09 | Slowing of disease progression in rheumatoid arthritis patients during long-term treatment with leflunomide or sulfasalazine. ( Kvien, TK; Larsen, A; Oed, C; Rau, R; Rosenburg, R; Rozman, B; Schattenkirchner, M; Scott, DL; Smolen, JS; Tikly, M; Westhovens, R, 2001) |
| "We previously reported that the new disease modifying antirheumatic drug leflunomide resulted in significant improvement in functional ability compared with placebo and sulfasalazine in a 6 month double blind, randomized, Phase III trial in rheumatoid arthritis (RA)." | 5.09 | Improved functional ability in patients with rheumatoid arthritis--longterm treatment with leflunomide versus sulfasalazine. European Leflunomide Study Group. ( Jones, P; Kalden, JR; Kvien, TK; Oed, C; Rosenburg, R; Rozman, B; Schattenkirchner, M; Scott, DL; Smolen, JS; Williams, BD; Williams, RB, 2001) |
| "358 patients with rheumatoid arthritis in a double blind trial were randomly allocated to receive either leflunomide 20 mg/day, placebo, or sulfasalazine 2 g/day." | 5.09 | Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. ( Kalden, JR; Kvien, TK; Larsen, A; Loew-Friedrich, I; Nash, P; Oed, C; Schattenkirchner, M; Scott, DL; Smolen, JS; van de Putte, LB, 2001) |
| "Between 1993 and 1995, 109 patients diagnosed with probable or definite rheumatoid arthritis of recent onset were initially treated with analgesics; if they had persistent active disease, they were treated subsequently with the disease-modifying drugs chloroquine or salazopyrine (delayed treatment)." | 5.09 | Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. ( Breedveld, FC; Hazes, JM; Lard, LR; Speyer, I; vander Horst-Bruinsma, IE; Visser, H; Zwinderman, AH, 2001) |
| "Data analysis from a randomized clinical trial with 155 rheumatoid arthritis (RA) patients; median age 50 yr, early and active disease (diagnosis < 2 yr); one group treated with a combination of sulphasalazine (SSZ; 2000 mg/day), methotrexate (MTX; 7." | 5.09 | Bone turnover, joint damage and bone mineral density in early rheumatoid arthritis treated with combination therapy including high-dose prednisolone. ( Boers, M; Geusens, P; Markusse, HM; te Koppele, JM; van der Laan, WH; van der Linden, S; Verhoeven, AC, 2001) |
| "Long term treatment of 190 cases of rheumatoid arthritis with either methotrexate or salazosulfapyridine was analyzed for their efficacy and adverse effects." | 5.08 | [Methotrexate and salazosulfapyridine in the long-term treatment of rheumatoid arthritis]. ( Ichikawa, Y; Kameda, H; Kawai, S; Matsuda, T; Shinozawa, T; Suzuki, Y; Yamada, H; Yoshida, T, 1995) |
| "In a recent study from our group, the combination of methotrexate and sulphasalazine (MTX + SASP) seemed superior to MTX alone in the treatment of rheumatoid arthritis (RA)." | 5.08 | Effect of methotrexate alone or in combination with sulphasalazine on the production and circulating concentrations of cytokines and their antagonists. Longitudinal evaluation in patients with rheumatoid arthritis. ( Barrera, P; Boerbooms, AM; Borm, GF; Haagsma, CJ; Van de Putte, LB; Van der Meer, JW; Van Riel, PL, 1995) |
| "In patients with rheumatoid arthritis, combination therapy with methotrexate, sulfasalazine, and hydroxychloroquine is more effective than either methotrexate alone or a combination of sulfasalazine, and hydroxychloroquine." | 5.08 | Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. ( Drymalski, W; Eckhoff, PJ; Erikson, N; Garwood, V; Haire, CE; Klassen, LW; Klein, H; Maloley, P; Moore, GF; O'Dell, JR; Palmer, W; Wees, S, 1996) |
| " The influence of sulphasalazine (SASP) on the pharmacokinetics of low dose methotrexate (MTX) and the relation between pharmacokinetic variables and clinical response was studied in 15 patients with active rheumatoid arthritis despite > 6 months of SASP treatment." | 5.08 | Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and relationship to clinical response. ( Haagsma, CJ; Russel, FG; Van de Putte, LB; Van Riel, PL; Vree, TB, 1996) |
| "To determine the safety and therapeutic potential of sulfasalazine (SSZ) in the treatment of a large cohort of patients with juvenile rheumatoid arthritis (JRA)." | 5.08 | Sulfasalazine therapy for juvenile rheumatoid arthritis. ( Imundo, LF; Jacobs, JC, 1996) |
| "To compare results of medium to longterm sulfasalazine and auranofin treatment in active rheumatoid arthritis (RA)." | 5.08 | Sulfasalazine has a better efficacy/toxicity profile than auranofin--evidence from a 5 year prospective, randomized trial. ( Capell, HA; McEntegart, A; Porter, D; Thomson, EA, 1996) |
| "To compare the efficacy of sulphasalazine, methotrexate, and the combination of both in patients with early rheumatoid arthritis (RA), not treated with disease-modifying anti-rheumatic drugs previously, we conducted a double-blind, double-dummy, controlled, clinical trial." | 5.08 | Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. ( de Jong, AJ; Haagsma, CJ; van de Putte, LB; van Riel, PL, 1997) |
| "The scheme 'Combination therapy in rheumatoid arthritis' (COBRA) in early rheumatoid arthritis (RA) involves administration of not only sulfasalazine but also prednisolone and methotrexate during the first six months." | 5.08 | [Combination therapy in early rheumatoid arthritis: the COBRA study]. ( Boers, M; van der Linden, S; Verhoeven, AC, 1997) |
| "Assessment of the cost-effectiveness and cost-utility of early intervention in rheumatoid arthritis (RA) patients, with combined step-down prednisolone, methotrexate and sulphasalazine, compared to sulphasalazine alone." | 5.08 | Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. COBRA Trial Group. Combinatietherapie Bij Reumat ( Bibo, JC; Boers, M; Engel, GL; van der Linden, S; Verhoeven, AC, 1998) |
| "To investigate the efficacy and tolerability of sulfasalazine (SSZ) in the treatment of early rheumatoid arthritis (RA)." | 5.07 | Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study. ( Hakola, M; Hannonen, P; Möttönen, T; Oka, M, 1993) |
| "To compare the effects of hydroxychloroquine and sulphasalazine alone and in combination in rheumatoid arthritis." | 5.07 | Hydroxychloroquine and sulphasalazine alone and in combination in rheumatoid arthritis: a randomised double blind trial. ( Egsmose, C; Faarvang, KL; Hansen, TM; Ingeman-Nielsen, M; Kryger, P; Pødenphant, J, 1993) |
| "One hundred and five patients with a diagnosis of early nonerosive rheumatoid arthritis (RA) were randomized to receive enteric coated sulfasalazine as Salazopyrin En-tabs or placebo for 6 months." | 5.07 | Sulfasalazine in early rheumatoid arthritis. The Australian Multicentre Clinical Trial Group. ( , 1992) |
| "Eighty-six patients with rheumatoid arthritis treated with sulfasalazine were followed for 5 years, or until treatment was discontinued." | 5.07 | Response to sulfasalazine in rheumatoid arthritis: life table analysis of a 5-year followup. ( Jones, E; Jones, JV; Woodbury, JF, 1991) |
| "Sulfasalazine (SLZ) is now a second-line treatment in rheumatoid arthritis (RA), as well as in psoriatic arthritis and ankylosing spondylitis." | 5.07 | [Sulfasalazine in rheumatoid arthritis]. ( Caspi, D; Fluser, D; Gedz, D; Horowitz, I; Rubinov, A; Scharf, Y; Segal, R; Shapira, D; Sukenik, S; Weinberger, A, 1991) |
| "An attempt was made to audit the clinical usefulness of sulphasalazine and penicillamine in patients with rheumatoid arthritis (RA) managed in a routine out-patient setting with assistance from general practitioners and to ascertain whether clinically significant differences can be shown between these two 'second-line' agents." | 5.06 | Degree and extent of response to sulphasalazine or penicillamine therapy for rheumatoid arthritis: results from a routine clinical environment over a two-year period. ( Capell, HA; Hunter, JA; Madhok, R; Marabani, M; Torley, H, 1990) |
| "Response to sulfasalazine was studied for 1 year in 45 patients with rheumatoid arthritis." | 5.06 | A one-year, open, prospective study of sulfasalazine in the treatment of rheumatoid arthritis: adverse reactions and clinical response in relation to laboratory variables, drug and metabolite serum levels, and acetylator status. ( Chalmers, IM; Hunter, T; Sitar, DS, 1990) |
| "The authors tested the therapeutic effectiveness and tolerance of the sulphonamide chemotherapeutic preparation sulfasalazine in 69 patients with active rheumatoid arthritis." | 5.06 | [Results of a clinical trial of sulfasalazine in rheumatoid arthritis]. ( Gatterová, J; Macek, J; Pelísková, Z; Trnavský, K, 1989) |
| "The effects of hydroxychloroquine and sulphasalazine on progression of joint damage shown by X-rays were compared in a double-blind, randomised trial in 60 patients with rheumatoid arthritis not previously treated with slow-acting antirheumatic drugs." | 5.06 | Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. ( Gribnau, FW; Nuver-Zwart, IH; vad de Putte, LB; van der Heijde, DM; van Riel, PL, 1989) |
| "Fifty-four patients with rheumatoid arthritis were randomized to either sulphasalazine or D-penicillamine in order to compare the short- and long-term efficacy of these two agents in the treatment of rheumatoid arthritis." | 5.06 | Sulphasalazine versus penicillamine in the treatment of rheumatoid arthritis. ( Breidahl, PD; Carroll, GJ; Tinsley, LM; Will, RK, 1989) |
| "In a double blind, single observer, 48 week study the effects of sulphasalazine (2 g daily) and hydroxychloroquine (400 mg daily months 0-6, thereafter 200 mg daily) were compared in 60 patients with definite or classical rheumatoid arthritis." | 5.06 | A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazine. ( Gribnau, FW; Nuver-Zwart, IH; van de Putte, LB; van Riel, PL, 1989) |
| "Sulfasalazine (SSZ), 3 gm daily, was compared with placebo for treatment of rheumatoid arthritis, in a 15-week randomized, parallel, double-blind trial." | 5.06 | Sulfasalazine in rheumatoid arthritis. A double-blind, placebo-controlled trial. ( Hepburn, B; Kaplan, SB; Lawson, JG; Pinals, RS, 1986) |
| "Twenty-six out-patients with active rheumatoid arthritis (RA) were randomly allocated to treatment with sulphasalazine (SASP) or D-penicillamine (DPA)." | 5.06 | Effects of sulphasalazine on faecal flora in patients with rheumatoid arthritis: a comparison with penicillamine. ( Cooke, EM; Neumann, VC; Shinebaum, R; Wright, V, 1987) |
| "One hundred eight-six patients with active rheumatoid arthritis were evaluated in a double-blind, randomized study that compared treatment with sulfasalazine (SSZ) (2 mg/day), gold sodium thiomalate (GST) (50 mg/week), and placebo (PBO)." | 5.06 | A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis. ( Clegg, DO; Dahl, SL; Luggen, ME; Michaels, RM; Oglesby, T; Schlegel, S; Ward, JR; Weisman, MH; Williams, HJ; Willkens, RF, 1988) |
| "Thirty-one patients with chronic active rheumatoid arthritis (RA) resistant to gold and/or penicillamine therapy, were treated with sulfasalazine, 2-3 g daily, in a 12-week open study." | 5.05 | Sulfasalazine in severe rheumatoid arthritis: a study to assess potential correlates of efficacy and toxicity. ( Chalmers, IM; Hunter, T; Martin, L; Sitar, DS, 1985) |
| "Pulsed methylprednisolone (PMP) has been shown to produce clinical improvement and reduction in the ESR and acute phase protein concentrations in patients with active rheumatoid arthritis and has been advocated for use either as an alternative to slow-acting antirheumatoid drugs (SAARDs) or in conjunction with SAARDs to accelerate the response to treatment." | 5.05 | Combination therapy with pulsed methylprednisolone in rheumatoid arthritis. ( Bird, H; Dixon, J; Hopkins, R; Neumann, V; Watkins, A; Wright, V, 1985) |
| "To evaluate the efficacy of the triple synthetic Disease Modifying Anti-Rheumatic Drugs (sDMARD) combination methotrexate, sulfasalazine and hydroxychloroquine versus a biologic DMARD (bDMARD) in the treatment of early rheumatoid arthritis." | 4.95 | Efficacy of triple association methotrexate, sulfasalazine and hydroxychloroquine in early treatment of rheumatoid arthritis with insufficient response to methotrexate: Meta-analysis of randomized controlled trials. ( Baillet, A; Bernard, AC; Clay, M; Gaudin, P; Mazouyès, A, 2017) |
| "A great body of evidence suggest that hydroxychloroquine, sulfasalazine, and non-fluorinated steroids can be continued throughout pregnancy, while methotrexate and leflunomide should be discontinued 3 months before pregnancy." | 4.93 | Challenges and treatment options for rheumatoid arthritis during pregnancy. ( Gerosa, M; Meroni, PL; Schioppo, T, 2016) |
| "This is a case of a 65-year-old man with seropositive erosive rheumatoid arthritis (RA), well controlled on methotrexate, sulfasalazine, low-dose prednisolone and monthly infusions of tocilizumab." | 4.89 | C reactive protein may not be reliable as a marker of severe bacterial infection in patients receiving tocilizumab. ( Bari, SF; Khan, A; Lawson, T, 2013) |
| " The earlier use of methotrexate and the introduction of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis have changed the natural characteristics of the disease." | 4.87 | [Systemic autoimmune disorders and pregnancy]. ( Kiss, CG; Kiss, E; Poór, G, 2011) |
| "Efficacy and safety of anti-tumor necrosis factor (TNF) antagonists (infliximab, etanercept, adalimumab) in combination with methotrexate for rheumatoid arthritis is well determined." | 4.84 | [Effective combination therapy of TNF antagonists with DMARDs]. ( Matsuda, T; Ohtsubo, H, 2007) |
| " This review of clinical studies shows that leflunomide is clinically efficacious and well tolerated when added to either sulfasalazine or MTX, as both an initial and ongoing treatment for rheumatoid arthritis (RA)." | 4.82 | Lefunomide in combination therapy. ( Breedveld, FC; Dougados, M; Emery, P; Kalden, JR; Smolen, JS; Strand, CV; van Riel, PL, 2004) |
| " We report a case in a 63-year-old woman who had been on sulfasalazine for 2 months to treat rheumatoid arthritis." | 4.82 | DRESS syndrome in a patient on sulfasalazine for rheumatoid arthritis. ( Ferraud, D; Michel, F; Navellou, JC; Toussirot, E; Wendling, D, 2005) |
| "Sulfasalazine (salazosulfapyridine) [Azulfidine, Salazopyrin] is a well established disease-modifying antirheumatic drug (DMARD) used in the treatment of patients with rheumatoid arthritis." | 4.82 | Sulfasalazine: a review of its use in the management of rheumatoid arthritis. ( Croom, KF; Plosker, GL, 2005) |
| "Because of radiographic evidence of progressive bone loss and the inability to eliminate synovial proliferation with methotrexate, it became apparent that therapy for rheumatoid arthritis needed further advancement." | 4.81 | Rational use of new and existing disease-modifying agents in rheumatoid arthritis. ( Kremer, JM, 2001) |
| "New treatments, such as leflunomide and biologic therapy, are making an important impact on the management of rheumatoid arthritis." | 4.81 | Advances in the medical management of rheumatoid arthritis. ( Scott, DL, 2002) |
| "Combination therapy with methotrexate may be the newest standard to which future therapies for rheumatoid arthritis are compared." | 4.80 | Rheumatoid arthritis: new developments in the use of existing therapies. ( O'Dell, JR; Scott, DL, 1999) |
| " The efficacy of these two therapeutics has been proven in rheumatoid arthritis, but with a short-term though remnant effect, leading to iterative injections and/or combinations with methotrexate." | 4.80 | [Role of anti-TNF therapy in rheumatoid arthritis]. ( Meyer, O, 2000) |
| "To estimate the short-term efficacy and toxicity of sulfasalazine for the treatment of rheumatoid arthritis (RA)." | 4.80 | Sulfasalazine for rheumatoid arthritis. ( Belseck, E; Shea, B; Suarez-Almazor, ME; Tugwell, P; Wells, G, 2000) |
| "To summarize the evidence on treatment withdrawal rates reported in observational studies and randomized controlled trials (RCTs) of methotrexate (MTX), parenteral gold (GST), sulphasalazine (SSZ) and hydroxychloroquine (HCQ) among patients with rheumatoid arthritis (RA)." | 4.80 | Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. ( Bombardier, C; Maetzel, A; Strand, V; Tugwell, P; Wells, G; Wong, A, 2000) |
| " Large placebo-controlled studies of both sulfasalazine and hydroxychloroquine have been reported and have demonstrated the efficacy of these agents in the treatment of early rheumatoid arthritis." | 4.79 | Disease-modifying antirheumatic drugs, including methotrexate, gold, antimalarials, and D-penicillamine. ( Brooks, P; Conaghan, PG, 1995) |
| "I wished to review the pharmacology and current clinical experience with the combination of methotrexate and sulfasalazine as a management for rheumatoid arthritis." | 4.79 | Combination sulfasalazine and methotrexate in the management of rheumatoid arthritis. ( Shiroky, JB, 1996) |
| "We report the use of granulocyte-macrophage colony stimulating factor (GM-CSF) in a case of rheumatoid arthritis with sulfasalazine induced agranulocytosis, leading to a rapid bone marrow recovery within 7 days." | 4.78 | Sulfasalazine induced agranulocytosis treated with granulocyte-macrophage colony stimulating factor. ( de Wolf, JT; Hazenberg, BP; Kuipers, EJ; Vellenga, E, 1992) |
| "Sulfasalazine has been used for a decade in the United Kingdom for treating rheumatoid arthritis." | 4.77 | Adverse reactions to sulfasalazine: the British experience. ( Dacre, JE; Scott, DL, 1988) |
| "Methotrexate (MTX) is recommended as a first-line conventional synthetic disease-modifying antirheumatic drug (csDMARD) for treating rheumatoid arthritis (RA)." | 4.31 | Iguratimod versus salazosulfapyridine in rheumatoid arthritis patients with an inadequate response to methotrexate: Adjusted with propensity score matching. ( Fukuda, K; Funahashi, K; Hayashi, S; Itami, T; Kinoshita, K; Kuroda, R; Maeda, T; Matsubara, T; Matsumura, I; Nozaki, Y; Oribe, M; Tomita, D, 2023) |
| " Tofacitinib is a Janus kinase inhibitor approved for treating rheumatoid arthritis and ulcerative colitis." | 4.31 | Tofacitinib for the treatment of inflammatory bowel disease-associated arthritis: two case reports. ( Haq, SA; Momen Majumder, MS; Rasker, JJ, 2023) |
| " Methotrexate (MTX), the anchor drug for RA treatment, is contraindicated during pregnancy." | 4.12 | Pregnancy outcomes in patients with rheumatoid arthritis who discontinue methotrexate treatment to conceive. ( Goto, Y; Kawahata, K; Kiyokawa, T; Nagafuchi, H; Ooka, S, 2022) |
| "Sulfasalazine has been widely used in treatment of rheumatoid arthritis and spondyloarthritis." | 4.12 | Adverse reaction profile of sulfasalazine and its persistence in chronic therapy of rheumatoid arthritis and spondyloarthritis: A multicentric observational study. ( David, R; Jayachandran, M; Koshy, V; Marwaha, V; Mithun, CB; Nair, AS; Padmanabhan, DS; Palatty, PL; Santhakumari, V; Singh, SK; Singhal, A; Suman, SK; Surendran, S; Tiwari, A; Yadav, P, 2022) |
| "To investigate the expression and roles of TAM (Tyro3/Axl/Mer) receptor tyrosine kinases (TK) in synovial fluid and synovial tissue of patients with rheumatoid arthritis (RA)." | 4.12 | Elevated expression of TAM receptor tyrosine kinase in synovial fluid and synovial tissue of rheumatoid arthritis. ( Bai, M; Hu, F; Su, Y; Xu, L; Xue, J; Yao, R; Zheng, L; Zhong, H; Zhu, H, 2022) |
| "To compare the real-life effectiveness of biologic therapy (a biologic disease-modifying antirheumatic drug plus methotrexate [MTX]) versus triple therapy (MTX plus sulfasalazine plus hydroxychloroquine/chloroquine) for sustained remission of rheumatoid arthritis (RA)." | 4.02 | Sustained Remission in Patients With Rheumatoid Arthritis Receiving Triple Therapy Compared to Biologic Therapy: A Swedish Nationwide Register Study. ( C Kapetanovic, M; Einarsson, JT; Geborek, P; Källmark, H; Nilsson, JÅ; Olofsson, T; Saxne, T, 2021) |
| " Here, we describe a case of tubercular osteomyelitis in an old fused hip of a patient with RA who received prednisolone, salazosulfapyridine (SASP), and low-dose methotrexate (MTX)." | 3.96 | Tuberculosis osteomyelitis in an old fused hip; activated by prednisolone, salazosulfapyridine, and low-dose methotrexate therapy in a patient with rheumatoid arthritis. ( Fukushi, JI; Ishitani, EI; Katsuki, I; Matsubara, H; Okada, F; Sonoda, Y, 2020) |
| "To evaluate the prophylactic effect of sulfasalazine against Pneumocystis jirovecii pneumonia (PJP) among rheumatoid arthritis (RA) patients." | 3.91 | Prophylactic effect of sulfasalazine against Pneumocystis pneumonia in patients with rheumatoid arthritis: A nested case-control study. ( Gosho, M; Nishino, J; Nunokawa, T; Shimada, K; Sugii, S; Tohma, S; Wagatsuma, Y; Yokogawa, N, 2019) |
| "Combination treatments for patients with rheumatoid arthritis (RA) with an inadequate response to methotrexate (MTX) alone include the addition of a tumor necrosis factor inhibitor (TNFi) or the addition of sulfasalazine (SSZ) and hydroxychloroquine to MTX (triple therapy)." | 3.91 | Low Persistence Rates in Patients With Rheumatoid Arthritis Treated With Triple Therapy and Adverse Drug Events Associated With Sulfasalazine. ( Cannon, GW; Curtis, JR; Erhardt, DP; Mikuls, TR; Sauer, BC; Teng, CC, 2019) |
| "To determine if the baseline presence of autoantibodies to peptidylarginine deiminase 4 (PAD4) predicts therapeutic response to biologic and conventional disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis (RA) in whom methotrexate (MTX) monotherapy was unsuccessful." | 3.91 | Association of Baseline Peptidylarginine Deiminase 4 Autoantibodies With Favorable Response to Treatment Escalation in Rheumatoid Arthritis. ( Cappelli, LC; Darrah, E; Mikuls, TR; O'Dell, JR; Rosen, A; Yu, F, 2019) |
| "To investigate the effects of hydroxychloroquine, sulfasalazine and methotrexate on ischemic stroke in patients with rheumatoid arthritis (RA)." | 3.88 | Methotrexate might reduce ischemic stroke in patients with rheumatoid arthritis: a population-based retrospective cohort study. ( Chen, CH; Chen, CM; Chiou, JY; Leong, PY; Li, YC; Lin, LC; Tam, HW; Wang, YH; Wei, JC, 2018) |
| " Patients treated with leflunomide had increases in BP and a greater risk of incident hypertension compared with patients treated with methotrexate (hazard ratio, 1." | 3.88 | Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis Is Associated With Changes in Blood Pressure. ( Baker, JF; Cannella, A; Cannon, GW; Caplan, L; Davis, LA; England, BR; George, M; Ibrahim, S; Michaud, K; Mikuls, TR; OʼDell, J; Sauer, B; Teng, CC, 2018) |
| "For patients with rheumatoid arthritis (RA) who have an inadequate response to methotrexate (MTX), the relative effectiveness of the combination of conventional disease-modifying antirheumatic drugs (DMARD) compared with the combination of tumor necrosis factor (TNF) inhibitors and MTX, as second-line therapy, is uncertain." | 3.85 | Triple Oral Therapy Versus Antitumor Necrosis Factor Plus Methotrexate (MTX) in Patients with Rheumatoid Arthritis and Inadequate Response to MTX: A Systematic Literature Review. ( Combe, B; De Bandt, M; Lukas, C; Mary, J; Morel, J, 2017) |
| "This study sought to investigate the genome-wide transcriptional effects of a combination of disease modifying anti-rheumatic drugs (tDMARD; methotrexate, sulfasalazine and hydroxychloroquine) in synovial tissues obtained from early rheumatoid arthritis (RA) patients." | 3.85 | Triple DMARD treatment in early rheumatoid arthritis modulates synovial T cell activation and plasmablast/plasma cell differentiation pathways. ( Guo, Y; Nagpal, S; Proudman, SM; Smith, MD; Walsh, AM; Wechalekar, MD; Weedon, H; Yin, X, 2017) |
| "Sulfasalazine is a commonly used drug for the treatment of rheumatoid arthritis and inflammatory bowel disease." | 3.85 | Sulfasalazine induces mitochondrial dysfunction and renal injury. ( Abdoli, N; Asadi, B; Azarpira, N; Heidari, R; Khodaei, F; Mohammadzadeh, R; Najibi, A; Niknahad, H; Ommati, MM; Rasti, M; Saeedi, A; Shirazi Yeganeh, B; Taheri, V; Zarei, M, 2017) |
| "To compare persistence and adherence to triple therapy with the nonbiologic disease-modifying antirheumatic drugs (DMARDs) methotrexate (MTX), hydroxychloroquine, and sulfasalazine, versus a tumor necrosis factor inhibitor (TNFi) plus MTX in patients with rheumatoid arthritis (RA)." | 3.85 | Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis. ( Cannon, GW; Curtis, JR; Harrison, DJ; Leng, J; Mikuls, TR; Sauer, BC; Tang, D; Teng, CC, 2017) |
| "Sulfasalazine has long been used for the treatment of rheumatoid arthritis and is often chosen as a first-line treatment." | 3.85 | Sulfasalazine induced immune thrombocytopenia in a patient with rheumatoid arthritis. ( Carlucci, F; Narayan, N; Rigby, S, 2017) |
| "Combination treatment with methotrexate, salazosulfapyridine and bucillamine as an alternative to treatment with TNF-inhibiting biologics in rheumatoid arthritis was investigated." | 3.83 | The usefulness of a new triple combination treatment utilizing methotrexate, salazosulfapyridine, and bucillamine in rheumatoid arthritis. ( Abe, C; Funahashi, K; Katayama, K; Kondo, M; Matsubara, T; Matsuno, H; Okada, M; Sagawa, A; Sakai, Y; Yamasaki, K, 2016) |
| "To compare the risk of incident hypertension between initiators of tumor necrosis factor (TNF)-α inhibitors and initiators of nonbiologic disease modifying antirheumatic drugs (hereafter referred to as nonbiologics) in rheumatoid arthritis patients taking methotrexate monotherapy." | 3.83 | Tumor Necrosis Factor-α Inhibitor Use and the Risk of Incident Hypertension in Patients with Rheumatoid Arthritis. ( Danaei, G; Desai, RJ; Kim, SC; Liao, KP; Schneeweiss, S; Solomon, DH, 2016) |
| "Several trials suggest that triple therapy (methotrexate, sulfasalazine, and hydroxychloroquine) and biologic disease-modifying antirheumatic drugs (DMARDs) have similar efficacy in patients with rheumatoid arthritis (RA)." | 3.83 | Brief Report: Intensification to Triple Therapy After Treatment With Nonbiologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis in the United States From 2009 to 2014. ( Brill, G; Choudhry, NK; Krumme, AA; Matlin, OS; Pezalla, EJ; Shrank, WH; Solomon, DH; Sparks, JA, 2016) |
| " Sulfasalazine (SSZ), a drug used in the treatment of rheumatoid arthritis (RA), inhibits glutamate-cystine transport, and suppressed CD44v-dependent tumor growth and increased sensitivity to cytotoxic drugs in an in vivo study." | 3.83 | Potential of sulfasalazine as a therapeutic sensitizer for CD44 splice variant 9-positive urogenital cancer. ( Kubo, T; Morikawa, A; Morita, T; Nagano, O; Saya, H; Takayama, T, 2016) |
| "The aim of this study was to assess the impact of low dose of methotrexate on bone mineral density (BMD) in patients with early rheumatoid arthritis (RA)." | 3.83 | The Impact of Low-Dose Disease-modifying Anti-rheumatics Drugs (DMARDs) on Bone Mineral Density of Premenopausal Women in Early Rheumatoid Arthritis. ( Boshnjaku, S; Mahmutaj, V; Rexhepi, M; Rexhepi, S; Sahatçiu-Meka, V, 2016) |
| "To develop a population model describing the disease activity (DAS28) time course in patients with early rheumatoid arthritis (RA) treated with triple disease-modifying anti-rheumatic drug (DMARD) therapy (methotrexate, sulfasalazine and hydroxychloroquine)." | 3.81 | A population model of early rheumatoid arthritis disease activity during treatment with methotrexate, sulfasalazine and hydroxychloroquine. ( Foster, DJ; Proudman, SM; Upton, RN; Wiese, MD; Wojciechowski, J, 2015) |
| "To estimate adherence and persistence with etanercept plus methotrexate (ETN-MTX) combination therapy and MTX, hydroxychloroquine, and sulfasalazine triple therapy at 1 year following treatment initiation in adults with rheumatoid arthritis (RA)." | 3.81 | Etanercept-Methotrexate Combination Therapy Initiators Have Greater Adherence and Persistence Than Triple Therapy Initiators With Rheumatoid Arthritis. ( Bonafede, M; Collier, DH; Harrison, DJ; Johnson, BH; Shah, N; Tang, DH, 2015) |
| "A young woman thought to have seronegative rheumatoid arthritis developed Stevens-Johnson syndrome after treatment with sulfasalazine; this resolved with prednisone." | 3.79 | Giant cell myocarditis in a patient with a spondyloarthropathy after a drug hypersensitivity reaction. ( Cooper, LT; Davies, RA; Grenon, J; Mesana, TG; Mielniczuk, LM; Mitoff, PR; Veinot, JP, 2013) |
| "Although etanercept (ETN) is effective when used in monotherapy for the treatment of rheumatoid arthritis (RA), ETN/methotrexate (MTX) combination therapy is more efficacious." | 3.78 | Etanercept in combination with conventional disease-modifying antirheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis patients intolerant to methotrexate. ( Koyama, Y; Ohta, T; Shiraishi, H; Uchino, A, 2012) |
| "Methotrexate is the most commonly used drug to treat rheumatoid arthritis." | 3.77 | In vitro risk assessment of AZD9056 perpetrating a transporter-mediated drug-drug interaction with methotrexate. ( Butters, C; Elsby, R; Fox, L; Layton, M; Sharma, P; Smith, V; Stresser, D; Surry, D, 2011) |
| "Despite the availability of several new agents for the treatment of rheumatoid arthritis (RA), sulfasalazine remains the mainstay because of both cost and experience with its use." | 3.75 | The effect of 677C>T and 1298A>C MTHFR polymorphisms on sulfasalazine treatment outcome in rheumatoid arthritis. ( Drozdzik, M; Dziedziejko, V; Gawronska-Szklarz, B; Gornik, W; Juzyszyn, Z; Kurzawski, M; Pawlik, A; Safranow, K, 2009) |
| "The Combinatietherapie Bij Reumatoide Artritis (COBRA) trial has proved that combination therapy with prednisolone, methotrexate and sulphasalazine is superior to sulphasalazine monotherapy in suppressing disease activity and radiological progression of early rheumatoid arthritis (RA)." | 3.74 | Why are Dutch rheumatologists reluctant to use the COBRA treatment strategy in early rheumatoid arthritis? ( Boers, M; Dijkmans, BA; Lems, WF; Plass, AM; van Tuyl, LH; Voskuyl, AE, 2007) |
| "A 58-year-old woman with rheumatoid arthritis (RA) developed fever, skin eruptions, leukocytopenia, and thrombocytopenia, 3 weeks after treatment with sulfasalazine." | 3.74 | Sulfasalazine-induced hypersensitivity syndrome and hemophagocytic syndrome associated with reactivation of Epstein-Barr virus. ( Hatakeyama, T; Komatsuda, A; Okamoto, Y; Sawada, K; Wakui, H, 2008) |
| "To study genetic polymorphisms in the folate pathway, a site of action of methotrexate (MTX) and sulfasalazine (SSZ), as predictors of efficacy of combination disease modifying antirheumatic drug (DMARD) regimens containing MTX and SSZ in early rheumatoid arthritis (RA)." | 3.74 | Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis. ( Cleland, LG; Gillis, D; Hissaria, P; James, HM; Lester, S; Proudman, SM; Somogyi, AA, 2008) |
| "To determine whether improvements in physical function and health related quality of life (HRQOL) are sustained over 2 years of blinded treatment with leflunomide (LEF), methotrexate (MTX), or sulfasalazine (SSZ) in patients with active rheumatoid arthritis (RA)." | 3.73 | Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. ( Cannon, GW; Crawford, B; Emery, P; Kalden, JR; Scott, DL; Smolen, JS; Strand, V; Tugwell, P, 2005) |
| "To study which factors are associated with longterm methotrexate (MTX) use in rheumatoid arthritis (RA)." | 3.72 | Longterm observational study of methotrexate use in a Dutch cohort of 1022 patients with rheumatoid arthritis. ( Bernelot Moens, HJ; Haagsma, CJ; Hoekstra, M; Kruijsen, MW; van de Laar, MA, 2003) |
| "To investigate whether interactions of sulfasalazine (SSZ) with reduced folate carrier (RFC), the dominant cell membrane transporter for natural folates and methotrexate (MTX), may limit the efficacy of combination therapy with MTX and SSZ in patients with rheumatoid arthritis." | 3.72 | Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications for combination therapies with methotrexate in rheumatoid arthritis. ( Assaraf, YG; Dijkmans, BA; Ifergan, I; Jansen, G; Lems, WF; Oerlemans, R; Scheper, RJ; van der Heijden, J, 2004) |
| " Our recent studies revealed the relationship between genetic polymorphisms of drug metabolizing enzymes and the efficacy of methotrexate or sulfasalazine in patients with rheumatoid arthritis, suggesting pharmacogenetics is applicable to the treatment of rheumatoid arthritis." | 3.71 | [Pharmacogenetics of disease modifying anti-rheumatic drugs]. ( Akama, H; Kamatani, N; Tanaka, E; Taniguchi, A; Urano, W; Yamanaka, H, 2002) |
| "Methotrexate (MTX) is one of the disease modifying antirheumatic drugs (DMARD) commonly used to treat rheumatoid arthritis (RA)." | 3.71 | Conventional DMARD options for patients with a suboptimal response to methotrexate. ( O'Dell, J, 2001) |
| "A severe systemic reaction to sulfasalazine developed in a 21-year old female with rheumatoid arthritis characterized by eosinophilia, granulomatous enteritis and myelotoxicity, cholestatic hepatitis, and seizures." | 3.71 | Is it Crohn's disease? A severe systemic granulomatous reaction to sulfasalazine in patient with rheumatoid arthritis. ( Fontana, RJ; Greenson, J; Haftel, HM; Quallich, LG, 2001) |
| "The case history is described of an elderly man with rheumatoid arthritis receiving treatment with sulfasalazine and the cyclooxygenase-2 inhibitor celecoxib who presented with severe shortness of breath, cough, and decreased exercise tolerance." | 3.71 | Migratory pulmonary infiltrates in a patient with rheumatoid arthritis. ( Aranda, CP; Cassai, N; Mehandru, S; Sidhu, GS; Smith, RL, 2002) |
| "To compare the impact of leflunomide on resource utilization and costs relative to that of etanercept and infliximab among patients with rheumatoid arthritis (RA) in a managed care setting." | 3.71 | Impact of leflunomide versus biologic agents on the costs of care for rheumatoid arthritis in a managed care population. ( Doyle, J; Huse, DM; Ollendorf, DA; Peterson, AN, 2002) |
| "New treatment options for patients with methotrexate (MTX)-naive rheumatoid arthritis (RA) have become available." | 3.71 | A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis. ( Choi, HK; Kuntz, KM; Seeger, JD, 2002) |
| "In this study we report our two years experience of methotrexate (MTX) in the management of rheumatoid arthritis (RA) at the Aga Khan University Hospital, Karachi." | 3.70 | Methotrexate in rheumatoid arthritis: a 2 year experience at a university hospital in Pakistan. ( Ali, AA; Beg, JA; Hussain, MA; Iqbal, MP; Mehboobali, N; Rahbar, MH, 1998) |
| " We describe a patient with rheumatoid arthritis (RA) treated with methotrexate (MTX), sulfasalazine, and low dose corticosteroids, whose case was seriously complicated by the occurrence of acute febrile pancytopenia." | 3.70 | Pancytopenia secondary to hemophagocytic syndrome in rheumatoid arthritis treated with methotrexate and sulfasalazine. ( Albert, A; Cazenave, JP; Javier, RM; Kuntz, JL; Sibilia, J, 1998) |
| "To study the long-term efficacy and safety of methotrexate (MTX), intramuscular gold, azathioprine (AZA), chloroquine (CQ), sulphasalazine (SASP), and D-penicillamine (DPA) in rheumatoid arthritis (RA) patients." | 3.70 | Long-term application of disease modifying antirheumatic drugs (DMARD). A single-center, observational study of 1681 patients with rheumatoid arthritis (RA). ( Keysser, C; Keysser, G; Keysser, M, 1999) |
| "To examine whether different combinations of disease-modifying anti-rheumatic drugs (DMARDs), including bucillamine (BUC), gold sodium thiomalate (GST), methotrexate (MTX), salazosulphapyridine (SASP) and dexamethasone (DEX; a steroid), act by inhibiting the production of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in cultured synoviocytes, causing a decrease in their serum concentrations in patients with rheumatoid arthritis (RA)." | 3.70 | Effects of combinations of anti-rheumatic drugs on the production of vascular endothelial growth factor and basic fibroblast growth factor in cultured synoviocytes and patients with rheumatoid arthritis. ( Aono, H; Hirano, D; Ishigami, S; Nagashima, M; Sasano, M; Takai, M; Wauke, K; Yoshino, S, 2000) |
| "We investigated the in vitro immunomodulatory effects of sulfasalazine on B cells in rheumatoid arthritis (RA)." | 3.69 | Effect of sulfasalazine on B cell hyperactivity in patients with rheumatoid arthritis. ( Akiyama, Y; Dohi, Y; Imai, F; Ishibashi, T; Suzuki, T; Tanaka, M, 1994) |
| "We describe the case of a 46-year-old woman with rheumatoid arthritis who developed a severe reaction to sulfasalazine, characterized by dysphasia, seizures, rash and the development of strongly positive pANCA (perinuclear antineutrophil cytoplasmic antibodies)." | 3.69 | Sulfasalazine induced seizures and dysphasia. ( Gordon, C; Heath, DA; Hill, ME; Situnayake, RD, 1994) |
| "We describe 2 cases of a lupus syndrome induced by sulfasalazine in rheumatoid arthritis." | 3.69 | Sulfasalazine induced lupus in rheumatoid arthritis. ( Andrieu, V; Caulier, M; Dromer, C; Fournie, B; Le Guennec, P, 1994) |
| "Patients with rheumatoid arthritis who did not respond sufficiently to auranofin therapy were divided into three groups to be continued on auranofin monotherapy (1), to be on combination therapy of auranofin and salazosulfapyridine (2) and to be given methotrexate concomitantly with auranofin (3), and clinical responses were compared in a prospective manner." | 3.69 | [Study on combined of auranofin, salazosulfapyridine and methotrexate in rheumatoid arthritis]. ( Akizuki, M; Fujii, T; Mimori, T; Suwa, A; Yosida, T, 1994) |
| "To analyze whether the intestinal mucosa in rheumatoid arthritis (RA) is immunologically abnormal and whether sulfasalazine (SSZ) possesses any local intestinal immunoregulatory effect." | 3.69 | Evidence of a local intestinal immunomodulatory effect of sulfasalazine in rheumatoid arthritis. ( Hafström, I; Kanerud, L; Scheynius, A, 1994) |
| "To identify the source of intestinal blood loss in rheumatoid arthritis patients being treated with nonsteroidal antiinflammatory drugs (NSAIDs) and assess the response to sulfasalazine and other disease-modifying antirheumatic drugs (DMARDs)." | 3.69 | Nonsteroidal antiinflammatory drug-induced small intestinal inflammation and blood loss. Effects of sulfasalazine and other disease-modifying antirheumatic drugs. ( Bjarnason, I; Gumpel, M; Hayllar, J; Macpherson, A; Price, AB; Smith, T, 1994) |
| "140 rectal mucosa biopsies were obtained from 86 patients with rheumatoid arthritis (RA), from 54 RA patients prior to or after a year basic therapy with either methotrexate or sulfa drug (sulfasalazine or salazopyridazine)." | 3.69 | [The effect of basic therapy on the morphological picture of the rectal mucosa in patients with rheumatoid arthritis]. ( Frizen, BN; Panchenko, KI; Vinogradov, IuN, 1995) |
| "The aim of the study was to evaluate the effects of treatment with methotrexate, sulphasalazine and aurothiomalate on polymorphonuclear leucocytes (PMN) in rheumatoid arthritis (RA)." | 3.69 | Effects of methotrexate, sulphasalazine and aurothiomalate on polymorphonuclear leucocytes in rheumatoid arthritis. ( Anderson, PL; Jensen, MP; Møller, BK; Obel, N; Stengaard-Pedersen, K; Storgaard, M, 1996) |
| "In an attempt to estimate the frequency of folate deficiency and haemolysis in a group of 25 outpatients with arthritis treated with sulphasalazine (SASP), haematological measurements, including plasma total homocysteine (tHcy) which is a sensitive marker of folate deficiency, serum folate (S-folate), erythrocyte (RBC) folate, S-cobalamin and routine indices of haemolysis were performed." | 3.69 | Folate and homocysteine status and haemolysis in patients treated with sulphasalazine for arthritis. ( Ekelund, S; Krogh Jensen, M; Svendsen, L, 1996) |
| "Sulfasalazine is widely used in rheumatoid arthritis and inflammatory bowel diseases." | 3.69 | Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity. ( Pruzanski, W; Ramamurthy, NS; Stefanski, E; Vadas, P, 1997) |
| "Sulfasalazine is an efficient treatment for rheumatoid arthritis (RA), but its mode of action is not known." | 3.68 | Variation in the serum IgA concentration and the production of IgA in vitro in rheumatoid arthritis treated by sulfasalazine. ( Anaya, JM; Bologna, C; Jorgensen, C; Reme, T; Sany, J, 1993) |
| "In a retrospective analysis a total of 167 patients with rheumatoid arthritis (RA) who had been treated with the basic therapy formulas of methotrexate (MTX) or sulfasalazine (SUL) were evaluated with respect to therapeutical result and side effects after a period of 12 months." | 3.68 | [Basic therapy of rheumatoid arthritis. Comparison of methotrexate and sulfasalazine]. ( Keitel, R; Keitel, W; Pap, T, 1993) |
| "The interaction between sulphasalazine and cimetidine has been studied, a drug combination which is quite likely in view of the higher incidence of peptic ulceration in patients with RA." | 3.68 | Lack of interaction between sulphasalazine and cimetidine in patients with rheumatoid arthritis. ( Breckenridge, AM; Bucknall, RC; Coleman, MD; Galvani, D; Park, BK; Pirmohamed, M, 1993) |
| " In this report we present a patient with an erosive seropositive rheumatoid arthritis developing the clinical and serological features of systemic lupus erythematosus including the occurrence of double-stranded DNA antibodies under sulfasalazine treatment." | 3.68 | Drug-related lupus in a patient with rheumatoid arthritis under sulfasalazine treatment. ( Deicher, H; Hammer, M; Hartung, K; Mau, W; Schmidt, RE; Wildhagen, K; Zeidler, H, 1993) |
| "The pharmacokinetic disposition of sulfasalazine and its metabolites was studied in 8 young and 12 elderly patients with active rheumatoid arthritis." | 3.68 | The effect of age and acetylator phenotype on the pharmacokinetics of sulfasalazine in patients with rheumatoid arthritis. ( McDermott, BJ; Roberts, SD; Taggart, AJ, 1992) |
| "The effects of sulfasalazine (SASP) and its metabolites sulfapyridine (SP) and 5-aminosalicylic acid (5-ASA) were investigated on release of prostaglandins (PG) and leukotrienes (LT) from synovial tissue of 37 patients with osteoarthritis, chondrocalcinosis and rheumatoid arthritis." | 3.68 | [Effect of sulfasalazine and its metabolites on prostaglandin and leukotriene liberation from human synovial tissue]. ( Kleemeyer, K; Peskar, BA; Peskar, BM; Wittenberg, HR, 1991) |
| "From the analysis of literature and first-hand data on methylprednisolone pulse-therapy for rheumatoid arthritis (RA) the conclusion is made that such therapy produces a rapid and pronounced though short-term effect on the disease activity." | 3.68 | [Clinical notes about methylprednisolone pulse-therapy in patients with rheumatoid arthritis]. ( Fomina, LL, 1991) |
| "A female patient with IgM RF seropositive rheumatoid arthritis according to criteria of the American Rheumatism Association was treated for 133 months with Penicillamine and for 17 months also with Sulfasalazine." | 3.68 | [Rheumatoid arthritis developing into systemic lupus erythematosus during long-term treatment with penicillamine and sulfasalazine]. ( Hrncír, Z; Pintérová, E; Rejchrt, S, 1991) |
| "A 56 year old woman with rheumatoid arthritis developed relapsing thrombocytopenia during successive treatments with aurothioglucose, sulphasalazine, and hydroxychloroquine." | 3.68 | Thrombocytopenia due to aurothioglucose, sulphasalazine, and hydroxychloroquine. ( Allebes, WA; Boerbooms, AM; van de Putte, LB; van Riel, PL; Wijnands, MJ, 1990) |
| "Seven clinical and laboratory indices of disease activity were compared with serum vitamin B12 levels in 32 patients with rheumatoid arthritis treated with penicillamine (16 patients) or sulphasalazine (16 patients) for up to 24 weeks." | 3.67 | Rheumatoid arthritis: is serum vitamin B12 high in active disease? ( Calverley, M; Cox, C; Grindulis, KA, 1984) |
| "The outcome of attempts to continue treatment indefinitely with either gold, penicillamine, sulphasalazine, or dapsone was studied in 240 patients with rheumatoid arthritis (RA)." | 3.67 | Outcome of attempts to treat rheumatoid arthritis with gold, penicillamine, sulphasalazine, or dapsone. ( Grindulis, KA; McConkey, B, 1984) |
| "The long term efficacy and tolerability of sulphasalazine (SASP) in the treatment of 21 patients with active classical or definite rheumatoid arthritis (RA) were examined and compared with the effects of penicillamine in a similarly active group of RA patients." | 3.67 | The long term effects of sulphasalazine in the treatment of rheumatoid arthritis and a comparative study with penicillamine. ( Bacon, PA; Crockson, AP; Farr, M; Tunn, E, 1984) |
| "Four patients with rheumatoid arthritis received a combination of methotrexate and sulfasalazine for a mean of 24 months (range 20-28 months)." | 3.67 | Combination methotrexate and sulfasalazine in the management of rheumatoid arthritis: case observations. ( Neville, C; Shiroky, JB; Watts, CS, 1989) |
| "A patient with rheumatoid arthritis and collagenous colitis apparently responding to sulfasalazine and prednisolone enemas is reported." | 3.67 | Collagenous colitis: possible response to sulfasalazine and local steroid therapy. ( Farah, DA; Lee, FD; McLay, A; Mills, PR; Russell, RI, 1985) |
| "Serum amyloid A protein (SAA), serum C-reactive protein (CRP) and the ESR were measured in 19 patients with rheumatoid arthritis before treatment and during therapy with gold, penicillamine or sulphasalazine for a mean period of 14." | 3.67 | Serum amyloid A protein during the treatment of rheumatoid arthritis with second-line drugs. ( Bacon, PA; Grindulis, KA; McConkey, B; Robinson, MW; Scott, DL, 1985) |
| "Groups of 15 patients with active rheumatoid arthritis have been treated with sulphasalazine, (salazosulfapyridine INN), zinc sulfate, captopril or methyl cysteine, and assessed by seven clinical measurements and six laboratory methods on eight occasions during a 24-week treatment period." | 3.67 | Biochemical and clinical changes occurring during the treatment of rheumatoid arthritis with novel antirheumatoid drugs. ( Bird, HA; Dixon, JS; Martin, MF; McKenna, F; Wright, V, 1985) |
| "The clinical outcome of rheumatoid arthritis patients treated long term with sulphasalazine or parenteral gold was studied." | 3.67 | Sulphasalazine in the long term management of rheumatoid arthritis. ( Amos, RS; Bax, DE, 1986) |
| "Thirty patients (22 women) with active rheumatoid arthritis participated in an open study of 6 months' treatment with either enteric-coated sulphasalazine (SASP) or SASP plus D-penicillamine (DPA)." | 3.67 | Sulphasalazine alone or in combination with D-penicillamine in rheumatoid arthritis. ( Astbury, C; Bird, HA; Dixon, JS; Hill, J; Taggart, AJ; Wright, V, 1987) |
| "A 55-year-old woman with rheumatoid arthritis in overlap with polymyositis received sulfasalazine for control of synovitis." | 3.67 | Cholestasis and fatal agranulocytosis complicating sulfasalazine therapy: case report and review of the literature. ( Mitrane, MP; Seibold, JR; Singh, A, 1986) |
| "Life-table analysis was applied to the records of 317 patients with rheumatoid arthritis (RA) treated with sulphasalazine (SAS), 201 treated with sodium aurothiomalate (gold), and 163 with penicillamine." | 3.67 | Long-term treatment of rheumatoid arthritis with sulphasalazine, gold, or penicillamine: a comparison using life-table methods. ( Grindulis, KA; McConkey, B; Situnayake, RD, 1987) |
| "Despite the extensive use of sulfasalazine (SAS) and/or 5-aminosalicylic acid (5-ASA) in patients with inflammatory bowel disease and, more recently, rheumatoid arthritis, their mode of action has not been elucidated so far." | 3.67 | Possible mode of action of 5-aminosalicylic acid. ( Dreyling, KW; Goebell, H; May, B; Peskar, BM; Schaarschmidt, K, 1987) |
| "Sulfasalazine is now an established 2nd line agent in the treatment of rheumatoid arthritis (RA) but its mode of action is unknown." | 3.67 | Sulfasalazine treatment and lymphocyte function in patients with rheumatoid arthritis. ( Bacon, PA; Farr, M; Salmon, M; Symmons, DP, 1988) |
| "We assessed the in vitro effects of sulfasalazine and its 2 main metabolites, sulfapyridine (SP) and 5-aminosalicylic acid (5-ASA) on functional aspects of peripheral blood lymphocytes (PBM) of normal controls and patients with rheumatoid arthritis (RA)." | 3.67 | In vitro immunomodulatory effects of sulfasalazine and its metabolites. ( Comer, SS; Jasin, HE, 1988) |
| "Forty-two patients with active rheumatoid arthritis treated with hydroxychloroquine sulphate (400 mg day-1) for six months have been compared with patients treated with D-penicillamine (n = 14), aurothiomalate (n = 13), sulphasalazine (n = 15) and chloroquine (n = 17) to compare the changes in articular index, plasma viscosity and ESR." | 3.67 | How reliable is ESR as a measure of disease activity in rheumatoid arthritis treated with hydroxychloroquine? ( Bird, HA; Dixon, JS; Greenwood, M, 1988) |
| "Sulfasalazine was synthesized almost 50 years ago specifically to treat rheumatoid arthritis." | 3.67 | History of enteric coated sulfasalazine in rheumatoid arthritis. ( Pinals, RS, 1988) |
| "Cross-sectional and longitudinal studies have been carried out to determine the incidence and clinical significance of eosinophilia in patients taking penicillamine for rheumatoid arthritis." | 3.66 | Eosinophilia in D-penicillamine therapy. ( Scott, DL; Smith, DH; Zaphiropoulos, GC, 1983) |
| " Secondary outcomes will include the incremental cost per reducing 1 case of relapse; patient reported intolerance to the treatment; adverse events; change of mean disease activity measured by DAS28, clinical disease activity index (CDAI) and simplified disease activity index (SDAI); the proportion of modified Sharp score increase < 0." | 3.01 | The efficacy, safety and cost-effectiveness of hydroxychloroquine, sulfasalazine, methotrexate triple therapy in preventing relapse among patients with rheumatoid arthritis achieving clinical remission or low disease activity: the study protocol of a rand ( Ji, P; Wu, Y; Yan, X; Yang, L; Zhang, Z; Zhao, J; Zhou, W, 2021) |
| "A total of 170 patients who had been treated for rheumatoid arthritis at our hospital from August 2016 and June 2018, were enrolled as research objects." | 2.90 | Observation of the clinical effect of the combined therapy of zushima tablet and western medicine in the treatment of rheumatoid arthritis and MRI test results. ( Ji, H; Sun, Q; Tang, Z, 2019) |
| " Adverse events (AEs) were reported in 114/122 (93." | 2.87 | Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients. ( Harigai, M; Hsu, B; Kato, Y; Nakano, T; Takeuchi, T; Tamamura, R; Tanaka, Y; Ukyo, Y; Yamanaka, H, 2018) |
| "The main aim of this study was to examine the differences between triple therapy (T: SSZ and HCQ added to MTX) and etanercept (E) added to MTX with regard to the infectious and gastrointestinal (GI) adverse events (AEs) reported in The Rheumatoid Arthritis Comparison of Active Therapies Trial." | 2.84 | Rheumatoid arthritis triple therapy compared with etanercept: difference in infectious and gastrointestinal adverse events. ( Brophy, MT; Chang, BH; Hannagan, K; O'Dell, JR; Quach, LT; Soe Thwin, S, 2017) |
| "To evaluate the efficacy and safety of orally administered once-daily peficitinib in combination with limited conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in patients with moderate-to-severe rheumatoid arthritis (RA)." | 2.84 | Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis. ( Cardiel, MH; Codding, C; Garg, JP; Genovese, MC; Greenwald, M; Kivitz, AJ; Shay, K; Wang, A; Wang, X; Zubrzycka-Sienkiewicz, A, 2017) |
| "Early treatment of rheumatoid arthritis (RA) has been shown to retard the development of joint damage for a period of up to 5 years." | 2.75 | Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial. ( Blåfield, H; Hannonen, P; Järvenpää, S; Karjalainen, A; Kautiainen, H; Korpela, M; Laasonen, L; Leirisalo-Repo, M; Möttönen, T; Puolakka, K; Rantalaiho, V, 2010) |
| "Sulfasalazine treatment was not found effective on enthesal abnormalities of IRD patients." | 2.73 | The effects of sulfasalazine treatment on enthesal abnormalities of inflammatory rheumatic diseases. ( Duyur Cakit, B; Erdem, HR; Genc, H; Kacar, M; Nacir, B; Saracoglu, M, 2007) |
| "Sulfasalazine was most frequently withdrawn (30%)." | 2.73 | Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use. ( Ayres, OC; Caughey, GE; Cleland, LG; Goldblatt, F; Hill, CL; James, MJ; Keen, HI; Lee, AT; Proudman, SM; Rischmueller, M; Stamp, LK, 2007) |
| " More patients completed the first year without unplanned DMARD changes and without dosage adjustment and fewer had DMARD changes due to side effects or inefficacy in the step-down group compared with step-up, whereas the number of adverse events was comparable." | 2.73 | Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis. ( Esselens, G; Verschueren, P; Westhovens, R, 2008) |
| "5 months) were randomized to receive step-up therapy (sulfasalazine [SSZ] monotherapy, then after 3 months, methotrexate [MTX] was added, and when the maximum tolerated dosage of MTX was reached, hydroxychloroquine [HCQ] was added) or parallel triple therapy (SSZ/MTX/HCQ)." | 2.73 | Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. ( Capell, HA; Kincaid, W; McMahon, AD; Porter, DR; Saunders, SA; Stirling, A; Vallance, R, 2008) |
| "Rheumatoid arthritis is a chronic, systemic inflammatory disease that carries an increased risk of mortality due to cardiovascular disease." | 2.72 | Cardiac Dysfunction in Rheumatoid Arthritis: The Role of Inflammation. ( Chen, J; Cooper, D; Norling, LV, 2021) |
| "Oral prednisolone was required by 63 patients." | 2.69 | Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. ( Ahonen, J; Blåfield, H; Forsberg, S; Friman, C; Hakala, M; Hakola, M; Hannonen, P; Ilva, K; Järvinen, P; Julkunen, H; Kautiainen, H; Koota, K; Korpela, M; Laasonen, L; Leirisalo-Repo, M; Luukkainen, R; Möttönen, T; Nissilä, M; Paimela, L; Pälvimäki, I; Piirainen, H; Puolakka, K; Vuori, K; Yli-Kerttula, U, 1999) |
| "Nausea was the most frequent side effect: 32%, 23%, 49% in the SASP, MTX, and SASP + MTX groups respectively (p = 0." | 2.69 | Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. ( Cantagrel, A; Combe, B; Dougados, M; Goupille, P; Leirisalo-Repo, M; Meusser, S; Olive, P; Paimela, L; Peldan, K; Rau, R; Schattenkirchner, M; Zeidler, H, 1999) |
| " The frequency and nature of adverse effects and changes in clinical and laboratory parameters of disease activity were measured after three and six months." | 2.68 | Low dose desensitisation does not reduce the toxicity of sulphasalazine in rheumatoid arthritis. ( Capell, HA; Hunter, JA; Madhok, R; McInnes, IB; Murphy, EA; Porter, D; Pullar, T; Thomson, EA, 1996) |
| " The elimination half-life of sulphasalazine was prolonged in the elderly whilst renal clearance was increased in slow acetylators at 'steady-state'." | 2.66 | The pharmacokinetics of sulphasalazine in young and elderly patients with rheumatoid arthritis. ( Ahnfelt, NO; Delargy, M; Elborn, S; Forbes, J; McDermott, B; Roberts, SD; Taggart, AJ, 1987) |
| "Nausea was the major side effect in the sulphasalazine treated group." | 2.65 | Comparison between penicillamine and sulphasalazine in rheumatoid arthritis: Leeds-Birmingham trial. ( Grindulis, KA; Hubball, S; McConkey, B; Neumann, VC; Wright, V, 1983) |
| " The highest risk of infection is associated with corticosteroids depending on the dose, so that a dosage as low as possible but stable in the perioperative period is recommended." | 2.55 | [Perioperative management of immunosuppressive treatment in patients undergoing joint surgery]. ( Krüger, K, 2017) |
| " Therefore, we decided to decrease the TCZ dosage by 10-20% approximately." | 2.52 | Tocilizumab-induced neutropenia in rheumatoid arthritis patients with previous history of neutropenia: case series and review of literature. ( Langevitz, P; Shoenfeld, Y; Shovman, O, 2015) |
| " Methotrexate has better bioavailability as injection." | 2.52 | [Update on Current Care Guidelines. Rheumatoid Arthritis (RA)]. ( , 2015) |
| "The primary goal in the treatment of rheumatoid arthritis (RA) is to maintain good quality of life by preventing joint destruction and avoiding disability." | 2.48 | [ Bone and cartilage destruction in RA and its intervention. Disease-modifying antirheumatic drugs]. ( Ichikawa, N; Yamanaka, H, 2012) |
| "This paper reviews recent approaches to treatment of early rheumatoid arthritis (RA) with disease-modifying antirheumatic drugs (DMARDs)." | 2.44 | Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs. ( Sizova, L, 2008) |
| "Rheumatoid arthritis is an autoimmune rheumatic condition of unknown origin." | 2.44 | [New ways in the management of rheumatoid arthritis in Hungary]. ( Gergely, P; Poór, G, 2007) |
| "Early aggressive treatment of rheumatoid arthritis is associated with improved disease control, slower radiological progression and improved functional outcomes." | 2.44 | Combination therapy for rheumatoid arthritis: methotrexate and sulfasalazine together or with other DMARDs. ( Alcorn, N; Capell, H; Dale, J; Madhok, R, 2007) |
| "Rheumatoid arthritis is a chronic multi-system disorder of unknown etiology with most common symptoms being persistent inflammatory synovitis, usually involving peripheral joints in a symmetrical pattern." | 2.43 | Rheumatoid arthritis: an update. ( Derk, CT, 2005) |
| "Rheumatoid arthritis is characterized by chronic synovitis resulting in bone and joint destruction in various delays, and ultimately leading to handicap." | 2.43 | [Armentarium and strategies for the treatment of rheumatoid arthritis]. ( Lioté, F, 2005) |
| "Therefore, active treatment of rheumatoid arthritis is indispensable." | 2.43 | [Rational therapeutic approach in rheumatoid arthritis]. ( Tłustochowicz, W, 2006) |
| "Leflunomide(Arava) is a novel immunomodulatory drug, the primary action of which is inhibition of de-novo pyrimidine synthesis by selective inhibition of dihydro-orotate dehydrogenase." | 2.41 | [Efficacy of leflunomide]. ( Hirohata, S, 2002) |
| " Longterm safety assessment is difficult for a number of reasons: there are relatively few trials that have followed patients beyond 5 years and the use of a combination of DMARD therapy with nonsteroidal antiinflammatory drugs and corticosteroids complicates the assessment of an observed adverse event with a particular drug." | 2.41 | Disease modifying antirheumatic drugs: longterm safety issues. ( Capell, HA, 2001) |
| "That DMARDs are effective in treating rheumatoid arthritis is beyond question-just how effective they are and what combinations of DMARDs will show improved efficacy will provide data for the next annual review." | 2.40 | Disease-modifying antirheumatic drugs. ( Brooks, P; Conaghan, PG; Li, E, 1998) |
| "Sulfasalazine is an effective treatment for rheumatoid arthritis (RA), producing improvements in disease parameters similar to those seen with penicillamine, hydroxychloroquine or oral or parenteral gold in comparative clinical trials." | 2.39 | Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis. ( Faulds, D; Noble, S; Rains, CP, 1995) |
| "Sulphasalazine a drug used for the treatment of rheumatoid arthritis (RA) shows a wide range of biological activities all of which might contribute to the beneficial clinical effect seen during treatment of RA." | 2.39 | Sulphasalazine: mechanism of action in rheumatoid arthritis. ( Björk, J; Smedegård, G, 1995) |
| "Sulfasalazine is a prodrug which is enzymatically split in the bowel to form sulfapyridine (the principal active metabolite) and 5-aminosalicylic acid." | 2.39 | Disease-modifying antirheumatic drugs. Potential effects in older patients. ( Furst, DE; Gardner, G, 1995) |
| " Open non-randomised uncontrolled studies have shown that antimalarials combined with cytotoxic agents are effective but highly toxic." | 2.39 | The use of antimalarials in combination with other disease modifying agents in RA--the British experience. ( Capell, HA; Duncan, MR, 1996) |
| "The disease RA itself is assumed to be a risk factor for the occurrence of adverse drug reactions during sulphasalazine therapy." | 2.38 | Rheumatoid arthritis: a risk factor for sulphasalazine toxicity? A meta-analysis. ( Van 'T Hof, MA; Van De Putte, LB; Van Riel, PL; Wijnands, MJ, 1993) |
| "Rheumatoid arthritis is associated with abnormalities in macrophage, lymphocyte, and fibroblast functions." | 2.38 | Pharmacology of antiarthritic drugs. ( Boyce, E, 1992) |
| " Despite the relationship between dose and efficacy and a good correlation between dose and serum concentrations of sulphasalazine and its metabolites, no relationship has been demonstrated between efficacy and serum concentrations of sulphasalazine or its metabolites, although there is some suggestion that higher concentrations on single dosing are achieved in patients who develop upper gastrointestinal symptoms." | 2.37 | Variables affecting efficacy and toxicity of sulphasalazine in rheumatoid arthritis. A review. ( Capell, HA; Pullar, T, 1986) |
| "Collagenous colitis has been associated with rheumatoid arthritis in only a few cases." | 2.37 | Collagenous colitis and rheumatoid arthritis with response to sulfasalazine. A case report and review of the literature. ( Okon, E; Pollak, A; Stalnikowicz, R; Wengrower, D, 1987) |
| "Sulfasalazine use was associated with a decreased PCP risk (adjusted IRR <0." | 1.91 | Efficacy of sulfasalazine for the prevention of Pneumocystis pneumonia in patients with rheumatoid arthritis: A multicentric self-controlled case series study. ( Chen, FY; Chinen, N; Kimura, M; Nunokawa, T; Setoguchi, K; Shimada, K; Sugihara, M; Tateishi, M, 2023) |
| "However, whether hepatitis B affects treatment outcome remains unclear." | 1.48 | Disease Characteristics and Change in Arthritis Activity according to Treatment in Hepatitis B Surface Antigen-positive Rheumatoid Arthritis Patients: a Retrospective Chart Review Study. ( Cha, HS; Choi, MS; Eun, Y; Jeong, H; Kim, H; Kim, IY; Koh, E; Lee, J, 2018) |
| "Maximum glucose intolerance was observed in patients who were on Non-HCQ drug combinations." | 1.46 | Prevalence of glucose intolerance in rheumatoid arthritis patients at a tertiary care centre in Haryana. ( Dangi, A; Rajput, R; Singh, H, 2017) |
| "Sulfasalazine (SSZ), which has an arylamine sulfonamide structure, is an anti-inflammatory drug used in the treatment of many rheumatic diseases." | 1.46 | Sulfasalazine-Related Hypersensitivity Reactions in Patients With Rheumatic Diseases. ( Cildag, S; Senturk, T, 2017) |
| "Prednisone use was associated with a significantly increased risk of mortality in patients with RA." | 1.43 | Prednisone Use and Risk of Mortality in Patients With Rheumatoid Arthritis: Moderation by Use of Disease-Modifying Antirheumatic Drugs. ( Chester Wasko, M; Dasgupta, A; Fries, JF; Ilse Sears, G; Ward, MM, 2016) |
| "The aim of this study was to evaluate the effect of treatment with methotrexate (MTX), by itself or combined with other non-biological disease-modifying antirheumatic drugs (DMARDs) (methotrexate, MTX with prednisolone, MTX with leflunomide, MTX with chloroquine, and MTX with sulfasalazine) on clinimetric outcomes in a retrospective cohort with a 6-month follow-up and under a Treat to Target (T2T) approach." | 1.42 | Treatment of rheumatoid arthritis with methotrexate alone and in combination with other conventional DMARDs using the T2T strategy. A cohort study. ( Castro, C; de la Hoz-Valle, J; Palomino, A; Sánchez, G; Santos-Moreno, PI; Villarreal, L, 2015) |
| " Cessation of at least one of MTX, SSZ or HCQ occurred because of an adverse event in 38%, remission in 7% and incomplete response in 28% of patients." | 1.42 | Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis. ( Cummins, L; Duggan, E; Katikireddi, VS; Pahau, H; Shankaranarayana, S; Su, KY; Thomas, R; Videm, V, 2015) |
| "If SASP is initiated at a low dosage (≤ 500 mg) and increased up to 1000 mg under careful monitoring, it is safe for HD patients." | 1.40 | Retrospective study of salazosulfapyridine in eight patients with rheumatoid arthritis on hemodialysis. ( Akiyama, Y; Furuta, E; Kato, Y; Mimura, T; Sakurai, Y, 2014) |
| " Toxicity was defined by cessation of SSA due to adverse effects and response as remission after 12 months of treatment." | 1.40 | Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis. ( Alotaibi, N; Cleland, LG; O'Doherty, C; Proudman, SM; Sorich, MJ; Suppiah, V; Wiese, MD, 2014) |
| "Drug-based treatment of rheumatoid arthritis (RA) has evolved markedly over the past 2 decades." | 1.39 | The decline in joint replacement surgery in rheumatoid arthritis is associated with a concomitant increase in the intensity of anti-rheumatic therapy: a nationwide register-based study from 1995 through 2010. ( Hakala, M; Jämsen, E; Kauppi, MJ; Lehto, MU; Malmivaara, A; Virta, LJ, 2013) |
| "Our study showed that treatment of early rheumatoid arthritis with a combination regime of traditional DMARDs is highly effective in controlling disease activity as well as cardiovascular risk." | 1.39 | Early, structured disease modifying anti-rheumatic drug (DMARD) therapy reduces cardiovascular risk in rheumatoid arthritis--a single centre study using non-biologic drugs. ( Biswas, M; Chatterjee, S; Ghosh, A; Ghosh, S; Sarkate, P, 2013) |
| " We collected clinical information, including patient background, treatment efficacy (evaluated using the DAS score), and adverse events observed." | 1.38 | Single-center, retrospective analysis of efficacy and safety of tacrolimus as a second-line DMARD in combination therapy and the risk factors contributing to adverse events in 115 patients with rheumatoid arthritis. ( Amano, H; Kageyama, M; Kempe, K; Kusaoi, M; Matsudaira, R; Matsushita, M; Morimoto, S; Nawata, M; Ogasawara, M; Onuma, S; Sekiya, F; Tada, K; Takasaki, Y; Tamura, N; Toyama, S; Yamaji, K, 2012) |
| " Recent change in permitted maximum dosage of MTX from 8 to 16 mg/week may improve its efficacy and continuation rate in treating Japanese RA patients." | 1.38 | Recent trends in use of nonbiologic DMARDs and evaluation of their continuation rates in single and dual combination therapies in rheumatoid arthritis patients in Japan. ( Kageyama, M; Kempe, K; Kon, T; Kusaoi, M; Matsudaira, R; Matsushita, M; Ogasawara, M; Onuma, S; Sekiya, F; Sugimoto, K; Tada, K; Takasaki, Y; Tamura, N; Yamaji, K, 2012) |
| "Treatment with Sulfasalazine with and without methotrexate produced good response in 71." | 1.37 | Post-chikungunya chronic arthritis--our experience with DMARDs over two year follow up. ( Ganu, AS; Ganu, MA, 2011) |
| "Clarithromycin was continued a further two months until the patient quit on her own and." | 1.36 | [A cutaneous infection by Mycobacterium chelonae in a patient with rheumatoid arthritis]. ( Azevedo, F; Baudrier, T; Duarte, AF; Ferreira, O; Mota, A; Simões, JS, 2010) |
| "Rheumatoid arthritis is one of most common chronic diseases, and represents a high cost for the health system." | 1.35 | [Financial cost of early rheumatoid arthritis in the first year of medical attention: three clinical scenarios in a third-tier university hospital in Colombia]. ( Díaz, J; González, A; Mora, C; Quintana, G, 2009) |
| "Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are chronic, progressive, systemic inflammatory rheumatic diseases that lead to serious disability." | 1.35 | Characteristics and medical management of patients with rheumatoid arthritis and ankylosing spondylitis. ( Akbulut, L; Altay, Z; Ataman, S; Aydoğ, E; Bal, A; Bodur, H; Delialioğlu, SU; Evcik, D; Günaydin, R; Gürsoy, S; Kavuncu, V; Kaya, T; Kocabaş, H; Kotevoğlu, N; Kuran, B; Madenci, E; Olmez, N; Ozel, S; Uğurlu, H; Yazgan, P, 2008) |
| "Spontaneous reporting systems for adverse drug reactions (ADRs) are handicapped by under-reporting and limited detail on individual cases." | 1.35 | Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: A case series from a local surveillance of serious adverse events. ( Amarasena, R; Bowman, S; Filer, A; Homer, D; Jobanputra, P; Jubb, R; Maggs, F; Rankin, E; Raza, K, 2008) |
| "To assess the incidence and severity of disease modifying antirheumatic drug (DMARD)-induced adverse effects (AE) in patients with rheumatoid arthritis (RA) taking/not taking glucocorticoids (GC)." | 1.35 | Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs. ( Arnold, S; Baerwald, CG; Häntzschel, H; Malysheva, OA; Pierer, M; Wagner, U; Wahle, M, 2008) |
| "She was started on hemodialysis (HD) for chronic renal failure in 1996." | 1.32 | [Pharmacokinetics of salazosulfapyridine in a hemodialysis patient]. ( Akiyama, Y; Fujimaki, T; Sakurai, Y, 2003) |
| "Current dosing strategies should be re-evaluated, and coping strategies for common AEs should be investigated." | 1.32 | Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study. ( Aletaha, D; Eberl, G; Grisar, J; Kapral, T; Machold, KP; Smolen, JS; Stamm, T, 2003) |
| "Histopathologic diagnosis was bronchiolitis obliterans organizing pneumonia (BOOP)." | 1.32 | Bronchiolitis obliterans organizing pneumonia associated with sulfasalazine in a patient with rheumatoid arthritis. ( Apaydin, D; Aydin, O; Ozer, C; Ozgür, E; Sahin, G; Ulubaş, B, 2004) |
| "Secondary osteoporosis is a feature of rheumatoid arthritis (RA)." | 1.31 | The effects of sulphasalazine on urinary excretion of the hydroxypyridinium crosslinks of collagen in patients with rheumatoid arthritis. ( Alí, I; Dílek, K; Göksal, K; Güner, T; Hüseyin, T, 2002) |
| " Synovial tissue explants from RA patients secreted a decreased amount of the chemokines IL-8 and growth-related gene product alpha (GROalpha) when treated with SASP over a broad range of concentrations based on the typical clinical dosage of 2 g/day." | 1.31 | The effect of sulfasalazine on rheumatoid arthritic synovial tissue chemokine production. ( Campbell, PL; Connors, MA; Koch, AE; Volin, MV; Woodruff, DC, 2002) |
| "5-aminosalicylates are extensively prescribed for the treatment of ulcerative colitis but have a wide range of described adverse effects." | 1.31 | Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. ( Langman, MJ; Ransford, RA, 2002) |
| "To evaluate rates on the adverse side effect and discontinuation of second-line drugs frequently used in the treatment of rheumatoid arthritis (RA)." | 1.31 | [Retrospective study of adverse events in patients with rheumatoid arthritis treated with second-line drugs]. ( Jiang, L; Ni, L; Zhao, N, 2002) |
| "Treatment with sulfasalazine correlated positively with BMD at 3 of the 5 measured bone sites." | 1.31 | Bone mineral density in men with rheumatoid arthritis is associated with erosive disease and sulfasalazine treatment but not with sex hormones. ( Hafström, I; Tengstrand, B, 2002) |
| " We examine whether there was a correlation between diplotype configurations (combinations of 2 haplotypes for a subject) at the NAT2 gene and the adverse effects of SSZ used for the treatment of rheumatoid arthritis (RA)." | 1.31 | Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene. ( Kamatani, N; Kitamura, Y; Matsuda, Y; Nakajima, H; Saito, M; Saito, T; Tanaka, E; Taniguchi, A; Urano, W; Yamanaka, H, 2002) |
| "Cells were dosed with each compound for 24 h in the presence or absence of PMA inducer and messenger RNA (mRNA) extracted and subjected to Northern blot analysis." | 1.31 | Effects of sulfasalazine and its metabolites on steady state messenger RNA concentrations for inflammatory cytokines, matrix metalloproteinases, and tissue inhibitors of metalloproteinase in rheumatoid synovial fibroblasts. ( Blackburn, WD; Minghetti, PP, 2000) |
| "The development of systemic lupus erythematosus (SLE)-related syndromes during treatment with sulphasalazine has been described and demonstrated to be influenced by genetic factors." | 1.31 | Development of lupus-related side-effects in patients with early RA during sulphasalazine treatment-the role of IL-10 and HLA. ( Forslid, J; Gröndal, G; Gunnarsson, I; Hassan Bakri, A; Klareskog, L; Larsson, P; Nordmark, B; Ringertz, B, 2000) |
| "In addition to patients with RA or MCTD, focal sialadenitis also affects a very high proportion of patients with AS or SpA." | 1.31 | Focal sialadenitis in patients with ankylosing spondylitis and spondyloarthropathy: a comparison with patients with rheumatoid arthritis or mixed connective tissue disease. ( Helenius, I; Helenius, LM; Hietanen, JH; Kautiainen, H; Lappalainen, M; Leirisalo-Repo, M; Lindqvist, C; Paimela, L; Piirainen, H; Suuronen, R, 2001) |
| " The average dosage of MTX used was calculated to be 590 mg." | 1.31 | [The effect of low dose methotrexate treatment on bone mineral density in patients with rheumatoid arthritis]. ( Kita, K; Sierakowski, S, 2002) |
| " There is no evidence that the dosage of drugs metabolized by the CYP3A4 isoenzyme needs to be adjusted for disease activity in RA." | 1.30 | Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. ( Beyeler, C; Bird, HA; Frey, BM, 1997) |
| " The proportion of adverse events was lowest in group 1 (14%) and highest in groups 3 and 4 (25%)." | 1.30 | Toxicity profile of dual methotrexate combinations with gold, hydroxychloroquine, sulphasalazine and minocycline in rheumatoid arthritis patients. ( Caspi, D; Elkayam, O; Segal, R; Yaron, M; Zhukovsky, G, 1997) |
| "During the past few years the treatment of rheumatoid arthritis, the most frequent of the rheumatic inflammatory systemic diseases has improved a great deal." | 1.30 | [Rheumatoid arthritis. Conservative therapeutic possibilities today and in the future]. ( Aeschlimann, AG, 1998) |
| "The 'aggressive' drug treatment consisted of institution of relatively fast-acting disease-modifying anti-rheumatic drugs (DMARDs) (sulphasalazine, methotrexate) immediately after diagnosis, and rapid adjustment of dosage and/or drug in the case of insufficient response as measured by a change in C-reactive protein (CRP) level." | 1.30 | Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression. ( Barendsen, BC; Bruyn, GA; Houtman, PM; Speerstra, F; Stenger, AA; Van Leeuwen, MA; van Rijswijk, MH; Velthuysen, E, 1998) |
| " Adverse events occurred in 64% of all patients (highest 85% in AS and lowest 50% in ulcerative colitis, CU)." | 1.29 | Side effects of sulphasalazine in patients with rheumatic diseases or inflammatory bowel disease. ( Laasila, K; Leirisalo-Repo, M, 1994) |
| "Development of drug-induced systemic lupus erythematosus (SLE) is an uncommon complication of the use of D-penicillamine and sulphasalazine." | 1.29 | Combination therapy for rheumatoid arthritis and drug-induced systemic lupus erythematosus. ( Borg, AA; Davis, MJ; Dawes, PT; Shadforth, MF, 1994) |
| " Serious or fatal adverse reactions were not observed." | 1.29 | Toxicity of sulphasalazine in rheumatoid arthritis. Possible protective effect of rheumatoid factors and corticosteroids. ( Gran, JT; Myklebust, G, 1993) |
| "The long-term use of second-line antirheumatic drugs was prospectively studied in a consecutive sample of 245 patients with recently diagnosed rheumatoid arthritis." | 1.28 | Long-term second-line treatment: a prospective drug survival study. ( van de Putte, LB; van Leeuwen, MA; van Riel, PL; van Rijswijk, MH; van't Hof, MA; Wijnands, MJ, 1992) |
| "Neutropenia is a recognized complication of sulphasalazine therapy in patients with rheumatoid arthritis." | 1.28 | Fatal neutropenic enterocolitis associated with sulphasalazine therapy for rheumatoid arthritis. ( Chakravarty, K; McCann, BG; Scott, DG, 1992) |
| "This retrospective study evaluated treatment with sulfasalazine (SAS) in a mean dosage of 2." | 1.28 | [Therapeutic maintenance and tolerance of sulfasalazine in rheumatoid polyarthritis. Retrospective study of 95 patients]. ( Bardin, T; Chevret, S; Dryll, A; Kuntz, D; Lioté, F; Pertuiset, E, 1992) |
| "Three per cent developed selective IgA deficiency between 8 and 20 weeks after starting SASP." | 1.28 | Immunodeficiencies associated with sulphasalazine therapy in inflammatory arthritis. ( Bacon, PA; Farr, M; Kitas, GD; Tunn, EJ, 1991) |
| "Rheumatoid arthritis is being increasingly treated with sulphasalazine." | 1.28 | Fibrosing alveolitis due to sulphasalazine in a patient with rheumatoid arthritis. ( Boyd, O; Gibbs, AR; Smith, AP, 1990) |
| " We therefore assessed small intestinal and joint inflammation in patients with rheumatoid arthritis before and after three to nine months' treatment with sulphasalazine (n = 40) and other second line drugs (n = 20), while keeping the dosage of non-steroidal anti-inflammatory drug at the same level." | 1.28 | Treatment of non-steroidal anti-inflammatory drug induced enteropathy. ( Bjarnason, I; Gumpel, JM; Hopkinson, N; Levi, AJ; Prouse, P; Smethurst, P; Zanelli, G, 1990) |
| "GM-CSF treatment for severe agranulocytosis deserves further investigation." | 1.28 | Treatment of drug-induced agranulocytosis with recombinant GM-CSF. ( Jonson, B; Kanerud, L; Palmblad, J, 1990) |
| "Four with Felty's syndrome developed a further fall in the total WBC associated with thrombocytopenia in two." | 1.28 | Sulphasalazine in rheumatoid arthritis: haematological problems and changes in haematological indices associated with therapy. ( Bacon, PA; Farr, M; Scott, DG; Symmons, DP; Tunn, EJ, 1989) |
| " However, its safety profile is far superior, and very long-term treatment with sulphasalazine is a safe option for treatment of rheumatoid arthritis." | 1.27 | Sulphasalazine: a safe, effective agent for prolonged control of rheumatoid arthritis. A comparison with sodium aurothiomalate. ( Amos, RS; Bax, DE, 1985) |
| "Nausea was a frequent problem in patients taking SP." | 1.27 | A study to determine the active moiety of sulphasalazine in rheumatoid arthritis. ( Astbury, C; Bird, HA; Hill, J; Le Gallez, P; Neumann, VC; Taggart, AJ, 1986) |
| "Sulphasalazine is an effective treatment for rheumatoid arthritis but the response in any individual is unpredictable." | 1.27 | Sulphasalazine for rheumatoid arthritis: relationship between dose, acetylator phenotype and response to treatment. ( Amos, RS; Bax, DE; Greaves, MS, 1986) |
| " The incidence and nature of adverse effects occurring in 774 patients with rheumatoid arthritis treated with sulphasalazine for periods ranging from one to 11 years were therefore noted." | 1.27 | Sulphasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11 years. ( Amos, RS; Bax, DE; Capell, HA; McConkey, B; Pullar, T; Situnayake, D, 1986) |
| "The side effect profile of sulphasalazine was documented in 200 patients with inflammatory joint disease treated with the drug for at least 1 year." | 1.27 | Side effect profile of 200 patients with inflammatory arthritides treated with sulphasalazine. ( Bacon, PA; Farr, M; Scott, DG, 1986) |
| "Rheumatoid arthritis is a disorder that frequently can be controlled with a program of physical therapy, rest and therapeutic doses of aspirin or another nonsteroidal anti-inflammatory medication." | 1.27 | Slow-acting anti-rheumatic drug therapy for rheumatoid arthritis. ( Clegg, DO; Ward, JR, 1987) |
| "Of a large importance in the treatment of the rheumatoid arthritis and of the osteoarthrosis is the method of clinical tests of non-steroidal antirheumatic drugs and of the so-called disease-activity modifying substances." | 1.27 | [Drug treatment of rheumatoid arthritis and osteoarthritis]. ( Pavelka, K; Trnavský, K, 1987) |
| "Numerous drugs are available for the treatment of rheumatoid arthritis." | 1.27 | Rheumatoid arthritis: a pharmacologic overview. ( Pinals, RS, 1988) |
| " It prevents relapses, particularly if the dosage is increased." | 1.27 | Sulfasalazine: II. Some notes on the discovery and development of salazopyrin. ( Svartz, N, 1988) |
| "Rheumatoid arthritis is a multisystem disease, with many clinical forms bearing close resemblance to systemic lupus erythematosus, dermatomyositis or polyarteritis nodosa." | 1.26 | Cutaneous rheumatoid vasculitis. ( Stern, WK, 1979) |
| " Salazopyrin is variably and comparatively poorly absorbed in man." | 1.23 | Salicylazosulfapyridine (salazopyrin or azopyrin) in rheumatoid arthritis and experimental polyarthritis. ( GARDNER, GM; KUZELL, WC, 1950) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 159 (18.51) | 18.7374 |
| 1990's | 249 (28.99) | 18.2507 |
| 2000's | 219 (25.49) | 29.6817 |
| 2010's | 195 (22.70) | 24.3611 |
| 2020's | 37 (4.31) | 2.80 |
| Authors | Studies |
|---|---|
| Kedia, AK | 1 |
| Mohansundaram, K | 1 |
| Goyal, M | 1 |
| Ravindran, V | 1 |
| Belani, PJ | 1 |
| Kavadichanda, CG | 1 |
| Negi, VS | 1 |
| Kussmann, M | 1 |
| Obermueller, M | 1 |
| Spettel, K | 1 |
| Winkler, S | 1 |
| Aletaha, D | 4 |
| Smeele, HTW | 2 |
| Neuman, RI | 2 |
| Berenguer, C | 1 |
| Danser, AHJ | 1 |
| Visser, W | 2 |
| Dolhain, RJEM | 3 |
| Förger, F | 2 |
| Raio, L | 1 |
| Baumann, M | 1 |
| Nagafuchi, H | 1 |
| Goto, Y | 1 |
| Kiyokawa, T | 1 |
| Ooka, S | 1 |
| Kawahata, K | 1 |
| Okazaki, T | 1 |
| Kodama, D | 1 |
| Yamadera, M | 1 |
| Sugiyama, Y | 1 |
| Tsuji, H | 1 |
| Nishida, F | 1 |
| Ooka, Y | 1 |
| Nakamichi, K | 1 |
| Hashikawa, K | 1 |
| Yanagihara, T | 1 |
| Yoshinaga, N | 1 |
| Oka, S | 1 |
| Asagoe, K | 1 |
| Barbulescu, A | 1 |
| Askling, J | 2 |
| Saevarsdottir, S | 8 |
| Kim, SC | 2 |
| Frisell, T | 1 |
| Nozaki, Y | 1 |
| Oribe, M | 1 |
| Tomita, D | 1 |
| Itami, T | 1 |
| Hayashi, S | 1 |
| Maeda, T | 1 |
| Fukuda, K | 1 |
| Kuroda, R | 1 |
| Funahashi, K | 2 |
| Matsubara, T | 3 |
| Kinoshita, K | 1 |
| Matsumura, I | 1 |
| Jayachandran, M | 1 |
| Koshy, V | 1 |
| David, R | 1 |
| Santhakumari, V | 1 |
| Padmanabhan, DS | 1 |
| Surendran, S | 1 |
| Tiwari, A | 1 |
| Mithun, CB | 1 |
| Singh, SK | 1 |
| Suman, SK | 1 |
| Yadav, P | 1 |
| Singhal, A | 1 |
| Nair, AS | 1 |
| Marwaha, V | 1 |
| Palatty, PL | 1 |
| Zheng, L | 1 |
| Xu, L | 1 |
| Hu, F | 1 |
| Xue, J | 1 |
| Bai, M | 1 |
| Yao, R | 1 |
| Zhu, H | 1 |
| Zhong, H | 1 |
| Su, Y | 2 |
| Ahmed, S | 1 |
| Konig, J | 1 |
| Kasselman, LJ | 1 |
| Renna, HA | 1 |
| De Leon, J | 1 |
| Carsons, SE | 1 |
| Reiss, AB | 1 |
| Hartman, L | 1 |
| Rasch, LA | 2 |
| Turk, SA | 1 |
| Ter Wee, MM | 3 |
| Kerstens, PJSM | 2 |
| van der Laken, CJ | 1 |
| Nurmohamed, MT | 4 |
| van Schaardenburg, D | 4 |
| van Tuyl, LHD | 3 |
| Voskuyl, AE | 9 |
| Boers, M | 30 |
| Lems, WF | 13 |
| Nunokawa, T | 3 |
| Chinen, N | 1 |
| Shimada, K | 3 |
| Kimura, M | 1 |
| Tateishi, M | 1 |
| Chen, FY | 1 |
| Setoguchi, K | 1 |
| Sugihara, M | 1 |
| Momen Majumder, MS | 1 |
| Haq, SA | 2 |
| Rasker, JJ | 2 |
| Koh, JH | 1 |
| Lee, EH | 1 |
| Cha, KH | 1 |
| Pan, CH | 1 |
| Kim, D | 1 |
| Kim, WU | 1 |
| Kim, W | 1 |
| Yeon, HR | 1 |
| Kim, JH | 3 |
| Kim, HA | 1 |
| Jung, JY | 1 |
| Kim, J | 1 |
| Choi, IA | 1 |
| Lee, KE | 1 |
| Conley, B | 1 |
| Bunzli, S | 1 |
| Bullen, J | 1 |
| O'Brien, P | 1 |
| Persaud, J | 1 |
| Gunatillake, T | 1 |
| Nikpour, M | 1 |
| Grainger, R | 1 |
| Barnabe, C | 1 |
| Lin, I | 1 |
| Wollheim, FA | 1 |
| Tang, Z | 1 |
| Sun, Q | 1 |
| Ji, H | 1 |
| Rebić, N | 1 |
| Sayre, EC | 1 |
| Zusman, EZ | 1 |
| Amiri, N | 1 |
| Baldwin, C | 1 |
| De Vera, MA | 1 |
| Pope, J | 1 |
| Rampakakis, E | 1 |
| Vaillancourt, J | 1 |
| Bessette, L | 1 |
| Lazovskis, J | 1 |
| Haraoui, B | 1 |
| Sampalis, JS | 1 |
| Xie, W | 1 |
| Li, J | 1 |
| Zhang, Z | 2 |
| Lukas, C | 2 |
| Mary, J | 2 |
| Debandt, M | 1 |
| Daïen, C | 1 |
| Morel, J | 3 |
| Cantagrel, A | 4 |
| Fautrel, B | 3 |
| Combe, B | 8 |
| Gomides, APM | 2 |
| de Albuquerque, CP | 2 |
| Santos, ABV | 1 |
| Bértolo, MB | 2 |
| Júnior, PL | 1 |
| Giorgi, RDN | 2 |
| Radominski, SC | 2 |
| Resende Guimarães, MFB | 1 |
| Bonfiglioli, KR | 1 |
| de Fátima Lobato da Cunha Sauma, M | 1 |
| Pereira, IA | 2 |
| Brenol, CV | 3 |
| da Mota, LMH | 1 |
| da Rocha Castelar Pinheiro, G | 1 |
| Pazmino, S | 2 |
| Boonen, A | 6 |
| Stouten, V | 2 |
| De Cock, D | 4 |
| Joly, J | 4 |
| Van der Elst, K | 4 |
| Westhovens, R | 9 |
| Verschueren, P | 5 |
| Curtis, JR | 11 |
| Palmer, JL | 1 |
| Reed, GW | 1 |
| Greenberg, J | 1 |
| Pappas, DA | 1 |
| Harrold, LR | 1 |
| Kremer, JM | 2 |
| Olofsson, T | 2 |
| Wallman, JK | 4 |
| Jöud, A | 1 |
| Schelin, MEC | 1 |
| Ernestam, S | 11 |
| van Vollenhoven, R | 3 |
| Lampa, J | 2 |
| Foers, AD | 1 |
| Garnham, AL | 1 |
| Smyth, GK | 1 |
| Proudman, SM | 11 |
| Cheng, L | 1 |
| Hill, AF | 1 |
| Pang, KC | 1 |
| Wicks, IP | 2 |
| Pers, YM | 1 |
| Padern, G | 1 |
| Okada, F | 1 |
| Fukushi, JI | 1 |
| Matsubara, H | 1 |
| Ishitani, EI | 1 |
| Sonoda, Y | 1 |
| Katsuki, I | 1 |
| Miller, H | 2 |
| Petersson, IF | 11 |
| Söderling, J | 1 |
| Neovius, M | 5 |
| Hetland, ML | 1 |
| Haavardsholm, EA | 2 |
| Rudin, A | 1 |
| Nordström, D | 1 |
| Nurmohamed, M | 3 |
| Gudbjornsson, B | 1 |
| Hørslev-Petersen, K | 2 |
| Uhlig, T | 3 |
| Grondal, G | 2 |
| Østergaard, M | 1 |
| Heiberg, MS | 1 |
| Twisk, J | 2 |
| Lend, K | 1 |
| Krabbe, S | 1 |
| Hyldstrup, LH | 1 |
| Lindqvist, J | 1 |
| Hultgård Ekwall, AK | 1 |
| Grøn, KL | 1 |
| Kapetanovic, M | 1 |
| Faustini, F | 1 |
| Tuompo, R | 1 |
| Lorenzen, T | 1 |
| Cagnotto, G | 1 |
| Baecklund, E | 1 |
| Hendricks, O | 1 |
| Vedder, D | 1 |
| Sokka-Isler, T | 1 |
| Husmark, T | 1 |
| Ljoså, MA | 2 |
| Brodin, E | 1 |
| Ellingsen, T | 1 |
| Söderbergh, A | 1 |
| Rizk, M | 1 |
| Olsson, ÅR | 1 |
| Larsson, P | 2 |
| Uhrenholt, L | 1 |
| Just, SA | 1 |
| Stevens, DJ | 1 |
| Laurberg, TB | 1 |
| Bakland, G | 2 |
| Olsen, IC | 2 |
| Zhao, J | 2 |
| Zhou, W | 1 |
| Wu, Y | 1 |
| Ji, P | 1 |
| Yang, L | 1 |
| Yan, X | 2 |
| Källmark, H | 1 |
| Einarsson, JT | 1 |
| Nilsson, JÅ | 2 |
| Saxne, T | 1 |
| Geborek, P | 10 |
| C Kapetanovic, M | 1 |
| Jan Danser, AH | 1 |
| Chen, J | 1 |
| Norling, LV | 1 |
| Cooper, D | 1 |
| Lillegraven, S | 1 |
| Paulshus Sundlisæter, N | 1 |
| Aga, AB | 1 |
| Sexton, J | 1 |
| Fremstad, H | 1 |
| Spada, C | 1 |
| Madland, TM | 1 |
| Høili, CA | 1 |
| Lexberg, Å | 1 |
| Hansen, IJW | 1 |
| Hansen, IM | 1 |
| Haukeland, H | 1 |
| Moholt, E | 1 |
| Solomon, DH | 4 |
| van der Heijde, D | 7 |
| Kvien, TK | 11 |
| Rannio, T | 1 |
| Asikainen, J | 1 |
| Hannonen, P | 9 |
| Yli-Kerttula, T | 1 |
| Ekman, P | 1 |
| Pirilä, L | 1 |
| Kuusalo, L | 2 |
| Mali, M | 1 |
| Puurtinen-Vilkki, M | 1 |
| Kortelainen, S | 1 |
| Paltta, J | 1 |
| Taimen, K | 1 |
| Kauppi, M | 1 |
| Laiho, K | 1 |
| Nyrhinen, S | 1 |
| Mäkinen, H | 2 |
| Isomäki, P | 1 |
| Uotila, T | 1 |
| Aaltonen, K | 1 |
| Kautiainen, H | 12 |
| Sokka, T | 1 |
| Peper, SM | 1 |
| Lew, R | 1 |
| Mikuls, T | 1 |
| Brophy, M | 2 |
| Rybin, D | 1 |
| Wu, H | 1 |
| O'Dell, J | 5 |
| De Bandt, M | 3 |
| Horsburgh, S | 1 |
| Ciechomska, M | 1 |
| O'Reilly, S | 1 |
| Rajput, R | 1 |
| Dangi, A | 1 |
| Singh, H | 1 |
| Konijn, NPC | 1 |
| den Uyl, D | 3 |
| van der Wijden, LKM | 1 |
| Bultink, IEM | 1 |
| Walsh, AM | 1 |
| Wechalekar, MD | 4 |
| Guo, Y | 1 |
| Yin, X | 1 |
| Weedon, H | 1 |
| Smith, MD | 3 |
| Nagpal, S | 1 |
| Krüger, K | 4 |
| Wabe, N | 1 |
| Wojciechowski, J | 2 |
| Cleland, LG | 7 |
| McWilliams, L | 3 |
| Lee, A | 1 |
| Proudman, S | 1 |
| Wiese, MD | 4 |
| Bergstra, SA | 3 |
| Landewé, RBM | 2 |
| Huizinga, TWJ | 2 |
| Allaart, CF | 15 |
| Kuijper, TM | 1 |
| Luime, JJ | 3 |
| Xiong, H | 1 |
| de Jong, P | 1 |
| van der Lubbe, P | 1 |
| van Zeben, D | 5 |
| Tchetverikov, I | 1 |
| Hazes, J | 1 |
| Weel, A | 1 |
| Akdemir, G | 2 |
| Heimans, L | 5 |
| Goekoop, RJ | 3 |
| van Oosterhout, M | 3 |
| van Groenendael, JHLM | 1 |
| Peeters, AJ | 6 |
| Steup-Beekman, GM | 3 |
| Lard, LR | 5 |
| de Sonnaville, PBJ | 1 |
| Grillet, BAM | 1 |
| Hazlewood, GS | 1 |
| Bombardier, C | 4 |
| Tomlinson, G | 1 |
| Marshall, D | 1 |
| Sánchez, E | 1 |
| García de la Torre, I | 1 |
| Sacnún, M | 1 |
| Goñi, M | 1 |
| Berbotto, G | 1 |
| Paira, S | 1 |
| Musuruana, JL | 1 |
| Graf, C | 1 |
| Alvarellos, A | 1 |
| Messina, OD | 1 |
| Babini, A | 1 |
| Strusberg, I | 1 |
| Marcos, JC | 2 |
| Scherbarth, H | 1 |
| Spindler, A | 1 |
| Quinteros, A | 1 |
| Toloza, S | 1 |
| Moreno, JLC | 1 |
| Catoggio, LJ | 1 |
| Tate, G | 1 |
| Eimon, A | 1 |
| Citera, G | 1 |
| Pellet, AC | 1 |
| Nasswetter, G | 1 |
| Cardiel, MH | 3 |
| Miranda, P | 1 |
| Ballesteros, F | 2 |
| Esquivel-Valerio, JA | 2 |
| Maradiaga-Ceceña, MA | 1 |
| Acevedo-Vásquez, EM | 1 |
| García, CG | 2 |
| Tusié-Luna, T | 1 |
| Pons-Estel, BA | 2 |
| Alarcón-Riquelme, ME | 1 |
| Niknahad, H | 1 |
| Heidari, R | 1 |
| Mohammadzadeh, R | 1 |
| Ommati, MM | 1 |
| Khodaei, F | 1 |
| Azarpira, N | 1 |
| Abdoli, N | 1 |
| Zarei, M | 1 |
| Asadi, B | 1 |
| Rasti, M | 1 |
| Shirazi Yeganeh, B | 1 |
| Taheri, V | 1 |
| Saeedi, A | 1 |
| Najibi, A | 1 |
| Wang, S | 1 |
| Ye, G | 1 |
| Zhang, Y | 1 |
| Guan, S | 1 |
| Liu, X | 1 |
| Ren, W | 1 |
| Tam, HW | 1 |
| Chen, CM | 1 |
| Leong, PY | 1 |
| Chen, CH | 1 |
| Li, YC | 1 |
| Wang, YH | 1 |
| Lin, LC | 1 |
| Chiou, JY | 1 |
| Wei, JC | 1 |
| Saidane, O | 1 |
| Sellami, M | 1 |
| Mahmoud, I | 1 |
| Ben Tekaya, A | 1 |
| Tekaya, R | 1 |
| Abdelmoula, L | 1 |
| Versteeg, GA | 1 |
| Steunebrink, LMM | 1 |
| Vonkeman, HE | 2 |
| Ten Klooster, PM | 3 |
| van der Bijl, AE | 1 |
| van de Laar, MAFJ | 2 |
| Takeuchi, T | 2 |
| Yamanaka, H | 8 |
| Harigai, M | 1 |
| Tamamura, R | 1 |
| Kato, Y | 2 |
| Ukyo, Y | 1 |
| Nakano, T | 1 |
| Hsu, B | 1 |
| Tanaka, Y | 3 |
| Yokogawa, N | 2 |
| Sugii, S | 3 |
| Baker, JF | 1 |
| Sauer, B | 1 |
| Teng, CC | 3 |
| George, M | 1 |
| Cannon, GW | 4 |
| Ibrahim, S | 1 |
| Cannella, A | 1 |
| England, BR | 1 |
| Michaud, K | 2 |
| Caplan, L | 1 |
| Davis, LA | 1 |
| OʼDell, J | 1 |
| Mikuls, TR | 10 |
| Eun, Y | 1 |
| Kim, IY | 1 |
| Jeong, H | 1 |
| Kim, H | 1 |
| Lee, J | 1 |
| Choi, MS | 1 |
| Koh, E | 1 |
| Cha, HS | 1 |
| Ramiro, S | 1 |
| Chopra, A | 1 |
| Govind, N | 1 |
| Silva, C | 1 |
| Murphy, EA | 3 |
| Jeimy, S | 1 |
| McRae, K | 1 |
| Pattani, R | 1 |
| Nishino, J | 1 |
| Gosho, M | 1 |
| Wagatsuma, Y | 1 |
| Tohma, S | 1 |
| Ford, M | 1 |
| Sahbudin, I | 1 |
| Filer, A | 2 |
| Steven, N | 1 |
| Fisher, BA | 1 |
| Erhardt, DP | 1 |
| Sauer, BC | 2 |
| Imai, R | 1 |
| Jinta, T | 1 |
| Bazzichi, L | 1 |
| Nacci, F | 1 |
| Sinigaglia, L | 1 |
| Bianchino, L | 1 |
| Caporali, R | 1 |
| Darrah, E | 1 |
| Yu, F | 1 |
| Cappelli, LC | 1 |
| Rosen, A | 1 |
| O'Dell, JR | 17 |
| Lian, BS | 1 |
| Busmanis, I | 1 |
| Lee, HY | 1 |
| Mota, LMHD | 1 |
| Kakehasi, AM | 1 |
| Duarte, ALBP | 1 |
| Cruz, BA | 1 |
| Castelar Pinheiro, GDR | 1 |
| Laurindo, IMM | 1 |
| Ubirajara Silva de Souza, MPG | 1 |
| de Freitas, MVC | 1 |
| Louzada-Júnior, P | 1 |
| Xavier, RM | 2 |
| Nisar, MK | 1 |
| Poppelaars, PBM | 1 |
| Tseng, CC | 1 |
| Lin, YZ | 1 |
| Lin, CH | 2 |
| Li, RN | 1 |
| Tsai, WC | 1 |
| Ou, TT | 1 |
| Wu, CC | 1 |
| Sung, WY | 1 |
| Yen, JH | 1 |
| Oude Voshaar, MAH | 1 |
| Fakhouri, W | 1 |
| de la Torre, I | 1 |
| Nicolay, C | 1 |
| El-Koussi, WM | 1 |
| Atia, NN | 1 |
| Saleh, GA | 1 |
| Hammam, N | 1 |
| Boulos, D | 1 |
| Metcalf, RG | 3 |
| Hall, C | 2 |
| Navarro-Millán, I | 3 |
| Charles-Schoeman, C | 2 |
| Yang, S | 3 |
| Bathon, JM | 3 |
| Bridges, SL | 6 |
| Chen, L | 3 |
| Cofield, SS | 6 |
| Dell'Italia, LJ | 1 |
| Moreland, LW | 7 |
| Paulus, HE | 3 |
| Mitoff, PR | 1 |
| Mesana, TG | 1 |
| Mielniczuk, LM | 1 |
| Grenon, J | 1 |
| Veinot, JP | 1 |
| Cooper, LT | 1 |
| Davies, RA | 1 |
| Rezaei, H | 2 |
| van Vollenhoven, RF | 17 |
| Forslind, K | 9 |
| McVie, T | 2 |
| Reynolds, RJ | 1 |
| Ranganath, VK | 4 |
| ter Wee, M | 1 |
| Kerstens, P | 2 |
| Voskuyl, A | 1 |
| Raterman, H | 1 |
| van Dillen, N | 1 |
| Dijkmans, B | 1 |
| Lems, W | 2 |
| McWilliams, DF | 1 |
| Kiely, PD | 1 |
| Young, A | 2 |
| Walsh, DA | 1 |
| Wevers-de Boer, KV | 3 |
| Visser, K | 4 |
| Harbers, JB | 3 |
| Bijkerk, C | 2 |
| Speyer, I | 3 |
| de Buck, MP | 2 |
| de Sonnaville, PB | 5 |
| Grillet, BA | 5 |
| Huizinga, TW | 12 |
| McMahon, DJ | 1 |
| Taylor, TH | 1 |
| Ahluwalia, V | 1 |
| Warren, SR | 1 |
| Lew, RA | 1 |
| Cannella, AC | 1 |
| Kunkel, G | 1 |
| Phibbs, CS | 1 |
| Anis, AH | 1 |
| Leatherman, S | 1 |
| Keystone, E | 1 |
| Yelin, E | 1 |
| Eriksson, JK | 3 |
| Bratt, J | 5 |
| Chatzidionysiou, K | 2 |
| Tanaka, E | 5 |
| Jämsen, E | 1 |
| Virta, LJ | 1 |
| Hakala, M | 6 |
| Kauppi, MJ | 2 |
| Malmivaara, A | 1 |
| Lehto, MU | 1 |
| Ratner, M | 1 |
| James, MJ | 3 |
| Spargo, LD | 2 |
| Sullivan, TR | 1 |
| Rischmueller, M | 2 |
| Flabouris, K | 1 |
| Lee, AT | 3 |
| Bari, SF | 1 |
| Khan, A | 1 |
| Lawson, T | 1 |
| Akiyama, Y | 3 |
| Sakurai, Y | 2 |
| Furuta, E | 1 |
| Mimura, T | 1 |
| Chen, HH | 1 |
| Chen, DY | 2 |
| Lai, KL | 1 |
| Chen, YM | 2 |
| Chou, YJ | 1 |
| Chou, P | 1 |
| Huang, N | 1 |
| Mohyuddin, GR | 1 |
| Sultan, F | 1 |
| Zhang, K | 1 |
| Khaleeq, G | 1 |
| Kälvesten, J | 1 |
| Steup-Beekman, M | 1 |
| Vermeer, M | 4 |
| Kievit, W | 1 |
| Kuper, HH | 4 |
| Braakman-Jansen, LM | 1 |
| Bernelot Moens, HJ | 4 |
| Zijlstra, TR | 1 |
| den Broeder, AA | 3 |
| van Riel, PL | 31 |
| Fransen, J | 7 |
| van de Laar, MA | 10 |
| Alotaibi, N | 1 |
| O'Doherty, C | 1 |
| Sorich, MJ | 2 |
| Suppiah, V | 1 |
| Koudijs, KK | 1 |
| Goekoop-Ruiterman, YP | 6 |
| Petersson, I | 1 |
| Albertsson, K | 3 |
| Karlsson, JA | 3 |
| He, YT | 4 |
| Ou, AH | 1 |
| Yang, XB | 1 |
| Chen, W | 1 |
| Fu, LY | 1 |
| Lu, AP | 3 |
| Yan, XP | 4 |
| Feng, XH | 3 |
| Su, L | 4 |
| Song, YJ | 3 |
| Zeng, SP | 3 |
| Liu, W | 4 |
| Qian, X | 4 |
| Zhu, WH | 3 |
| Lao, YR | 1 |
| Xu, WH | 1 |
| Wen, ZH | 1 |
| He, XH | 1 |
| Wang, BJ | 1 |
| Chen, GX | 1 |
| Xue, SQ | 1 |
| de Jong, PH | 2 |
| Hazes, JM | 5 |
| Han, HK | 1 |
| Huisman, M | 2 |
| van der Lubbe, PA | 4 |
| Gerards, AH | 4 |
| van Schaeybroeck, B | 1 |
| van Krugten, MV | 1 |
| Weel, AE | 2 |
| Hambardzumyan, K | 2 |
| Bolce, R | 1 |
| Cruickshank, SE | 1 |
| Sasso, EH | 1 |
| Chernoff, D | 1 |
| Chatterjee, S | 1 |
| Sarkate, P | 1 |
| Ghosh, S | 1 |
| Biswas, M | 1 |
| Ghosh, A | 1 |
| Dabrowska-Zamojcin, E | 1 |
| Herczyńska, MM | 1 |
| Pawlik, A | 3 |
| Zhang, LL | 1 |
| Wei, W | 1 |
| Zhang, XJ | 1 |
| van Tuyl, LH | 6 |
| Markusse, IM | 1 |
| de Vries-Bouwstra, JK | 5 |
| Han, KH | 2 |
| Schouffoer, AA | 1 |
| Kerstens, PJ | 9 |
| MacMullan, PA | 1 |
| Madigan, AM | 1 |
| Paul, N | 1 |
| Peace, AJ | 1 |
| Alagha, A | 1 |
| Nolan, KB | 1 |
| McCarthy, GM | 1 |
| Kenny, D | 1 |
| Santos-Moreno, PI | 1 |
| de la Hoz-Valle, J | 1 |
| Villarreal, L | 1 |
| Palomino, A | 1 |
| Sánchez, G | 1 |
| Castro, C | 1 |
| Corluy, L | 2 |
| Joos, R | 2 |
| Langenaken, C | 2 |
| Taelman, V | 2 |
| Raeman, F | 2 |
| Ravelingien, I | 2 |
| Vandevyvere, K | 2 |
| Lenaerts, J | 2 |
| Geens, E | 2 |
| Geusens, P | 6 |
| Vanhoof, J | 3 |
| Durnez, A | 2 |
| Remans, J | 2 |
| Vander Cruyssen, B | 2 |
| Van Essche, E | 2 |
| Sileghem, A | 2 |
| De Brabanter, G | 2 |
| Meyfroidt, S | 2 |
| Cacciapaglia, F | 1 |
| Anelli, MG | 1 |
| Rinaldi, A | 1 |
| Serafino, L | 1 |
| Covelli, M | 1 |
| Scioscia, C | 1 |
| Iannone, F | 1 |
| Lapadula, G | 1 |
| Onuora, S | 1 |
| Foster, DJ | 1 |
| Upton, RN | 1 |
| Harman, H | 1 |
| Tekeoğlu, I | 1 |
| Kaban, N | 1 |
| Harman, S | 1 |
| Shovman, O | 1 |
| Shoenfeld, Y | 1 |
| Langevitz, P | 1 |
| Uutela, T | 2 |
| Järvenpää, S | 3 |
| Salomaa, S | 1 |
| Häkkinen, A | 1 |
| Kastbom, A | 1 |
| Klareskog, L | 6 |
| Lundberg, K | 1 |
| van Nies, JA | 1 |
| Tsonaka, R | 1 |
| Gaujoux-Viala, C | 1 |
| van der Helm-van Mil, AH | 1 |
| da Chakr, RM | 1 |
| Andrade, NP | 1 |
| Toni, M | 1 |
| Laurindo, IM | 1 |
| Brenol, JC | 1 |
| Lin, KM | 1 |
| Cheng, TT | 1 |
| Lin, JC | 1 |
| Chen, CJ | 1 |
| Simões, RG | 1 |
| Maia, H | 1 |
| Levitsky, A | 2 |
| Matsuno, H | 1 |
| Okada, M | 1 |
| Sakai, Y | 1 |
| Abe, C | 1 |
| Katayama, K | 1 |
| Sagawa, A | 1 |
| Yamasaki, K | 1 |
| Kondo, M | 1 |
| Bonafede, M | 1 |
| Johnson, BH | 1 |
| Tang, DH | 1 |
| Shah, N | 1 |
| Harrison, DJ | 2 |
| Collier, DH | 1 |
| Jani, M | 1 |
| Chinoy, H | 1 |
| Warren, RB | 1 |
| Griffiths, CE | 1 |
| Plant, D | 1 |
| Fu, B | 1 |
| Morgan, AW | 1 |
| Wilson, AG | 1 |
| Isaacs, JD | 1 |
| Hyrich, K | 1 |
| Barton, A | 1 |
| Puolakka, K | 8 |
| Blåfield, H | 5 |
| Eklund, KK | 1 |
| Ilva, K | 3 |
| Kaipiainen-Seppänen, O | 3 |
| Karjalainen, A | 3 |
| Korpela, M | 9 |
| Valleala, H | 1 |
| Leirisalo-Repo, M | 15 |
| Rantalaiho, V | 3 |
| Cummins, L | 1 |
| Katikireddi, VS | 1 |
| Shankaranarayana, S | 1 |
| Su, KY | 1 |
| Duggan, E | 1 |
| Videm, V | 1 |
| Pahau, H | 1 |
| Thomas, R | 1 |
| Chester Wasko, M | 1 |
| Dasgupta, A | 1 |
| Ilse Sears, G | 1 |
| Fries, JF | 1 |
| Ward, MM | 1 |
| Erlandsson, MC | 1 |
| Bokarewa, MI | 1 |
| Boer, KV | 1 |
| Molenaar, ET | 1 |
| van Groenendael, JH | 2 |
| Desai, RJ | 1 |
| Schneeweiss, S | 1 |
| Danaei, G | 1 |
| Liao, KP | 1 |
| Sparks, JA | 1 |
| Krumme, AA | 1 |
| Shrank, WH | 1 |
| Matlin, OS | 1 |
| Brill, G | 1 |
| Pezalla, EJ | 1 |
| Choudhry, NK | 1 |
| Kim, G | 1 |
| Barner, JC | 1 |
| Rascati, K | 1 |
| Richards, K | 1 |
| Vivar, N | 1 |
| Jalal, H | 1 |
| Cofield, S | 1 |
| Takayama, T | 1 |
| Kubo, T | 1 |
| Morikawa, A | 1 |
| Morita, T | 1 |
| Nagano, O | 1 |
| Saya, H | 1 |
| Malaviya, AN | 2 |
| Gogia, SB | 1 |
| Rexhepi, S | 1 |
| Rexhepi, M | 1 |
| Sahatçiu-Meka, V | 1 |
| Mahmutaj, V | 1 |
| Boshnjaku, S | 1 |
| Akashi, K | 1 |
| Saegusa, J | 1 |
| Nakamachi, Y | 1 |
| Nakazawa, T | 1 |
| Kumagai, S | 2 |
| Morinobu, A | 2 |
| Tang, D | 1 |
| Leng, J | 1 |
| Gerosa, M | 1 |
| Schioppo, T | 1 |
| Meroni, PL | 1 |
| Ito, S | 1 |
| Bansback, N | 1 |
| Shojania, K | 1 |
| Lacaille, D | 1 |
| Wabe, NT | 1 |
| Oude Voshaar, MA | 1 |
| Schenk, O | 1 |
| Elshafie, AI | 1 |
| Elkhalifa, AD | 1 |
| Elbagir, S | 1 |
| Aledrissy, MI | 1 |
| Elagib, EM | 1 |
| Nur, MA | 1 |
| Weitoft, T | 1 |
| Rönnelid, J | 1 |
| Yin Lee, Y | 1 |
| Shahbazian, A | 1 |
| Wang, X | 2 |
| Elashoff, D | 1 |
| Paulus, H | 1 |
| Bathon, J | 1 |
| Louis Bridges, S | 1 |
| Reddy, ST | 1 |
| Cárdenas, M | 1 |
| de la Fuente, S | 1 |
| Castro-Villegas, MC | 1 |
| Romero-Gómez, M | 1 |
| Ruiz-Vílchez, D | 1 |
| Calvo-Gutiérrez, J | 1 |
| Escudero-Contreras, A | 1 |
| Del Prado, JR | 1 |
| Collantes-Estévez, E | 1 |
| Font, P | 1 |
| Narayan, N | 1 |
| Rigby, S | 1 |
| Carlucci, F | 1 |
| Ince-Askan, H | 1 |
| Hazes, JMW | 1 |
| Mazouyès, A | 1 |
| Clay, M | 1 |
| Bernard, AC | 1 |
| Gaudin, P | 1 |
| Baillet, A | 1 |
| Bolce, RJ | 1 |
| Quach, LT | 1 |
| Chang, BH | 1 |
| Brophy, MT | 1 |
| Soe Thwin, S | 1 |
| Hannagan, K | 1 |
| Liao, TL | 1 |
| Liu, HJ | 1 |
| Genovese, MC | 1 |
| Greenwald, M | 1 |
| Codding, C | 1 |
| Zubrzycka-Sienkiewicz, A | 1 |
| Kivitz, AJ | 1 |
| Wang, A | 1 |
| Shay, K | 1 |
| Garg, JP | 1 |
| Cildag, S | 1 |
| Senturk, T | 1 |
| Sizova, L | 1 |
| Shenoy, P | 1 |
| Misra, R | 1 |
| Jain, M | 1 |
| Agarwal, V | 1 |
| Gubar', EE | 1 |
| Bochkova, AG | 1 |
| Bunchuk, NV | 1 |
| Garnero, P | 3 |
| Dijkmans, BA | 20 |
| He, Y | 4 |
| Lu, A | 4 |
| Zha, Y | 2 |
| Tsang, I | 1 |
| van der Kooij, SM | 3 |
| Güler-Yüksel, M | 2 |
| Zwinderman, AH | 2 |
| de Beus, WM | 1 |
| Ronday, HK | 3 |
| Breedveld, FC | 7 |
| Plass, AM | 3 |
| Homer, D | 2 |
| Nightingale, P | 1 |
| Jobanputra, P | 3 |
| Codreanu, C | 2 |
| Fiocco, U | 2 |
| Gaubitz, M | 2 |
| Geusens, PP | 2 |
| Pavelka, K | 3 |
| Sambrook, PN | 2 |
| Smolen, JS | 11 |
| Khandker, R | 1 |
| Singh, A | 2 |
| Wajdula, J | 2 |
| Fatenejad, S | 2 |
| Liu, XD | 1 |
| Zhang, JL | 1 |
| Zheng, HG | 1 |
| Liu, FY | 1 |
| Chen, Y | 1 |
| Nakayama, S | 1 |
| Yokote, T | 1 |
| Kobayashi, K | 1 |
| Hirata, Y | 1 |
| Hara, S | 1 |
| Akioka, T | 1 |
| Miyoshi, T | 1 |
| Tsuji, M | 1 |
| Takubo, T | 1 |
| Hanafusa, T | 1 |
| Brasington, R | 1 |
| Houitte, R | 1 |
| Abgueguen, P | 1 |
| Masson, C | 1 |
| Gergely, P | 2 |
| Poór, G | 2 |
| Nikolaisen, C | 1 |
| Mikkelsen, K | 3 |
| Kaufmann, C | 2 |
| Rødevand, E | 3 |
| Nossent, JC | 1 |
| Yukawa, N | 1 |
| Mimori, T | 3 |
| Berkhof, J | 1 |
| Knol, DL | 1 |
| Rijmen, F | 1 |
| Twisk, JW | 2 |
| Uitdehaag, BJ | 1 |
| Klarenbeek, NB | 3 |
| Nakajima, M | 1 |
| Ueda, N | 1 |
| Ohara, H | 1 |
| Abe, M | 1 |
| Kinoshita, M | 1 |
| Julkunen, H | 3 |
| Luosujärvi, R | 2 |
| Möttönen, T | 11 |
| Teraki, Y | 1 |
| Izaki, S | 1 |
| Landewé, RB | 2 |
| Han, H | 2 |
| van der Linden, S | 11 |
| van de Laar, M | 2 |
| van Denderen, JC | 3 |
| Westedt, ML | 2 |
| Jacobs, P | 3 |
| van de Brink, H | 1 |
| Schipper, LG | 3 |
| Barrera, P | 4 |
| Østensen, M | 1 |
| Kurzawski, M | 2 |
| Gawronska-Szklarz, B | 1 |
| Gornik, W | 2 |
| Dziedziejko, V | 1 |
| Safranow, K | 1 |
| Juzyszyn, Z | 1 |
| Drozdzik, M | 2 |
| Cöster, L | 1 |
| Waltbrand, E | 1 |
| Zickert, A | 1 |
| Theander, J | 1 |
| Thörner, A | 1 |
| Hellström, H | 1 |
| Teleman, A | 1 |
| Dackhammar, C | 1 |
| Akre, F | 1 |
| Ljung, L | 1 |
| Oding, R | 1 |
| Chatzidionysiou, A | 1 |
| Wörnert, M | 1 |
| Goldbach-Mansky, R | 1 |
| Wilson, M | 1 |
| Fleischmann, R | 1 |
| Olsen, N | 1 |
| Silverfield, J | 1 |
| Kempf, P | 1 |
| Kivitz, A | 1 |
| Sherrer, Y | 1 |
| Pucino, F | 1 |
| Csako, G | 1 |
| Costello, R | 1 |
| Pham, TH | 1 |
| Snyder, C | 1 |
| Tao, X | 1 |
| Wesley, R | 1 |
| Lipsky, PE | 1 |
| Suresh, R | 1 |
| Gupta, S | 1 |
| Sathananthan, R | 1 |
| Mora, C | 1 |
| González, A | 1 |
| Díaz, J | 1 |
| Quintana, G | 1 |
| Ohara, G | 1 |
| Satoh, H | 1 |
| Kohno, M | 1 |
| Goto, D | 1 |
| Sumida, T | 1 |
| Hizawa, N | 1 |
| Bahat, G | 1 |
| Celik, HG | 1 |
| Tufan, F | 1 |
| Saka, B | 1 |
| Yeşilova, Z | 1 |
| Kantarcioğlu, M | 1 |
| Erçin, CN | 1 |
| Safalioğlu, M | 1 |
| Kilciler, G | 1 |
| Koç, E | 1 |
| Atli, M | 1 |
| Uygun, A | 1 |
| Svensson, B | 1 |
| Hafström, I | 5 |
| Tarkowski, A | 2 |
| Bokarewa, M | 1 |
| Houbiers, JG | 1 |
| Buttgereit, F | 1 |
| In 't Hout, J | 1 |
| Leij, S | 1 |
| Szczepański, L | 1 |
| Szombati, I | 1 |
| Sierakowski, S | 3 |
| Miltenburg, AM | 1 |
| Jiang, M | 2 |
| Zha, Q | 2 |
| Katchamart, W | 1 |
| Johnson, S | 1 |
| Lin, HJ | 1 |
| Phumethum, V | 1 |
| Salliot, C | 1 |
| Lee, HJ | 1 |
| Waller, RD | 1 |
| Stebbings, S | 1 |
| Highton, J | 1 |
| Orlovich, DA | 1 |
| Schmierer, D | 1 |
| Fawcett, JP | 1 |
| Ferreira, O | 1 |
| Duarte, AF | 1 |
| Baudrier, T | 1 |
| Mota, A | 1 |
| Simões, JS | 1 |
| Azevedo, F | 1 |
| Chen, LA | 1 |
| Su, LH | 1 |
| Chang, YJ | 1 |
| Hsu, YL | 1 |
| Tsai, TH | 1 |
| Laasonen, L | 4 |
| Nagy, ZB | 1 |
| Csanád, M | 1 |
| Tóth, K | 1 |
| Börzsönyi, B | 1 |
| Demendi, C | 1 |
| Rigó, J | 1 |
| Joó, JG | 1 |
| Yang, D | 1 |
| Arkfeld, D | 1 |
| Fong, TL | 1 |
| Karmakar, GC | 1 |
| Wong, CA | 1 |
| Horwood, F | 1 |
| Anderson, G | 1 |
| Önal, S | 1 |
| Nazıroğlu, M | 1 |
| Çolak, M | 1 |
| Bulut, V | 1 |
| Flores-Arce, MF | 1 |
| Engvall, IL | 1 |
| Tengstrand, B | 2 |
| Brismar, K | 1 |
| Suzuki, T | 4 |
| Ishihara, K | 1 |
| Partlett, R | 1 |
| Roussou, E | 1 |
| Marks, WH | 1 |
| Mittal, N | 1 |
| Sharma, A | 1 |
| Jose, V | 1 |
| Mittal, R | 1 |
| Wanchu, A | 1 |
| Bambery, P | 1 |
| Kawai, S | 5 |
| Yamamoto, K | 1 |
| Miyasaka, N | 1 |
| Bao, J | 1 |
| Dai, SM | 1 |
| Elsby, R | 1 |
| Fox, L | 1 |
| Stresser, D | 1 |
| Layton, M | 1 |
| Butters, C | 1 |
| Sharma, P | 1 |
| Smith, V | 1 |
| Surry, D | 1 |
| Rojas-Serrano, J | 1 |
| Pérez, LL | 1 |
| Moctezuma, F | 1 |
| Álvarez-Hernández, E | 1 |
| Vázquez-Mellado, J | 1 |
| Montiel, JL | 1 |
| Burgos-Vargas, R | 1 |
| Wada, Y | 1 |
| Kobayashi, D | 1 |
| Murakami, S | 1 |
| Oda, M | 1 |
| Hanawa, H | 1 |
| Kuroda, T | 1 |
| Nakano, M | 1 |
| Narita, I | 1 |
| Lu, C | 3 |
| Hoekstra, M | 3 |
| Haagsma, CJ | 10 |
| Posthumus, MD | 3 |
| Brus, HL | 3 |
| Koyama, Y | 1 |
| Shiraishi, H | 1 |
| Ohta, T | 1 |
| Uchino, A | 1 |
| Ganu, MA | 1 |
| Ganu, AS | 1 |
| Ogasawara, M | 2 |
| Tamura, N | 3 |
| Kageyama, M | 2 |
| Onuma, S | 2 |
| Kusaoi, M | 2 |
| Toyama, S | 1 |
| Sekiya, F | 2 |
| Matsudaira, R | 2 |
| Nawata, M | 1 |
| Tada, K | 2 |
| Matsushita, M | 2 |
| Kempe, K | 2 |
| Amano, H | 1 |
| Morimoto, S | 1 |
| Yamaji, K | 2 |
| Takasaki, Y | 2 |
| Söderlin, MK | 1 |
| Bergman, S | 1 |
| Kiss, E | 1 |
| Kiss, CG | 1 |
| Urata, Y | 1 |
| Uesato, R | 1 |
| Tanaka, D | 1 |
| Nakamura, Y | 1 |
| Motomura, S | 1 |
| Dirven, L | 1 |
| Ewals, JA | 2 |
| Kawai, VK | 1 |
| Grijalva, CG | 1 |
| Arbogast, PG | 1 |
| Delzell, E | 1 |
| Ouellet-Hellstrom, R | 1 |
| Herrinton, L | 1 |
| Liu, L | 1 |
| Mitchel, EF | 1 |
| Stein, CM | 1 |
| Griffin, MR | 1 |
| Hodkinson, B | 1 |
| Musenge, E | 1 |
| Ally, M | 1 |
| Meyer, PW | 1 |
| Anderson, R | 1 |
| Tikly, M | 2 |
| Lie, E | 1 |
| Kalstad, S | 1 |
| Hoekstra, MO | 1 |
| van Riel, P | 2 |
| Ichikawa, N | 1 |
| Kon, T | 1 |
| Sugimoto, K | 1 |
| Golicki, D | 1 |
| Newada, M | 1 |
| Lis, J | 1 |
| Pol, K | 1 |
| Hermanowski, T | 1 |
| Tłustochowicz, M | 1 |
| Cetinkaya, B | 1 |
| Guzeldemir, E | 1 |
| Ogus, E | 1 |
| Bulut, S | 1 |
| Kwok, KY | 1 |
| Leung, MH | 1 |
| St Clair, EW | 2 |
| Zhang, J | 1 |
| Howard, G | 1 |
| Liu, T | 1 |
| Wang, XR | 1 |
| An, Y | 1 |
| Zhou, YS | 1 |
| Zhang, XY | 1 |
| Duan, TJ | 1 |
| Zhu, JX | 1 |
| Li, XF | 2 |
| Wang, LZ | 1 |
| Wang, CH | 1 |
| Wang, YF | 1 |
| Yang, R | 1 |
| Wang, GC | 1 |
| Lu, X | 1 |
| Zhu, P | 1 |
| Chen, LN | 1 |
| Jin, HT | 1 |
| Liu, XY | 1 |
| Sun, L | 1 |
| Chen, HY | 1 |
| Cui, LF | 1 |
| Shu, R | 1 |
| Liu, BL | 1 |
| Zhang, ZL | 1 |
| Li, GT | 1 |
| Li, ZB | 1 |
| Yang, J | 1 |
| Li, JF | 1 |
| Jia, B | 1 |
| Zhang, FX | 1 |
| Tao, JM | 1 |
| Han, SL | 1 |
| Lin, JY | 1 |
| Wei, MQ | 1 |
| Liu, XM | 1 |
| Ke, D | 1 |
| Hu, SX | 1 |
| Ye, C | 1 |
| Yang, XY | 1 |
| Li, H | 1 |
| Huang, CB | 1 |
| Gao, M | 1 |
| Lai, P | 1 |
| Song, LJ | 1 |
| Wang, Y | 1 |
| Wang, XY | 1 |
| Mu, R | 1 |
| Li, ZG | 2 |
| Kita, J | 1 |
| Tamai, M | 1 |
| Arima, K | 1 |
| Kawashiri, SY | 1 |
| Horai, Y | 1 |
| Iwamoto, N | 1 |
| Okada, A | 1 |
| Koga, T | 1 |
| Nakashima, Y | 1 |
| Yamasaki, S | 1 |
| Nakamura, H | 1 |
| Origuchi, T | 1 |
| Ida, H | 1 |
| Aoyagi, K | 1 |
| Uetani, M | 1 |
| Eguchi, K | 1 |
| Kawakami, A | 1 |
| Barendregt, PJ | 1 |
| de Jager, MH | 1 |
| Maska, LB | 1 |
| Sayles, HR | 1 |
| Luukkainen, R | 3 |
| Julkunen, HA | 1 |
| Paimela, L | 8 |
| Moilanen, E | 1 |
| Hannonen, PJ | 3 |
| Davis, JM | 1 |
| Matteson, EL | 1 |
| Sandoo, A | 1 |
| Dimitroulas, T | 1 |
| Toms, TE | 1 |
| Hodson, J | 1 |
| Veldhuijzen van Zanten, JJ | 1 |
| Smith, JP | 1 |
| Kitas, GD | 5 |
| Popplewell, M | 1 |
| Mulherin, D | 1 |
| Daïen, CI | 1 |
| Fesler, P | 1 |
| du Cailar, G | 1 |
| Daïen, V | 1 |
| Mura, T | 1 |
| Dupuy, AM | 1 |
| Cristol, JP | 1 |
| Ribstein, J | 1 |
| Perdan-Pirkmajer, K | 1 |
| Hočevar, A | 1 |
| Rotar, Ž | 1 |
| Žibert, J | 1 |
| Marolt, VF | 1 |
| Gučev, F | 1 |
| Tomšič, M | 1 |
| Mucke, HA | 1 |
| Sacnun, MP | 1 |
| Wojdyla, D | 1 |
| Saurit, V | 1 |
| Pinto, MR | 1 |
| Cordeiro de Azevedo, AB | 1 |
| da Silveira, IG | 1 |
| Ximenes, AC | 1 |
| Massardo, L | 1 |
| Rojas-Villarraga, A | 1 |
| Oñate, RV | 1 |
| Hernandez, MP | 1 |
| García-De La Torre, I | 1 |
| Khoury, VJ | 1 |
| Millán, A | 1 |
| Soriano, ER | 1 |
| van Tuyl, L | 1 |
| van den Broek, M | 1 |
| Kostense, PJ | 2 |
| Rantalaiho, VM | 1 |
| Leff, R | 2 |
| Paulsen, G | 1 |
| Haire, C | 4 |
| Mallek, J | 1 |
| Eckhoff, PJ | 3 |
| Fernandez, A | 2 |
| Blakely, K | 2 |
| Wees, S | 4 |
| Stoner, J | 1 |
| Hadley, S | 1 |
| Felt, J | 1 |
| Palmer, W | 5 |
| Waytz, P | 1 |
| Churchill, M | 1 |
| Klassen, L | 1 |
| Moore, G | 1 |
| Ferraccioli, GF | 1 |
| Gremese, E | 1 |
| Tomietto, P | 1 |
| Favret, G | 1 |
| Damato, R | 1 |
| Di Poi, E | 1 |
| Scott, DL | 19 |
| Strand, V | 6 |
| Dílek, K | 1 |
| Alí, I | 1 |
| Göksal, K | 1 |
| Hüseyin, T | 1 |
| Güner, T | 1 |
| Volin, MV | 2 |
| Campbell, PL | 2 |
| Connors, MA | 1 |
| Woodruff, DC | 1 |
| Koch, AE | 2 |
| Ransford, RA | 1 |
| Langman, MJ | 1 |
| Jiang, L | 1 |
| Zhao, N | 1 |
| Ni, L | 1 |
| Landewé, R | 2 |
| Verhoeven, A | 1 |
| Christgau, S | 1 |
| Schiemann, U | 1 |
| Kellner, H | 1 |
| Taniguchi, A | 5 |
| Urano, W | 4 |
| Nakajima, H | 1 |
| Matsuda, Y | 1 |
| Kitamura, Y | 1 |
| Saito, M | 1 |
| Saito, T | 1 |
| Kamatani, N | 7 |
| Misiūniene, N | 1 |
| Baranauskaite, A | 1 |
| Akama, H | 1 |
| Kobayashi, S | 2 |
| Kanai, Y | 1 |
| Hirohata, S | 1 |
| Osiri, M | 1 |
| Shea, B | 2 |
| Robinson, V | 1 |
| Suarez-Almazor, M | 2 |
| Tugwell, P | 6 |
| Wells, G | 5 |
| Aydin, Y | 1 |
| Ozçakar, L | 1 |
| Yildiz, M | 1 |
| Akinci, A | 1 |
| Lu, SJ | 1 |
| Shao, J | 1 |
| Li, XR | 1 |
| Schnabel, A | 1 |
| Gross, WL | 1 |
| Klaukka, T | 1 |
| Kaarela, K | 2 |
| Ujfalussy, I | 1 |
| Koó, E | 1 |
| Seszták, M | 1 |
| Stucki, G | 1 |
| Chamot, AM | 1 |
| Gerster, JC | 1 |
| Langenegger, T | 1 |
| Seitz, M | 2 |
| Michel, BA | 1 |
| Johnsen, V | 1 |
| Førre, Ø | 1 |
| Haga, HJ | 1 |
| Nordvåg, BY | 1 |
| Maillefert, JF | 2 |
| Goupille, P | 2 |
| Dougados, M | 5 |
| Klimiuk, PA | 1 |
| Chwiećko, J | 1 |
| Fujimaki, T | 1 |
| Wilson, J | 1 |
| Douglas, K | 1 |
| Burls, A | 1 |
| Balabanova, RM | 1 |
| Stamm, T | 2 |
| Kapral, T | 2 |
| Eberl, G | 1 |
| Grisar, J | 1 |
| Machold, KP | 1 |
| ZYLBERBLAT, L | 1 |
| SVARTZ, N | 2 |
| BOHMAN, F | 1 |
| Tascioglu, F | 1 |
| Oner, C | 1 |
| Armagan, O | 1 |
| Bonanno, D | 1 |
| Fedele, R | 1 |
| Minciullo, P | 1 |
| Quattrocchi, P | 1 |
| Ferlazzo, B | 1 |
| Conaghan, PG | 6 |
| Emery, P | 9 |
| Santodomingo-Rubido, J | 1 |
| Gilmartin, B | 1 |
| Wolffsohn, JS | 1 |
| Griffiths, RI | 1 |
| Bar-Din, M | 1 |
| MacLean, CH | 1 |
| Sullivan, EM | 1 |
| Herbert, RJ | 1 |
| Yelin, EH | 1 |
| Marino, C | 2 |
| McDonald, E | 2 |
| Landewe, S | 1 |
| Van Wijngaerden, E | 1 |
| Kruijsen, MW | 1 |
| Furst, DE | 4 |
| van der Heijden, J | 2 |
| de Jong, MC | 1 |
| Oerlemans, R | 2 |
| Kathmann, I | 1 |
| Scheffer, GL | 1 |
| Scheper, RJ | 2 |
| Assaraf, YG | 2 |
| Jansen, G | 2 |
| Vuori, K | 2 |
| KUZELL, WC | 1 |
| GARDNER, GM | 1 |
| van Aken, J | 1 |
| le Cessie, S | 1 |
| Komada, F | 1 |
| Kita, T | 1 |
| Ozaki, S | 1 |
| Ishida, H | 1 |
| Sano, H | 1 |
| Okumura, K | 1 |
| Wick, MC | 2 |
| Lindblad, S | 3 |
| Weiss, RJ | 2 |
| te Koppele, J | 1 |
| Ulubaş, B | 1 |
| Sahin, G | 2 |
| Ozer, C | 1 |
| Aydin, O | 1 |
| Ozgür, E | 1 |
| Apaydin, D | 1 |
| Kalden, JR | 5 |
| Strand, CV | 1 |
| Müller-Ladner, U | 1 |
| Rüther, W | 1 |
| Burmester, GR | 4 |
| Capell, HA | 37 |
| Madhok, R | 17 |
| Hunter, JA | 18 |
| Porter, D | 5 |
| Morrison, E | 3 |
| Larkin, J | 1 |
| Thomson, EA | 5 |
| Hampson, R | 3 |
| Poon, FW | 1 |
| Weinblatt, ME | 2 |
| Choy, EH | 1 |
| Goriachev, DV | 1 |
| Erdes, ShF | 1 |
| Ifergan, I | 1 |
| Lemmel, EM | 1 |
| Zerbini, CA | 1 |
| Brin, S | 1 |
| Cobankara, V | 1 |
| Ozatli, D | 1 |
| Kiraz, S | 1 |
| Oztürk, MA | 1 |
| Ertenli, I | 1 |
| Türk, T | 1 |
| Apras, S | 1 |
| Haznedaroglu, IC | 1 |
| Calgüneri, M | 1 |
| Korthals-de Bos, I | 1 |
| Van Tulder, M | 1 |
| Verhoeven, AC | 10 |
| Adèr, HJ | 1 |
| Bibo, J | 1 |
| Jolly, M | 1 |
| Curran, JJ | 1 |
| Kirwan, J | 1 |
| Issa, SN | 1 |
| Ruderman, EM | 1 |
| Järvinen, P | 2 |
| Ahonen, J | 2 |
| Forsberg, S | 2 |
| Michel, F | 1 |
| Navellou, JC | 1 |
| Ferraud, D | 1 |
| Toussirot, E | 1 |
| Wendling, D | 2 |
| Kawasaki, Y | 2 |
| Moriyama, M | 2 |
| Shibata, K | 2 |
| Gomita, Y | 2 |
| Bolten, W | 1 |
| Kawabata, D | 1 |
| Crawford, B | 1 |
| Moens, HB | 1 |
| Fath, R | 1 |
| Derk, CT | 1 |
| Orita, M | 1 |
| Katakura, Y | 1 |
| Kobayashi, M | 2 |
| Ishii, T | 1 |
| Watanabe, Y | 1 |
| Yotsuyanagi, H | 1 |
| Suzuki, M | 1 |
| Itoh, F | 1 |
| Kusabe, T | 1 |
| Waguri-Nagaya, Y | 1 |
| Tanikawa, T | 1 |
| Aoyama, M | 1 |
| Fukuoka, M | 1 |
| Otsuka, T | 1 |
| Asai, K | 1 |
| Edwards, CJ | 2 |
| Arden, NK | 2 |
| Fisher, D | 2 |
| Saperia, JC | 1 |
| Reading, I | 1 |
| Van Staa, TP | 2 |
| Cooper, C | 2 |
| Ayhan-Ardic, FF | 1 |
| Oken, O | 1 |
| Yorgancioglu, ZR | 1 |
| Ustun, N | 1 |
| Gokharman, FD | 1 |
| Plosker, GL | 1 |
| Croom, KF | 1 |
| Zha, QL | 3 |
| Petersen, K | 1 |
| Schned, E | 1 |
| Mitka, M | 1 |
| Ranganathan, P | 2 |
| Hvatum, M | 1 |
| Kanerud, L | 6 |
| Hällgren, R | 4 |
| Brandtzaeg, P | 1 |
| Lioté, F | 4 |
| Bejia, I | 1 |
| Ben Hammouda, S | 1 |
| Riahi, K | 1 |
| Zinelabidine, F | 1 |
| Mediouni, B | 1 |
| Touzi, M | 1 |
| Bergaoui, N | 1 |
| Caughey, GE | 2 |
| Porter, DR | 5 |
| Munro, RA | 2 |
| McInnes, IB | 2 |
| Steven, M | 1 |
| Zoma, A | 2 |
| Sambrook, M | 1 |
| Wui Poon, F | 1 |
| McDonald, F | 1 |
| Tierney, A | 1 |
| Henderson, N | 1 |
| Ford, I | 1 |
| Rudas, T | 1 |
| Czerny, B | 1 |
| Herczynska, M | 1 |
| Resman-Targoff, BH | 1 |
| van Halm, VP | 1 |
| Kampmann, P | 1 |
| Højlyng, N | 1 |
| Pedersen, M | 1 |
| Scherer, HU | 1 |
| Genc, H | 1 |
| Duyur Cakit, B | 1 |
| Nacir, B | 1 |
| Saracoglu, M | 1 |
| Kacar, M | 1 |
| Erdem, HR | 1 |
| Iwatani, M | 1 |
| Inoue, E | 2 |
| Nakamura, T | 1 |
| Nakajima, A | 1 |
| Hara, M | 3 |
| Tomatsu, T | 2 |
| Meyer, O | 2 |
| Berthelot, JM | 1 |
| Flipo, RM | 1 |
| Saraux, A | 1 |
| Guillemin, F | 2 |
| Le Loët, X | 1 |
| Lin, SQ | 1 |
| Mochizuki, T | 1 |
| Momohara, S | 1 |
| Ikari, K | 1 |
| Kawamura, K | 1 |
| Tsukahara, S | 1 |
| Iwamoto, T | 1 |
| Okamoto, H | 1 |
| Nishimoto, K | 1 |
| Abe, T | 1 |
| Sugawara, S | 2 |
| Mizushima, Y | 1 |
| Hoshi, K | 2 |
| Irimajiri, S | 1 |
| Hashimoto, H | 1 |
| Yoshino, S | 4 |
| Matsui, N | 1 |
| Nobunaga, M | 2 |
| Nakano, S | 1 |
| Suematsu, A | 1 |
| Tajiri, Y | 1 |
| Nakashima, T | 1 |
| Taka, J | 1 |
| Ochi, S | 1 |
| Oda, H | 1 |
| Nakamura, K | 1 |
| Tanaka, S | 2 |
| Takayanagi, H | 1 |
| Schoels, M | 1 |
| Keen, HI | 1 |
| Stamp, LK | 1 |
| Goldblatt, F | 1 |
| Ayres, OC | 1 |
| Hill, CL | 1 |
| Suzuki, Y | 3 |
| Wakabayashi, T | 1 |
| Saito, E | 1 |
| Suwa, A | 3 |
| Tłustochowicz, W | 1 |
| Golding, A | 1 |
| Haque, UJ | 1 |
| Giles, JT | 1 |
| Furihata, S | 1 |
| Kamitsuji, S | 1 |
| Yamanaka, M | 1 |
| Ohtsubo, H | 1 |
| Matsuda, T | 2 |
| Dale, J | 1 |
| Alcorn, N | 1 |
| Capell, H | 2 |
| Yu, X | 1 |
| Ma, J | 1 |
| Tian, J | 1 |
| Jiang, S | 1 |
| Xu, P | 1 |
| Wang, L | 1 |
| Kondo, S | 1 |
| Tanimoto, K | 1 |
| Okamura, S | 1 |
| Chambers, C | 1 |
| Koren, G | 1 |
| Tutuncu, ZN | 1 |
| Johnson, D | 1 |
| Jones, KL | 1 |
| Field, M | 1 |
| Bingham, CO | 1 |
| Miner, MM | 1 |
| Komatsuda, A | 1 |
| Okamoto, Y | 1 |
| Hatakeyama, T | 1 |
| Wakui, H | 1 |
| Sawada, K | 1 |
| Goodemote, P | 1 |
| Jamieson, B | 1 |
| Hoffman, R | 1 |
| Borm, GF | 2 |
| Lemmens, WA | 1 |
| Esselens, G | 1 |
| Furukawa, K | 1 |
| Ohtani, T | 1 |
| Furukawa, F | 1 |
| Song, Y | 1 |
| Zeng, S | 1 |
| Zhu, W | 1 |
| Feng, X | 1 |
| Vroom, F | 1 |
| van Roon, EN | 1 |
| Brouwers, JR | 1 |
| de Jong-van den Berg, LT | 1 |
| James, HM | 1 |
| Gillis, D | 1 |
| Hissaria, P | 1 |
| Lester, S | 1 |
| Somogyi, AA | 1 |
| Bodur, H | 1 |
| Ataman, S | 1 |
| Akbulut, L | 1 |
| Evcik, D | 1 |
| Kavuncu, V | 1 |
| Kaya, T | 1 |
| Günaydin, R | 1 |
| Kuran, B | 1 |
| Kotevoğlu, N | 1 |
| Bal, A | 1 |
| Aydoğ, E | 1 |
| Altay, Z | 1 |
| Uğurlu, H | 1 |
| Kocabaş, H | 1 |
| Olmez, N | 1 |
| Yazgan, P | 1 |
| Gürsoy, S | 1 |
| Madenci, E | 1 |
| Ozel, S | 1 |
| Delialioğlu, SU | 1 |
| Soejima, M | 1 |
| Kawaguchi, Y | 1 |
| Amarasena, R | 1 |
| Maggs, F | 1 |
| Bowman, S | 1 |
| Rankin, E | 1 |
| Raza, K | 1 |
| Jubb, R | 1 |
| Malysheva, OA | 1 |
| Wahle, M | 1 |
| Wagner, U | 1 |
| Pierer, M | 1 |
| Arnold, S | 1 |
| Häntzschel, H | 1 |
| Baerwald, CG | 1 |
| Verpoort, KN | 1 |
| Schreuder, GM | 1 |
| Terwiel, JP | 1 |
| Toes, RE | 1 |
| de Vries, RR | 1 |
| Saunders, SA | 1 |
| Stirling, A | 1 |
| Vallance, R | 1 |
| Kincaid, W | 1 |
| McMahon, AD | 1 |
| McConkey, B | 19 |
| Amos, RS | 15 |
| Durham, S | 1 |
| Forster, PJ | 2 |
| Hubball, S | 2 |
| Walsh, L | 3 |
| Wright, V | 7 |
| Amos, R | 1 |
| Farr, M | 18 |
| Bacon, PA | 17 |
| Delamere, JP | 1 |
| Grindulis, KA | 11 |
| Smith, DH | 2 |
| Zaphiropoulos, GC | 1 |
| Neumann, VC | 6 |
| Pullar, T | 18 |
| Good, CS | 1 |
| Calverley, M | 1 |
| Cox, C | 1 |
| Crisp, AJ | 1 |
| Tunn, E | 2 |
| Crockson, AP | 3 |
| Ichikawa, Y | 2 |
| Shinozawa, T | 1 |
| Yoshida, T | 1 |
| Kameda, H | 1 |
| Yamada, H | 1 |
| Sheldon, P | 3 |
| Pell, P | 1 |
| Boerbooms, AM | 3 |
| Van de Putte, LB | 24 |
| Van der Meer, JW | 2 |
| Helliwell, PS | 2 |
| Choy, E | 1 |
| Kingsley, G | 1 |
| Hirakata, M | 1 |
| Nakamura, A | 1 |
| Inada, S | 1 |
| Salaffi, F | 1 |
| Carotti, M | 1 |
| Cervini, C | 1 |
| Rains, CP | 1 |
| Noble, S | 1 |
| Faulds, D | 1 |
| Brooks, P | 5 |
| Kaplan, S | 1 |
| Cronstein, BN | 1 |
| Butler, EP | 2 |
| Crockson, RA | 2 |
| Engström, GN | 1 |
| Laversuch, CJ | 1 |
| Collins, DA | 1 |
| Charles, PJ | 1 |
| Bourke, BE | 1 |
| Kosunen, TU | 1 |
| Benno, P | 1 |
| Alam, M | 1 |
| Henriksson, K | 1 |
| Norin, E | 1 |
| Uribe, A | 1 |
| Midtvedt, T | 1 |
| Laasila, K | 1 |
| Borg, AA | 2 |
| Davis, MJ | 2 |
| Dawes, PT | 3 |
| Shadforth, MF | 2 |
| McInnes, I | 1 |
| Hunter, J | 1 |
| Malfait, AM | 1 |
| Verbruggen, G | 2 |
| Almqvist, KF | 1 |
| Broddelez, C | 1 |
| Veys, EM | 2 |
| Jorgensen, C | 1 |
| Bologna, C | 1 |
| Anaya, JM | 1 |
| Reme, T | 1 |
| Sany, J | 1 |
| Gran, JT | 1 |
| Myklebust, G | 1 |
| Hakola, M | 2 |
| Oka, M | 2 |
| Shiroky, JB | 5 |
| Keitel, W | 1 |
| Keitel, R | 1 |
| Pap, T | 1 |
| Faarvang, KL | 1 |
| Egsmose, C | 1 |
| Kryger, P | 1 |
| Pødenphant, J | 1 |
| Ingeman-Nielsen, M | 1 |
| Hansen, TM | 2 |
| Peel, N | 1 |
| al-Dehaimi, A | 1 |
| Colwell, A | 1 |
| Russell, G | 1 |
| Eastell, R | 1 |
| Fuchs, HA | 2 |
| Gough, A | 2 |
| Sheeran, T | 1 |
| Arthur, V | 1 |
| Panayi, G | 1 |
| Slotkoff, AT | 1 |
| Katz, P | 1 |
| Walker, EM | 1 |
| Carty, JE | 1 |
| van den Brink, HR | 2 |
| van Wijk, MJ | 1 |
| Geertzen, RG | 1 |
| Bijlsma, JW | 2 |
| Nisar, M | 1 |
| Carlisle, L | 1 |
| Imai, F | 1 |
| Ishibashi, T | 1 |
| Tanaka, M | 1 |
| Dohi, Y | 1 |
| Hill, ME | 1 |
| Gordon, C | 1 |
| Situnayake, RD | 5 |
| Heath, DA | 1 |
| Caulier, M | 1 |
| Dromer, C | 1 |
| Andrieu, V | 1 |
| Le Guennec, P | 1 |
| Fournie, B | 1 |
| McCarthy, C | 1 |
| Coughlan, R | 1 |
| Fujii, T | 1 |
| Yosida, T | 1 |
| Akizuki, M | 1 |
| Scheynius, A | 2 |
| Hayllar, J | 1 |
| Smith, T | 1 |
| Macpherson, A | 1 |
| Price, AB | 1 |
| Gumpel, M | 1 |
| Bjarnason, I | 2 |
| Mongey, AB | 1 |
| Hess, EV | 1 |
| Girgis, L | 1 |
| Sauerwein, RW | 1 |
| Demacker, PN | 1 |
| Crilly, A | 4 |
| Watson, J | 5 |
| Sturrock, RD | 6 |
| McCarthy, CJ | 1 |
| Eustace, S | 1 |
| Coughlan, RJ | 1 |
| Taneichi, K | 1 |
| Baba, Y | 1 |
| Sakai, I | 1 |
| Shibaki, H | 1 |
| Axtens, RS | 1 |
| Morand, EF | 1 |
| Littlejohn, GO | 1 |
| Nord, CE | 1 |
| de Rooij, DJ | 1 |
| Vree, TB | 2 |
| Russel, FJ | 1 |
| van't Hof, MA | 3 |
| Morgan, SL | 1 |
| Baggott, JE | 1 |
| Alarcón, GS | 1 |
| Siam, AR | 1 |
| Hammoudeh, M | 1 |
| Waring, R | 1 |
| Pirmohamed, M | 1 |
| Coleman, MD | 1 |
| Galvani, D | 1 |
| Bucknall, RC | 1 |
| Breckenridge, AM | 1 |
| Park, BK | 1 |
| Wijnands, MJ | 4 |
| Van 'T Hof, MA | 3 |
| van der Heijde, DM | 9 |
| van 't Hof, M | 1 |
| Astbury, C | 9 |
| Platt, R | 1 |
| Dixon, JS | 5 |
| Le Gallez, P | 4 |
| Hill, J | 5 |
| Bird, HA | 12 |
| Canvin, JM | 1 |
| el-Gabalawy, HS | 1 |
| Chalmers, IM | 3 |
| Bradley, SM | 3 |
| Barr, K | 1 |
| Troughton, PR | 1 |
| Gooi, HC | 3 |
| Wildhagen, K | 1 |
| Hartung, K | 1 |
| Hammer, M | 1 |
| Mau, W | 1 |
| Schmidt, RE | 1 |
| Deicher, H | 1 |
| Zeidler, H | 4 |
| Nicassio, PM | 1 |
| Radojevic, V | 1 |
| Weisman, MH | 2 |
| Culbertson, AL | 1 |
| Lewis, C | 1 |
| Clemmey, P | 1 |
| Wilkieson, CA | 1 |
| van Gestel, AM | 4 |
| Smedegård, G | 2 |
| Björk, J | 2 |
| Prevoo, ML | 1 |
| van Rijswijk, MH | 4 |
| Waterhouse, L | 2 |
| Johnson, AE | 1 |
| Jubb, RW | 1 |
| Frizen, BN | 1 |
| Panchenko, KI | 1 |
| Vinogradov, IuN | 1 |
| Gardner, G | 1 |
| Haire, CE | 1 |
| Erikson, N | 2 |
| Drymalski, W | 3 |
| Garwood, V | 1 |
| Maloley, P | 2 |
| Klassen, LW | 4 |
| Klein, H | 1 |
| Moore, GF | 4 |
| Peltomaa, R | 1 |
| Helve, T | 2 |
| Ciconelli, RM | 1 |
| Ferraz, MB | 1 |
| Visioni, RA | 1 |
| Oliveira, LM | 1 |
| Atra, E | 1 |
| Khattak, FH | 1 |
| Morris, IM | 2 |
| Mattingly, PC | 1 |
| Storgaard, M | 1 |
| Jensen, MP | 1 |
| Stengaard-Pedersen, K | 2 |
| Møller, BK | 1 |
| Anderson, PL | 1 |
| Obel, N | 1 |
| Gaffney, A | 1 |
| Gaffney, P | 1 |
| Stohl, W | 1 |
| Arkfeld, DG | 1 |
| Schinagl, EF | 1 |
| Strauss, PC | 1 |
| Zurier, RB | 1 |
| DeMarco, DM | 1 |
| Liu, NY | 1 |
| Duncan, MR | 2 |
| Russel, FG | 1 |
| Krogh Jensen, M | 1 |
| Ekelund, S | 1 |
| Svendsen, L | 1 |
| Beyeler, C | 2 |
| Banks, R | 1 |
| Thompson, D | 1 |
| Forbes, MA | 1 |
| Cooper, EH | 1 |
| Imundo, LF | 1 |
| Jacobs, JC | 1 |
| Heath, KJ | 1 |
| Sampson, MJ | 1 |
| Ridley, SA | 1 |
| Merkel, PA | 1 |
| Dooley, MA | 1 |
| Dawson, DV | 1 |
| Pisetsky, DS | 2 |
| Polisson, RP | 1 |
| McEntegart, A | 2 |
| Lokki, ML | 1 |
| Koskimies, S | 1 |
| Galindo-Rodriguez, G | 1 |
| Avina-Zubieta, JA | 1 |
| Fitzgerald, A | 1 |
| LeClerq, SA | 1 |
| Russell, AS | 1 |
| Suarez-Almazor, ME | 2 |
| Frey, BM | 1 |
| Box, SA | 1 |
| Nishiya, K | 2 |
| ten Wolde, S | 1 |
| Hermans, J | 1 |
| De Clerck, LS | 1 |
| Mertens, AV | 1 |
| De Gendt, CM | 1 |
| Bridts, CH | 1 |
| Stevens, WJ | 1 |
| Throughton, PR | 1 |
| Lehmann, T | 1 |
| Markusse, HM | 3 |
| Schouten, HJ | 1 |
| Pruzanski, W | 1 |
| Stefanski, E | 1 |
| Vadas, P | 1 |
| Ramamurthy, NS | 1 |
| Elkayam, O | 1 |
| Yaron, M | 1 |
| Zhukovsky, G | 1 |
| Segal, R | 2 |
| Caspi, D | 2 |
| Tsai, CY | 1 |
| Yu, CL | 1 |
| Tsai, YY | 1 |
| Kung, YY | 1 |
| Wu, TH | 1 |
| Tsai, ST | 1 |
| de Jong, AJ | 1 |
| Gunnarsson, I | 2 |
| Pettersson, E | 1 |
| Lundberg, I | 1 |
| Ringertz, B | 2 |
| Listing, J | 1 |
| Alten, R | 1 |
| Brauer, D | 1 |
| Eggens, U | 1 |
| Gromnica-Ihle, E | 1 |
| Hagemann, D | 1 |
| Hauer, R | 1 |
| Milleck, D | 1 |
| Reuter, U | 1 |
| Schlittgen, R | 1 |
| Sörensen, H | 1 |
| Zink, A | 1 |
| Wollenhaupt, J | 1 |
| Sokka, TM | 1 |
| Kautiainen, HJ | 1 |
| Aeschlimann, AG | 1 |
| Günaydin, I | 1 |
| Kötter, I | 1 |
| Jacki, S | 1 |
| Daikeler, T | 1 |
| Kanz, L | 1 |
| Li, E | 1 |
| Ali, AA | 1 |
| Iqbal, MP | 1 |
| Hussain, MA | 1 |
| Mehboobali, N | 1 |
| Beg, JA | 1 |
| Rahbar, MH | 1 |
| Sibilia, J | 2 |
| Javier, RM | 1 |
| Albert, A | 1 |
| Cazenave, JP | 1 |
| Kuntz, JL | 1 |
| Taal, E | 2 |
| Wiegman, O | 2 |
| van der Graaff, WL | 1 |
| Prins, AP | 1 |
| van Lier, RA | 1 |
| Nepom, BS | 1 |
| Gersuk, VH | 1 |
| Gaur, L | 1 |
| Thiele, G | 1 |
| Nepom, GT | 1 |
| Veale, DJ | 2 |
| Maple, C | 1 |
| Kirk, G | 1 |
| McLaren, M | 1 |
| Belch, JJ | 1 |
| Sieper, J | 1 |
| Maiden, N | 1 |
| Hansen, A | 1 |
| Jensen, T | 1 |
| Hidaka, M | 1 |
| Ohsawa, I | 1 |
| Endo, M | 1 |
| Fujita, T | 1 |
| Ohi, H | 1 |
| Kanmatsuse, K | 1 |
| Kusumi, Y | 1 |
| Yamaguchi, Y | 1 |
| Bibo, JC | 1 |
| Engel, GL | 1 |
| Altindağ, ZZ | 1 |
| Inanici, F | 1 |
| Hasçelik, Z | 1 |
| Stenger, AA | 2 |
| Van Leeuwen, MA | 3 |
| Houtman, PM | 2 |
| Bruyn, GA | 2 |
| Speerstra, F | 1 |
| Barendsen, BC | 1 |
| Velthuysen, E | 1 |
| Maetzel, A | 2 |
| Rozman, B | 3 |
| Larsen, A | 3 |
| Loew-Friedrich, I | 3 |
| Oed, C | 4 |
| Rosenburg, R | 3 |
| Brus, H | 1 |
| Rasker, J | 1 |
| Pham, B | 1 |
| Cranney, A | 1 |
| Lassere, M | 1 |
| Edmonds, J | 1 |
| Saudan, A | 1 |
| Feist, E | 1 |
| Krause, A | 1 |
| Gordon, MM | 1 |
| Cherin, P | 1 |
| Ryan, L | 1 |
| Nissilä, M | 2 |
| Yli-Kerttula, U | 1 |
| Piirainen, H | 2 |
| Pälvimäki, I | 1 |
| Koota, K | 1 |
| Friman, C | 1 |
| Blom, HJ | 1 |
| Giesendorf, BA | 1 |
| van Oppenraaij-Emmerzaal, D | 1 |
| Olive, P | 1 |
| Schattenkirchner, M | 4 |
| Meusser, S | 1 |
| Rau, R | 2 |
| Peldan, K | 1 |
| Harada, S | 1 |
| Mitsunobu, F | 1 |
| Kodama, F | 1 |
| Hosaki, Y | 1 |
| Mifune, T | 1 |
| Tsugeno, H | 1 |
| Okamoto, M | 1 |
| Yamamura, M | 1 |
| Makino, H | 1 |
| Tanizaki, Y | 1 |
| Schattner, A | 1 |
| Rojkovich, B | 1 |
| Hodinka, L | 1 |
| Bálint, G | 1 |
| Szegedi, G | 1 |
| Varjú, T | 1 |
| Tamási, L | 1 |
| Molnár, E | 1 |
| Szilágyi, M | 1 |
| Szocsik, K | 1 |
| Harlow, LA | 1 |
| Woods, JM | 1 |
| Amin, MA | 1 |
| Tokuhira, M | 1 |
| Reda, D | 1 |
| Henderson, W | 1 |
| Giobbie-Hurder, A | 1 |
| Williams, D | 1 |
| Diani, A | 1 |
| Docsa, S | 1 |
| Keysser, M | 1 |
| Keysser, G | 1 |
| Keysser, C | 1 |
| Hisakawa, N | 1 |
| Tahara, K | 1 |
| Matsumori, A | 1 |
| Ito, H | 1 |
| Hashimoto, K | 1 |
| Nakatani, K | 1 |
| Takatori, K | 1 |
| Nuver-Zwart, IH | 5 |
| Sharp, JT | 1 |
| Leung, H | 1 |
| Hurley, F | 1 |
| van Rijthoven, AW | 1 |
| Minghetti, PP | 1 |
| Blackburn, WD | 1 |
| Belseck, E | 1 |
| van Jaarsveld, CH | 1 |
| Jacobs, JW | 1 |
| van der Veen, MJ | 1 |
| Blaauw, AA | 1 |
| Kruize, AA | 1 |
| Hofman, DM | 1 |
| van Albada-Kuipers, GA | 1 |
| Heurkens, AH | 1 |
| ter Borg, EJ | 1 |
| Haanen, HC | 1 |
| van Booma-Frankfort, C | 1 |
| Schenk, Y | 1 |
| Rahman, P | 1 |
| Hefferton, D | 1 |
| Robb, D | 1 |
| Richardson, C | 1 |
| Griffiths, B | 1 |
| Green, MJ | 1 |
| McGonagle, D | 1 |
| Wakefield, RJ | 1 |
| Reece, RJ | 1 |
| Miles, S | 1 |
| Adebajo, A | 1 |
| Helliwell, P | 1 |
| Martin, M | 1 |
| Huston, G | 1 |
| Pease, C | 1 |
| Isaacs, J | 1 |
| Nordmark, B | 1 |
| Hassan Bakri, A | 1 |
| Forslid, J | 1 |
| Wong, A | 1 |
| Nagashima, M | 2 |
| Asano, G | 1 |
| Wauke, K | 1 |
| Hirano, D | 1 |
| Ishigami, S | 1 |
| Aono, H | 1 |
| Takai, M | 1 |
| Sasano, M | 1 |
| Soesan, M | 1 |
| van Oers, MH | 1 |
| van Soesbergen, RM | 1 |
| Islam, MN | 1 |
| Alam, MN | 1 |
| Moyenuzzaman, M | 1 |
| Patwary, MI | 1 |
| Rahman, MH | 1 |
| Helmy, M | 1 |
| Shohayeb, M | 1 |
| Helmy, MH | 1 |
| el-Bassiouni, EA | 1 |
| Helenius, LM | 1 |
| Hietanen, JH | 1 |
| Helenius, I | 1 |
| Lappalainen, M | 1 |
| Suuronen, R | 1 |
| Lindqvist, C | 1 |
| Wildy, KS | 1 |
| Wasko, MC | 1 |
| Williams, BD | 1 |
| Jones, P | 1 |
| Williams, RB | 1 |
| Nash, P | 1 |
| Sacks, R | 1 |
| Quallich, LG | 1 |
| Greenson, J | 1 |
| Haftel, HM | 1 |
| Fontana, RJ | 1 |
| Neff, L | 1 |
| Zeisel, M | 1 |
| Schöller-Guinard, M | 1 |
| Klein, JP | 1 |
| Wachsmann, D | 1 |
| Lau, G | 1 |
| Kwan, C | 1 |
| Chong, SM | 1 |
| Visser, H | 1 |
| vander Horst-Bruinsma, IE | 1 |
| te Koppele, JM | 1 |
| van der Laan, WH | 1 |
| Keso, L | 1 |
| Oksanen, K | 1 |
| Ahonen, M | 1 |
| Jacobsen, S | 1 |
| Skjødt, H | 1 |
| Sørensen, SF | 1 |
| Petersen, J | 1 |
| Junker, P | 1 |
| Ochi, T | 1 |
| Kondo, H | 1 |
| Nishioka, K | 2 |
| Nobuyuki, N | 1 |
| Ilonen, J | 1 |
| Franzen, P | 1 |
| Koski, J | 1 |
| Gripenberg-Gahmberg, M | 1 |
| Myllykangas-Luosujärvi, R | 1 |
| Mehandru, S | 1 |
| Smith, RL | 1 |
| Sidhu, GS | 1 |
| Cassai, N | 1 |
| Aranda, CP | 1 |
| Kita, K | 1 |
| Ollendorf, DA | 1 |
| Peterson, AN | 1 |
| Doyle, J | 1 |
| Huse, DM | 1 |
| Limburg, PC | 1 |
| Westra, J | 1 |
| Choi, HK | 1 |
| Seeger, JD | 1 |
| Kuntz, KM | 1 |
| Minaur, NJ | 1 |
| Kounali, D | 1 |
| Vedi, S | 1 |
| Compston, JE | 1 |
| Beresford, JN | 1 |
| Bhalla, AK | 1 |
| Stern, WK | 1 |
| Vyse, T | 1 |
| So, AK | 1 |
| Axford, JS | 1 |
| Sumar, N | 1 |
| Alavi, A | 1 |
| Isenberg, DA | 1 |
| Bodman, KB | 1 |
| Roitt, IM | 1 |
| Samanta, A | 1 |
| Webb, C | 3 |
| Fleming, J | 1 |
| Sheldon, PJ | 2 |
| Hamadeh, MA | 1 |
| Atkinson, J | 1 |
| Smith, LJ | 1 |
| Nolla, JM | 1 |
| Fiter, J | 1 |
| Mateo, L | 1 |
| Chakravarty, K | 1 |
| Scott, DG | 3 |
| McCann, BG | 1 |
| Boyce, E | 1 |
| Kuipers, EJ | 1 |
| Vellenga, E | 1 |
| de Wolf, JT | 1 |
| Hazenberg, BP | 1 |
| Murphy, NG | 1 |
| Kay, EA | 1 |
| Hilliquin, P | 1 |
| Munoz, A | 1 |
| Menkes, CJ | 1 |
| Taggart, AJ | 10 |
| McDermott, BJ | 1 |
| Roberts, SD | 2 |
| Maier, KP | 1 |
| Sturrock, R | 1 |
| Danis, VA | 1 |
| Franic, GM | 1 |
| Rathjen, DA | 1 |
| Laurent, RM | 1 |
| Brooks, PM | 2 |
| Felson, DT | 2 |
| Anderson, JJ | 2 |
| Meenan, RF | 2 |
| Deleuran, B | 1 |
| Kristensen, M | 1 |
| Paludan, K | 1 |
| Zachariae, C | 1 |
| Larsen, CG | 1 |
| Zachariae, E | 1 |
| Thestrup-Pedersen, K | 1 |
| Taha, AS | 2 |
| Russell, RI | 3 |
| Brooks, H | 1 |
| Taylor, HG | 1 |
| Nichol, FE | 1 |
| Pertuiset, E | 1 |
| Chevret, S | 1 |
| Bardin, T | 1 |
| Dryll, A | 1 |
| Kuntz, D | 2 |
| MacCarthy, J | 2 |
| Gribnau, FW | 4 |
| Jones, E | 1 |
| Jones, JV | 1 |
| Woodbury, JF | 1 |
| Olenginski, TP | 1 |
| Harrington, TM | 1 |
| Carlson, JP | 1 |
| Wittenberg, HR | 1 |
| Kleemeyer, K | 1 |
| Peskar, BM | 2 |
| Peskar, BA | 1 |
| Feltelius, N | 2 |
| Gudmundsson, S | 1 |
| Wennersten, L | 1 |
| Sjöberg, O | 1 |
| Marcus, RW | 1 |
| Fomina, LL | 1 |
| Tsitlanadze, VG | 1 |
| Shalamberidze, LP | 1 |
| Dzidziguri, LM | 1 |
| Kartvelishvili, EIu | 1 |
| Shakulashvili, NA | 1 |
| Gegeshidze, DG | 1 |
| Astvatsaturova, TR | 1 |
| Rejchrt, S | 1 |
| Hrncír, Z | 1 |
| Pintérová, E | 1 |
| Bliddal, H | 2 |
| Stangerup, M | 1 |
| Sukenik, S | 1 |
| Horowitz, I | 1 |
| Rubinov, A | 1 |
| Fluser, D | 1 |
| Scharf, Y | 1 |
| Shapira, D | 1 |
| Weinberger, A | 1 |
| Gedz, D | 1 |
| Scott, JT | 1 |
| Nishioka, N | 1 |
| Sakuma, A | 1 |
| Azuma, T | 1 |
| Iwasaki, Y | 1 |
| Tunn, EJ | 2 |
| Honkanen, VE | 1 |
| Matsuoka, Y | 1 |
| Yamamoto, S | 1 |
| Nakamura, M | 1 |
| Araki, M | 1 |
| Shizuku, T | 1 |
| Fujita, Y | 1 |
| Tsuboi, S | 1 |
| Okamoto, S | 1 |
| Miura, H | 1 |
| Wijelath, E | 1 |
| Smith, J | 1 |
| Winkler, V | 2 |
| Vértes, P | 1 |
| Dacre, JE | 2 |
| Greenwood, A | 1 |
| Treasure, L | 1 |
| Huskisson, EC | 3 |
| Sienknecht, CW | 1 |
| Sigidin, IaA | 3 |
| Zhukovskaia, GN | 1 |
| Donovan, S | 1 |
| Hawley, S | 1 |
| Boyd, O | 1 |
| Gibbs, AR | 1 |
| Smith, AP | 1 |
| Hopkinson, N | 1 |
| Zanelli, G | 1 |
| Prouse, P | 1 |
| Smethurst, P | 1 |
| Gumpel, JM | 2 |
| Levi, AJ | 1 |
| Marabani, M | 2 |
| Torley, H | 1 |
| Sitar, DS | 2 |
| Hunter, T | 2 |
| Juby, L | 1 |
| Zebouni, L | 1 |
| Marouf, ES | 1 |
| Shi, GY | 1 |
| Murphy, PT | 1 |
| O'Donnell, JR | 1 |
| Allebes, WA | 1 |
| Palmblad, J | 1 |
| Jonson, B | 1 |
| Lowe, JR | 1 |
| Campbell, D | 1 |
| Jaffe, IA | 1 |
| Konstantinova, M | 1 |
| Konstantinova, V | 1 |
| Schwarzer, AC | 1 |
| Arnold, MH | 1 |
| McCrae, F | 1 |
| Reglinski, J | 1 |
| Smith, WE | 2 |
| Brzeski, M | 1 |
| Yocum, DE | 1 |
| Wilder, RL | 1 |
| Klippel, JH | 2 |
| Pelísková, Z | 3 |
| Trnavský, K | 4 |
| Gatterová, J | 1 |
| Macek, J | 1 |
| Symmons, DP | 3 |
| vad de Putte, LB | 1 |
| Hardin, JG | 1 |
| Carroll, GJ | 1 |
| Will, RK | 1 |
| Breidahl, PD | 1 |
| Tinsley, LM | 1 |
| Farre, JM | 1 |
| Perez, T | 1 |
| Hautefeuille, P | 1 |
| Tonnel, F | 1 |
| Duquesnoy, B | 1 |
| Delcambre, B | 1 |
| Lyle, WH | 1 |
| Ridley, MG | 1 |
| Cheung, NT | 1 |
| Myles, AB | 1 |
| Pointud, P | 1 |
| Cauhape, P | 1 |
| Favreau, A | 1 |
| Eiberg, B | 1 |
| Helin, P | 1 |
| Svejgaard, A | 1 |
| Watts, CS | 1 |
| Neville, C | 1 |
| Baranovskiĭ, PV | 1 |
| Vysotskiĭ, IIu | 1 |
| Waterworth, RF | 1 |
| Aussedat, R | 1 |
| Guerci, A | 1 |
| Lederlin, P | 1 |
| Trechot, P | 1 |
| Pourel, J | 1 |
| Debiais, F | 1 |
| Azais, I | 1 |
| Boiffard, O | 1 |
| Vincent, MH | 1 |
| Alcalay, M | 1 |
| Bontoux, D | 1 |
| Lafeuillade, A | 1 |
| Bolla, G | 1 |
| Horschowski, N | 1 |
| Fossat, C | 1 |
| David, M | 1 |
| Salvator, V | 1 |
| Schiano, A | 1 |
| Farah, DA | 1 |
| Mills, PR | 1 |
| Lee, FD | 1 |
| McLay, A | 1 |
| Bax, DE | 10 |
| Robinson, MW | 1 |
| Martin, MF | 1 |
| McKenna, F | 1 |
| Hammarström, L | 1 |
| Smith, CI | 1 |
| Situnayake, D | 2 |
| Martin, L | 1 |
| Neumann, V | 1 |
| Hopkins, R | 1 |
| Dixon, J | 1 |
| Watkins, A | 1 |
| Bird, H | 1 |
| Muirden, KD | 1 |
| Greaves, MS | 4 |
| Vácha, J | 1 |
| Znojová, M | 1 |
| Nohejl, J | 1 |
| Hoult, JR | 1 |
| Gaston, JS | 1 |
| Rickinson, AB | 1 |
| Yao, QY | 1 |
| Epstein, MA | 1 |
| MacGilchrist, AJ | 1 |
| Pinals, RS | 4 |
| Kaplan, SB | 1 |
| Lawson, JG | 1 |
| Hepburn, B | 2 |
| Prouse, PJ | 1 |
| Shawe, D | 1 |
| Greaves, M | 1 |
| Bax, D | 1 |
| Mitrane, MP | 1 |
| Seibold, JR | 1 |
| Holmdahl, R | 1 |
| Rubin, K | 1 |
| Jonsson, R | 1 |
| Andersson, M | 1 |
| Lee, EJ | 1 |
| Ang, SB | 1 |
| Clegg, DO | 2 |
| Ward, JR | 2 |
| Khan, MF | 1 |
| Brown, DH | 1 |
| Villar Grimalt, A | 1 |
| Puche Azorín, P | 1 |
| Tumanova, IG | 1 |
| Fowler, PD | 1 |
| Sheeran, TP | 1 |
| Mielants, H | 1 |
| Proot, F | 1 |
| Wengrower, D | 1 |
| Pollak, A | 1 |
| Okon, E | 1 |
| Stalnikowicz, R | 1 |
| Takaya, M | 1 |
| Shinebaum, R | 1 |
| Cooke, EM | 1 |
| Ralston, SH | 1 |
| Willocks, LJ | 1 |
| Shaw, RW | 1 |
| Pitkeathly, DA | 1 |
| Dreyling, KW | 1 |
| May, B | 1 |
| Schaarschmidt, K | 1 |
| Goebell, H | 1 |
| Svenson, KL | 1 |
| Pollare, T | 1 |
| Lithell, H | 1 |
| McDermott, B | 1 |
| Delargy, M | 1 |
| Elborn, S | 1 |
| Forbes, J | 1 |
| Ahnfelt, NO | 1 |
| Coppock, J | 1 |
| Ghozlan, R | 1 |
| Dupuis, M | 1 |
| Schwak, A | 1 |
| Jorro, P | 1 |
| Lecarpentier, C | 1 |
| Guillon, C | 1 |
| Nuver-Zwart, HH | 1 |
| Bachrach, WH | 1 |
| Williams, HJ | 2 |
| Dahl, SL | 1 |
| Willkens, RF | 1 |
| Oglesby, T | 1 |
| Schlegel, S | 1 |
| Michaels, RM | 1 |
| Luggen, ME | 1 |
| Salmon, M | 1 |
| Comer, SS | 1 |
| Jasin, HE | 1 |
| Klein, HP | 1 |
| Rupp, M | 1 |
| Thiele-Fischbach, A | 1 |
| Chapman, P | 1 |
| Rudge, SR | 1 |
| Perrett, D | 1 |
| Kitas, G | 1 |
| Greenwood, M | 1 |
| Laurikainen, J | 1 |
| Somhegyi, A | 1 |
| Gömör, B | 1 |
| Vardhan, H | 1 |
| Kabra, P | 1 |
| Rohatgi, K | 1 |
| Singh, RR | 1 |
| Boey, ML | 1 |
| Lee, E | 1 |
| Feng, PH | 1 |
| Skosey, JL | 1 |
| López, R | 1 |
| Cuquet, J | 1 |
| Fitó, R | 1 |
| Pujol, R | 1 |
| Brodrick, A | 1 |
| Shiroky, J | 1 |
| Yunus, MB | 1 |
| Mizushima, H | 1 |
| Yoshizawa, H | 1 |
| Koshino, T | 1 |
| Tanaka, K | 1 |
| Jajić, I | 1 |
| Markan-Sosić, V | 1 |
| Sosić, Z | 1 |
| Jajić, Z | 1 |
| Phlippen, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Sulfasalazine Versus Leflunomide Based Combination Disease Modifying Anti-rheumatic Drug Therapy (DMARD) in Patients With Rheumatoid Arthritis Failing Methotrexate Monotherapy : A Randomized Control Trial[NCT02930343] | Phase 3 | 136 participants (Actual) | Interventional | 2016-09-30 | Terminated (stopped due to Due to time constraints, the study was halted prematurely) | ||
| Etude et Suivi Des POlyarthrites Indifférenciées Récentes[NCT03666091] | 813 participants (Actual) | Observational | 2002-11-13 | Active, not recruiting | |||
| A 2 Year Prospective Multicentre Randomised Controlled Trial Comparing Effectiveness in Daily Practice of Different Treatment Strategies for Early Rheumatoid Arthritis.[NCT01172639] | Phase 4 | 400 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| A Prospective Randomized, Open, Multi-Center Trial Comparing TNF-Blockade + MTX to MTX+SSZ+HCQ in Patients With Early RA With an Inadequate Response to MTX[NCT00764725] | Phase 4 | 487 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| A Multicenter, Randomized, Open-label, Blinded-assessor, Phase 4 Study in Patients With Early Rheumatoid Arthritis to Compare Active Conventional Therapy Versus Three Biologic Treatments, and Two De-escalation Strategies in Patients Who Respond to Treatme[NCT01491815] | Phase 4 | 812 participants (Actual) | Interventional | 2012-12-14 | Active, not recruiting | ||
| The Efficacy, Safety and Cost-effectiveness of Hydroxychloroquine, Sulfasalazine, Methotrexate Triple Therapy in Preventing Relapse Among Patients With Rheumatoid Arthritis Achieving Clinical Remission or Low Disease Activity[NCT02320630] | 240 participants (Anticipated) | Interventional | 2015-10-31 | Recruiting | |||
| REmission in Rheumatoid Arthritis - Assessing WIthrawal of Disease-modifying Antirheumatic Drugs in a Non-inferiority Design[NCT01881308] | Phase 4 | 320 participants (Actual) | Interventional | 2013-06-17 | Completed | ||
| CSP #551 - Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy[NCT00405275] | 353 participants (Actual) | Interventional | 2007-07-31 | Completed | |||
| A Multicenter, Randomized, Double-blind, Parallel Group Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously as Monotherapy, in Japanese Subjects With Active Rheumatoid Arthritis Unresponsive to Methotrexate or[NCT01689532] | Phase 3 | 122 participants (Actual) | Interventional | 2012-11-30 | Completed | ||
| Secondary Event Prevention Using Population Risk Management After PCI[NCT02694185] | 5,269 participants (Actual) | Interventional | 2016-10-01 | Active, not recruiting | |||
| Effectiveness of a Combination of Methotrexate and a Step Down Glucocorticoid Regimen (COBRA-Slim) for Remission Induction in Patients With Early Rheumatoid Arthritis (RA), With or Without Fast Access to 24 Weeks of Tumor Necrosis Factor (TNF) Blockade in[NCT03649061] | Phase 4 | 284 participants (Actual) | Interventional | 2018-06-08 | Completed | ||
| Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)[NCT00259610] | Phase 4 | 755 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Patients[NCT01565655] | Phase 2 | 289 participants (Actual) | Interventional | 2012-06-19 | Completed | ||
| Impact of Association of Individual and Group Therapeutic Education Sessions on the Acquisition of Safety Skills by Patients With Chronic Inflammatory Rheumatism (CIR) Treated With Subcutaneous Biotherapy, Compared to Individual Therapeutic Education Sess[NCT03838939] | 120 participants (Actual) | Interventional | 2019-01-21 | Completed | |||
| Comparison of Infliximab With Sulfasalazine/Hydroxychloroquine Initiated After Methotrexate by Rheumatoid Arthritis Patients Treated in Clinical Practice (Real-World Emulation of SWEFOT Trial)[NCT05051137] | 509 participants (Actual) | Observational | 2006-01-12 | Completed | |||
| A Randomized, Controlled, Open-label Study to Assess the Efficacy of T2 Versus Azathioprine for the Maintenance of Clinical and Endoscopic Remission in Subjects With Crohn's Disease After Surgical Resection[NCT01015391] | 100 participants (Anticipated) | Interventional | 2009-11-30 | Recruiting | |||
| Phase 1/2 Study of Tripterygium Wilfordii Hook F (TwHF) Treatment for Evaluation the Efficacy and Safety in Immune Non-responders With HIV-1 Infection[NCT01666990] | Phase 1/Phase 2 | 60 participants (Anticipated) | Interventional | 2012-06-30 | Recruiting | ||
| Effects of Tofacitinib on Body Composition, Bone Mineral Density and Bone Marrow Adiposity in Patients With Rheumatoid Arthritis: the TOFAT Project[NCT04175886] | 10 participants (Actual) | Observational | 2020-02-25 | Terminated (stopped due to Design has to been modified due to the results from ORAL Surveillance) | |||
| Better After CHoosing. Randomly Allocated or Patient Preference Based Treatment With Filgotinib or TNFi in Patients With Active Rheumatoid Arthritis (BACH)[NCT04985435] | Phase 4 | 100 participants (Anticipated) | Interventional | 2021-05-12 | Recruiting | ||
| Use of TNF-blocking Therapy in Combination With DMARDs in Patients With Early Rheumatoid Arthritis[NCT00908089] | Phase 4 | 100 participants (Actual) | Interventional | 2003-03-31 | Active, not recruiting | ||
| Uncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid Arthritis and Candidates With a Biological Monotherapy[NCT02087696] | Phase 4 | 122 participants (Anticipated) | Interventional | 2014-05-31 | Recruiting | ||
| Comparison of the Efficacy and Safety of Two Different Starting Dosages of Prednisolone in Early Active Rheumatoid Arthritis: a Randomized, Placebo Controlled Trial[NCT02000336] | Phase 3 | 395 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| Treat-to-target in RA: Collaboration To Improve adOption and adhereNce (TRACTION)[NCT02260778] | 11 participants (Actual) | Interventional | 2014-09-30 | Active, not recruiting | |||
| Cell Phone Based Automated Monitoring of Patients With Early Rheumatoid Arthritis[NCT02424877] | 165 participants (Actual) | Interventional | 2013-08-01 | Completed | |||
| Clinical (Sleep, Pain and Atrial Fibrillation) and Hospital Stay Effects of Reiki and Manual Therapy After Open Heart Surgery[NCT05853250] | 345 participants (Actual) | Interventional | 2017-06-26 | Completed | |||
| Prospective Randomized Trial Comparing Clamp Versus Clampless Robot Assisted Partial Nephrectomy[NCT02287987] | 200 participants (Anticipated) | Interventional | 2014-10-31 | Enrolling by invitation | |||
| Aromatherapy for Management of Chemotherapy-induced Symptoms[NCT02670941] | Early Phase 1 | 31 participants (Actual) | Interventional | 2016-01-31 | Terminated (stopped due to Slow accrual; Received grant funding for a similar but different study.) | ||
| Potential Benefits of the Somatic Psychoeducational Intervention for Improving the Health and Wellness of Healthcare Providers[NCT05766852] | 70 participants (Anticipated) | Interventional | 2023-10-23 | Recruiting | |||
| A Home-based Personalized Multidomain RCT From the Canadian Therapeutic Platform for Multidomain Interventions to Prevent Dementia (CAN-THUMBS UP)[NCT05375513] | 275 participants (Anticipated) | Interventional | 2023-06-05 | Recruiting | |||
| Evaluation of a Mind-body Based Application for the Treatment of Chronic/Persistent Pain.[NCT05090683] | 197 participants (Actual) | Interventional | 2021-10-15 | Active, not recruiting | |||
| The Efficacy of Ultrasound Guided Posterior Sacroiliac Ligament Corticosteroid Injection in Pregnancy-Related Pelvic Girdle Pain: A Randomized Controlled Trial[NCT02044991] | Phase 2 | 2 participants (Actual) | Interventional | 2013-10-24 | Terminated (stopped due to The study was halted prematurely due to poor recruitment) | ||
| Clinically Important Changes in Rheumatoid Arthritis[NCT00056602] | 192 participants (Actual) | Observational | 2003-03-18 | Completed | |||
| Evaluation of the Effect of Cilostazol on the Clinical Outcomes of Rheumatoid Arthritis Patients[NCT05671497] | Phase 2/Phase 3 | 70 participants (Anticipated) | Interventional | 2022-11-01 | Recruiting | ||
| Switching Anti-TNF-alpha Agents in Patients With RA With An Inadequate Response to TNF-alpha Inhibition[NCT00796705] | Phase 4 | 13 participants (Actual) | Interventional | 2008-11-30 | Terminated (stopped due to Lack of Enrollment) | ||
| Diagnostic Utility of Anti-mutated Citrullinated Vimentin Antibodies,Anti Cyclic Citrullinated Peptide Antibodies and Rheumatoid Factor in Rheumatoid Arthritis[NCT03224377] | 80 participants (Anticipated) | Observational | 2017-10-09 | Not yet recruiting | |||
| Wireless Motion Sensors for Rheumatoid Arthritis Patients - Pilot Study and Preliminary Validation Effort[NCT02296632] | 7 participants (Actual) | Observational | 2014-11-30 | Completed | |||
| Monoarticular Corticosteroid Injection Versus Systemic Administration in the Treatment of Rheumatoid Arthritis Patients: A Randomized Double-Blind Controlled Study[NCT00506896] | Phase 2 | 60 participants (Actual) | Interventional | 2004-07-31 | Completed | ||
| The Effect of Tocilizumab (Anti-interleukin-6) Treatment on microRNA Expression and Adipokine Levels in Rheumatoid Arthritis Patients[NCT03149796] | 80 participants (Actual) | Observational | 2011-03-23 | Completed | |||
| Safety, Activity, and Pharmacology of Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease[NCT03656627] | Phase 1 | 7 participants (Actual) | Interventional | 2019-06-27 | Terminated (stopped due to low accrual) | ||
| A Double Blind Randomized Controlled Trial to Compare Biannual Peripheral Magnetic Resonance Imaging, Radiography, and Standard of Care on Pharmacotherapeutic Escalation in Inflammatory Arthritis[NCT00808496] | Phase 4 | 186 participants (Anticipated) | Interventional | 2009-06-30 | Active, not recruiting | ||
| Inflammation Impact on Pain in Patients With Knee Osteoarthritis[NCT03389906] | 32 participants (Actual) | Interventional | 2017-12-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Ultrasound 7 score (US-7) Calculates ultrasound score in 7 joints using greyscale and power doppler to evaluate for disease activity (synovitis, tenosynovitis) and damage (erosions) Score minimum value= 0 Maximum value = 108 Higher score indicates worse disease (NCT02930343)
Timeframe: 12 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Group 1- MTX+LEF+HCQ | 3.5 |
| Group 2- MTX+SSZ+HCQ | 4 |
Indian version of Health assessment Questionnaire (iHAQ) Comprises of 12 questions relating to functional activity iHAQ score ranges from 0 to 3 (minimum 0, maximum 3) Higher scores indicate more disability (NCT02930343)
Timeframe: 12 weeks
| Intervention | score on a scale (Median) |
|---|---|
| Group 1- MTX+LEF+HCQ | 0.7 |
| Group 2- MTX+SSZ+HCQ | 0.5 |
"EULAR response criteria for Rheumatoid arthritis includes- estimation of DAS 28 ESR, that includes-~Tender joint count 28~Swollen joint count 28~ESR~Patient global assessment of health" (NCT02930343)
Timeframe: 12 weeks
| Intervention | participants (Number) |
|---|---|
| Group 1- MTX+LEF+HCQ | 40 |
| Group 2- MTX+SSZ+HCQ | 37 |
Infections, transaminitis, nausea, vomiting, derranged renal function tests etc (NCT02930343)
Timeframe: 24 weeks
| Intervention | Participants (Count of Participants) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total number of any adverse events | Serious adverse events | Any gastrointestinal adverse reaction | Nausea | Diarrhea | Switch to parenteral Methotrexate | Raised liver enzymes > 2 times upper limit normal | Herpes labialis | upper respiratory tract infection | urinary tract infection | Hypertension | hairfall | Cytopenia | |
| Group 1- MTX+LEF+HCQ | 15 | 0 | 11 | 4 | 1 | 5 | 1 | 0 | 5 | 1 | 1 | 2 | 0 |
| Group 2- MTX+SSZ+HCQ | 21 | 0 | 16 | 6 | 1 | 14 | 1 | 2 | 5 | 0 | 0 | 2 | 0 |
"Number of patients with a change of > 0.22 in the Health Assessment Questionnaire (HAQ) score over the period between baseline and week 104.~A change of > 0.22 in this score is considered as clinical relevant for rheumatoid arthritis patients." (NCT01172639)
Timeframe: Baseline-week104
| Intervention | Participants (Count of Participants) |
|---|---|
| CoBRA Classic High Risk Group | 71 |
| CoBRA Slim High Risk Group | 62 |
| CoBRA Avant-garde High Risk Group | 64 |
| CoBRA Slim Low Risk Group | 25 |
| Tight Step Up Low Risk Group | 26 |
"Number of patients in remission according to DAS28-CRP (Disease Activity Score based on 28 joint count and C-reactive Protein) at week 104. (co-primary endpoints)~DAS28-CRP is calculated with the following formula : 0.56*SQRT TJC28+0.28*SQRT SJC28+0.36*ln (CRP+1)+0.014*GH+0.96 in which TJC is the tender joint count, SJC the Swollen Joint Count and GH the general health estimated by the patient on a Visual Analogue Scale (VAS).~A value below 2.6 is indicating remission, below or equal to 3.2 low disease activity, between 3.2 and 5.1 moderate disease activity and above 5.1 high disease activity." (NCT01172639)
Timeframe: week 104
| Intervention | Participants (Count of Participants) |
|---|---|
| CoBRA Classic High Risk Group | 64 |
| CoBRA Slim High Risk Group | 71 |
| CoBRA Avant-garde High Risk Group | 69 |
| CoBRA Slim Low Risk Group | 29 |
| Tight Step Up Low Risk Group | 34 |
"Number of patients in remission according to DAS28-CRP (Disease Activity Score based on 28 joint count and C-reactive Protein) at week 16.~DAS28-CRP is calculated with the following formula : 0.56*SQRT TJC28+0.28*SQRT SJC28+0.36*ln (CRP+1)+0.014*GH+0.96 in which TJC is the tender joint count, SJC the Swollen Joint Count and GH the general health estimated by the patient on a Visual Analogue Scale (VAS).~A value below 2.6 is indicating remission, below or equal to 3.2 low disease activity, between 3.2 and 5.1 moderate disease activity and above 5.1 high disease activity." (NCT01172639)
Timeframe: week 16
| Intervention | Participants (Count of Participants) |
|---|---|
| CoBRA Classic High Risk Group | 69 |
| CoBRA Slim High Risk Group | 72 |
| CoBRA Avant-garde High Risk Group | 61 |
| CoBRA Slim Low Risk Group | 25 |
| Tight Step Up Low Risk Group | 23 |
"Number of patients in remission according to DAS28-CRP (Disease Activity Score based on 28 joint count and C-reactive Protein) at week 52. (co-primary end point)~DAS28-CRP is calculated with the following formula : 0.56*SQRT TJC28+0.28*SQRT SJC28+0.36*ln (CRP+1)+0.014*GH+0.96 in which TJC is the tender joint count, SJC the Swollen Joint Count and GH the general health estimated by the patient on a Visual Analogue Scale (VAS).~A value below 2.6 is indicating remission, below or equal to 3.2 low disease activity, between 3.2 and 5.1 moderate disease activity and above 5.1 high disease activity." (NCT01172639)
Timeframe: week 52
| Intervention | Participants (Count of Participants) |
|---|---|
| CoBRA Classic High Risk Group | 63 |
| CoBRA Slim High Risk Group | 57 |
| CoBRA Avant-garde High Risk Group | 57 |
| CoBRA Slim Low Risk Group | 29 |
| Tight Step Up Low Risk Group | 29 |
"Number of patients in remission according to SDAI (Simplified Disease Activity Index) at week 16.~SDAI is calculated with the following formula : TJC28+SJC28+GH+GA ph in which TJC is the number of tender joints, SJC the number of Swollen Joint and GH the general health assessed by the patient on a Visual Analogue Scale (VAS) and GA ph the general assessment of the physician on a VAS.~A value below 3.3 is indicating remission, between 3.4 and 11.0 low disease activity, between 11.1 and 26.0 moderate disease activity and above 26.0 high disease activity." (NCT01172639)
Timeframe: week 16
| Intervention | Participants (Count of Participants) |
|---|---|
| CoBRA Classic High Risk Group | 42 |
| CoBRA Slim High Risk Group | 33 |
| CoBRA Avant-garde High Risk Group | 44 |
| CoBRA Slim Low Risk Group | 12 |
| Tight Step Up Low Risk Group | 12 |
"Number of patients in remission according to SDAI (Simplified Disease Activity Index) at week 104.~SDAI is calculated with the following formula : TJC28+SJC28+GH+GA ph in which TJC is the number of tender joints, SJC the number of Swollen Joint and GH the general health assessed by the patient on a Visual Analogue Scale (VAS) and GA ph the general assessment of the physician on a VAS.~A value below 3.3 is indicating remission, between 3.4 and 11.0 low disease activity, between 11.1 and 26.0 moderate disease activity and above 26.0 high disease activity." (NCT01172639)
Timeframe: week 104
| Intervention | Participants (Count of Participants) |
|---|---|
| CoBRA Classic High Risk Group | 31 |
| CoBRA Slim High Risk Group | 28 |
| CoBRA Avant-garde High Risk Group | 41 |
| CoBRA Slim Low Risk Group | 20 |
| Tight Step Up Low Risk Group | 13 |
"Number of patients in remission according to SDAI (Simplified Disease Activity Index) at week 52.~SDAI is calculated with the following formula : TJC28+SJC28+GH+GA ph in which TJC is the number of tender joints, SJC the number of Swollen Joint and GH the general health assessed by the patient on a Visual Analogue Scale (VAS) and GA ph the general assessment of the physician on a VAS.~A value below 3.3 is indicating remission, between 3.4 and 11.0 low disease activity, between 11.1 and 26.0 moderate disease activity and above 26.0 high disease activity." (NCT01172639)
Timeframe: week 52
| Intervention | Participants (Count of Participants) |
|---|---|
| CoBRA Classic High Risk Group | 36 |
| CoBRA Slim High Risk Group | 27 |
| CoBRA Avant-garde High Risk Group | 39 |
| CoBRA Slim Low Risk Group | 20 |
| Tight Step Up Low Risk Group | 15 |
"Average difference between 48-week and Baseline DAS28.~The Disease Activity Score for 28 Joints (DAS28) is a well-validated composite outcome measure ranging from 2-10 (higher scores indicating more disease) that incorporates a tender and swollen joint count of 28 joints, a laboratory measure of systemic inflammation (ESR) and a patient-reported general assessment of health on a visual analog scale (ranging from 0-10cm) all into one measure.~Low disease activity is defined as DAS28 ≤ 3.2 units." (NCT00405275)
Timeframe: 48 weeks after baseline assessment
| Intervention | units on a scale (Mean) |
|---|---|
| Triple | -2.12 |
| Etanercept | -2.29 |
A TEAE was defined as an event that occurred in the treatment period during which it emerged (that is [i.e.] started or worsened in severity, relation, or other attribute), and even if the event continued to be present. (NCT01689532)
Timeframe: Baseline upto Week 68
| Intervention | participants (Number) |
|---|---|
| Sirukumab 50 Milligram (mg) | 56 |
| Sirukumab 100 mg | 58 |
The DAS28 based on C-Reactive Protein (CRP) is a statistically derived index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. DAS28 (CRP) remission is defined as a DAS28 (CRP) value of less than (<) 2.6 at any study visit. (NCT01689532)
Timeframe: At Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Sirukumab 50 Milligram (mg) | 49.2 |
| Sirukumab 100 mg | 59.0 |
The HAQ-DI is a 20-question instrument that assesses the degree of difficulty a participant has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living), each scored from 0 (no difficulty) to 3 (inability to perform a task in that area). HAQ-DI responders who maintain a change from baseline of > -0.22 in HAQ-DI score. (NCT01689532)
Timeframe: Baseline upto Week 52
| Intervention | percentage of participants (Number) |
|---|---|
| Sirukumab 50 Milligram (mg) | 70.5 |
| Sirukumab 100 mg | 65.6 |
Major clinical response is achieving ACR 70 for 6 continuous months. The ACR 70 Response is defined as >=70 percent improvement in swollen joint count (66 joints) and tender joint count (68 joints) and >=70 percent improvement in 3 of following 5 assessments: patient's assessment of pain using VAS (0-10 mm, 0 mm=no pain and 10 mm=worst possible pain), patient's global assessment of disease activity by using VAS, (The scale ranges from 0 mm to 100 mm, [0 mm=no pain to 100 mm=worst possible pain]), physician's global assessment of disease activity using VAS, participant's assessment of physical function measured by HAQ-DI and CRP. Achievement of major clinical response reflects an enhanced level of therapeutic efficacy and sustained reduction of signs and symptoms of rheumatoid arthritis (RA). (NCT01689532)
Timeframe: Week 52
| Intervention | percentage of participants (Number) |
|---|---|
| Sirukumab 50 Milligram (mg) | 13.1 |
| Sirukumab 100 mg | 24.6 |
HAQ-DI consisted of 20-question in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living), each scored from 0 (no difficulty) to 3 (inability to perform a task in that area). Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty. AUC of change from baseline in HAQ-DI score is the AUC of change from baseline in HAQ-DI score versus the time. AUC was calculated based on the measurement (i.e., observed HAQ-DI score change from baseline) at scheduled visits using the trapezoidal rule. Functional status was determined as a cumulative measure of HAQ-DI over 1 year by using the AUC of the change from baseline in HAQ-DI score through week 52. Decreases in AUC of change from baseline in HAQ-DI indicate a greater average improvement in physical function over time. (NCT01689532)
Timeframe: Baseline, Weeks 24 and 52
| Intervention | units on a scale*week (Mean) | |
|---|---|---|
| Week 0 Through Week 24 | Week 0 Through Week 52 | |
| Sirukumab 100 mg | -69.2439 | -187.4068 |
| Sirukumab 50 Milligram (mg) | -74.0645 | -189.2531 |
The CDAI score is a derived score combining tender joints (28 joints), swollen joints (28 joints), patient's global assessment of disease activity, and physician's global assessments of disease activity. The total score range is 0-76. Score interpretation: Remission <=2.8; Low Disease Activity CDAI > 2.8 and <=10; Moderate Disease Activity CDAI >10 and <=22; High Disease Activity CDAI > 22. (NCT01689532)
Timeframe: Baseline, Weeks 16 and 24
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Change at Week 16 | Change at Week 24 | |
| Sirukumab 100 mg | 35.69 | -22.69 | -23.86 |
| Sirukumab 50 Milligram (mg) | 31.36 | -19.43 | -20.27 |
The DAS28 based on C-Reactive Protein (CRP) is a statistically derived index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. (NCT01689532)
Timeframe: Baseline, Weeks 16 and 24
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Change at Week 16 | Change at Week 24 | |
| Sirukumab 100 mg | 5.805 | -3.069 | -3.185 |
| Sirukumab 50 Milligram (mg) | 5.566 | -2.858 | -2.949 |
Duration of morning stiffness was defined as the time elapsed when participant woke up in the morning and was able to resume normal activities without stiffness in minutes (If none was present = 0; If morning stiffness was continuing at the time of assessment or was unusual compared to the recent past, average of duration of stiffness over the past 3 days was reported; If stiffness persisted the entire day, 1440 minutes was recorded). Negative values for this outcome measure represent improvement, i.e. shortening of duration of morning stiffness. (NCT01689532)
Timeframe: Baseline, Weeks 16 and 24
| Intervention | minute (Mean) | |
|---|---|---|
| Change at Week 16 | Change at Week 24 | |
| Sirukumab 100 mg | -160.4 | -169.4 |
| Sirukumab 50 Milligram (mg) | -103.8 | -77.6 |
"Change from Baseline to end point in Euro Quality of life (Qol)-5 Dimension Questionnaire (EQ-5D). A higher score indicates an improvement in health in the Health Status Index. The EuroQol-5 is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=extreme problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1, with 1.00 indicating full health and 0 representing dead." (NCT01689532)
Timeframe: Baseline, Weeks 16, 24 and 52
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Change at Week 16 | Change at Week 24 | Change at Week 52 | |
| Sirukumab 100 mg | 0.18 | 0.19 | 0.19 |
| Sirukumab 50 Milligram (mg) | 0.16 | 0.17 | 0.16 |
The EQ-5D VAS records the participant's self-rated health on a vertical, VAS, with 0 representing the worst imaginable health state and 100 representing the best imaginable health state. The EQ VAS is used as a quantitative measure of health outcome as judged by the individual participant. (NCT01689532)
Timeframe: Baseline, Weeks 16, 24 and 52
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Change at Week 16 | Change at Week 24 | Change at Week 52 | |
| Sirukumab 100 mg | 25.93 | 28.85 | 31.50 |
| Sirukumab 50 Milligram (mg) | 30.20 | 32.46 | 33.54 |
The HAQ-DI is a 20-question instrument that assesses the degree of difficulty a participant has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living), each scored from 0 (no difficulty) to 3 (inability to perform a task in that area). Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty. (NCT01689532)
Timeframe: Baseline, at Week 16 and 24
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Change at Week 16 | Change at Week 24 | |
| Sirukumab 100 mg | 1.1721 | -0.4980 | -0.5697 |
| Sirukumab 50 Milligram (mg) | 1.3484 | -0.5676 | -0.5738 |
The SF-36 is a survey of participant health. It consists of 8 individual domains, which are weighted sums of the questions in their section. The 8 domains are: vitality (VT), physical functioning (PF), bodily pain (BP), general health (GH), Role-Physical (RP), Role-Emotional (RE), social functioning (SF) and mental health (MH). Each of these 8 scales (domains) is scored from 0 to 100 with higher scores indicating better health. Based on the scale scores, the summary mental component score (MCS) is derived. Scales contributing most to the scoring of the SF-36 MCS include the VT, SF, RE and MH. Other domains not noted contribute to the scoring but to a lesser degree. The scoring is derived based on an algorithm that has been developed in a software provided by the developer. The summary MCS score is also scaled from 0 to 100 with higher scores indicating better health. (NCT01689532)
Timeframe: Baseline, Weeks 16, 24 and 52
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline (Mental Component Score [MCS]) | Change at Week 16 (MCS) | Change at Week 24 (MCS) | Change at Week 52 (MCS) | |
| Sirukumab 100 mg | 46.55 | 6.46 | 6.81 | 6.27 |
| Sirukumab 50 Milligram (mg) | 45.49 | 5.38 | 5.82 | 6.74 |
The SF-36 is a survey of participant health. It consists of 8 individual domains, which are weighted sums of the questions in their section. The 8 domains are: vitality (VT), physical functioning (PF), bodily pain (BP), general health (GH), Role-Physical (RP), Role-Emotional (RE), social functioning (SF) and mental health (MH). Each of these 8 scales (domains) is scored from 0 to 100 with higher scores indicating better health. Based on the scale scores, the summary physical component score (PCS) is derived. Scales contributing most to the scoring of the SF-36 PCS include the PF, RP, BP and GH. Other domains not noted contribute to the scoring but to a lesser degree. The scoring is derived based on an algorithm that has been developed in a software provided by the developer. The summary PCS score is also scaled from 0 to 100 with higher scores indicating better health. (NCT01689532)
Timeframe: Baseline, Weeks 16, 24 and 52
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline (Physical Component Score [PCS]) | Change at Week 16 (PCS) | Change at Week 24 (PCS) | Change at Week 52 (PCS) | |
| Sirukumab 100 mg | 24.10 | 12.48 | 14.72 | 14.30 |
| Sirukumab 50 Milligram (mg) | 22.12 | 12.12 | 12.45 | 13.67 |
The SDAI score is a derived score combining tender joints (28 joints), swollen joints (28 joints), patient's global assessment of disease activity, physician's global assessments of disease activity, and CRP. The total score range is 0-86. Score interpretation: Remission SDAI <=3.3; Low Disease Activity SDAI >3.3 and <=11; Moderate Disease Activity SDAI >11 and <=26; High Disease Activity SDAI >26. (NCT01689532)
Timeframe: Baseline, Weeks 16 and 24
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Change at Week 16 | Change at Week 24 | |
| Sirukumab 100 mg | 38.911 | -25.896 | -27.064 |
| Sirukumab 50 Milligram (mg) | 34.318 | -22.365 | -23.206 |
Serum CRP is a marker of systemic inflammation. A negative percent change from baseline in CRP represents improvement. (NCT01689532)
Timeframe: Baseline, Weeks 16 and 24
| Intervention | percent change (Mean) | |
|---|---|---|
| Change at Week 16 | Change at Week 24 | |
| Sirukumab 100 mg | -98.97 | -98.99 |
| Sirukumab 50 Milligram (mg) | -98.60 | -98.64 |
The HAQ-DI is a 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping and activities of daily living). Responses in each functional area are scored from 0 to 3 (0=no difficulty and 3=inability to perform a task in that area). Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty. Here, 'n' signifies those participants who were evaluable for the specific timepoint. (NCT01689532)
Timeframe: Baseline, Weeks 16 and 24
| Intervention | percent change (Mean) | |
|---|---|---|
| Change at Week 16 (n= 59, 58) | Change at Week 24 (n= 59, 58) | |
| Sirukumab 100 mg | -46.18 | -48.98 |
| Sirukumab 50 Milligram (mg) | -38.90 | -42.25 |
Sixty six (66) joints were assessed for swelling by investigator to determine the number of joints that were considered swollen. A negative change from baseline in swollen joint count indicates improvement. (NCT01689532)
Timeframe: Baseline, Weeks 16 and 24
| Intervention | percent change (Mean) | |
|---|---|---|
| Change at Week 16 | Change at Week 24 | |
| Sirukumab 100 mg | -73.84 | -75.82 |
| Sirukumab 50 Milligram (mg) | -65.66 | -71.16 |
Sixty eight (68) joints were assessed for tenderness to determine the number of joints that were considered tender. A negative change from baseline in the tender joint count indicates improvement. (NCT01689532)
Timeframe: Baseline, Weeks 16 and 24
| Intervention | percent change (Mean) | |
|---|---|---|
| Change at Week 16 | Change at Week 24 | |
| Sirukumab 100 mg | -65.58 | -67.34 |
| Sirukumab 50 Milligram (mg) | -63.95 | -65.58 |
Participants assessed their average pain during the past week on a visual analogue scale (VAS). The scale ranged from 0 (no pain) to 10 (the worst possible pain). (NCT01689532)
Timeframe: Baseline, Weeks 16 and 24
| Intervention | percent change (Mean) | |
|---|---|---|
| Change at Week 16 | Change at Week 24 | |
| Sirukumab 100 mg | -52.94 | -57.56 |
| Sirukumab 50 Milligram (mg) | -53.44 | -52.45 |
Participants rated their disease activity using the Visual Analog Scale (VAS) on a scale of 0 (very well) to 10 (very poor). (NCT01689532)
Timeframe: Baseline, Weeks 16 and 24
| Intervention | percent change (Mean) | |
|---|---|---|
| Change at Week 16 | Change at Week 24 | |
| Sirukumab 100 mg | -53.15 | -56.94 |
| Sirukumab 50 Milligram (mg) | -50.64 | -51.55 |
Physician's Global Assessment of Disease Activity was assessed using the VAS on a scale of 0 (no arthritis activity) to 10 (extremely active arthritis). (NCT01689532)
Timeframe: Baseline, Weeks 16 and 24
| Intervention | percent change (Mean) | |
|---|---|---|
| Change at Week 16 | Change at Week 24 | |
| Sirukumab 100 mg | -66.17 | -68.44 |
| Sirukumab 50 Milligram (mg) | -65.28 | -67.54 |
The ACR 20 Response is defined as greater than or equal to (>=) 20 percent improvement in swollen joint count (66 joints) and tender joint count (68 joints) and >=20 percent improvement in 3 of following 5 assessments: patient's assessment of pain using Visual Analog Scale (VAS; 0-10 millimeter [mm], 0 mm=no pain and 10 mm=worst possible pain), patient's global assessment of disease activity by using VAS (the scale ranges from 0 mm to 100 mm, [0 mm=no pain to 100 mm=worst possible pain]), physician's global assessment of disease activity using VAS, participant's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, defined as a 20-question instrument assessing 8 functional areas. The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and serum C-Reactive Protein (CRP). (NCT01689532)
Timeframe: At Weeks 16 and 24
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Week 16 | Week 24 | |
| Sirukumab 100 mg | 72.1 | 82.0 |
| Sirukumab 50 Milligram (mg) | 77.0 | 73.8 |
The ACR 50 Response is defined as >=50 percent improvement in swollen joint count (66 joints) and tender joint count (68 joints) and >=50 percent improvement in 3 of following 5 assessments: patient's assessment of pain using VAS (0-10 mm, 0 mm=no pain and 10 mm=worst possible pain), patient's global assessment of disease activity by using VAS (the scale ranges from 0 mm to 100 mm, [0 mm=no pain to 100 mm=worst possible pain]), physician's global assessment of disease activity using VAS, participant's assessment of physical function measured by HAQ-DI and serum CRP. (NCT01689532)
Timeframe: At Weeks 16 and 24
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Week 16 | Week 24 | |
| Sirukumab 100 mg | 57.4 | 63.9 |
| Sirukumab 50 Milligram (mg) | 47.5 | 49.2 |
The ACR 70 Response is defined as >=70 percent improvement in swollen joint count (66 joints) and tender joint count (68 joints) and >=70 percent improvement in 3 of following 5 assessments: patient's assessment of pain using VAS (0-10 mm, 0 mm=no pain and 10 mm=worst possible pain), patient's global assessment of disease activity by using VAS (the scale ranges from 0 mm to 100 mm, [0 mm=no pain to 100 mm=worst possible pain]), physician's global assessment of disease activity using VAS, participant's assessment of physical function measured by HAQ-DI and CRP. (NCT01689532)
Timeframe: At Weeks 16 and 24
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Week 16 | Week 24 | |
| Sirukumab 100 mg | 32.8 | 36.1 |
| Sirukumab 50 Milligram (mg) | 26.2 | 24.6 |
The ACR 90 Response is defined as >=90 percent improvement in swollen joint count (66 joints) and tender joint count (68 joints) and >=90 percent improvement in 3 of following 5 assessments: patient's assessment of pain using VAS (0-10 mm, 0 mm=no pain and 10 mm=worst possible pain), patient's global assessment of disease activity by using VAS (the scale ranges from 0 mm to 100 mm, [0 mm=no pain to 100 mm=worst possible pain]), physician's global assessment of disease activity using VAS, participant's assessment of physical function measured by HAQ-DI and CRP. (NCT01689532)
Timeframe: At Weeks 16 and 24
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Week 16 | Week 24 | |
| Sirukumab 100 mg | 11.5 | 14.8 |
| Sirukumab 50 Milligram (mg) | 8.2 | 6.6 |
The HAQ-DI is a 20-question instrument that assesses the degree of difficulty a participant has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living), each scored from 0 (no difficulty) to 3 (inability to perform a task in that area). HAQ-DI response was defined as change of > -0.22 from baseline in HAQ-DI score. (NCT01689532)
Timeframe: At Weeks 16 and 24
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Week 16 | Week 24 | |
| Sirukumab 100 mg | 67.2 | 70.5 |
| Sirukumab 50 Milligram (mg) | 75.4 | 73.8 |
The Boolean based ACR/EULAR remission is achieved if all of the following 4 criteria at that visit are met: tender joint count (68 joints) <=1; swollen joint count (66 joints) <=1; CRP <=1 milligram per deciliter (mg/dL); and patient's global assessment of disease activity on visual analog scale (VAS) <=1 on a 0 to 10 scale. (NCT01689532)
Timeframe: At Weeks 16, 24 and 52
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Week 16 | Week 24 | Week 52 | |
| Sirukumab 100 mg | 14.8 | 8.2 | 13.1 |
| Sirukumab 50 Milligram (mg) | 4.9 | 9.8 | 8.2 |
The DAS28 based on C-Reactive Protein (CRP) is a statistically derived index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. Good responders: improvement from baseline greater than (>) 1.2 with DAS28 less than or equal to (<=) 3.2; moderate responders: improvement from baseline >1.2 with DAS28 >3.2 to <=5.1 or improvement from baseline >0.6 to <=1.2 with DAS28 <=5.1; non-responders: improvement from baseline <=0.6 or improvement from baseline >0.6 and <=1.2 with DAS28 >5.1. (NCT01689532)
Timeframe: At Weeks 16 and 24
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Week 16 | Week 24 | |
| Sirukumab 100 mg | 96.7 | 96.7 |
| Sirukumab 50 Milligram (mg) | 90.2 | 88.5 |
The SDAI score is a derived score combining tender joints (28 joints), swollen joints (28 joints), patient's global assessment of disease activity on VAS, physician's global assessments of disease activity on VAS, and CRP. SDAI-based ACR/EULAR remission is defined as a SDAI value of <=3.3 at the visit. (NCT01689532)
Timeframe: At Weeks 16, 24 and 52
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Week 16 | Week 24 | Week 52 | |
| Sirukumab 100 mg | 19.7 | 18.0 | 26.2 |
| Sirukumab 50 Milligram (mg) | 14.8 | 16.4 | 18.0 |
Cardiovascular Events (CVEs) such as mortality, myocardial infarction, stroke, or repeat revascularization among IHD patients at 12 months post-PCI and progressive erosive disease demonstrated in patients with rheumatic disease will be monitored. CVEs will be monitored to determine if there is a reduction in the occurrence of those events as a result of the intervention. (NCT02694185)
Timeframe: 1 year
| Intervention | Cardiovascular events (Mean) |
|---|---|
| Experimental Group | 15.2 |
| Control Group | 14.3 |
To establish the cost to implement and maintain the intervention, above the cost of usual care. Incremental Cost Effectiveness (ICE) is the cost to achieve a 10% improvement in PDC, and the cost of CVE prevented. (NCT02694185)
Timeframe: through study completion, an average of 1 year
| Intervention | dollars per patient (Median) |
|---|---|
| Experimental Group | 821.45 |
| Control Group | 893.55 |
Proportion of Days Covered (PDC) is measured by looking at the number of doses of medication a patient has versus days in the month (if a patient has 20 days of medication for a 30 day period their PDC is 20/30, 2/3, or 66.7%). Used to assess the effectiveness of the intervention, PDC will be tested among IHD patients in the year after PCI and among rheumatology clinic patients chronically prescribed DMARDs. (NCT02694185)
Timeframe: 1 year
| Intervention | percentage of days covered (Mean) | ||
|---|---|---|---|
| Anti-platelet | Beta-Blocker | Statin | |
| Control Group | 75.6 | 73.3 | 71.2 |
| Experimental Group | 82.6 | 78.4 | 78.8 |
"Outcome measured was the observed-group analysis of the DAS28-ESR between weeks 48 and 102. DAS28 is a calculated scale using a formula that includes the number of tender joints and swollen joints (28 joints maximum). The following is the calculation: DAS28 = 0.56 * sqrt(tender28) + 0.28 * sqrt(swollen28) + 0.70 * ln(ESR) + 0.014 * GH. The ESR is the rate at which red blood cells sediment in a period of one hour.~The total range for the DAS28ESR goes from 0.0 to 9.2; this indicates the current activity of the rheumatoid arthritis of a subject. A DAS28 above 5.1 means high disease activity whereas a DAS28 below 3.2 indicates low disease activity." (NCT00259610)
Timeframe: Change of the Mean of DAS28-ESR between weeks 48 - 102.
| Intervention | Scores on a scale (Mean) |
|---|---|
| MTX + Immediate Etanercept | 3.0 |
| MTX+ Immediate SSZ +HCQ | 2.9 |
| MTX + Step-up Etanercept | 3.1 |
| MTX + Step-up SSZ + HCQ(ST) | 2.8 |
Changes in disease progression between treatment groups will be described by the mean score at two years as assessed after adjustment for the baseline radiographic score. Radiographs were observed of hands, wrists, and feet. The range of scores available for the modified Sharp Score is 0 to 448. The erosion score per joint of the hands can range from 0 to 5. The maximal erosion score for each hand is thus 80, considering the 16 areas for erosions per hand. Joint space narrowing and joint subluxation or luxation are combined in a single score with a range of 0 to 4 with a max score of 60. The erosion score per joint can range from 0 to 10, with each side of the joint independently scored from 0 to 5. The maximal erosion score per foot is thus 60. The joint space narrowing and joint (sub)luxation are combined in a single score with a range of 0 to 4. The maximal narrowing/(sub)luxation score per foot is thus 24. (NCT00259610)
Timeframe: Year 2, Week 102
| Intervention | Scores on a scale (Mean) |
|---|---|
| MTX + Immediate Etanercept | 7.0 |
| MTX+ Immediate SSZ +HCQ | 7.3 |
| MTX + Step-up Etanercept | 4.8 |
| MTX + Step-up SSZ + HCQ(ST) | 6.2 |
Pain is measured using the Pain Numeric Rating Scale (NRS), which ranges from 0 to 10 with higher scores indicating greater pain. This measure is recorded at baseline (0 weeks) and 8 weeks. The change in pain between these two time points (i.e., the difference score) is compared between the two groups. (NCT02044991)
Timeframe: 8 weeks
| Intervention | change score on the NRS pain scale (Median) |
|---|---|
| Treatment | -3 |
Disability is measured at baseline (0 weeks) and week 8 using the Oswestry Disability Index (ODI), which is a measure of low back pain that ranges from 0 points to 100 with higher scores indicating greater disability. The change in disability between these two time points (i.e., the difference score) is compared between the two groups. (NCT02044991)
Timeframe: 8 weeks
| Intervention | change score on the ODI scale (Median) |
|---|---|
| Treatment | -15.25 |
Pelvic functioning is measured at baseline (0 weeks) and week 8 using the Pelvic Girdle Questionnaire (PGQ), which ranges from 0 to 100 points with higher scores revealing greater pelvic girdle pain. The change in pelvic functioning between these two time points (i.e., the difference score) is compared between the two groups. (NCT02044991)
Timeframe: 8 weeks
| Intervention | change score on the PGQ scale (Median) |
|---|---|
| Treatment | -35.5 |
The DAS28 is a score on a scale (0 to 10) indicating current activity of rheumatoid arthritis (>5.1=high disease activity; <=3.2=low disease activity; <2.6=remission); a continuous variable which is a composite of 4 variables(the number of tender joints out of 28, the number of swollen joints out of 28 joints, serum C-reactive protein in mg/L (CRP) and subject assessment of disease activity measure on a visual analogue scale (VAS) of 100 mm). (NCT00796705)
Timeframe: Baseline, Week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Non-Switcher/ Adalimumab or Etanercept | -1.4 |
| Switcher/ Adalimumab to Etanercept or Etanercept to Adalimuma | -1.7 |
The DAS28 is a score on a scale (0 to 10) indicating current activity of rheumatoid arthritis (>5.1=high disease activity; <=3.2=low disease activity; <2.6=remission); a continuous variable which is a composite of 4 variables(the number of tender joints out of 28, the number of swollen joints out of 28 joints, serum C-reactive protein in mg/L (CRP) and subject assessment of disease activity measure on a visual analogue scale (VAS) of 100 mm). (NCT00796705)
Timeframe: Baseline, Week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Non-Switcher/Adalimumab Alternating With Placebo | -2.0 |
| Non-Switcher/Etanercept | -0.9 |
| Switcher/Adalimumab to Etanercept | -1.7 |
| Switcher/Etanercept to Adalimumab Alternating With Placebo | -1.5 |
The EULAR definition of a Moderate Response is a decrease from baseline in the DAS28[CRP] value of ≥ 1.2. (NCT00796705)
Timeframe: Baseline, Week 12
| Intervention | participants (Number) |
|---|---|
| Non-Switcher/Adalimumab Alternating With Placebo | 3 |
| Non-Switcher/Etanercept | 1 |
| Switcher/Adalimumab to Etanercept | 2 |
| Switcher/Etanercept to Adalimumab Alternating With Placebo | 1 |
The DAS28 is a score on a scale (0 to 10) indicating current activity of rheumatoid arthritis (>5.1=high disease activity; <=3.2=low disease activity; <2.6=remission); a continuous variable which is a composite of 4 variables(the number of tender joints out of 28, the number of swollen joints out of 28 joints, serum C-reactive protein in mg/L (CRP) and subject assessment of disease activity measure on a visual analogue scale (VAS) of 100 mm). (NCT00796705)
Timeframe: Week 12
| Intervention | participants (Number) |
|---|---|
| Non-Switcher/Adalimumab Alternating With Placebo | 0 |
| Non-Switcher/Etanercept | 0 |
| Switcher/Adalimumab to Etanercept | 1 |
| Switcher/Etanercept to Adalimumab Alternating With Placebo | 1 |
The DAS28 is a score on a scale (0 to 10) indicating current activity of rheumatoid arthritis (>5.1=high disease activity; <=3.2=low disease activity; <2.6=remission); a continuous variable which is a composite of 4 variables(the number of tender joints out of 28, the number of swollen joints out of 28 joints, serum C-reactive protein in mg/L (CRP) and subject assessment of disease activity measure on a visual analogue scale (VAS) of 100 mm). (NCT00796705)
Timeframe: Week 12
| Intervention | participants (Number) |
|---|---|
| Non-Switcher/Adalimumab Alternating With Placebo | 1 |
| Non-Switcher/Etanercept | 1 |
| Switcher/Adalimumab to Etanercept | 2 |
| Switcher/Etanercept to Adalimumab Alternating With Placebo | 1 |
"The American College of Rheumatology (ACR) 20 Responder Index is defined as someone who achieved at least 20% improvement in the tender and swollen 28-joint count, and 20% improvement in at least three of the following 5 measures:~Patient's pain assessment (Visual Analogue Scale (VAS) 100 mm)~Patient's global assessment of disease activity (VAS 100 mm)~Physician's global assessment of disease activity (VAS 100 mm)~Patient self-assessed disability (Health Assessment Questionnaire (HAQ) score)~Acute phase reactant (CRP)" (NCT00796705)
Timeframe: Week 12
| Intervention | participants (Number) |
|---|---|
| Non-Switcher/Adalimumab Alternating With Placebo | 3 |
| Non-Switcher/Etanercept | 2 |
| Switcher/Adalimumab to Etanercept | 3 |
| Switcher/Etanercept to Adalimumab Alternating With Placebo | 1 |
"The American College of Rheumatology (ACR) 50 Responder Index is defined as someone who achieved at least 50% improvement in the tender and swollen 28-joint count, and 50% improvement in at least three of the following 5 measures:~Patient's pain assessment (Visual Analogue Scale (VAS) 100 mm)~Patient's global assessment of disease activity (VAS 100 mm)~Physician's global assessment of disease activity (VAS 100 mm)~Patient self-assessed disability (Health Assessment Questionnaire (HAQ) score)~Acute phase reactant (CRP)" (NCT00796705)
Timeframe: Week 12
| Intervention | participants (Number) |
|---|---|
| Non-Switcher/Adalimumab Alternating With Placebo | 2 |
| Non-Switcher/Etanercept | 0 |
| Switcher/Adalimumab to Etanercept | 1 |
| Switcher/Etanercept to Adalimumab Alternating With Placebo | 0 |
"The American College of Rheumatology (ACR) 70 Responder Index is defined as someone who achieved at least 70% improvement in the tender and swollen 28- joint count, and 70% improvement in at least three of the following the following 5 measures:~Patient's pain assessment (Visual Analogue Scale (VAS) 100 mm)~Patient's global assessment of disease activity (VAS 100 mm)~Physician's global assessment of disease activity (VAS 100 mm)~Patient self-assessed disability (Health Assessment Questionnaire (HAQ) score)~Acute phase reactant (CRP)" (NCT00796705)
Timeframe: Week 12
| Intervention | participants (Number) |
|---|---|
| Non-Switcher/Adalimumab Alternating With Placebo | 0 |
| Non-Switcher/Etanercept | 0 |
| Switcher/Adalimumab to Etanercept | 0 |
| Switcher/Etanercept to Adalimumab Alternating With Placebo | 0 |
140 reviews available for sulfasalazine and Arthritis, Rheumatoid
| Article | Year |
|---|---|
Safety of long-term use of four common conventional disease modifying anti-rheumatic drugs in rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Methotrexate; Sulfasalazine; Tumor Necrosis Fac | 2021 |
What are the core recommendations for rheumatoid arthritis care? Systematic review of clinical practice guidelines.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Hydroxychloroquine; Methotrexate; Practi | 2023 |
Cardiac Dysfunction in Rheumatoid Arthritis: The Role of Inflammation.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheuma | 2021 |
[Perioperative management of immunosuppressive treatment in patients undergoing joint surgery].
Topics: Adrenal Cortex Hormones; Antimalarials; Antirheumatic Agents; Arthritis, Rheumatoid; Arthroplasty, R | 2017 |
[DMARDs (disease-modifying antirheumatic drugs)].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cysteine; Humans; Japan; Methotrexate; Sulfasalazine; T | 2013 |
C reactive protein may not be reliable as a marker of severe bacterial infection in patients receiving tocilizumab.
Topics: Aged; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Inf | 2013 |
Sulfasalazine induced lung toxicity masquerading as sarcoidosis--case report and review of the literature.
Topics: Arthritis, Rheumatoid; Colitis, Ulcerative; Granuloma; Humans; Sarcoidosis; Sulfasalazine | 2013 |
Tocilizumab-induced neutropenia in rheumatoid arthritis patients with previous history of neutropenia: case series and review of literature.
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Etanercept; Female; | 2015 |
[Update on Current Care Guidelines. Rheumatoid Arthritis (RA)].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Decision Making; Exercise Therapy; Glucocorticoids; Hum | 2015 |
Challenges and treatment options for rheumatoid arthritis during pregnancy.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Female; Humans; Hydroxychloroquine | 2016 |
[DMARDs (Focusing on iguratimod)].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Cysteine; Drug Discovery; Drug Interactions; | 2016 |
Efficacy of triple association methotrexate, sulfasalazine and hydroxychloroquine in early treatment of rheumatoid arthritis with insufficient response to methotrexate: Meta-analysis of randomized controlled trials.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Follow-Up Studies; H | 2017 |
Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Disea | 2008 |
[Antirheumatic agents for treatment of rheumatoid arthritis].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cysteine; Gold Sodium Thiomalate; Humans; Isoxazoles; L | 2008 |
[New ways in the management of rheumatoid arthritis in Hungary].
Topics: Abatacept; Adalimumab; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, | 2007 |
[Effect of disease modifying anti-rheumatic drugs on radiographic progression in rheumatoid arthritis].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cyclosporine; Cysteine; Disease Progression; Drug Thera | 2009 |
The BeSt story: on strategy trials in rheumatoid arthritis.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Clinical T | 2009 |
Methotrexate in combination with sulfasalazine is more effective in rheumatoid arthritis patients who failed sulfasalazine than in patients naive to both drugs.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Female; | 2009 |
Management of RA medications in pregnant patients.
Topics: Abatacept; Acetaminophen; Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoc | 2009 |
Predictors for remission in rheumatoid arthritis patients: A systematic review.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Haplotypes; Humans; Interleukin-2; Male; Methotrexate; | 2010 |
New-onset psoriasis associated with etanercept therapy.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Etanercept; Humans; Immunoglobulin G; Isoxazoles | 2010 |
[The goal for the treatment of rheumatoid arthritis should be remission].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Finland; Glucocorticoids; Hu | 2010 |
The treatment of rheumatoid arthritis during pregnancy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Female; Humans; Hydroxychloroquine; | 2011 |
Tripterygium wilfordii Hook F. versus Sulfasalazine in the treatment of rheumatoid arthritis: a well-designed clinical trial of a botanical demonstrating effectiveness.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Drugs, Chinese Herbal; Humans; Periodicals as Topic | 2011 |
A Chinese herb Tripterygium wilfordii Hook F in the treatment of rheumatoid arthritis: mechanism, efficacy, and safety.
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Apoptosis; Arthritis, Rheumatoid; Cell Adhesion Mole | 2011 |
[Systemic autoimmune disorders and pregnancy].
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antimalarials; Antiphospholipid Syndrome; Arthrit | 2011 |
[Treatment of rheumatic diseases: current status and future prospective. Topics: II. Immunosuppressant/antirheumatic drugs; 2. Salazosulfapyridine].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Sulfasalazine | 2011 |
[ Bone and cartilage destruction in RA and its intervention. Disease-modifying antirheumatic drugs].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bone and Bones; Cartilage; Clinical Trials as Topic; Cy | 2012 |
Leflunomide in monotherapy of rheumatoid arthritis: meta-analysis of randomized trials.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; D | 2012 |
My treatment approach to rheumatoid arthritis.
Topics: Abatacept; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Muri | 2012 |
Iguratimod: a new disease-modifying antirheumatic drug.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Drug Therapy, Combination; Humans; | 2012 |
Meta-analysis suggests that intensive non-biological combination therapy with step-down prednisolone (COBRA strategy) may also 'disconnect' disease activity and damage in rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Humans; | 2013 |
[Gastrointestinal side effects in the therapy of rheumatologic diseases].
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic | 2002 |
[Combination therapy of disease-modifying antirheumatic drugs(DMARDs) in rheumatoid arthritis].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Auranofin; Clinical Trials as Topic; Drug Therapy, Comb | 2002 |
[Efficacy of leflunomide].
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase II as Topic; Double-Bli | 2002 |
Leflunomide for treating rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Isoxaz | 2003 |
[Combination therapy in rheumatoid arthritis].
Topics: Adjuvants, Immunologic; Antirheumatic Agents; Arthritis, Rheumatoid; Cyclosporine; Drug Therapy, Com | 2003 |
[Current concepts of pharmacotherapy in rheumatoid arthritis].
Topics: Adult; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents | 2003 |
Lefunomide in combination therapy.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Dru | 2004 |
[Diagnosis and therapy of rheumatoid arthritis].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rh | 2004 |
Rheumatoid arthritis: more aggressive approach improves outlook.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthrit | 2004 |
Rheumatoid arthritis.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Auranofin; Azathioprine; Cyclop | 2003 |
Damage control in rheumatoid arthritis. Hard-hitting, early treatment is crucial to curbing joint destruction.
Topics: Arthritis, Rheumatoid; Azathioprine; Disease Progression; Humans; Hydroxychloroquine; Immunologic Fa | 2004 |
DRESS syndrome in a patient on sulfasalazine for rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Eruptions; Eosinophilia; Exanthema; Female; Herpes | 2005 |
[Disease modifying anti-rheumatic drugs (DMARDs): an overview].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Benzopyrans; Cysteine; Evidence-Based Medicine; Gold So | 2005 |
[Adverse effects of DMARDs in treatment of rheumatoid arthritis].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Gold Sodium Thiomalate; Hematologic Diseases; H | 2005 |
[Tailor-made medicine and genomic drug discovery in rheumatoid arthritis].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Arylamine N-Acetyltransferase; Drug Design; Genome, Hum | 2005 |
Rheumatoid arthritis: an update.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Diagnosis, Dif | 2005 |
Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antimalarials; Antirheumatic Agents; Arthritis, Rheum | 2005 |
[A case of salazosulfapyridine induced hypersensitivity syndrome].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Hypersensitivity; Female; Humans; Middle Aged; Sul | 2005 |
Sulfasalazine: a review of its use in the management of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Half-Life; Humans; In Vitro Techniques; Randomized Cont | 2005 |
Pharmacogenetics of therapies in rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprine; Humans; Immunologic Factors; Methotrexate | 2005 |
[Armentarium and strategies for the treatment of rheumatoid arthritis].
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheu | 2005 |
Medical therapy: where are we now?
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Hydroxychloroquine; | 2006 |
[Biologicals in the treatment of rheumatic diseases].
Topics: Abatacept; Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monocl | 2006 |
[Pharmacogenomics of antirheumatic drugs and personalized medicine for rheumatoid arthritis].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Individuality; Methotrexate; Pharmacogenetics; | 2007 |
Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient.
Topics: Aged; Aging; Antimalarials; Antirheumatic Agents; Arthritis, Rheumatoid; Glomerular Filtration Rate; | 2007 |
[Inhibition of radiographic progression in rheumatoid arthritis by anti-rheumatic drugs (DMARDs)].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Cyclosporine; Disease Progres | 2007 |
[Rational therapeutic approach in rheumatoid arthritis].
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, | 2006 |
Rheumatoid arthritis and reproduction.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Hydroxychloroquine; Immunosuppre | 2007 |
[Effective combination therapy of TNF antagonists with DMARDs].
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthrit | 2007 |
Combination therapy for rheumatoid arthritis: methotrexate and sulfasalazine together or with other DMARDs.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Methotrexate; Random | 2007 |
Are new agents used to treat rheumatoid arthritis safe to take during pregnancy? Organization of Teratology Information Specialists (OTIS) study.
Topics: Abnormalities, Drug-Induced; Antimalarials; Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprin | 2007 |
Treatment, management, and monitoring of established rheumatoid arthritis.
Topics: Abatacept; Adalimumab; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, | 2007 |
Pharmacogenomics in rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprine; Biotransformation; Genetic Predisposition | 2008 |
Do drugs change the course of rheumatoid arthritis?
Topics: Arthritis, Rheumatoid; Azathioprine; Blood Sedimentation; C-Reactive Protein; Chloroquine; Cyclophos | 1980 |
Sulphasalazine: a 'new' antirheumatic drug.
Topics: Agranulocytosis; Anemia; Antibody Formation; Arthritis, Rheumatoid; Bile; Chemical and Drug Induced | 1984 |
How do second-line agents work?
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cyclophosphamide; Cyclosporine; Gold; Humans; Penicilla | 1995 |
Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Dosage Forms; Drug Administration Schedule; Drug Therap | 1995 |
Disease-modifying antirheumatic drugs, including methotrexate, gold, antimalarials, and D-penicillamine.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimalarials; Antirheumatic Agents; Arthritis, Rheumatoid; | 1995 |
A novel approach to the development of anti-inflammatory agents: adenosine release at inflamed sites.
Topics: Adenosine; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Humans; Inflammation; Methotrexate; Sulf | 1995 |
Sulphasalazine-induced autoimmune abnormalities in patients with rheumatic disease.
Topics: Adult; Arthritis, Rheumatoid; Autoimmune Diseases; Autoimmunity; Female; Humans; Lupus Erythematosus | 1995 |
Approach to the patient with rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Antimalarials; Arthritis, Rheumatoid; Female; Humans; Immunosuppressive Ag | 1994 |
Disease-modifying antirheumatic drugs, including methotrexate, sulfasalazine, gold, antimalarials, and penicillamine.
Topics: Age Factors; Antimalarials; Arthritis, Rheumatoid; Clinical Trials as Topic; Cysteine; Digestive Sys | 1994 |
[Medical management of rheumatoid arthritis].
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Organogold Compounds; | 1993 |
Rheumatoid arthritis: a risk factor for sulphasalazine toxicity? A meta-analysis.
Topics: Arthritis, Rheumatoid; Humans; Inflammatory Bowel Diseases; Risk Factors; Spinal Diseases; Sulfasala | 1993 |
Second line (disease modifying) treatment in rheumatoid arthritis: which drug for which patient?
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Auranofin; Blood Sedimentation; | 1993 |
Slow-acting antirheumatic drugs. Drug interactions of clinical significance.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Interactions; Gold; Humans; Hydroxychloroquine; Pe | 1995 |
How and when should combination therapy be used? The role of an anchor drug.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Sulfasalazine | 1995 |
Combining sulphasalazine and methotrexate in rheumatoid arthritis: early clinical impressions.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Methotrexate; Sulfas | 1995 |
Clinical efficacy of sulphasalazine--a review.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Interactions; Humans; Me | 1995 |
Sulphasalazine: mechanism of action in rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Sulfasalazine | 1995 |
Rheumatoid arthritis--changing theories and treatment modalities.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, | 1995 |
Disease-modifying antirheumatic drugs. Potential effects in older patients.
Topics: Aged; Aging; Antimalarials; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Methotrexate; Sulfa | 1995 |
The use of antimalarials in combination with other disease modifying agents in RA--the British experience.
Topics: Antimalarials; Antineoplastic Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials a | 1996 |
Combination sulfasalazine and methotrexate in the management of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Methotrexate; Sulfas | 1996 |
Sulphasalazine in the treatment of rheumatoid arthritis.
Topics: Anti-Infective Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Sulfapyridine; Sulfasala | 1997 |
Disease-modifying antirheumatic drugs.
Topics: Antimalarials; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Gold; Humans; | 1997 |
[Combined administration of long-acting antirheumatic drugs in the treatment of chronic polyarthritis].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprine; Clinical Trials as Topic; Cyclosporins; D | 1997 |
Combination of sulphasalazine and methotrexate in the treatment of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Methotrexate; Qualit | 1998 |
Disease-modifying antirheumatic drugs.
Topics: Antimalarials; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Liver | 1998 |
Triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine in patients with rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cyclosporine; Drug Therapy, Combination; Humans; Hydrox | 1998 |
[Combination therapy of rheumatoid arthritis].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimalarials; Antirheumatic Agents; Arthritis, Rheumatoid; | 1998 |
Is there a role for antibiotics in the treatment of patients with rheumatoid arthritis?
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; M | 1999 |
[62nd Congress of the American College of Rheumatology, San Diego, 8-12 November 1998].
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheuma | 1999 |
Disease-modifying antirheumatic drugs.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Gold Sodium Thiomalate; Huma | 1999 |
Sulfasalazine treatment for rheumatoid arthritis: a metaanalysis of 15 randomized trials.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Gold Sodium Thiomalate; Humans; Hydroxychloroqu | 1999 |
[Rheumatoid polyarthritis: etiology, diagnosis, course, treatment principles].
Topics: Adrenal Cortex Hormones; Adult; Aged; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Antirheum | 1999 |
Rheumatoid arthritis: new developments in the use of existing therapies.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Hydroxychloroquine; | 1999 |
[Role of anti-TNF therapy in rheumatoid arthritis].
Topics: Adult; Animals; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Etanercept; Hum | 2000 |
Sulfasalazine for rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Sulfas | 2000 |
Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Hydroxychloroquine; Methotrexate; Organogold Co | 2000 |
Rational use of new and existing disease-modifying agents in rheumatoid arthritis.
Topics: Adjuvants, Immunologic; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Cyclosp | 2001 |
Disease modifying antirheumatic drugs: longterm safety issues.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Hydroxychloroquine; Methotrexate; Safety; Sulfa | 2001 |
Current concepts regarding pharmacologic treatment of rheumatoid and osteoarthritis.
Topics: Adjuvants, Immunologic; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumat | 2001 |
Progress in the treatment of rheumatoid arthritis.
Topics: Analgesics; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprine; Cyclo | 2001 |
Advances in the medical management of rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rh | 2002 |
Pharmacology of antiarthritic drugs.
Topics: Adrenal Cortex Hormones; Antimalarials; Arthritis, Rheumatoid; Aurothioglucose; Azathioprine; Cyclop | 1992 |
Sulfasalazine induced agranulocytosis treated with granulocyte-macrophage colony stimulating factor.
Topics: Adult; Agranulocytosis; Arthritis, Rheumatoid; Bone Marrow; Female; Granulocyte-Macrophage Colony-St | 1992 |
Current concepts in the management of rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Aged; Antibiotics, Antineoplastic; Antirheumatic Agents; Arthritis, Rheumat | 1992 |
[Salazosulfapyridine in rheumatoid arthritis. A study of 49 patients].
Topics: Adult; Aged; Arthritis, Rheumatoid; Drug Combinations; Drug Tolerance; Female; Glucosamine; Humans; | 1992 |
Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials.
Topics: Antimalarials; Arthritis, Rheumatoid; Clinical Trials as Topic; Humans; Methotrexate; Sulfasalazine | 1992 |
[Sulfasalazine in the treatment of rheumatoid arthritis. A multicenter open study of 150 patients during 6 months].
Topics: Aged; Aged, 80 and over; Arthritis, Rheumatoid; Female; Humans; Immunosuppressive Agents; Male; Sulf | 1992 |
Disease-modifying antirheumatic drugs: gold, penicillamine, antimalarials, and sulfasalazine.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimalarials; Antirheumatic Agents; Arthritis, Rheumatoid; | 1991 |
[Current status of drug therapy in chronic polyarthritis].
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Chloroquin | 1991 |
The use of combinations of disease-modifying antirheumatic agents in rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimalarials; Arthritis, Rheumatoid; Clinical Trials as To | 1990 |
Care of the person with rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Methot | 1990 |
Disease-modifying antirheumatic drugs: gold, penicillamine, antimalarials, and sulfasalazine.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimalarials; Arthritis, Rheumatoid; Gold; Humans; Penicil | 1990 |
The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses.
Topics: Antimalarials; Arthritis, Rheumatoid; Auranofin; Gold; Humans; Meta-Analysis as Topic; Methotrexate; | 1990 |
[Advances in the research on antirheumatic drug: sulfasalazine].
Topics: Arthritis, Rheumatoid; Humans; Spondylitis, Ankylosing; Sulfasalazine | 1990 |
Combination therapy of rheumatoid arthritis--rationale and overview.
Topics: Antimalarials; Antineoplastic Agents; Arthritis, Rheumatoid; Gold; Humans; Injections, Intramuscular | 1990 |
Combination therapy in rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antimalarials; Arthritis, Rheumatoid; Azathioprin | 1990 |
Experimental basis of innovative therapies of rheumatoid arthritis.
Topics: Animals; Antibodies, Monoclonal; Arthritis, Rheumatoid; Autoimmune Diseases; Chronic Disease; Cyclos | 1989 |
Rheumatoid arthritis therapy: the slow-acting agents.
Topics: Age Factors; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antimalarials; Arthr | 1989 |
Sulphasalazine and related drugs in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Humans; Sulfasalazine | 1989 |
[Sulfasalazine in rheumatoid arthritis].
Topics: Arthritis, Rheumatoid; Humans; Sulfasalazine | 1989 |
A rheumatological dilemma: is it possible to modify the course of rheumatoid arthritis? Can we answer the question?
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Auranofin; Aurothioglucose; Azathioprine; Clinical | 1985 |
The use of chloroquine and D-penicillamine in the treatment of rheumatoid arthritis.
Topics: Anti-Glomerular Basement Membrane Disease; Arthritis, Rheumatoid; Captopril; Chloroquine; Clinical T | 1986 |
Pharmacological and biochemical actions of sulphasalazine.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials as Topic; Colitis, U | 1986 |
Variables affecting efficacy and toxicity of sulphasalazine in rheumatoid arthritis. A review.
Topics: Acetylation; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Dose-Response Relations | 1986 |
Assessing the progression of joint damage in rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Arthrography; Clinical Trials as Top | 1986 |
Collagenous colitis and rheumatoid arthritis with response to sulfasalazine. A case report and review of the literature.
Topics: Aged; Arthritis, Rheumatoid; Colitis; Collagen Diseases; Colonoscopy; Humans; Male; Sulfasalazine | 1987 |
Sulphasalazine in arthritis--an old drug rediscovered.
Topics: Arthritis, Rheumatoid; Humans; Sulfasalazine | 1987 |
The pharmacology and biochemical action of second-line agents.
Topics: Animals; Antimalarials; Arthritis, Rheumatoid; Biomechanical Phenomena; Chemical Phenomena; Chemistr | 1988 |
[Experience in the use of salazopyrine EN in patients with spondylarthritis ankylopoietica and rheumatoid arthritis].
Topics: Adult; Arthritis, Rheumatoid; Drug Combinations; Female; Glucosamine; Humans; Male; Middle Aged; Spo | 1988 |
The clinical efficacy of sulphasalazine in rheumatic disease.
Topics: Arthritis, Rheumatoid; Digestive System; Hematologic Diseases; Humans; Sulfasalazine | 1988 |
Adverse reactions to sulfasalazine: the British experience.
Topics: Arthritis, Rheumatoid; Humans; Sulfasalazine; United Kingdom | 1988 |
Comparisons of sulfasalazine to gold and placebo in the treatment of rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Gold Sodium Thiomalate; Humans; Multicenter Studies | 1988 |
Sulfasalazine in the rheumatic disease.
Topics: Arthritis, Rheumatoid; Autoimmune Diseases; Central Nervous System; Chemical and Drug Induced Liver | 1988 |
Investigational therapy in rheumatoid arthritis: a critical review.
Topics: Arthritis, Rheumatoid; Blood Component Removal; Cyclophosphamide; Cyclosporins; Drainage; Humans; Le | 1988 |
235 trials available for sulfasalazine and Arthritis, Rheumatoid
| Article | Year |
|---|---|
Comparison between leflunomide and sulfasalazine based triple therapy in methotrexate refractory rheumatoid arthritis: an open-label, non-inferiority randomized controlled trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Hydroxychloroquine; | 2022 |
Combined Conventional Synthetic Disease Modifying Therapy vs. Infliximab for Rheumatoid Arthritis: Emulating a Randomized Trial in Observational Data.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Hydroxychloroquine; | 2022 |
Hydroxychloroquine Effects on THP-1 Macrophage Cholesterol Handling: Cell Culture Studies Corresponding to the TARGET Cardiovascular Trial.
Topics: Arthritis, Rheumatoid; Atherosclerosis; Cell Culture Techniques; Cholesterol; Humans; Hydroxychloroq | 2022 |
Favourable effect of a 'second hit' after 13 weeks in early RA non-responders: the Amsterdam COBRA treat-to-target randomized trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Methotrexate; Predni | 2023 |
Observation of the clinical effect of the combined therapy of zushima tablet and western medicine in the treatment of rheumatoid arthritis and MRI test results.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Drugs, Chinese Herbal; Female; Humans; Magnetic | 2019 |
An open-label randomized controlled trial of DMARD withdrawal in RA patients achieving therapeutic response with certolizumab pegol combined with DMARDs.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Certolizumab Pegol; Deprescriptions; Drug | 2020 |
Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort.
Topics: Adult; Anti-Citrullinated Protein Antibodies; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort St | 2019 |
Two-year cost-effectiveness of different COBRA-like intensive remission induction schemes in early rheumatoid arthritis: a piggyback study on the pragmatic randomised controlled CareRA trial.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cost-Benefit Analysis; Drug Therapy, Combination; | 2020 |
Pain Over Two Years After Start of Biologic Versus Conventional Combination Treatment in Early Rheumatoid Arthritis: Results From a Swedish Randomized Controlled Trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthralgia; Arthritis, Rheumatoid; Biological Products; Drug Ther | 2021 |
Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial.
Topics: Abatacept; Adult; Aged; Anti-Citrullinated Protein Antibodies; Antibodies, Monoclonal, Humanized; An | 2020 |
The efficacy, safety and cost-effectiveness of hydroxychloroquine, sulfasalazine, methotrexate triple therapy in preventing relapse among patients with rheumatoid arthritis achieving clinical remission or low disease activity: the study protocol of a rand
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cost-Benefit Analysis; Drug Therapy, Combination; Human | 2021 |
Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug The | 2021 |
Rheumatoid Arthritis Treatment After Methotrexate: The Durability of Triple Therapy Versus Etanercept.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Ca | 2017 |
Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Comorbidity; Disease Progression; Drug Adm | 2017 |
Rheumatoid arthritis patients with continued low disease activity have similar outcomes over 10 years, regardless of initial therapy.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Administration S | 2017 |
Effects of psychosocial factors on monitoring treatment effect in newly diagnosed rheumatoid arthritis patients over time: response data from the tREACH study.
Topics: Antirheumatic Agents; Anxiety; Arthritis, Rheumatoid; Depression; Disease Progression; Drug Therapy, | 2018 |
Clinical and radiological outcomes of 5-year drug-free remission-steered treatment in patients with early arthritis: IMPROVED study.
Topics: Adalimumab; Adult; Aged; Antirheumatic Agents; Arthritis; Arthritis, Rheumatoid; Disease Progression | 2018 |
[Flipping moxibustion of
Topics: Acupuncture Points; Antirheumatic Agents; Arthritis, Rheumatoid; Combined Modality Therapy; Humans; | 2017 |
Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthri | 2018 |
Subcutaneous tocilizumab alone or with a csDMARD in rheumatoid arthritis patients: subanalysis of Italian data from a multicenter phase IIIb/IV trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroq | 2019 |
Normal mortality of the COBRA early rheumatoid arthritis trial cohort after 23 years of follow-up.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combina | 2019 |
Effectiveness of different combinations of DMARDs and glucocorticoid bridging in early rheumatoid arthritis: two-year results of CareRA.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug Administration S | 2019 |
Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cholesterol, HDL; Cholesterol, LDL; Drug T | 2013 |
Evaluation of hand bone loss by digital X-ray radiogrammetry as a complement to clinical and radiographic assessment in early rheumatoid arthritis: results from the SWEFOT trial.
Topics: Absorptiometry, Photon; Analysis of Variance; Antibodies, Monoclonal; Antirheumatic Agents; Arthriti | 2013 |
Clinical response within 12 weeks as a predictor of future low disease activity in patients with early RA: results from the TEAR Trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Etanerc | 2013 |
A non-inferiority trial of an attenuated combination strategy ('COBRA-light') compared to the original COBRA strategy: clinical results after 26 weeks.
Topics: Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug | 2014 |
Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Therapy, | 2013 |
A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study.
Topics: Adalimumab; Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antirheumatic | 2014 |
Therapies for active rheumatoid arthritis after methotrexate failure.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; E | 2013 |
Biological vs. conventional combination treatment and work loss in early rheumatoid arthritis: a randomized trial.
Topics: Adult; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combinatio | 2013 |
Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; Docosahexaenoic Acids | 2015 |
Four-month metacarpal bone mineral density loss predicts radiological joint damage progression after 1 year in patients with early rheumatoid arthritis: exploratory analyses from the IMPROVED study.
Topics: Absorptiometry, Photon; Antirheumatic Agents; Arthritis, Rheumatoid; Bone Density; Disease Progressi | 2015 |
Health-related quality of life and functional ability in patients with early arthritis during remission steered treatment: results of the IMPROVED study.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug Adm | 2013 |
Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Disease Progression; Drug Therapy, | 2015 |
Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Cost-Benefit Analy | 2015 |
Traditional Chinese medicine versus western medicine as used in China in the management of rheumatoid arthritis: a randomized, single-blind, 24-week study.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; China; Drug Administration Schedule; Drugs, Chinese Her | 2014 |
Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial.
Topics: Administration, Oral; Adult; Aged; Antirheumatic Agents; Area Under Curve; Arthritis, Rheumatoid; Di | 2014 |
Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial.
Topics: Adipokines; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; C-React | 2015 |
Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Co | 2015 |
Initial high-dose prednisolone combination therapy using COBRA and COBRA-light in early rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug Therapy, Combina | 2015 |
Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Cyclosporine; Dise | 2014 |
Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Early Medical I | 2015 |
Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Early Medical I | 2015 |
Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Early Medical I | 2015 |
Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Early Medical I | 2015 |
Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
Topics: Adalimumab; Adrenal Cortex Hormones; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Hu | 2014 |
Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial.
Topics: Antibody Specificity; Antirheumatic Agents; Arthritis, Rheumatoid; Autoantibodies; Disease Progressi | 2016 |
Predicted vs. observed radiographic progression in early rheumatoid arthritis (POPeRA): results from a randomized trial.
Topics: Adult; Aged; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Female; Follow-U | 2015 |
Impact of physicians' adherence to treat-to-target strategy on outcomes in early rheumatoid arthritis in the NEO-RACo trial.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Double-Blind M | 2015 |
Two-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study).
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Early Diagnosis; Fema | 2016 |
Infliximab Versus Conventional Combination Treatment and Seven-Year Work Loss in Early Rheumatoid Arthritis: Results of a Randomized Swedish Trial.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; Hydro | 2016 |
Cost-Effectiveness of Triple Therapy Versus Etanercept Plus Methotrexate in Early Aggressive Rheumatoid Arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biological Factors; Cohort Studies; Cost-Benefit Analys | 2016 |
Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-la
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Drug Therapy, Combinat | 2017 |
Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-la
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Drug Therapy, Combinat | 2017 |
Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-la
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Drug Therapy, Combinat | 2017 |
Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-la
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Drug Therapy, Combinat | 2017 |
Further Simplification of the Simple Erosion Narrowing Score With Item Response Theory Methodology.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Humans; | 2016 |
Improvement of High-Density Lipoprotein Function in Patients With Early Rheumatoid Arthritis Treated With Methotrexate Monotherapy or Combination Therapies in a Randomized Controlled Trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Etanercept; Female; Humans; | 2017 |
Rheumatoid arthritis triple therapy compared with etanercept: difference in infectious and gastrointestinal adverse events.
Topics: Abscess; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Etaner | 2017 |
Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis.
Topics: Adamantane; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, R | 2017 |
[Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis].
Topics: Adult; Aged; Antirheumatic Agents; Arthralgia; Arthritis, Rheumatoid; Dose-Response Relationship, Dr | 2008 |
Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Collagen Type II; Drug Adminis | 2008 |
Differential effect on symptoms treated with traditional Chinese medicine and western combination therapy in RA patients.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; D | 2008 |
Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis.
Topics: Acute Disease; Aged; Analysis of Variance; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, | 2009 |
Providing patients with information about disease-modifying anti-rheumatic drugs: Individually or in groups? A pilot randomized controlled trial comparing adherence and satisfaction.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Counseling; Female; Hum | 2009 |
Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Ther | 2009 |
[Clinical randomized study of bee-sting therapy for rheumatoid arthritis].
Topics: Acupuncture Points; Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; | 2008 |
Relapse-remission and remission-relapse switches in rheumatoid arthritis patients were modeled by random effects.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Methotrexate; Models | 2009 |
A comparative study of the effects of bucillamine and salazosulfapyridine in the treatment of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Cysteine; Drug Therapy, Combination | 2009 |
The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug | 2009 |
Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combina | 2010 |
Methotrexate therapy in rheumatoid arthritis after failure to sulphasalazine: to switch or to add?
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Epidemiologic M | 2009 |
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Hy | 2009 |
Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; D | 2009 |
Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; D | 2009 |
Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; D | 2009 |
Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; D | 2009 |
The selective estrogen receptor alpha agonist Org 37663 induces estrogenic effects but lacks antirheumatic activity: a phase IIa trial investigating efficacy and safety of Org 37663 in postmenopausal female rheumatoid arthritis patients receiving stable b
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Estrogen Receptor alpha; Fem | 2010 |
Does gastrointestinal adverse drug reaction influence therapeutic effect in the treatment of rheumatoid arthritis?
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Diclofenac; Drug Therapy, Combination; Drugs, Chinese H | 2010 |
The effects of an orally administered probiotic on sulfasalazine metabolism in individuals with rheumatoid arthritis: a preliminary study.
Topics: Administration, Oral; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Bifidobacterium; Bio | 2010 |
Accelerated hand bone mineral density loss is associated with progressive joint damage in hands and feet in recent-onset rheumatoid arthritis.
Topics: Absorptiometry, Photon; Adult; Aged; Antibodies, Monoclonal; Arthritis, Rheumatoid; Bone Density; Di | 2010 |
Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Finland | 2010 |
Effects of different medical treatments on serum copper, selenium and zinc levels in patients with rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid | 2011 |
Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months.
Topics: Absorptiometry, Photon; Adiponectin; Adipose Tissue; Adult; Aged; Antibodies, Monoclonal; Antirheuma | 2010 |
Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDs--a multicenter, double-blind, parallel-group trial.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Cysteine; Double-Blind Method; Drug Therapy, Com | 2011 |
Association between tongue appearance in Traditional Chinese Medicine and effective response in treatment of rheumatoid arthritis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Chi-Square Distribution; Color; Diagnosis, Diffe | 2011 |
Treating to target matrix metalloproteinase 3 normalisation together with disease activity score below 2.6 yields better effects than each alone in rheumatoid arthritis patients: T-4 Study.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Biomarkers; Drug Moni | 2012 |
Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Therapy; Drug Resist | 2012 |
Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Therapy; Drug Resist | 2012 |
Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Therapy; Drug Resist | 2012 |
Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Therapy; Drug Resist | 2012 |
A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.
Topics: Administration, Oral; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; | 2012 |
Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial.
Topics: Administration, Oral; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female | 2013 |
Serum cotinine as a biomarker of tobacco exposure and the association with treatment response in early rheumatoid arthritis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Cotinine; Double-Blind Method; Drug | 2012 |
Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study).
Topics: Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid | 2013 |
Etanercept normalises left ventricular mass in patients with rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Echocardiography; Etanerce | 2013 |
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Comb | 2013 |
Changing sulphasalazine to methotrexate does not improve the 2-year outcomes of the initial single DMARD treatment in early rheumatoid arthritis: subanalysis of the FIN-RACo trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Hydroxychloroquine; | 2013 |
Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combina | 2002 |
Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; | 2002 |
The effects of disease-modifying anti-rheumatic drugs on the Health Assessment Questionnaire score. Lessons from the leflunomide clinical trials database.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Databases, Factual; Female; Follow-Up Studies; Health S | 2002 |
Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study.
Topics: Arthritis, Rheumatoid; Biomarkers; Blood Sedimentation; Collagen Type I; Collagen Type II; Disease P | 2002 |
[Clinical observation on treatment of rheumatoid arthritis by combined therapy with methotrexate, sulfasalazine and Chinese herbal medicine].
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Therapy, Combinati | 2002 |
Effectiveness of a measurement feedback system on outcome in rheumatoid arthritis: a controlled clinical trial.
Topics: Acute Disease; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Hu | 2003 |
Long term structural effects of combination therapy in patients with early rheumatoid arthritis: five year follow up of a prospective double blind controlled study.
Topics: Adult; Aged; Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; | 2003 |
The effect of low-dose methotrexate on bone mineral density in patients with early rheumatoid arthritis.
Topics: Absorptiometry, Photon; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Bone Density; Female; Hu | 2003 |
Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Disability Evaluation; | 2004 |
Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Disease Progression; Epitopes | 2004 |
N-acetyltransferase 2 genotype-related efficacy of sulfasalazine in patients with rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Arylamine N-Acetyltransferase; Female; Genotype; Humans | 2004 |
Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Collagen; | 2004 |
Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Double-Blind Method; Drug Ad | 2004 |
When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide?
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, R | 2005 |
Successful treatment of rheumatoid arthritis is associated with a reduction in serum sE-selectin and thrombomodulin level.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Drug Therapy, Combination; E-Selecti | 2004 |
Indirect and total costs of early rheumatoid arthritis: a randomized comparison of combined step-down prednisolone, methotrexate, and sulfasalazine with sulfasalazine alone.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Cost-Benefit Ana | 2004 |
Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Disability Evaluation; | 2005 |
Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial.
Topics: Adrenal Cortex Hormones; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthri | 2005 |
[Correlations of clinical symptoms and treatment efficacy in patients with rheumatoid arthritis treated with Chinese herbal drugs or Western medicine].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Arthritis, Rheumatoid; Drugs, Chinese He | 2005 |
Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Etanercept; Fem | 2006 |
[Analysis on symptomatic factors of rheumatoid arthritis and its correlation with therapeutic efficacy].
Topics: Adult; Arthritis, Rheumatoid; Diagnosis, Differential; Drug Therapy, Combination; Drugs, Chinese Her | 2005 |
Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; D | 2006 |
Reduction of cardiovascular risk factors with longterm fish oil treatment in early rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arachidonic Acid; Arthritis, Rheumatoid; Cardiovascular Diseases; | 2006 |
Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrograph | 2007 |
The effect of 3435C>T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs.
Topics: Adult; Aged; Alleles; Antirheumatic Agents; Arthritis, Rheumatoid; ATP Binding Cassette Transporter, | 2006 |
The effects of sulfasalazine treatment on enthesal abnormalities of inflammatory rheumatic diseases.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Disability Evaluation; Female; Health Status; Hu | 2007 |
Efficacy profile of bucillamine in rheumatoid arthritis patients in a large observational cohort study, IORRA.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cohort Studies; Cysteine; Drug Thera | 2006 |
[Predictive role of diagnostic information in treatment efficacy of rheumatoid arthritis based on neural network model analysis].
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Diclofenac; Drugs, Chinese Herbal; Female; Human | 2007 |
Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Double-Blind Method; Female; Humans; | 2007 |
Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Arthr | 2007 |
Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; D | 2007 |
A controlled study of double filtration plasmapheresis in the treatment of active rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Male; Methotrexate; Middle | 2007 |
Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug Administration S | 2008 |
Correlations between symptoms as assessed in traditional chinese medicine (TCM) and ACR20 efficacy response: a comparison study in 396 patients with rheumatoid arthritis treated with TCM or Western medicine.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; | 2007 |
Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies.
Topics: Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Autoantibodies; Di | 2008 |
Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; Hydroxychlor | 2008 |
Comparison between penicillamine and sulphasalazine in rheumatoid arthritis: Leeds-Birmingham trial.
Topics: Adult; Aged; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protein; Clinical Trials as Topi | 1983 |
Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Blood Sedimentation; Clinical Trials as Topic; Doubl | 1983 |
Sulphasalazine in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Humans; Sulfasalazine | 1983 |
[Methotrexate and salazosulfapyridine in the long-term treatment of rheumatoid arthritis].
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Follow-Up Studies; Humans; Male; M | 1995 |
Effect of methotrexate alone or in combination with sulphasalazine on the production and circulating concentrations of cytokines and their antagonists. Longitudinal evaluation in patients with rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Cytokines; Drug Combinations; Female; Humans; Longitudinal Studi | 1995 |
Serum soluble interleukin-2 receptor levels in rheumatoid arthritis: effect of methotrexate, sulphasalazine and hydroxychloroquine therapy.
Topics: Adult; Aged; Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; | 1995 |
Outcome of second line therapy in rheumatoid arthritis.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Middle Aged; Or | 1994 |
Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Double-Blind Method; Fe | 1993 |
Hydroxychloroquine and sulphasalazine alone and in combination in rheumatoid arthritis: a randomised double blind trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy | 1993 |
Adverse interaction between intramuscular methylprednisolone and sulphasalazine in patients with early rheumatoid arthritis. A pilot study.
Topics: Adult; Aged; Arthritis, Rheumatoid; Double-Blind Method; Drug Interactions; Female; Humans; Injectio | 1994 |
Methotrexate and sulphasalazine as combination therapy in rheumatoid arthritis.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; Ma | 1994 |
[The indications for the use of salazosulfapyridine in rheumatoid arthritis patients].
Topics: Adult; Age Factors; Aged; Antibodies, Antinuclear; Arthritis, Rheumatoid; Female; HLA Antigens; Huma | 1994 |
Combination of methotrexate and sulphasalazine vs methotrexate alone: a randomized open clinical trial in rheumatoid arthritis patients resistant to sulphasalazine therapy.
Topics: Adult; Aged; Arthritis, Rheumatoid; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male | 1994 |
Validity of single variables and indices to measure disease activity in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Azathioprine; Blood Sedimentation; C-Reactive Protein; Disabled Persons; Hemo | 1993 |
The role of helplessness in the response to disease modifying drugs in rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Behavior; Cognition; Disability Evaluation; Female; Gold; Helple | 1993 |
Combining sulphasalazine and methotrexate in rheumatoid arthritis: early clinical impressions.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Methotrexate; Sulfas | 1995 |
Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Cri
Topics: Adult; Aged; Arthritis, Rheumatoid; Cohort Studies; Discriminant Analysis; Europe; Female; Humans; H | 1996 |
A double-blind controlled study comparing sulphasalazine with placebo in rheumatoid factor (RF)-negative rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Blood Sedimentation; Double-Blind Method; Female; Humans; Leukoc | 1995 |
The effect of auranofin and sulphasalazine therapy on circulating levels of interleukin 6 in rheumatoid arthritis patients.
Topics: Arthritis, Rheumatoid; Auranofin; Biological Assay; Humans; Interleukin-6; Sulfasalazine | 1995 |
Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combina | 1996 |
Comparison of intramuscular gold and sulphasalazine in the treatment of early rheumatoid arthritis. A one year prospective study.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Follow-Up Studies; Gold Sodium Thiomalat | 1995 |
A randomized double-blind controlled trial of sulphasalazine combined with pulses of methylprednisolone or placebo in the treatment of rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; D | 1996 |
Low dose desensitisation does not reduce the toxicity of sulphasalazine in rheumatoid arthritis.
Topics: Anorexia; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Administration Sche | 1996 |
Development and validation of response criteria in rheumatoid arthritis: steps towards an international consensus on prognostic markers.
Topics: Arthritis, Rheumatoid; Biomarkers; Double-Blind Method; Evaluation Studies as Topic; Humans; Hydroxy | 1996 |
Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Hydroxy | 1996 |
Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and relationship to clinical response.
Topics: Antirheumatic Agents; Area Under Curve; Arthritis, Rheumatoid; Biological Availability; Drug Interac | 1996 |
Sulfasalazine therapy for juvenile rheumatoid arthritis.
Topics: Adolescent; Adult; Arthritis, Rheumatoid; Blood Sedimentation; Child; Child, Preschool; Cohort Studi | 1996 |
Interleukin-2 receptor levels in sera of patients with rheumatoid arthritis treated with sulfasalazine, parenteral gold, or placebo.
Topics: Adult; Aged; Arthritis, Rheumatoid; Blood Sedimentation; Female; Gold Sodium Thiomalate; Humans; Joi | 1996 |
Sulfasalazine has a better efficacy/toxicity profile than auranofin--evidence from a 5 year prospective, randomized trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Auranofin; Blood Sedimentation; C-Reactive Protein; Dem | 1996 |
Sulphasalazine in the treatment of rheumatoid arthritis.
Topics: Anti-Infective Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Sulfapyridine; Sulfasala | 1997 |
The effect of sulphasalazine on neutrophil superoxide generation in rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Neutrophils; Severity of Illness Index; Sulfani | 1997 |
Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Administration Sc | 1997 |
Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Administration Sc | 1997 |
Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Administration Sc | 1997 |
Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Administration Sc | 1997 |
Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Administration Sc | 1997 |
Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Administration Sc | 1997 |
Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Administration Sc | 1997 |
Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Administration Sc | 1997 |
Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Administration Sc | 1997 |
Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; Dose-Response Relatio | 1997 |
[Combination therapy in early rheumatoid arthritis: the COBRA study].
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Cost of Illness; Double-Blind | 1997 |
Effects of patient education on compliance with basic treatment regimens and health in recent onset active rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Male; Middle Aged; Patient Compliance; | 1998 |
Validation of rheumatoid arthritis improvement criteria that include simplified joint counts.
Topics: Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Humans; Joints; Methotrexate; | 1998 |
Validation of rheumatoid arthritis improvement criteria that include simplified joint counts.
Topics: Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Humans; Joints; Methotrexate; | 1998 |
Validation of rheumatoid arthritis improvement criteria that include simplified joint counts.
Topics: Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Humans; Joints; Methotrexate; | 1998 |
Validation of rheumatoid arthritis improvement criteria that include simplified joint counts.
Topics: Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Humans; Joints; Methotrexate; | 1998 |
Validation of rheumatoid arthritis improvement criteria that include simplified joint counts.
Topics: Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Humans; Joints; Methotrexate; | 1998 |
Validation of rheumatoid arthritis improvement criteria that include simplified joint counts.
Topics: Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Humans; Joints; Methotrexate; | 1998 |
Validation of rheumatoid arthritis improvement criteria that include simplified joint counts.
Topics: Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Humans; Joints; Methotrexate; | 1998 |
Validation of rheumatoid arthritis improvement criteria that include simplified joint counts.
Topics: Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Humans; Joints; Methotrexate; | 1998 |
Validation of rheumatoid arthritis improvement criteria that include simplified joint counts.
Topics: Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Humans; Joints; Methotrexate; | 1998 |
Intention-to-treat analysis of 200 patients with rheumatoid arthritis 12 years after random allocation to either sulfasalazine or penicillamine.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Follow-Up Studi | 1998 |
Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. COBRA Trial Group. Combinatietherapie Bij Reumat
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Cost-Benefit Analysis; Disease Progression; Doub | 1998 |
Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.
Topics: Algorithms; Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; | 1999 |
Determinants of compliance with medication in patients with rheumatoid arthritis: the importance of self-efficacy expectations.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Logistic Models; Male; Mid | 1999 |
Determinants of compliance with medication in patients with rheumatoid arthritis: the importance of self-efficacy expectations.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Logistic Models; Male; Mid | 1999 |
Determinants of compliance with medication in patients with rheumatoid arthritis: the importance of self-efficacy expectations.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Logistic Models; Male; Mid | 1999 |
Determinants of compliance with medication in patients with rheumatoid arthritis: the importance of self-efficacy expectations.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Logistic Models; Male; Mid | 1999 |
Smallest detectable difference in radiological progression.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Bl | 1999 |
Does sulphasalazine cause drug induced systemic lupus erythematosus? No effect evident in a prospective randomised trial of 200 rheumatoid patients treated with sulphasalazine or auranofin over five years.
Topics: Antibodies, Antinuclear; Antirheumatic Agents; Arthritis, Rheumatoid; Auranofin; Follow-Up Studies; | 1999 |
Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Co | 1999 |
Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Co | 1999 |
Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Co | 1999 |
Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Co | 1999 |
Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Co | 1999 |
Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Co | 1999 |
Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Co | 1999 |
Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Co | 1999 |
Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Co | 1999 |
Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Digestive System; Double-Blind Method; Drug Therapy, Co | 1999 |
Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Administration Schedule; Drug | 1999 |
Cyclosporin and sulfasalazine combination in the treatment of early rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclosporine; Drug Therapy, C | 1999 |
Additive triple DMARD combination therapy of a low dose of sulfhydryl compounds, sulfasalazine and methotrexate in the treatment of rheumatoid arthritis: a clinical trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protein; D | 1999 |
Disease modification in rheumatoid arthritis with leflunomide.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind M | 1999 |
Leflunomide improves quality of life in rheumatoid arthritis.
Topics: Activities of Daily Living; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis | 1999 |
Alternative methods for analysis of radiographic damage in a randomized, double blind, parallel group clinical trial comparing hydroxychloroquine and sulfasalazine.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Humans; Hydroxychloroquine; Radiog | 2000 |
Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progre | 2000 |
Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial. On behalf of the Rheumatic Research Foundation Utrecht, The Netherlands.
Topics: Adult; Aged; Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Auranofin; Aurothiog | 2000 |
Treatment of poor-prognosis early rheumatoid arthritis. A randomized study of treatment with methotrexate, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone.
Topics: Adrenal Cortex Hormones; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Cyclosporine; Dr | 2000 |
Efficacy of sulphasalazine plus methotrexate in rheumatoid arthritis.
Topics: Adult; Anorexia; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoi | 2000 |
American College of Rheumatology criteria for improvement in rheumatoid arthritis should only be calculated from scores that decrease on improvement.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, | 2001 |
Antioxidants as adjuvant therapy in rheumatoid disease. A preliminary study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Antirheumatic Agents; Arthritis, Rheum | 2001 |
Slowing of disease progression in rheumatoid arthritis patients during long-term treatment with leflunomide or sulfasalazine.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Disease Progression; Do | 2001 |
Improved functional ability in patients with rheumatoid arthritis--longterm treatment with leflunomide versus sulfasalazine. European Leflunomide Study Group.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cohort Stud | 2001 |
Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protein; C | 2001 |
Inflammation and damage in an individual joint predict further damage in that joint in patients with early rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combina | 2001 |
Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies.
Topics: Activities of Daily Living; Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antir | 2001 |
Bone turnover, joint damage and bone mineral density in early rheumatoid arthritis treated with combination therapy including high-dose prednisolone.
Topics: Adult; Aged; Amino Acids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirhe | 2001 |
COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; D | 2002 |
Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combinat | 2002 |
Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Cohort Studies; Drug T | 2002 |
Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Bone and Bones; Bone Density; Dose-Respons | 2002 |
Prospective trial comparing the use of sulphasalazine and auranofin as second line drugs in patients with rheumatoid arthritis.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Auranofin; Blood Sedimentation; C-Reactive Pr | 1992 |
Circulating cytokine levels in patients with rheumatoid arthritis: results of a double blind trial with sulphasalazine.
Topics: Arthritis, Rheumatoid; Double-Blind Method; Humans; Interleukin-1; Interleukin-6; Sulfasalazine; Tim | 1992 |
Sulfasalazine in early rheumatoid arthritis. The Australian Multicentre Clinical Trial Group.
Topics: Adolescent; Adult; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protein; Child; Enzyme-Lin | 1992 |
[Sulfasalazine in the treatment of rheumatoid arthritis. A multicenter open study of 150 patients during 6 months].
Topics: Aged; Aged, 80 and over; Arthritis, Rheumatoid; Female; Humans; Immunosuppressive Agents; Male; Sulf | 1992 |
Hemolysis during low-dose sulfasalazine treatment in rheumatoid arthritis patients.
Topics: Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Haptoglobins; Hemoglobins; Hemolysis; Hemop | 1991 |
Response to sulfasalazine in rheumatoid arthritis: life table analysis of a 5-year followup.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Female; Follow-Up Studies; Humans | 1991 |
[The comparative effectiveness of using basic preparations in the combined therapy of rheumatoid arthritis].
Topics: Adult; Arthritis, Rheumatoid; Azathioprine; Drug Therapy, Combination; Female; Humans; Male; Middle | 1991 |
[Sulfasalazine in rheumatoid arthritis].
Topics: Arthritis, Rheumatoid; Humans; Patient Dropouts; Sulfasalazine | 1991 |
[A double blind comparative study of 1g/day, 2g/day salazosulfapyridine and placebo in rheumatoid arthritis].
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Double-Blind Method; Female; Humans; Male; Mi | 1991 |
[A double blind comparative study between salazosulfapyridine enteric coated tablets (PJ-306) and lobenzarit disodium (CCA) in rheumatoid arthritis].
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Double-Blin | 1991 |
The use of combinations of disease-modifying antirheumatic agents in rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimalarials; Arthritis, Rheumatoid; Clinical Trials as To | 1990 |
Sulphasalazine versus hydroxychloroquine in rheumatoid arthritis: 3-year follow-up.
Topics: Arthritis, Rheumatoid; Double-Blind Method; Drug Evaluation; Follow-Up Studies; Humans; Hydroxychlor | 1990 |
Sulphasalazine treatment in rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Female; Humans; Male; Middle Aged; Randomized Controlled Trials | 1990 |
Tolerability of enteric-coated sulphasalazine in rheumatoid arthritis: results of a co-operating clinics study.
Topics: Arthritis, Rheumatoid; Central Nervous System Diseases; Drug Eruptions; Female; Gastrointestinal Dis | 1990 |
Degree and extent of response to sulphasalazine or penicillamine therapy for rheumatoid arthritis: results from a routine clinical environment over a two-year period.
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administrati | 1990 |
A one-year, open, prospective study of sulfasalazine in the treatment of rheumatoid arthritis: adverse reactions and clinical response in relation to laboratory variables, drug and metabolite serum levels, and acetylator status.
Topics: Acetylation; Adult; Aged; Antibodies; Arthritis, Rheumatoid; Clinical Trials as Topic; Complement Sy | 1990 |
The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses.
Topics: Antimalarials; Arthritis, Rheumatoid; Auranofin; Gold; Humans; Meta-Analysis as Topic; Methotrexate; | 1990 |
Sensitivity of a Dutch Health Assessment Questionnaire in a trial comparing hydroxychloroquine vs. sulphasalazine.
Topics: Adult; Aged; Arthritis, Rheumatoid; Double-Blind Method; Female; Health Surveys; Humans; Hydroxychlo | 1990 |
[Results of a clinical trial of sulfasalazine in rheumatoid arthritis].
Topics: Adult; Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Pro | 1989 |
Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Arthrography; Clinical Trials as Topic; Double-Blind Method; Fem | 1989 |
Sulphasalazine versus penicillamine in the treatment of rheumatoid arthritis.
Topics: Acetyltransferases; Arthritis, Rheumatoid; Arthrography; Clinical Trials as Topic; Female; Humans; M | 1989 |
A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazine.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Dose-Response Relationship | 1989 |
A rheumatological dilemma: is it possible to modify the course of rheumatoid arthritis? Can we answer the question?
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Auranofin; Aurothioglucose; Azathioprine; Clinical | 1985 |
Which component of sulphasalazine is active in rheumatoid arthritis?
Topics: Adult; Aged; Aminosalicylic Acids; Arthritis, Rheumatoid; Humans; Mesalamine; Middle Aged; Sulfanila | 1985 |
Sulphasalazine in the treatment of rheumatoid arthritis: relationship of dose and serum levels to efficacy.
Topics: Adult; Aged; Arthritis, Rheumatoid; Blood Sedimentation; Clinical Trials as Topic; Dose-Response Rel | 1985 |
Sulfasalazine in severe rheumatoid arthritis: a study to assess potential correlates of efficacy and toxicity.
Topics: Adult; Aged; Arthritis, Rheumatoid; Blood Sedimentation; Clinical Trials as Topic; Female; Humans; M | 1985 |
Does sulphasalazine cause folate deficiency in rheumatoid arthritis?
Topics: Arthritis, Rheumatoid; Erythrocyte Indices; Folic Acid Deficiency; Humans; Penicillamine; Sulfasalaz | 1985 |
Combination therapy with pulsed methylprednisolone in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Drug Combinations; Female; Humans; Infusions, Parenteral; Male; Methylprednis | 1985 |
The use of chloroquine and D-penicillamine in the treatment of rheumatoid arthritis.
Topics: Anti-Glomerular Basement Membrane Disease; Arthritis, Rheumatoid; Captopril; Chloroquine; Clinical T | 1986 |
[Experience with sulphasalazine (salazopyrin) in the treatment of rheumatoid arthritis].
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Evaluation; Humans; Sulfasalazine | 1986 |
Pharmacological and biochemical actions of sulphasalazine.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials as Topic; Colitis, U | 1986 |
Assessing the progression of joint damage in rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Arthrography; Clinical Trials as Top | 1986 |
Sulfasalazine in rheumatoid arthritis. A double-blind, placebo-controlled trial.
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Double-Blind Method; Humans; Patient Dropouts; Reac | 1986 |
[New basic preparations with prolonged action in the treatment of rheumatoid arthritis].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials as Topic; Hum | 1987 |
Effect of sulphasalazine on the radiological progression of rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Arthrography; Clinical Trials as Topic; Humans; Prospective Studies; Sulfasal | 1987 |
Combination therapy in rheumatoid arthritis--study design.
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Penicillamine; S | 1987 |
Effects of sulphasalazine on faecal flora in patients with rheumatoid arthritis: a comparison with penicillamine.
Topics: Arthritis, Rheumatoid; Bacteria; Clostridium perfringens; Escherichia coli; Feces; Humans; Middle Ag | 1987 |
Outcome of long-term treatment of rheumatoid arthritis with second-line agents.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Gastrointestinal Diseases | 1987 |
The pharmacokinetics of sulphasalazine in young and elderly patients with rheumatoid arthritis.
Topics: Acetylation; Adult; Aged; Aging; Arthritis, Rheumatoid; Clinical Trials as Topic; Female; Half-Life; | 1987 |
Long term experience of salazopyrin EN in rheumatoid arthritis (RA).
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Therapy, Combination | 1987 |
[The treatment of rheumatoid polyarthritis using salazosulfapyridine (Salazopyrine). A 6-month open study of 34 patients].
Topics: Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid | 1988 |
[Sulfasalazine as an antirheumatism agent; a review of the literature].
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Humans; Sulfasalazine | 1988 |
A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis.
Topics: Adolescent; Adult; Arthritis, Rheumatoid; Blood Sedimentation; Clinical Trials as Topic; Gold Sodium | 1988 |
Comparison of responses to and adverse effects of graded doses of sulfasalazine in the treatment of rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Clinical Trials as Topic; Double-Blind Method; Drug Administration Sch | 1988 |
Comparisons of sulfasalazine to gold and placebo in the treatment of rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Gold Sodium Thiomalate; Humans; Multicenter Studies | 1988 |
Sulfasalazine in the rheumatic disease.
Topics: Arthritis, Rheumatoid; Autoimmune Diseases; Central Nervous System; Chemical and Drug Induced Liver | 1988 |
[Double-blind study of the effects of sulfasalazine in patients with rheumatoid arthritis].
Topics: Adult; Aged; Arthritis, Rheumatoid; Child; Double-Blind Method; Humans; Infant; Middle Aged; Randomi | 1988 |
495 other studies available for sulfasalazine and Arthritis, Rheumatoid
| Article | Year |
|---|---|
In vitro evaluation of disease-modifying antirheumatic drugs against rheumatoid arthritis associated pathogens of the oral microflora.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Methotrexate; Microbiota; Sulfasalazine | 2021 |
Comment on: The sFlt-1 to PlGF ratio in pregnant women with rheumatoid arthritis: impact of disease activity and sulfasalazine use. Reply.
Topics: Arthritis, Rheumatoid; Female; Humans; Pregnancy; Pregnant Women; Sulfasalazine | 2022 |
Comment on: The sFlt-1 to PlGF ratio in pregnant women with rheumatoid arthritis: impact of disease activity and sulfasalazine use.
Topics: Arthritis, Rheumatoid; Female; Humans; Pregnancy; Pregnant Women; Sulfasalazine | 2022 |
Pregnancy outcomes in patients with rheumatoid arthritis who discontinue methotrexate treatment to conceive.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; Methotrexate | 2022 |
[Progressive multifocal leukoencephalopathy in a patient with rheumatoid arthritis under salazosulfapyridine treatment].
Topics: Activities of Daily Living; Aged, 80 and over; Arthritis, Rheumatoid; Humans; JC Virus; Leukoencepha | 2021 |
[Regression of diffuse large B-cell lymphoma after discontinuation of salazosulfapyridine].
Topics: Arthritis, Rheumatoid; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoproliferative Disorders; Male; | 2022 |
Iguratimod versus salazosulfapyridine in rheumatoid arthritis patients with an inadequate response to methotrexate: Adjusted with propensity score matching.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Methotrexate; Propen | 2023 |
Adverse reaction profile of sulfasalazine and its persistence in chronic therapy of rheumatoid arthritis and spondyloarthritis: A multicentric observational study.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Drug-Related Side Effects an | 2022 |
Elevated expression of TAM receptor tyrosine kinase in synovial fluid and synovial tissue of rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Complement C3; Humans; Osteoarthritis; Receptor Protein-Tyrosine Kinases; Rhe | 2022 |
Efficacy of sulfasalazine for the prevention of Pneumocystis pneumonia in patients with rheumatoid arthritis: A multicentric self-controlled case series study.
Topics: Arthritis, Rheumatoid; Humans; Methotrexate; Opportunistic Infections; Pneumocystis carinii; Pneumon | 2023 |
Tofacitinib for the treatment of inflammatory bowel disease-associated arthritis: two case reports.
Topics: Adult; Arthritis, Rheumatoid; Colitis, Ulcerative; Crohn Disease; Female; Humans; Inflammatory Bowel | 2023 |
Factors associated with the composition of the gut microbiome in patients with established rheumatoid arthritis and its value for predicting treatment responses.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Gastrointestinal Microbiome; Humans; RNA, Ribosomal, 16 | 2023 |
Association between SYVN1 and SEL1 genetic polymorphisms and remission in rheumatoid arthritis patients treated with TNF-α inhibitors: a machine learning approach.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Endoplasmic Reticulum-Associated Degradation; Humans; P | 2023 |
Nanna Svartz (1890-1986) and the discovery of sulfasalazine.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Sulfasalazine | 2023 |
Perinatal use and discontinuation of disease-modifying anti-rheumatic drugs and biologics in women with rheumatoid arthritis: a cohort study.
Topics: Abatacept; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Antirh | 2020 |
The impact of different criteria sets on early remission and identifying its predictors in rheumatoid arthritis: results from an observational cohort (2009-2018).
Topics: Adult; Age Factors; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; C-Reacti | 2020 |
Rheumatoid artrhitis treatment in Brazil: data from a large real-life multicenter study.
Topics: Adrenal Cortex Hormones; Antirheumatic Agents; Arthritis, Rheumatoid; Brazil; Chi-Square Distributio | 2020 |
Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; B | 2021 |
Circulating Small Noncoding RNA Biomarkers of Response to Triple Disease-modifying Antirheumatic Drug Therapy in White Women With Early Rheumatoid Arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Drug Therapy, Combination; Female; Humans; | 2020 |
Revisiting the cardiovascular risk of hydroxychloroquine in RA.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antimalarials; Arthritis, Rheumatoid; Azithromycin; Ca | 2020 |
Tuberculosis osteomyelitis in an old fused hip; activated by prednisolone, salazosulfapyridine, and low-dose methotrexate therapy in a patient with rheumatoid arthritis.
Topics: Aged; Antirheumatic Agents; Antitubercular Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; | 2020 |
Mortality over 14 years in MTX-refractory patients randomized to a strategy of addition of infliximab or sulfasalazine and hydroxychloroquine.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; | 2021 |
Sustained Remission in Patients With Rheumatoid Arthritis Receiving Triple Therapy Compared to Biologic Therapy: A Swedish Nationwide Register Study.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Chloroquine; Drug Therapy, | 2021 |
The sFlt-1 to PlGF ratio in pregnant women with rheumatoid arthritis: impact of disease activity and sulfasalazine use.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Female; Humans; Membrane Proteins; P | 2022 |
Three out of four disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12 months: results from the FIN-ERA cohort.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Cohort Studies; Drug | 2017 |
Triple Oral Therapy Versus Antitumor Necrosis Factor Plus Methotrexate (MTX) in Patients with Rheumatoid Arthritis and Inadequate Response to MTX: A Systematic Literature Review.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Drug Therapy, Combination; Humans; | 2017 |
CpG-specific methylation at rheumatoid arthritis diagnosis as a marker of treatment response.
Topics: ADAMTS Proteins; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Butyrophilins; CpG Islands | 2017 |
Prevalence of glucose intolerance in rheumatoid arthritis patients at a tertiary care centre in Haryana.
Topics: Adult; Arthritis, Rheumatoid; Body Mass Index; Drug Therapy, Combination; Female; Glucose Intoleranc | 2017 |
Triple DMARD treatment in early rheumatoid arthritis modulates synovial T cell activation and plasmablast/plasma cell differentiation pathways.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Arthroscopy; Biopsy; Case-Control Studies; | 2017 |
Disease activity trajectories in early rheumatoid arthritis following intensive DMARD therapy over 3 years: association with persistence to therapy.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Chi-Square Distribution; Disease Progressi | 2017 |
A Bayesian model that jointly considers comparative effectiveness research and patients' preferences may help inform GRADE recommendations: an application to rheumatoid arthritis treatment recommendations.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Comparative Effectiveness Research; Drug | 2018 |
Effects of Amerindian Genetic Ancestry on Clinical Variables and Therapy in Patients with Rheumatoid Arthritis.
Topics: Adult; Age Factors; Aged; Alleles; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Ar | 2017 |
Sulfasalazine induces mitochondrial dysfunction and renal injury.
Topics: Acute Kidney Injury; Administration, Oral; Animals; Antioxidants; Arthritis, Rheumatoid; Biomarkers; | 2017 |
Methotrexate might reduce ischemic stroke in patients with rheumatoid arthritis: a population-based retrospective cohort study.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Databases, Factual; Female; Humans; Hydroxychloroquine; | 2018 |
[Rheumatoid arthritis and polycythemia vera JAK2 negative association: Polycythemia may be worsening under methotrexate?]
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Janus Kinase 2; Male; Methotrexate; Poly | 2018 |
Long-term disease and patient-reported outcomes of a continuous treat-to-target approach in patients with early rheumatoid arthritis in daily clinical practice.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Drug Therapy, Combina | 2018 |
Effect of sulfasalazine use on the presence of Pneumocystis organisms in the lung among patients with rheumatoid arthritis: A test-negative design case-control study with PCR tests.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Lung; Male; Middle Aged; P | 2019 |
Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis Is Associated With Changes in Blood Pressure.
Topics: Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Pressure; Female; | 2018 |
Disease Characteristics and Change in Arthritis Activity according to Treatment in Hepatitis B Surface Antigen-positive Rheumatoid Arthritis Patients: a Retrospective Chart Review Study.
Topics: Adult; Alanine Transaminase; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; C-Rea | 2018 |
Sex-associated Treatment Differences and Their Outcomes in Rheumatoid Arthritis: Results from the METEOR Register.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Follow- | 2018 |
A 63-year-old returned traveller with fever, rash, hepatitis and eosinophilia.
Topics: Adrenal Cortex Hormones; Antirheumatic Agents; Arthritis, Rheumatoid; Chemical and Drug Induced Live | 2018 |
Prophylactic effect of sulfasalazine against Pneumocystis pneumonia in patients with rheumatoid arthritis: A nested case-control study.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Case-Control Studies; Databases, Factual; Female; | 2019 |
High proportion of drug hypersensitivity reactions to sulfasalazine following its use in anti-PD-1-associated inflammatory arthritis.
Topics: Aged; Arthritis, Rheumatoid; Drug Hypersensitivity; Female; Humans; Male; Middle Aged; Programmed Ce | 2018 |
Low Persistence Rates in Patients With Rheumatoid Arthritis Treated With Triple Therapy and Adverse Drug Events Associated With Sulfasalazine.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Drug Therapy, Combination; Drug-R | 2019 |
Organizing pneumonia in a patient with rheumatoid arthritis with progression to usual interstitial pneumonia.
Topics: Arthritis, Rheumatoid; Cryptogenic Organizing Pneumonia; Disease Progression; Humans; Lung; Male; Mi | 2019 |
Association of Baseline Peptidylarginine Deiminase 4 Autoantibodies With Favorable Response to Treatment Escalation in Rheumatoid Arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Autoantibodies; Drug Therapy, Combination; | 2019 |
Relapsing Course of Sulfasalazine-Induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Complicated by Alopecia Universalis and Vitiligo.
Topics: Alopecia; Antirheumatic Agents; Arthritis, Rheumatoid; Biopsy; Cyclosporine; Dermatologic Agents; Dr | 2018 |
2017 recommendations of the Brazilian Society of Rheumatology for the pharmacological treatment of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Brazil; Decision Making; Drug Substitution; Drug Therap | 2018 |
Early arthritis clinic is effective for rheumatoid and psoriatic arthritides.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antirheumatic Agents; Arthritis, Psoria | 2019 |
Genetic and epigenetic alteration of the programmed cell death 1 in rheumatoid arthritis.
Topics: Anti-Citrullinated Protein Antibodies; Antirheumatic Agents; Arthritis, Rheumatoid; Case-Control Stu | 2019 |
Long-term clinical, functional, and cost outcomes for early rheumatoid arthritis patients who did or did not achieve early remission in a real-world treat-to-target strategy.
Topics: Adult; Aged; Arthritis, Rheumatoid; Biological Products; Female; Health Care Costs; Humans; Male; Me | 2019 |
Innovative HPTLC method for simultaneous determination of ternary mixture of certain DMARDs in real samples of rheumatoid arthritis patients: an application of quality by design approach.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Chromatography, Thin Layer; Female; Humans; Hydr | 2019 |
The neutrophil-lymphocyte ratio in early rheumatoid arthritis and its ability to predict subsequent failure of triple therapy.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; Hydroxychlor | 2019 |
Giant cell myocarditis in a patient with a spondyloarthropathy after a drug hypersensitivity reaction.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Biopsy; Drug Hypersensitivity; Echocardiography; | 2013 |
Baseline factors predicting change from the initial DMARD treatment during the first 2 years of rheumatoid arthritis: experience in the ERAN inception cohort.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Disability Evaluation; Dru | 2013 |
Making rational treatment decisions in rheumatoid arthritis when methotrexate fails.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Etanercept; Female; Humans; Hydroxychloroquine; Immunog | 2013 |
Conventional triple therapy as good as etanercept for uncontrolled rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Etanercept; Humans; Hydroxyc | 2013 |
Not better but quite good: effects on work loss of combination treatment for rheumatoid arthritis with and without biological agents.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Hydroxychloroqu | 2013 |
Rheumatoid arthritis. Triple therapy or etanercept after methotrexate failure in RA?
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Etanercept; Humans; Hydroxyc | 2013 |
The decline in joint replacement surgery in rheumatoid arthritis is associated with a concomitant increase in the intensity of anti-rheumatic therapy: a nationwide register-based study from 1995 through 2010.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Arthroplasty, Replacement; Female; Finland; Humans; Hyd | 2013 |
Amgen best-seller challenged by generics.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biosimilar Pharmaceuticals; Chloroquine; Clinical Trial | 2013 |
[Rheumatoid arthritis: lower work loss during treatment with biologicals?--Modern treatment principles reduce work loss in rheumatoid arthritis].
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Hydroxychloroqu | 2013 |
Retrospective study of salazosulfapyridine in eight patients with rheumatoid arthritis on hemodialysis.
Topics: Aged; Arthritis, Rheumatoid; Female; Humans; Male; Middle Aged; Renal Dialysis; Retrospective Studie | 2014 |
Periodontitis and etanercept discontinuation risk in anti-tumor necrosis factor-naive rheumatoid arthritis patients: a nationwide population-based cohort study.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Comorbidity; Drug Therapy, Combination; Etanerce | 2013 |
Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cost-Benefit Analysis; Female; Follow-Up S | 2013 |
Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Arylamine N-Acetyltransferase; ATP Binding | 2014 |
Early, structured disease modifying anti-rheumatic drug (DMARD) therapy reduces cardiovascular risk in rheumatoid arthritis--a single centre study using non-biologic drugs.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Cardiovasc | 2013 |
[Association between AIF-1 gene polymorphisms and response to rheumatoid arthritis treatment with sulphasalazine].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Calcium-Binding Proteins; DNA-Binding Proteins; Female; | 2013 |
Genetic polymorphisms affect efficacy and adverse drug reactions of DMARDs in rheumatoid arthritis.
Topics: Alleles; Antirheumatic Agents; Arthritis, Rheumatoid; Arylamine N-Acetyltransferase; B-Cell Activati | 2014 |
Sulfasalazine and its metabolites inhibit platelet function in patients with inflammatory arthritis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Platelets; Cohort Studies; Female; Humans; | 2016 |
Treatment of rheumatoid arthritis with methotrexate alone and in combination with other conventional DMARDs using the T2T strategy. A cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Cohort Stu | 2015 |
Rheumatoid arthritis: Methotrexate and bridging glucocorticoids in early RA.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Glucocorticoids; Humans; Isoxazoles; Male; Meth | 2014 |
A population model of early rheumatoid arthritis disease activity during treatment with methotrexate, sulfasalazine and hydroxychloroquine.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theor | 2015 |
Factors influencing ultrasonographic remission in patients with rheumatoid arthritis.
Topics: Adalimumab; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic A | 2015 |
Patients with rheumatoid arthritis have better functional and working ability but poorer general health and higher comorbidity rates today than in the late 1990s.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Produc | 2015 |
Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts.
Topics: Adult; Aged; Antirheumatic Agents; Area Under Curve; Arthritis, Rheumatoid; Autoantibodies; Cohort S | 2015 |
Daily practice feasibility and effectiveness of treating long-standing rheumatoid arthritis to target with synthetic disease-modifying antirheumatic drugs: a prospective cohort study.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Feasibility Stu | 2015 |
Tumor necrosis factor-α antagonist therapy for concomitant rheumatoid arthritis and hepatitis C virus infection: a case series study.
Topics: Adalimumab; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumato | 2015 |
Rheumatoid lung.
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Male; Methotrexate; M | 2015 |
The usefulness of a new triple combination treatment utilizing methotrexate, salazosulfapyridine, and bucillamine in rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Cysteine; Drug Therap | 2016 |
Etanercept-Methotrexate Combination Therapy Initiators Have Greater Adherence and Persistence Than Triple Therapy Initiators With Rheumatoid Arthritis.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Databases, Factual; Drug Thera | 2015 |
Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis.
Topics: Adalimumab; Adult; Aged; Antibodies; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthri | 2015 |
Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; D | 2015 |
Prednisone Use and Risk of Mortality in Patients With Rheumatoid Arthritis: Moderation by Use of Disease-Modifying Antirheumatic Drugs.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Co | 2016 |
Serum survivin predicts responses to treatment in active rheumatoid arthritis: a post hoc analysis from the SWEFOT trial.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Drug Therapy, Combination; Female; H | 2015 |
Tumor Necrosis Factor-α Inhibitor Use and the Risk of Incident Hypertension in Patients with Rheumatoid Arthritis.
Topics: Adalimumab; Adult; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprine | 2016 |
Brief Report: Intensification to Triple Therapy After Treatment With Nonbiologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis in the United States From 2009 to 2014.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; Hydro | 2016 |
Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
Topics: Adolescent; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Female; Hispani | 2016 |
Potential of sulfasalazine as a therapeutic sensitizer for CD44 splice variant 9-positive urogenital cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arthritis, Rheumatoid; Humans; Hyaluronan Rece | 2016 |
Treatment of rheumatoid arthritis (RA) in India-how and by whom: results from a speciality clinic-use of low-dose methotrexate (MTX) was inexplicably suboptimal.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Delayed Diagnosis; Drug Therapy, Combination; Fem | 2016 |
The Impact of Low-Dose Disease-modifying Anti-rheumatics Drugs (DMARDs) on Bone Mineral Density of Premenopausal Women in Early Rheumatoid Arthritis.
Topics: Absorptiometry, Photon; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; Bon | 2016 |
Hepatitis B Virus Reactivation Following Salazosulfapyridine Monotherapy in a Patient with Rheumatoid Arthritis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; DNA, Viral; Hepatitis B; Hepatitis B Surface Anti | 2016 |
Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Databases, Factual; Drug Sub | 2017 |
Improving patient-centred care for rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Canada; Decision Making; Drug Therapy, Combination; Eta | 2016 |
Effect of Adherence to Protocolized Targeted Intensifications of Disease-modifying Antirheumatic Drugs on Treatment Outcomes in Rheumatoid Arthritis: Results from an Australian Early Arthritis Cohort.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Australia; Disease Progression; Dose-Respo | 2016 |
Active Rheumatoid Arthritis in Central Africa: A Comparative Study Between Sudan and Sweden.
Topics: Adolescent; Adult; Age of Onset; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoi | 2016 |
Cost-effectiveness of clinical remission by treat to target strategy in established rheumatoid arthritis: results of the CREATE registry.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Cost-Benefit Analysis; Data | 2016 |
Sulfasalazine induced immune thrombocytopenia in a patient with rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Blood Platelets; Humans; Male; Purpura, Thrombocytopenic, Idiopathic; R | 2017 |
Identifying Clinical Factors Associated With Low Disease Activity and Remission of Rheumatoid Arthritis During Pregnancy.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Autoantibodies; C-Reactive Protein; Female; Huma | 2017 |
A Multi-Biomarker Disease Activity Score and the Choice of Second-Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Blood Sedimentation; C-Reactive Protein; Ch | 2017 |
Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: a case-control study in Asia.
Topics: Abatacept; Adalimumab; Adrenal Cortex Hormones; Adult; Aged; Antibodies, Monoclonal; Antibodies, Mon | 2017 |
Sulfasalazine-Related Hypersensitivity Reactions in Patients With Rheumatic Diseases.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug Hyp | 2017 |
Lymphoma-like presentation in suspected rheumatoid arthritis due to sulphasalazine hypersensitivity syndrome.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Diagnosis, Differential; Drug Eruptions; Drug Hy | 2008 |
Discordant perspectives of rheumatologists and patients on COBRA combination therapy in rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Attitude of Health Personnel; Attitude to Health; Drug | 2008 |
[Megaloblastic anemia associated with salazosulfapyridine treatment for rheumatoid arthritis].
Topics: Aged; Anemia, Megaloblastic; Antirheumatic Agents; Arthritis, Rheumatoid; Folic Acid; Folic Acid Def | 2008 |
Disease-modifying antirheumatic drugs.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprine; Humans; Hydroxychloroquine; Isoxazoles; L | 2009 |
Salazopyrine-induced aseptic meningitis.
Topics: Amoxicillin; Anti-Bacterial Agents; Arthritis, Rheumatoid; Ceftriaxone; Drug Combinations; Female; F | 2009 |
Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway.
Topics: Adult; Age Factors; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Confidence In | 2009 |
Salazosulfapyridine-induced hypersensitivity syndrome triggered by methotrexate.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Eruptions; Drug Therapy, Combination; Female; Huma | 2009 |
Facilitating the use of COBRA combination therapy in early rheumatoid arthritis: a pilot implementation study.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug The | 2009 |
The effect of 677C>T and 1298A>C MTHFR polymorphisms on sulfasalazine treatment outcome in rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Gene Frequency; Genotype; Humans; | 2009 |
The Chinese herbal remedy Tripterygium wilfordii Hook F in the treatment of rheumatoid arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; D | 2009 |
Sulphasalazine induced three-week syndrome.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Edema; Exanthema; Female; Hum | 2009 |
[Financial cost of early rheumatoid arthritis in the first year of medical attention: three clinical scenarios in a third-tier university hospital in Colombia].
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthrit | 2009 |
Development of rheumatoid arthritis during the course of gefitinib therapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Interaction | 2009 |
Drug rash with eosinophilia and systemic symptoms syndrome induced by sulfasalazine.
Topics: Aged; Ampicillin; Anti-Bacterial Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Ceftriaxone; D | 2010 |
Sulfasalazine-induced hypersensitivity: a case report of DRESS syndrome.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Hypersensitivity; Hepatomegaly; Humans; Mal | 2009 |
Increased expression of proto-oncogene survivin predicts Joint destruction and persistent disease activity in early rheumatoid arthritis.
Topics: Adult; Aged; Antibodies; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Female; H | 2010 |
[A cutaneous infection by Mycobacterium chelonae in a patient with rheumatoid arthritis].
Topics: Anti-Bacterial Agents; Arthritis, Rheumatoid; Ciprofloxacin; Clarithromycin; Drug Combinations; Fema | 2010 |
Current concepts in the genetic diagnostics of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprine; Genetic Predisposition to Disease; HLA-DR | 2010 |
Development of anti-CCP-positive rheumatoid arthritis following pegylated interferon-α2a treatment for chronic hepatitis C infection.
Topics: Antirheumatic Agents; Antiviral Agents; Arthritis, Rheumatoid; Autoantibodies; Drug Carriers; Hepati | 2010 |
Sulphasalazine lung toxicity: report of two cases.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Bronchiectasis; Cough; Crohn Disease; Female; Hu | 2010 |
Achilles paratendonitis as the initial manifestation of rheumatoid arthritis.
Topics: Achilles Tendon; Antirheumatic Agents; Arthritis, Rheumatoid; Diagnosis, Differential; Disease Progr | 2011 |
Causes of DMARD withdrawal following ADR within 6 months of initiation among Indian rheumatoid arthritis patients.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2012 |
In vitro risk assessment of AZD9056 perpetrating a transporter-mediated drug-drug interaction with methotrexate.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; ATP Binding Cassette Transporter, Subfamily G, | 2011 |
Current smoking status is associated to a non-ACR 50 response in early rheumatoid arthritis. A cohort study.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Drug Therapy, Combination; Femal | 2011 |
Cardiac AA amyloidosis in a patient with rheumatoid arthritis and systemic sclerosis: the therapeutic potential of biological reagents.
Topics: Aged; Amyloidosis; Antibodies, Antinuclear; Antirheumatic Agents; Arthritis, Rheumatoid; Benzimidazo | 2011 |
Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort | 2011 |
Etanercept in combination with conventional disease-modifying antirheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis patients intolerant to methotrexate.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Cysteine; Drug Substitu | 2012 |
Post-chikungunya chronic arthritis--our experience with DMARDs over two year follow up.
Topics: Adult; Aged; Alphavirus Infections; Antirheumatic Agents; Arthritis, Rheumatoid; Chikungunya Fever; | 2011 |
Single-center, retrospective analysis of efficacy and safety of tacrolimus as a second-line DMARD in combination therapy and the risk factors contributing to adverse events in 115 patients with rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cysteine; Disease Progression; Drug Therap | 2012 |
Absent "Window of Opportunity" in smokers with short disease duration. Data from BARFOT, a multicenter study of early rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Health Status; Humans; Inflammatio | 2011 |
Towards personalized treatment: predictors of short-term HAQ response in recent-onset active rheumatoid arthritis are different from predictors of rapid radiological progression.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive | 2012 |
Changes in cotherapies after initiation of disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; | 2011 |
Response to traditional disease-modifying anti-rheumatic drugs in indigent South Africans with early rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Drug Therapy, Combination; Fe | 2012 |
Effectiveness of sulfasalazine and methotrexate in 1102 DMARD-naive patients with early RA.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Drug Evaluation; Female; Human | 2012 |
A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry.
Topics: Adult; Aged; Ambulatory Care Facilities; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies | 2012 |
Recent trends in use of nonbiologic DMARDs and evaluation of their continuation rates in single and dual combination therapies in rheumatoid arthritis patients in Japan.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Cysteine; Drug Therapy, Combination; Female; Hum | 2012 |
Proinflammatory and anti-inflammatory cytokines in gingival crevicular fluid and serum of patients with rheumatoid arthritis and patients with chronic periodontitis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Chronic Periodontitis; | 2013 |
Tight control early rheumatoid arthritis clinic in Hong Kong: a pilot study.
Topics: Adult; Aged; Arthritis, Rheumatoid; Female; Follow-Up Studies; Humans; Male; Methotrexate; Middle Ag | 2012 |
[Sulphasalazine in patients with rheumatoid arthritis in China: a cross-sectional study].
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; C | 2012 |
Significant improvement in MRI-proven bone edema is associated with protection from structural damage in very early RA patients managed using the tight control approach.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Bone Diseases; Disease Progression; Edema; | 2013 |
Clinical remission following treatment with tumour necrosis factor-alpha antagonists is not accompanied by changes in asymmetric dimethylarginine in patients with rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arginine; Arthritis, Rheumatoid; Biomarkers; Female; Humans; Long | 2012 |
Sulphonamide-induced remission in rheumatoid arthritis--a thought-provoking prescribing error.
Topics: Anti-Infective Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Hand Joints; Humans; Induction C | 2013 |
Tumour necrosis factor-alpha inhibitor-induced hepatic injury in patients with rheumatoid arthritis: two case reports and an analysis of the laboratory data from the Slovenian national biologicals registry.
Topics: Adalimumab; Adult; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; B | 2013 |
Treatment of early rheumatoid arthritis in a multinational inception cohort of Latin American patients: the GLADAR experience.
Topics: Adult; Antimalarials; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Disease Managemen | 2012 |
Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort.
Topics: Abdominal Pain; Adalimumab; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2012 |
[Rheumatoid arthritis: progress in diagnosis and treatment. Topics: IV. Treatment; 2. Antirheumatic agents, 1) non-biologic agents].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cysteine; Female; Humans; Methotrexate; Sulfasalazine; | 2012 |
The effects of sulphasalazine on urinary excretion of the hydroxypyridinium crosslinks of collagen in patients with rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Adult; Aged; Amino Acids; Arthritis, Rheumatoid; Collagen; Female; Humans; | 2002 |
[2 years data of controlled trials with leflunomide vs. methotrexate and leflunomide vs. sulfasalazine].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Follow-Up Studies; Humans; Is | 2002 |
The effect of sulfasalazine on rheumatoid arthritic synovial tissue chemokine production.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; C | 2002 |
Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Chemical and Drug Induced Liver Inju | 2002 |
[Retrospective study of adverse events in patients with rheumatoid arthritis treated with second-line drugs].
Topics: Adult; Anorexia; Antirheumatic Agents; Arthritis, Rheumatoid; Exanthema; Female; Gastrointestinal Di | 2002 |
Bone mineral density in men with rheumatoid arthritis is associated with erosive disease and sulfasalazine treatment but not with sex hormones.
Topics: Absorptiometry, Photon; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Body Mass Index; B | 2002 |
Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene.
Topics: Acetylation; Antirheumatic Agents; Arthritis, Rheumatoid; Arylamine N-Acetyltransferase; Female; Hap | 2002 |
The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses.
Topics: Acute Disease; Aged; Antimalarials; Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprine; Chron | 2002 |
[Diagnosis and treatment of rheumatoid arthritis].
Topics: Adult; Aged; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, R | 2002 |
[Pharmacogenetics of disease modifying anti-rheumatic drugs].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Arylamine N-Acetyltransferase; Humans; Methotrexate; Me | 2002 |
Liaison between rheumatoid arthritis and ulcerative colitis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Colitis, Ulcerative; Drug Therapy, Combination; | 2003 |
[Evidence-based treatment of methotrexate-resistant rheumatoid arthritis. Combinations of conventional disease-modifying antirheumatic agents].
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, | 2003 |
Methotrexate is the leading DMARD in Finland.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Finland; Humans; Hydroxychloroquine; Insurance, Health; | 2003 |
Termination of disease-modifying antirheumatic drugs in rheumatoid arthritis and in psoriatic arthritis. A comparative study of 270 cases.
Topics: Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; | 2003 |
[Serum interleukin 6 (il-6A) concentration correlates with matrix metalloproteinases and their tissue inhibitors in rheumatoid arthritis].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Enzyme-Linked | 2003 |
[Pharmacokinetics of salazosulfapyridine in a hemodialysis patient].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Administration Schedule; Female; Humans; Kidney Fa | 2003 |
A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Attitude of Health Personnel; Choice Behavior; Consulta | 2004 |
Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protein; Chi-Squa | 2003 |
[Treatment of primary chronic rheumatism with salazopyrine].
Topics: Arthritis; Arthritis, Rheumatoid; Drug Combinations; Glucosamine; Rheumatic Diseases; Sulfasalazine; | 1954 |
Treatment of rheumatoid arthritis with salicylazosulfapyridine.
Topics: Arthritis; Arthritis, Rheumatoid; Humans; Sulfanilamide; Sulfanilamides; Sulfasalazine; Sulfonamides | 1958 |
Gold treatment in rheumatoid arthritis with some notes on hormone-gold and hormone-salazopyrin therapy.
Topics: Adrenocorticotropic Hormone; Arthritis; Arthritis, Rheumatoid; Cortisone; Gold; Humans; Sulfanilamid | 1954 |
[Idiopathic hypereosinophilic syndrome associated with rheumatoid arthritis. A case report].
Topics: Arthritis, Rheumatoid; Autoimmune Diseases; Cyclosporine; Female; Glucocorticoids; Humans; Hypereosi | 2003 |
Cyclosporin and methotrexate therapy.
Topics: Arthritis, Rheumatoid; Cyclosporine; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Me | 2003 |
Drug-induced bilateral transient myopia with the sulphonamide sulphasalazine.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthriti | 2003 |
Medical resource use and costs among rheumatoid arthritis patients receiving disease-modifying antirheumatic drug therapy.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Direct Service Costs; Drug Costs; Drug Therapy, Combina | 2000 |
Late onset hypersensitivity to sulfasalazine in a patient with ankylosing spondylitis: comment on the article by Paul et al.
Topics: Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Biopsy; Drug Eruptions; Female | 2000 |
High incidence of hepatotoxicity of isoniazid treatment for tuberculosis chemoprophylaxis in patients with rheumatoid arthritis treated with methotrexate or sulfasalazine and anti-tumour necrosis factor inhibitors.
Topics: Adult; Aged; Antirheumatic Agents; Antitubercular Agents; Arthritis, Rheumatoid; Chemical and Drug I | 2003 |
Longterm observational study of methotrexate use in a Dutch cohort of 1022 patients with rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Drug Therapy, | 2003 |
Acquired resistance of human T cells to sulfasalazine.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biological Transport, Active; Drug Resistance, Multiple | 2004 |
Acquired resistance of human T cells to sulfasalazine: stability of the resistant phenotype and sensitivity to non-related DMARDs.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; ATP Binding Cassette Transporter, | 2004 |
Salicylazosulfapyridine (salazopyrin or azopyrin) in rheumatoid arthritis and experimental polyarthritis.
Topics: Animals; Arthritis; Arthritis, Rheumatoid; Body Weight; Erythrocyte Count; Gold; Humans; Joints; Leu | 1950 |
Estimated prediagnosis radiological progression: an important tool for studying the effects of early disease modifying antirheumatic drug treatment in rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Auranofin; Disease Progression; Feasibilit | 2005 |
Bronchiolitis obliterans organizing pneumonia associated with sulfasalazine in a patient with rheumatoid arthritis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cryptogenic Organizing Pneumonia; Female; Glucoco | 2004 |
Two is better than one? Combination therapy in rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Etanercept; Humans; Immunogl | 2004 |
[Markov model of decision making for basic therapy of rheumatoid arthritis: oder of monotherapy and expenses for drug therapy].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cost-Benefit Analysis; Decision Making; Humans; Markov | 2004 |
Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications for combination therapies with methotrexate in rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; ATP Binding Cassette Transporter, Subfamily B, Member 1 | 2004 |
Chlamydial infection preceding the development of rheumatoid arthritis: a brief report.
Topics: Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Chlamy | 2004 |
Low dose prednisolone for treatment of RA.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Data Interpretation, Statisti | 2004 |
[Examination of the escape phenomenon in disease modifying antirheumatic drugs].
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protein; Cysteine | 2005 |
[Treatment with leflunomide in rheumatoid arthritis].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Europe; Humans; Isoxazoles; | 2005 |
Clinical and radiological disease-course in a Swedish DMARD-treated early RA-inception cohort: an observational study.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Disease Progression; Dose- | 2004 |
Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase III as Topic; Disability Evaluat | 2005 |
[When to begin rheumatism treatment? Initial combination therapy helps fastest].
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Cyclo | 2004 |
[Three joints swollen, blood sedimentation increased. Methotrexate to be given immediately?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sediment | 2004 |
The inhibitory effect of disease-modifying anti-rheumatic drugs and steroids on gliostatin/platelet-derived endothelial cell growth factor production in human fibroblast-like synoviocytes.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cells; Cells, Cul | 2005 |
[Effectiveness of methotrexate for the escape by salazosulfapyridine].
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Blood Sedimentation; C-Reactive Prote | 2005 |
The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Databases, Factual; Drug Utilization; Family Prac | 2005 |
Pulmonary involvement in lifelong non-smoking patients with rheumatoid arthritis and ankylosing spondylitis without respiratory symptoms.
Topics: Adult; Aged; Arthritis, Rheumatoid; C-Reactive Protein; Female; Humans; Lung; Male; Methotrexate; Mi | 2006 |
Early rheumatoid arthritis treatments weighed.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Huma | 2005 |
The gut-joint axis: cross reactive food antibodies in rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cross Reactions; Dietary Proteins; Enzyme- | 2006 |
DRESS syndrome induced by sulphasalazine in rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Eruptions; Eosinophilia; Exanthema; Female; Humans | 2006 |
Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cardiovascular Diseases; Case-Control Studies; Fe | 2006 |
[Life-threatening liver failure and severe dyscrasias in blood and lymph nodes caused by sulphasalazine].
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Cell Count; Chemical and Drug Induced Live | 2006 |
Clinical practice format for choosing a second-line disease modifying anti-rheumatic drug in early rheumatoid arthritis after failure of 6 months' first-line DMARD therapy.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Decision Support Techniques; Drug Administr | 2007 |
Spontaneous multiple insufficiency fractures after pelvic abscess and sepsis in a rheumatoid arthritis patient treated with high-load corticosteroid therapy: a case report.
Topics: Abdominal Abscess; Adrenal Cortex Hormones; Arthritis, Rheumatoid; Bone and Bones; Female; Fractures | 2007 |
Scientific basis for the efficacy of combined use of antirheumatic drugs against bone destruction in rheumatoid arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Bone Resorption; Cell Differentiation; Cells, | 2007 |
Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; Drug Administration Schedule | 2007 |
Why are Dutch rheumatologists reluctant to use the COBRA treatment strategy in early rheumatoid arthritis?
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Attitude of Health Personnel; | 2007 |
Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Arylamine N-Acetyltransferase; Female; Hap | 2007 |
[Transient leukemoid reaction of plasma cells in a patient with rheumatoid arthritis].
Topics: Aged; Arthritis, Rheumatoid; Female; Humans; Leukemoid Reaction; Methotrexate; Plasma Cells; Sulfasa | 2007 |
The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Infectious; Arthritis, Rheumatoid; Female; Humans; Male; Methotrexa | 2007 |
Sulfasalazine-induced hypersensitivity syndrome and hemophagocytic syndrome associated with reactivation of Epstein-Barr virus.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Hypersensitivity; Epstein-Barr Virus Infections; F | 2008 |
Clinical inquiries. Are DMARDs effective for rheumatologic diseases besides rheumatoid arthritis?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Ps | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
COBRA combination therapy in daily practice--getting back to the future.
Topics: Abatacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Art | 2008 |
Infectious mononucleosis-like syndrome induced by salazosulfapyridine in a patient with rheumatoid arthritis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Arylamine N-Acetyltransferase; Cells, Cultured; | 2007 |
Treatment of pregnant and non-pregnant rheumatic patients: a survey among Dutch rheumatologists.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Attitude of Health Personnel; Data Collection; Drug Mon | 2008 |
Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Folic A | 2008 |
Characteristics and medical management of patients with rheumatoid arthritis and ankylosing spondylitis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Female; Humans; Male; Methotrexate; | 2008 |
Prospective study of the association between NAT2 gene haplotypes and severe adverse events with sulfasalazine therapy in patients with rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Arylamine N-Acetyltransferase; Female; Gen | 2008 |
Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: A case series from a local surveillance of serious adverse events.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, | 2008 |
Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoi | 2008 |
Sulphasalazine in rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protein; Female; Humans; Male; M | 1980 |
Sulphasalazine desensitisation in rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Desensitization, Immunologic; Female; Humans; Sulfasalazine | 1982 |
Sulphasalazine induced selective IgA deficiency in rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protein; Dysgammaglobulinemia; Female; | 1983 |
Eosinophilia in D-penicillamine therapy.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Cross-Sectional Studies; Dapsone; Eosinophilia; Fem | 1983 |
Sulphasalazine in rheumatoid arthritis: an old drug revived.
Topics: Arthritis, Rheumatoid; Drug Administration Schedule; Humans; Sulfasalazine | 1984 |
Rheumatoid arthritis: is serum vitamin B12 high in active disease?
Topics: Adult; Aged; Arthritis, Rheumatoid; Female; Humans; Male; Middle Aged; Penicillamine; Sulfasalazine; | 1984 |
Outcome of attempts to treat rheumatoid arthritis with gold, penicillamine, sulphasalazine, or dapsone.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Dapsone; Female; Gold Sodium Thiomalate; Humans; Mal | 1984 |
Sulphasalazine in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Colitis, Ulcerative; Humans; Lupus Erythematosus, Systemic; Sulfasalazine | 1984 |
The long term effects of sulphasalazine in the treatment of rheumatoid arthritis and a comparative study with penicillamine.
Topics: Adult; Aged; Arthritis, Rheumatoid; Drug Eruptions; Drug Tolerance; Dyspepsia; Female; Humans; Male; | 1984 |
Comparison of the effects of sulphasalazine, 5-aminosalicylic acid and sulphapyridine on the humoral response to antigen in vivo.
Topics: Administration, Oral; Aminosalicylic Acids; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibo | 1995 |
Should tests for proteinuria be included in the monitoring schedule of sulphasalazine?
Topics: Arthritis, Rheumatoid; Drug Monitoring; Female; Humans; Male; Middle Aged; Prevalence; Proteinuria; | 1995 |
[A case of rheumatoid arthritis complicated with salazosulfapyridine-induced aplastic anemia].
Topics: Anemia, Aplastic; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Transfusion, Autologous; Erythr | 1995 |
Lichen planus in patients with rheumatoid arthritis treated with sulfasalazine.
Topics: Aged; Arthritis, Rheumatoid; Drug Eruptions; Female; Humans; Lichen Planus; Male; Middle Aged; Predn | 1995 |
Salazopyrin in rheumatoid arthritis. 1978.
Topics: Arthritis, Rheumatoid; History, 20th Century; Humans; Sulfasalazine | 1994 |
Evidence for differential effects of sulphasalazine on systemic and mucosal immunity in rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Female; Gliadin; Humans; Immune Tolerance; Immunoglobulin A; Imm | 1995 |
Effect of long term intramuscular gold therapy on the seroprevalence of Helicobacter pylori in patients with early rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Bacterial; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Helicobacte | 1995 |
Abnormal colonic microbial function in patients with rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Bilirubin; Cholestanol; Cholesterol; Colon; Eubacterium; Feces; Female; | 1994 |
Side effects of sulphasalazine in patients with rheumatic diseases or inflammatory bowel disease.
Topics: Adult; Arthritis, Rheumatoid; Colitis, Ulcerative; Crohn Disease; Female; Humans; Male; Spondylitis, | 1994 |
Combination therapy for rheumatoid arthritis and drug-induced systemic lupus erythematosus.
Topics: Adult; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; Lupus Erythematosus, System | 1994 |
Coculture of human articular chondrocytes with peripheral blood mononuclear cells as a model to study cytokine-mediated interactions between inflammatory cells and target cells in the rheumatoid joint.
Topics: Adult; Aggrecans; Arthritis, Rheumatoid; Cartilage, Articular; Cell Communication; Cells, Cultured; | 1994 |
Variation in the serum IgA concentration and the production of IgA in vitro in rheumatoid arthritis treated by sulfasalazine.
Topics: Arthritis, Rheumatoid; Cells, Cultured; Humans; Immunoglobulin A; Leukocytes, Mononuclear; Lymphocyt | 1993 |
Toxicity of sulphasalazine in rheumatoid arthritis. Possible protective effect of rheumatoid factors and corticosteroids.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Arthritis, Rheumatoid; Drug Eruptions; Female; Gas | 1993 |
Unsubstantiated "risk" of antifolate toxicity with combination methotrexate and sulfasalazine therapy.
Topics: Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Methotrexate; Risk Factors; Sulfasalazine | 1993 |
[Basic therapy of rheumatoid arthritis. Comparison of methotrexate and sulfasalazine].
Topics: Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follo | 1993 |
A disease activity index: its use in clinical trials and disease assessment in patients with rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Therapy, Combination; Hu | 1993 |
Sulfasalazine may interfere with HPLC assay of urinary pyridinium crosslinks.
Topics: Amino Acids; Arthritis, Rheumatoid; Chromatography, High Pressure Liquid; Collagen; Humans; Sulfasal | 1994 |
The use of the disease activity score in the analysis of clinical trials in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Blood Sedimentation; Clinical Trials as Topic; Gold Sodium Thiomalate; Humans | 1993 |
Sulphasalazine-induced systemic lupus erythematosus in a patient with erosive arthritis.
Topics: Adult; Arthritis, Rheumatoid; Female; Humans; Lupus Erythematosus, Systemic; Sulfasalazine | 1994 |
Influence of corticosteroid pulse therapy on the serum levels of soluble interleukin 2 receptor, interleukin 6 and interleukin 8 in patients with rheumatoid arthritis.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Dehydroepiandrosterone; Dehydroepiandrosteron | 1994 |
Effect of sulfasalazine on B cell hyperactivity in patients with rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; B-Lymphocytes; Female; Humans; Immunoglobulins; In Vitro Techniques; K | 1994 |
Sulfasalazine induced seizures and dysphasia.
Topics: Antibodies, Antineutrophil Cytoplasmic; Aphasia; Arthritis, Rheumatoid; Autoantibodies; Female; Huma | 1994 |
Sulfasalazine induced lupus in rheumatoid arthritis.
Topics: Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Antinuclear; Antibody Specificity; Arthrit | 1994 |
Sulphasalazine desensitisation in patients with arthritis.
Topics: Adult; Aged; Arthritis, Juvenile; Arthritis, Psoriatic; Arthritis, Rheumatoid; Desensitization, Immu | 1994 |
[Study on combined of auranofin, salazosulfapyridine and methotrexate in rheumatoid arthritis].
Topics: Adult; Aged; Arthritis, Rheumatoid; Auranofin; Drug Evaluation; Drug Therapy, Combination; Female; H | 1994 |
Evidence of a local intestinal immunomodulatory effect of sulfasalazine in rheumatoid arthritis.
Topics: Adjuvants, Immunologic; Adult; Aged; Arthritis, Rheumatoid; Biopsy; CD3 Complex; CD4 Antigens; CD8 A | 1994 |
Nonsteroidal antiinflammatory drug-induced small intestinal inflammation and blood loss. Effects of sulfasalazine and other disease-modifying antirheumatic drugs.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Enteritis; Female; Gastrointes | 1994 |
Sulphasalazine-induced systemic lupus erythematosus.
Topics: Antibodies, Antinuclear; Arthritis, Rheumatoid; Female; Humans; Lupus Erythematosus, Systemic; Sulfa | 1994 |
Interference of circulating azathioprine but not methotrexate or sulfasalazine with measurements of interleukin-6 bioactivity.
Topics: Arthritis, Rheumatoid; Azathioprine; Biological Assay; Humans; Hybridomas; Interleukin-6; Methotrexa | 1994 |
Production of interleukin-6 by monocytes isolated from rheumatoid arthritis patients receiving second-line drug therapy.
Topics: Arthritis, Rheumatoid; Auranofin; Gold Sodium Thiomalate; Humans; Interleukin-6; Lipopolysaccharides | 1994 |
Simultaneous presentation of rheumatoid arthritis in a sibling pair.
Topics: Adolescent; Arthritis, Rheumatoid; Female; Follow-Up Studies; Humans; Nuclear Family; Sulfasalazine; | 1994 |
Combination therapy with methotrexate and sulphasalazine in rheumatoid arthritis--tolerance of therapy.
Topics: Adult; Aged; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Ma | 1994 |
Effect of sulphasalazine on gastrointestinal microflora and on mucosal heat shock protein expression in patients with rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Digestive System; Feces; Female; Gastric Mucosa; Heat-Shock Prot | 1994 |
Serum concentrations of soluble interleukin 2 receptor in patients with rheumatoid arthritis: effect of second line drugs.
Topics: Arthritis, Rheumatoid; Auranofin; Blood Sedimentation; C-Reactive Protein; Gold Sodium Thiomalate; H | 1993 |
Methotrexate and sulfasalazine combination therapy: is it worth the risk?
Topics: Aged; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Humans; M | 1993 |
Sulfasalazine induced systemic lupus erythematosus in a patient with rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Female; Humans; Lupus Erythematosus, Systemic; Sulfasalazine | 1993 |
Sulphoxidation status in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Humans; Penicillamine; Sulfasalazine; Sulfoxides | 1993 |
Lack of interaction between sulphasalazine and cimetidine in patients with rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Cimetidine; Dose-Response Relationship, Drug; Drug Interactions; | 1993 |
Optimizing the assessment of disease activity during treatment with anti-rheumatoid drugs.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Cytidine Deaminase; Female; Gold; Humans; Hydroxych | 1993 |
Fatal agranulocytosis with sulfasalazine therapy in rheumatoid arthritis.
Topics: Aged; Agranulocytosis; Arthritis, Rheumatoid; Female; Humans; Sulfasalazine | 1993 |
Sequential study of bacterial antibody levels and faecal flora in rheumatoid arthritis patients taking sulphasalazine.
Topics: Adult; Aged; Antibodies, Bacterial; Arthritis, Rheumatoid; Clostridium perfringens; Colony Count, Mi | 1993 |
Drug-related lupus in a patient with rheumatoid arthritis under sulfasalazine treatment.
Topics: Adult; Antibodies, Antinuclear; Arthritis, Rheumatoid; DNA; Female; Humans; Lupus Erythematosus, Sys | 1993 |
Toleration, side-effects and efficacy of sulphasalazine in rheumatoid arthritis patients of different ages.
Topics: Adult; Age Distribution; Age Factors; Aged; Arthritis, Rheumatoid; Female; Humans; Life Tables; Male | 1993 |
Radical Intervention in Early Rheumatoid Arthritis. The Case for Enteric-Coated Sulphasalazine, Methotrexate and Combination Regimes. Proceedings of a workshop. Camogli, Italy, September 1994.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Methotrexate; Sulfasalazine | 1995 |
Combination of sulphasalazine and methotrexate in the management of rheumatoid arthritis--view based on personal clinical experience.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; Male; | 1995 |
Long-term usage and side-effect profile of sulphasalazine in rheumatoid arthritis.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Male; M | 1995 |
Sulphasalazine-induced autoimmune abnormalities in patients with rheumatic disease.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Autoimmune Diseases; Humans; Lupus Erythematosus, Syste | 1995 |
[The effect of basic therapy on the morphological picture of the rectal mucosa in patients with rheumatoid arthritis].
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Biopsy; Female; Humans; Intestinal Mucosa; Male; | 1995 |
Sulphasalazine-induced systemic lupus erythematosus in a patient with rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Lupus Erythematosus, Systemic; Middle A | 1996 |
Combination therapy with sulphasalazine and azathioprine.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprine; Drug Ther | 1996 |
Effects of methotrexate, sulphasalazine and aurothiomalate on polymorphonuclear leucocytes in rheumatoid arthritis.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Antirheumatic Agents; Arthritis, Rheumatoid; Chemotaxi | 1996 |
Rheumatoid arthritis and heparin.
Topics: Anti-Inflammatory Agents; Anticoagulants; Arthritis, Rheumatoid; Drug Therapy, Combination; Heparin; | 1996 |
Treatment of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Hydroxychloroquine; | 1996 |
Treatment of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Sulfasalazine; Tablets, Enteric-Coated | 1996 |
Treatment of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Hydroxychloroquine; | 1996 |
Folate and homocysteine status and haemolysis in patients treated with sulphasalazine for arthritis.
Topics: Adolescent; Adult; Aged; Arthritis; Arthritis, Rheumatoid; Colitis, Ulcerative; Erythrocytes; Female | 1996 |
Bone alkaline phosphatase in rheumatoid arthritis: a longitudinal study.
Topics: Aged; Alkaline Phosphatase; Arthritis, Rheumatoid; Bone and Bones; Female; gamma-Glutamyltransferase | 1996 |
An unusual cause for collapse in a patient with arthritis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Critical Care; Diagnosis, Differential; Female; H | 1996 |
Prognostic significance of complement alleles Bf and C4 in early rheumatoid arthritis.
Topics: Adult; Aged; Alleles; Antirheumatic Agents; Arthritis, Rheumatoid; Complement C4a; Complement C4b; C | 1996 |
Antibody levels to Clostridium perfringens and response to sulphasalazine.
Topics: Anti-Bacterial Agents; Antibodies, Bacterial; Arthritis, Rheumatoid; Clostridium Infections; Clostri | 1996 |
Variations and trends in the prescription of initial second line therapy for patients with rheumatoid arthritis.
Topics: Antimalarials; Antirheumatic Agents; Arthritis, Rheumatoid; Auranofin; Female; Gold; Humans; Male; M | 1997 |
Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Energy Metabolism; Female; Gold Sodium Thi | 1997 |
Co-existence of non-Hodgkin's lymphoma in the leukemic phase and polyarthritis simulating rheumatoid arthritis.
Topics: Anti-Infective Agents; Arthritis; Arthritis, Rheumatoid; Diagnosis, Differential; Humans; Leukocytos | 1997 |
Effect of resumption of second line drugs in patients with rheumatoid arthritis that flared up after treatment discontinuation.
Topics: Acute Disease; Aged; Antimalarials; Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprine; Femal | 1997 |
Actin polymerisation in neutrophils of rheumatoid arthritis patients in relation to treatment with non-steroidal anti-inflammatory drugs.
Topics: Actins; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Biopolymers; Drug Synergism; | 1997 |
Rheumatoid arthritis: not yet curable with early intensive therapy.
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Hu | 1997 |
Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Benzophenones; Cells, Cultured; Dinoprostone; Gelat | 1997 |
Toxicity profile of dual methotrexate combinations with gold, hydroxychloroquine, sulphasalazine and minocycline in rheumatoid arthritis patients.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Gold; Humans; | 1997 |
Pure red cell aplasia in a man with RA.
Topics: Aged; Arthritis, Rheumatoid; Danazol; Humans; Male; Methotrexate; Red-Cell Aplasia, Pure; Sulfasalaz | 1997 |
Use of sulfasalazine in rheumatic diseases.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Sulfasalazine | 1997 |
Predisposing factors in sulphasalazine-induced systemic lupus erythematosus.
Topics: Adolescent; Adult; Aged; Antibodies, Antinuclear; Arthritis, Juvenile; Arthritis, Psoriatic; Arthrit | 1997 |
Importance of psychological well being and disease activity in termination of an initial DMARD therapy.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Attitude to Health; Cohort Studies; Female; Heal | 1997 |
A retrospective study of treating RA patients with various combinations of slow-acting antirheumatic drugs in a county hospital.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Child; Drug | 1997 |
Effect of social deprivation on disease severity and outcome in patients with rheumatoid arthritis.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Follow-Up Studies; Heal | 1997 |
[Rheumatoid arthritis. Conservative therapeutic possibilities today and in the future].
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, R | 1998 |
Collagenous colitis associated with rheumatoid arthritis and anticardiolipin antibodies.
Topics: Anti-Inflammatory Agents; Antibodies, Anticardiolipin; Arthritis, Rheumatoid; Colitis; Collagen Dise | 1998 |
Methotrexate in rheumatoid arthritis: a 2 year experience at a university hospital in Pakistan.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Drug Therapy, Combination; Fe | 1998 |
Pancytopenia secondary to hemophagocytic syndrome in rheumatoid arthritis treated with methotrexate and sulfasalazine.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bacteremia; Bone Marrow Cells; Escherichia coli Infecti | 1998 |
Prognostic value of Th1/Th2 ratio in rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Prognosis; Severity of Illness Index; Sulfasala | 1998 |
HLA-DRB1 typing in rheumatoid arthritis: predicting response to specific treatments.
Topics: Adult; Aged; Alleles; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Administration Schedule; Dru | 1998 |
Soluble cell adhesion molecules--P-selectin and ICAM-1, and disease activity in patients receiving sulphasalazine for active rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; E-Selectin; Female; Humans; In | 1998 |
[Basic therapeutics in the management of various forms of arthritis].
Topics: Antimalarials; Antirheumatic Agents; Arthritis, Rheumatoid; Cyclosporine; Humans; Methotrexate; Poly | 1998 |
[Beneficial effect of salazosulfapyridine (SASP) in a patient with secondary renal amyloidosis].
Topics: Amyloidosis; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Female; Humans; Kidney | 1998 |
Urinary neopterin excretion and dihydropteridine reductase activity in rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protein; D | 1998 |
Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Disease Pro | 1998 |
How Canadian and US rheumatologists treat moderate or aggressive rheumatoid arthritis: a survey.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Canada; Data Collection; Drug Prescriptions; Drug Thera | 1998 |
Validity of area-under-the-curve analysis to summarize effect in rheumatoid arthritis clinical trials.
Topics: Antirheumatic Agents; Area Under Curve; Arthritis, Rheumatoid; Cyclosporine; Double-Blind Method; Dr | 1999 |
[Reactive arthritis. Diagnosis, differential diagnosis and therapy].
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Reactive; Arthritis, R | 1999 |
Combination therapy in rheumatoid arthritis: a comment.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cyclosporine; Drug Therapy, Combination; Follow-Up Stud | 1999 |
Giant cell arteritis associated with rheumatoid arthritis monitored by magnetic resonance angiography.
Topics: Anti-Inflammatory Agents; Arthritis, Juvenile; Arthritis, Rheumatoid; Female; Giant Cell Arteritis; | 1999 |
Treatment considerations in early rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Cyclosporine; Drug Therapy, C | 1997 |
Treatment with sulfasalazine or sulfapyridine, but not 5-aminosalicyclic acid, inhibits basic fibroblast growth factor-induced endothelial cell chemotaxis.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Biocompatible | 1999 |
Long-term application of disease modifying antirheumatic drugs (DMARD). A single-center, observational study of 1681 patients with rheumatoid arthritis (RA).
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprine; Chloroquine; Dose-Response R | 1999 |
The changing face of rheumatoid arthritis therapy: results of serial surveys.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Data Collection; Drug Therapy, Combination; Humans; Hyd | 2000 |
[Pharmacotherapy of patients with (early) rheumatoid arthritis].
Topics: Agranulocytosis; Antirheumatic Agents; Arthritis, Rheumatoid; Cyclosporine; Humans; Methotrexate; Su | 2000 |
Effects of sulfasalazine and its metabolites on steady state messenger RNA concentrations for inflammatory cytokines, matrix metalloproteinases, and tissue inhibitors of metalloproteinase in rheumatoid synovial fibroblasts.
Topics: Arthritis, Rheumatoid; Cells, Cultured; Cytokines; Fibroblasts; Homeostasis; Humans; Inflammation Me | 2000 |
Drugs for rheumatoid arthritis.
Topics: Administration, Oral; Adrenal Cortex Hormones; Anorexia; Anti-Inflammatory Agents, Non-Steroidal; An | 2000 |
Increased MDR1 P-glycoprotein expression in methotrexate resistance: comment on the article by Yudoh et al.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; ATP Binding Cassette Transporter, Subfamily B, Member 1 | 2000 |
Development of lupus-related side-effects in patients with early RA during sulphasalazine treatment-the role of IL-10 and HLA.
Topics: Adult; Antibodies, Antinuclear; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Coh | 2000 |
Imbalance in production between vascular endothelial growth factor and endostatin in patients with rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Collagen; Cysteine; Drug Therapy, Co | 2000 |
Effects of combinations of anti-rheumatic drugs on the production of vascular endothelial growth factor and basic fibroblast growth factor in cultured synoviocytes and patients with rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, | 2000 |
Cyclosporin for sulphasalazine-induced aplastic anaemia in a patient with early rheumatoid arthritis.
Topics: Aged; Anemia, Aplastic; Antirheumatic Agents; Arthritis, Rheumatoid; Cyclosporine; Female; Humans; I | 2000 |
Conventional DMARD options for patients with a suboptimal response to methotrexate.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Cyclosporine; Drug Resistance; | 2001 |
[Chronic polyarthritis].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials, Phase III as Topic; | 2001 |
Focal sialadenitis in patients with ankylosing spondylitis and spondyloarthropathy: a comparison with patients with rheumatoid arthritis or mixed connective tissue disease.
Topics: Adult; Anti-Inflammatory Agents; Antibodies, Antinuclear; Antirheumatic Agents; Arthritis; Arthritis | 2001 |
Is the cure worse than the disease?
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Lung Diseases, Interstitial; Male; Sulfasalazin | 2001 |
Is it Crohn's disease? A severe systemic granulomatous reaction to sulfasalazine in patient with rheumatoid arthritis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Chemical and Drug Induced Liver Injury; Crohn Di | 2001 |
NF-kappaB and the MAP kinases/AP-1 pathways are both involved in interleukin-6 and interleukin-8 expression in fibroblast-like synoviocytes stimulated by protein I/II, a modulin from oral streptococci.
Topics: Anti-Bacterial Agents; Apigenin; Arthritis, Rheumatoid; Bacterial Proteins; Cells, Cultured; Curcumi | 2001 |
The 3-week sulphasalazine syndrome strikes again.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Fatal Outcome; Female; Hepatitis; Humans; Myocar | 2001 |
Demonstration of response in rheumatoid arthritis patients who are nonresponders according to the American College of Rheumatology 20% criteria: the paradox of beneficial treatment effects in nonresponders in the ATTRACT trial. Anti-Tumor Necrosis Factor
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug | 2001 |
[Thrombocytopenia in a patient with rheumatoid arthritis during sulphasalazine therapy].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Blood Platelets; Diagnosis, Differential; Humans; Male; | 1998 |
[Diagnosis and treatment of early rheumatoid arthritis].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Sulfasalazine; Time Factors | 2002 |
[A survey of the doses of methotrexate and salazosulfapyridine in Japanese patients with rheumatoid arthritis].
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Utilization; Drug Utilization Review; | 2002 |
Migratory pulmonary infiltrates in a patient with rheumatoid arthritis.
Topics: Aged; Airway Obstruction; Antirheumatic Agents; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inh | 2002 |
[The effect of low dose methotrexate treatment on bone mineral density in patients with rheumatoid arthritis].
Topics: Absorptiometry, Photon; Adult; Arthritis, Rheumatoid; Bone Density; Female; Humans; Methotrexate; Os | 2002 |
Impact of leflunomide versus biologic agents on the costs of care for rheumatoid arthritis in a managed care population.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Arthritis, | 2002 |
A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis.
Topics: Analysis of Variance; Arthritis, Rheumatoid; Cohort Studies; Cost-Benefit Analysis; Decision Making; | 2002 |
If I had... Severe rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Dapsone; Gold; Humans; Pen | 1978 |
Salazopyrin in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protein; Female; Humans; Male; Middle Aged; S | 1978 |
Cutaneous rheumatoid vasculitis.
Topics: Adult; Arthritis, Rheumatoid; Female; Humans; Male; Middle Aged; Skin; Sulfasalazine; Vasculitis, Le | 1979 |
Sulphasalazine induced autoimmune syndrome.
Topics: Adult; Arthritis, Rheumatoid; Autoimmune Diseases; Chemical and Drug Induced Liver Injury; Drug Erup | 1992 |
Changes in normal glycosylation mechanisms in autoimmune rheumatic disease.
Topics: Adult; Aged; Arthritis, Rheumatoid; Autoimmune Diseases; Female; Galactosyltransferases; Glycosylati | 1992 |
Long-term second-line treatment: a prospective drug survival study.
Topics: Arthritis, Rheumatoid; Aurothioglucose; Humans; Hydroxychloroquine; Penicillamine; Prospective Studi | 1992 |
Sulphasalazine therapy in rheumatoid arthritis: qualitative changes in lymphocytes and correlation with clinical response.
Topics: Arthritis, Rheumatoid; Blood Viscosity; C-Reactive Protein; Humans; Longitudinal Studies; Lymphocyte | 1992 |
Sulfasalazine-induced pulmonary disease.
Topics: Acute Disease; Aged; Arthritis, Rheumatoid; Crohn Disease; Female; Humans; Male; Pulmonary Fibrosis; | 1992 |
[Treatment of rheumatoid polyarthritis with salazosulfapyridine].
Topics: Arthritis, Rheumatoid; Drug Combinations; Female; Glucosamine; Humans; Male; Middle Aged; Sulfasalaz | 1992 |
Fatal neutropenic enterocolitis associated with sulphasalazine therapy for rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Enterocolitis; Humans; Male; Neutropenia; Sulfasalazine | 1992 |
[Rheumatoid arthritis and anemia; various aspects concerning prevalence, pathogenesis, diagnosis and therapy].
Topics: Anemia, Hemolytic; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Humans; Sulfasala | 1992 |
Variations among rheumatologists in prescribing and monitoring of disease modifying antirheumatoid drugs.
Topics: Antimalarials; Arthritis, Rheumatoid; Drug Administration Schedule; Drug Monitoring; Drug Prescripti | 1992 |
The effect of age and acetylator phenotype on the pharmacokinetics of sulfasalazine in patients with rheumatoid arthritis.
Topics: Acetylation; Adult; Age Factors; Aged; Arthritis, Rheumatoid; Drug Administration Schedule; Female; | 1992 |
[Aminosalicylates in chronic inflammatory intestinal diseases and rheumatoid arthritis].
Topics: Aminosalicylic Acids; Arthritis, Rheumatoid; Colitis, Ulcerative; Crohn Disease; Humans; Mesalamine; | 1992 |
IL-6 and soluble IL-2 receptor in rheumatoid arthritis patients treated with second line drugs.
Topics: Arthritis, Rheumatoid; Gold Sodium Thiomalate; Humans; Interleukin-6; Receptors, Interleukin-2; Sulf | 1992 |
The effect of second-line antirheumatic drugs on interleukin-8 mRNA synthesis and protein secretion in human endothelial cells.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Endothelium, Vascular; Gene Expression; Gold Sodium | 1992 |
Influence of acetylator status on sulphasalazine efficacy and toxicity in patients with rheumatoid arthritis.
Topics: Acetylation; Adolescent; Adult; Aged; Arthritis, Rheumatoid; Female; Humans; Liver; Male; Middle Age | 1992 |
Helicobacter pylori and peptic ulcers in rheumatoid arthritis patients receiving gold, sulfasalazine, and nonsteroidal anti-inflammatory drugs.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Duodenal Ulcer; Female; Gold S | 1992 |
The three week sulphasalazine syndrome.
Topics: Arthritis, Rheumatoid; Chemical and Drug Induced Liver Injury; Humans; Male; Middle Aged; Prednisolo | 1992 |
[Therapeutic maintenance and tolerance of sulfasalazine in rheumatoid polyarthritis. Retrospective study of 95 patients].
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Drug Tolerance; Fema | 1992 |
Variations between rheumatologists in using sulphasalazine.
Topics: Aged; Arthritis, Rheumatoid; Drug Utilization; Follow-Up Studies; Humans; Middle Aged; Prospective S | 1991 |
Transverse myelitis secondary to sulfasalazine.
Topics: Arthritis, Rheumatoid; Humans; Male; Middle Aged; Myelitis, Transverse; Sulfasalazine | 1991 |
[Effect of sulfasalazine and its metabolites on prostaglandin and leukotriene liberation from human synovial tissue].
Topics: 6-Ketoprostaglandin F1 alpha; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Arthrit | 1991 |
[Desensitization to salazopyrine in rheumatoid polyarthritis].
Topics: Arthritis, Rheumatoid; Desensitization, Immunologic; Drug Combinations; Drug Hypersensitivity; Femal | 1991 |
Drugs for rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, | 1991 |
Enumeration of IgA producing cells by the enzyme linked immunospot (ELISPOT) technique to evaluate sulphasalazine effects in inflammatory arthritides.
Topics: Antibody-Producing Cells; Arthritis, Psoriatic; Arthritis, Rheumatoid; Enzyme-Linked Immunosorbent A | 1991 |
Sulfasalazine induced taste disturbances.
Topics: Aged; Aged, 80 and over; Arthritis, Rheumatoid; Female; Humans; Male; Sulfasalazine; Taste Disorders | 1991 |
[Clinical notes about methylprednisolone pulse-therapy in patients with rheumatoid arthritis].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Dimercaprol; Drug Therapy, Combination; Female; Humans; | 1991 |
[Rheumatoid arthritis developing into systemic lupus erythematosus during long-term treatment with penicillamine and sulfasalazine].
Topics: Adult; Arthritis, Rheumatoid; Female; Humans; Lupus Erythematosus, Systemic; Penicillamine; Sulfasal | 1991 |
Psoriasis-like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy.
Topics: Aged; Arthritis, Rheumatoid; Female; Hand Dermatoses; Humans; Psoriasis; Sulfasalazine | 1991 |
The gold standard in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Gold; Humans; Penicillamine; Prognosis; Sulfasalazine | 1991 |
Nonsteroidal peptic damage in rheumatoid patients receiving second-line drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Therapy, Combination; Endoscopy | 1991 |
Immunodeficiencies associated with sulphasalazine therapy in inflammatory arthritis.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Dysgammaglobulinemia; Female; Humans; IgA Deficiency | 1991 |
The factors affecting plasma glutathione peroxidase and selenium in rheumatoid arthritis: a multiple linear regression analysis.
Topics: Adult; Antioxidants; Arachidonic Acids; Arthritis, Rheumatoid; Fatty Acids; Female; Glutathione Pero | 1991 |
[A case of secondary amyloidosis which gastrointestinal symptoms improved by treatment with salazosulfapyridine].
Topics: Aged; Amyloidosis; Arthritis, Rheumatoid; Female; Gastrointestinal Diseases; Humans; Sulfasalazine | 1991 |
Is the beneficial effect of sulfasalazine due to inhibition of synovial neovascularization?
Topics: Aminosalicylic Acids; Arthritis, Rheumatoid; Cell Division; Endothelium, Vascular; Humans; Mesalamin | 1991 |
Can we develop simple response criteria for slow acting antirheumatic drugs?
Topics: Arthritis, Rheumatoid; Cohort Studies; Female; Humans; Male; Middle Aged; Penicillamine; Prospective | 1990 |
[New principle of the treatment of rheumatoid arthritis: combined basic therapy].
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Delayed-Action Preparations; Dru | 1990 |
Fibrosing alveolitis due to sulphasalazine in a patient with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Bronchoalveolar Lavage Fluid; Female; Humans; Middle Aged; Pulmonary Alveoli; | 1990 |
Treatment of non-steroidal anti-inflammatory drug induced enteropathy.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Enteritis; Female; Huma | 1990 |
Assessing combination therapy in rheumatoid arthritis: treatment with sulphasalazine and penicillamine.
Topics: Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; Male; Penicillamine; Prospective S | 1990 |
Sulphasalazine in the treatment of rheumatoid arthritis: a renewed challenge.
Topics: Arthritis, Rheumatoid; Humans; Sulfasalazine; Time Factors | 1990 |
Comparison of the single dose pharmacokinetics of sulphasalazine in rheumatoid arthritis and inflammatory bowel disease.
Topics: Adult; Arthritis, Rheumatoid; Colitis, Ulcerative; Crohn Disease; Female; Humans; Male; Middle Aged; | 1990 |
Long-term radiographic progression in treated rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Humans; Hydroxychloroquine; Penicillamine; Radiography; Sulfasalazine; Time F | 1990 |
Neutropenia in patients with rheumatoid arthritis, treated with sulphasalazine.
Topics: Adult; Arthritis, Rheumatoid; Female; Humans; Male; Middle Aged; Neutropenia; Sulfasalazine | 1990 |
Sulphasalazine induced agranulocytosis in a patient with rheumatoid arthritis.
Topics: Adult; Agranulocytosis; Arthritis, Rheumatoid; Female; Humans; Sulfasalazine | 1990 |
Thrombocytopenia due to aurothioglucose, sulphasalazine, and hydroxychloroquine.
Topics: Arthritis, Rheumatoid; Aurothioglucose; Female; HLA-B8 Antigen; HLA-DR3 Antigen; Humans; Hydroxychlo | 1990 |
Treatment of drug-induced agranulocytosis with recombinant GM-CSF.
Topics: Agranulocytosis; Arthritis, Rheumatoid; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Ma | 1990 |
Clinical and laboratory effects of prolonged therapy with sulfasalazine, gold or penicillamine: the effects of disease duration on treatment response.
Topics: Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protein; Female; Gold; Humans; Male; Penicill | 1990 |
Methylsulphasalazine in rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Blood Cell Count; Female; Humans; Male; Middle Aged; Osmolar Con | 1990 |
[Pharmachem's salazopyrine in rheumatoid arthritis].
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Bulgaria; Chronic Disea | 1990 |
The action of myocrisin on membrane bound sulphhydryl groups.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Dithionitrobenzoic Acid; Drug Combin | 1990 |
Sulphasalazine in rheumatoid arthritis: haematological problems and changes in haematological indices associated with therapy.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Felty Syndrome; Female; Hematologic Diseases; Humans | 1989 |
Ten years of sulphasalazine use in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Humans; Sulfasalazine | 1989 |
Drugs for rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Azathioprin | 1989 |
[Eosinophil pleuritis induced by salazosulfapyridine].
Topics: Arthritis, Rheumatoid; Eosinophilia; Humans; Male; Middle Aged; Pleurisy; Sulfasalazine | 1989 |
Leucopenia during sulphasalazine treatment for rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Cohort Studies; Female; Humans; Leukopenia; Male; Middle Aged; P | 1989 |
Sulphasalazine in rheumatoid arthritis: haematological problems.
Topics: Arthritis, Rheumatoid; Hepatolenticular Degeneration; Humans; Penicillamine; Sulfasalazine | 1989 |
Profound leucopenia with Salazopyrin EN.
Topics: Aged; Arthritis, Rheumatoid; Humans; Leukopenia; Male; Sulfasalazine | 1989 |
Concentrations of sulfasalazine and its metabolites.
Topics: Arthritis, Rheumatoid; Humans; Sulfasalazine | 1989 |
[Megaloblastic anemia caused by sulfasalazine in rheumatoid arthritis or ankylosing spondylitis?].
Topics: Anemia, Macrocytic; Anemia, Megaloblastic; Arthritis, Rheumatoid; Humans; Male; Middle Aged; Spondyl | 1989 |
[Agranulocytosis in rheumatoid polyarthritis treated with sulfasalazine].
Topics: Agranulocytosis; Arthritis, Rheumatoid; Humans; Male; Middle Aged; Sulfasalazine | 1989 |
HLA types in patients with rheumatoid arthritis developing leucopenia after both gold and sulphasalazine treatment.
Topics: Adult; Arthritis, Rheumatoid; Female; Gold Sodium Thiomalate; HLA-DR Antigens; Humans; Leukopenia; M | 1989 |
Combination methotrexate and sulfasalazine in the management of rheumatoid arthritis: case observations.
Topics: Aged; Arthritis, Rheumatoid; Chronic Disease; Drug Evaluation; Drug Therapy, Combination; Female; Hu | 1989 |
The use of sulphasalazine and azathioprine in combination to treat rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Azathioprine; Drug Therapy, Combination; Female; Humans; Middle Aged; Sulfasa | 1989 |
[Salazosulfapyridine (sulfasalazine)in inflammatory rheumatic diseases].
Topics: Arthritis, Rheumatoid; Humans; Sulfasalazine | 1989 |
Fatal agranulocytosis in sulfasalazine treated rheumatoid arthritis.
Topics: Agranulocytosis; Arthritis, Rheumatoid; Female; Humans; Middle Aged; Neutropenia; Sulfasalazine | 1989 |
[The treatment of rheumatoid polyarthritis using salazosulfapyridine. Apropos of 23 cases].
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Consumer Behavior; Drug Tolerance; Female; Hu | 1989 |
[Lymphadenopathy due to sulfasalazine in rheumatoid polyarthritis].
Topics: Aged; Arthritis, Rheumatoid; Female; Humans; Hyperplasia; Lymphatic Diseases; Sulfasalazine | 1989 |
Collagenous colitis: possible response to sulfasalazine and local steroid therapy.
Topics: Administration, Oral; Arthritis, Rheumatoid; Colitis; Collagen; Enema; Female; Humans; Microscopy, E | 1985 |
Fifty years of sulphonamides.
Topics: Arthritis, Rheumatoid; History of Medicine; Humans; Sulfasalazine | 1985 |
Sulphasalazine: a safe, effective agent for prolonged control of rheumatoid arthritis. A comparison with sodium aurothiomalate.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Blood Sedimentation; Female; Gold; Gold Sodium Thios | 1985 |
Serum amyloid A protein during the treatment of rheumatoid arthritis with second-line drugs.
Topics: Adult; Aged; Amyloid; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protein; Female; Gold S | 1985 |
Biochemical and clinical changes occurring during the treatment of rheumatoid arthritis with novel antirheumatoid drugs.
Topics: Adult; Aged; Arthritis, Rheumatoid; Blood Viscosity; Captopril; Cysteine; Female; Humans; Male; Midd | 1985 |
Sulphasalazine in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Humans; Sulfasalazine | 1985 |
False-positive Waaler-Rose test in IgA deficiency.
Topics: Antibodies, Anti-Idiotypic; Arthritis, Rheumatoid; Drug Combinations; Dysgammaglobulinemia; False Po | 1985 |
Sulphasalazine in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Humans; Leukopenia; Sulfasalazine | 1985 |
Which component of sulphasalazine is active in rheumatoid arthritis?
Topics: Arthritis, Rheumatoid; Humans; Sulfapyridine; Sulfasalazine | 1985 |
Hypogammaglobulinaemia and thrombocytopenia associated with sulphasalazine therapy in rheumatoid arthritis.
Topics: Agammaglobulinemia; Arthritis, Rheumatoid; Female; Humans; Middle Aged; Sulfasalazine; Thrombocytope | 1985 |
Raised serum alkaline phosphatase and aspartate transaminase levels in two rheumatoid patients treated with sulphasalazine.
Topics: Aged; Alkaline Phosphatase; Arthritis, Rheumatoid; Aspartate Aminotransferases; Chemical and Drug In | 1985 |
"Disease-modifying" drugs in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Chloroquine; Gold Sodium Thiomalate; Humans; Hydroxychloroquine; Immunosuppre | 1985 |
Effect of acetylator phenotype on efficacy and toxicity of sulphasalazine in rheumatoid arthritis.
Topics: Acetylation; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Humans; Phenotype; Prospective | 1985 |
Sulphasalazine in rheumatoid arthritis: desensitising the patient with a skin rash.
Topics: Arthritis, Rheumatoid; Desensitization, Immunologic; Drug Eruptions; Female; Humans; Male; Sulfasala | 1986 |
The effect of antirheumatic drugs on circulating immune complexes in rheumatoid arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antigen-Antibody Complex; Arthritis, Rheumatoid; Blood Sedime | 1986 |
[Early detection of chronic polyarthritis. Does early treatment change the course?].
Topics: Anti-Inflammatory Agents; Antimalarials; Arthritis, Rheumatoid; Diagnosis, Differential; Follow-Up S | 1986 |
Sulphasalazine therapy in RA.
Topics: Arthritis, Rheumatoid; Female; Humans; Male; Sulfasalazine | 1986 |
A study to determine the active moiety of sulphasalazine in rheumatoid arthritis.
Topics: Adult; Aged; Aminosalicylic Acids; Arthritis, Rheumatoid; Female; Humans; Male; Mesalamine; Middle A | 1986 |
Sulphasalazine treatment in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Humans; Sulfasalazine | 1986 |
Selection of suitable patients for second-line therapy in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Blood Sedimentation; Diagnosis-Related Groups; Female; Humans; Male; Random A | 1986 |
Sulphasalazine for rheumatoid arthritis: relationship between dose, acetylator phenotype and response to treatment.
Topics: Acetylation; Adolescent; Adult; Aged; Arthritis, Rheumatoid; Blood Sedimentation; Dose-Response Rela | 1986 |
[Use of the AIMS questionnaire for evaluating the results of pharmacotherapy of rheumatoid arthritis].
Topics: Adult; Aged; Arthritis, Rheumatoid; Female; Humans; Male; Middle Aged; Sulfasalazine; Surveys and Qu | 1986 |
Sulphasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11 years.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Female; Humans; Leukopenia; Male; Middle Aged; Sulfa | 1986 |
Symposium on enteric-coated sulphasalazine in rheumatoid arthritis. Proceedings of a symposium. London, December 6, 1985.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Humans; Sulfasalazine; Tablets, Ente | 1986 |
History of the development of sulphasalazine in rheumatology.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Prot | 1986 |
5-Aminosalicylic acid or sulphapyridine. Which is the active moiety of sulphasalazine in rheumatoid arthritis?
Topics: Adult; Aged; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; F | 1986 |
Comparison of white blood cell dyscrasias during sulphasalazine therapy of rheumatoid arthritis and inflammatory bowel disease.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Colitis, Ulcerative; Crohn Dis | 1986 |
Side effect profile of 200 patients with inflammatory arthritides treated with sulphasalazine.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Female; Humans; Male; M | 1986 |
Sulphasalazine for rheumatoid arthritis. Studies on dose, acetylator phenotype and efficacy.
Topics: Acetylation; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Dose-Response Relations | 1986 |
Long term outcome of treatment with sulphasalazine in rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Humans; Sulfasalazine | 1986 |
Sulphasalazine in the long term management of rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Female; Gold; Humans; Male; Sulfasal | 1986 |
The abnormal cytotoxic T cell response to Epstein-Barr virus in rheumatoid arthritis is correlated with disease activity and occurs in other arthropathies.
Topics: Arthritis, Rheumatoid; Female; Herpesvirus 4, Human; Humans; Immunity, Cellular; Male; Sulfasalazine | 1986 |
Sulphasalazine hepatotoxicity: lack of a hypersensitivity response.
Topics: Arthritis, Rheumatoid; Chemical and Drug Induced Liver Injury; Female; Humans; Middle Aged; Sulfasal | 1986 |
Macrocytic anaemia in patients treated with sulphasalazine for rheumatoid arthritis.
Topics: Adult; Aged; Anemia, Macrocytic; Arthritis, Rheumatoid; Female; Folic Acid Deficiency; Humans; Male; | 1986 |
Macrocytic anaemia in patients treated with sulphasalazine for rheumatoid arthritis.
Topics: Anemia, Macrocytic; Arthritis, Rheumatoid; Humans; Sulfasalazine | 1987 |
Sulphasalazine alone or in combination with D-penicillamine in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; Male; Penicillamine; Sulfasalazine | 1987 |
Cholestasis and fatal agranulocytosis complicating sulfasalazine therapy: case report and review of the literature.
Topics: Agranulocytosis; Arthritis, Rheumatoid; Cholestasis, Intrahepatic; Female; Humans; Middle Aged; Myos | 1986 |
Role of T lymphocytes in murine collagen induced arthritis.
Topics: Animals; Arthritis; Arthritis, Experimental; Arthritis, Rheumatoid; Collagen; Disease Models, Animal | 1986 |
Simple and sensitive high-performance liquid chromatographic assay for 5-aminosalicylic acid and acetyl-5-aminosalicylic acid in serum.
Topics: Aminosalicylic Acids; Arthritis, Rheumatoid; Chromatography, High Pressure Liquid; Humans; Mesalamin | 1987 |
Slow-acting anti-rheumatic drug therapy for rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Azathioprine; Cyclophosphamide; Gold; Humans; Hydroxychloroquine; Methotrexat | 1987 |
Long-term treatment of rheumatoid arthritis with sulphasalazine, gold, or penicillamine: a comparison using life-table methods.
Topics: Actuarial Analysis; Arthritis, Rheumatoid; Gold; Humans; Penicillamine; Sulfasalazine; Time Factors | 1987 |
Alteration of thiol and superoxide dismutase status in rheumatoid arthritis treated with sulphasalazine.
Topics: Adult; Aged; Arthritis, Rheumatoid; Erythrocytes; Female; Free Radicals; Humans; Male; Middle Aged; | 1987 |
Acetylation, sulphasalazine and its effects.
Topics: Acetylation; Arthritis, Rheumatoid; Colitis, Ulcerative; Gastrointestinal Diseases; Humans; Sulfasal | 1987 |
[Salazopyrine in the treatment of rheumatoid arthritis].
Topics: Arthritis, Rheumatoid; Drug Combinations; Glucosamine; Humans; Sulfasalazine | 1987 |
Sulphasalazine and hepatic transaminases.
Topics: Arthritis, Rheumatoid; Humans; Liver; Sulfasalazine; Transaminases | 1987 |
Sulphasalazine in rheumatoid arthritis: desensitising the patient with a skin rash.
Topics: Arthritis, Rheumatoid; Erythema; Humans; Sulfasalazine | 1987 |
Combination chemotherapy in rheumatoid arthritis.
Topics: Analgesics; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Meth | 1987 |
Sulphasalazine in rheumatoid arthritis: pointers to a gut-mediated immune effect.
Topics: Arthritis, Rheumatoid; Humans; Intestines; Lymphocyte Activation; Lymphocytes; Salicylates; Salicyli | 1987 |
Sulfasalazine in "intractable" rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Female; Humans; Male; Middle Aged; Sulfasalazine | 1987 |
[Sulfasalazine therapy in patients with rheumatoid arthritis].
Topics: Administration, Oral; Adult; Arthritis, Rheumatoid; Female; Humans; Male; Middle Aged; Sulfasalazine | 1987 |
HLA-B27 related arthritis, sulphasalazine and rheumatoid arthritis.
Topics: Arthritis; Arthritis, Rheumatoid; Endothelium, Lymphatic; HLA Antigens; HLA-B27 Antigen; Humans; Lym | 1987 |
[Drug treatment of rheumatoid arthritis and osteoarthritis].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cartilage, Articular; Humans; Joints | 1987 |
Macrocytosis and sulphasalazine treatment of rheumatoid arthritis.
Topics: Aged; Anemia, Macrocytic; Arthritis, Rheumatoid; Female; Humans; Male; Middle Aged; Sulfasalazine | 1987 |
Possible mode of action of 5-aminosalicylic acid.
Topics: Aminosalicylic Acids; Arachidonic Acid; Arachidonic Acids; Arthritis, Rheumatoid; Colitis, Ulcerativ | 1987 |
Combination chemotherapy in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Penicillamine; Sulfasalazine | 1988 |
Impaired glucose handling in active rheumatoid arthritis: relationship to peripheral insulin resistance.
Topics: Adrenal Cortex Hormones; Adult; Aged; Arthritis, Rheumatoid; Blood Glucose; C-Peptide; Female; Human | 1988 |
Circulating inhibitor bound elastase in patients with ankylosing spondylitis and rheumatoid arthritis and the influence of sulphasalazine treatment.
Topics: Acute-Phase Reaction; Adult; Aged; alpha 1-Antitrypsin; Arthritis, Rheumatoid; Blood Proteins; Femal | 1988 |
Rheumatoid arthritis: a pharmacologic overview.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Gold; Human | 1988 |
Sulfasalazine: I. An historical perspective.
Topics: Animals; Arthritis, Rheumatoid; Colitis, Ulcerative; Crohn Disease; History, 20th Century; Humans; S | 1988 |
Sulfasalazine: II. Some notes on the discovery and development of salazopyrin.
Topics: Animals; Arthritis, Rheumatoid; Colitis, Ulcerative; History, 20th Century; Humans; Sulfasalazine; S | 1988 |
[The basic therapy of rheumatoid arthritis].
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Drug Combinations; Drug Evaluation; Glucosamine; Go | 1988 |
Sulfasalazine treatment and lymphocyte function in patients with rheumatoid arthritis.
Topics: Aminosalicylic Acids; Arthritis, Rheumatoid; Cell Survival; Female; Humans; Lectins; Leukocyte Count | 1988 |
In vitro immunomodulatory effects of sulfasalazine and its metabolites.
Topics: Aminosalicylic Acids; Arthritis, Rheumatoid; Cell Division; Cells, Cultured; Humans; Immune System; | 1988 |
[Drug-induced alveolitis caused by salazosulfapyridine].
Topics: Adult; Arthritis, Rheumatoid; Female; Humans; Pneumonia; Pulmonary Alveoli; Sulfasalazine; Time Fact | 1988 |
Sulphasalazine and inflammatory bowel disease.
Topics: Arthritis, Rheumatoid; Crohn Disease; Enema; Humans; Sulfasalazine; Tablets, Enteric-Coated | 1987 |
Sulphasalazine in rheumatoid arthritis: combination therapy with D-penicillamine or sodium aurothiomalate.
Topics: Adult; Aged; Arthritis, Rheumatoid; Drug Administration Schedule; Drug Therapy, Combination; Female; | 1988 |
How reliable is ESR as a measure of disease activity in rheumatoid arthritis treated with hydroxychloroquine?
Topics: Arthritis, Rheumatoid; Blood Sedimentation; Blood Viscosity; Chloroquine; Drug Administration Schedu | 1988 |
[Acute rheumatoid arthritis--unsolved problems in treatment].
Topics: Acute Disease; Aged; Arthritis, Rheumatoid; Humans; Male; Prednisolone; Sulfasalazine | 1988 |
Effect of sulphasalazine and its metabolites on mitogen induced transformation of lymphocytes--clues to its clinical action?
Topics: Aminosalicylic Acids; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cells | 1988 |
Sulphasalazine in the treatment of rheumatoid arthritis in India.
Topics: Arthritis, Rheumatoid; Humans; India; Sulfasalazine | 1988 |
Sulphasalazine in rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Female; Humans; Male; Middle Aged; Sulfasalazine | 1988 |
History of enteric coated sulfasalazine in rheumatoid arthritis.
Topics: Adjuvants, Pharmaceutic; Arthritis, Rheumatoid; History, 20th Century; Humans; Sulfasalazine; Tablet | 1988 |
What is a disease modifying antirheumatic drug?
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; HLA-B Antigens; HLA-B27 Antigen; Humans; Sulfasalaz | 1988 |
Leucopenia in rheumatoid arthritis: relationship to gold or sulphasalazine therapy.
Topics: Adult; Aged; Arthritis, Rheumatoid; Blood Sedimentation; Female; Gold; Humans; Leukocyte Count; Leuk | 1988 |
[Sulfasalazine-induced megaloblastic anemia in rheumatoid arthritis].
Topics: Anemia, Macrocytic; Anemia, Megaloblastic; Arthritis, Rheumatoid; Humans; Male; Middle Aged; Sulfasa | 1988 |
Plasma and synovial fluid concentrations of sulphasalazine and two of its metabolites in rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Female; Humans; Male; Middle Aged; Sulfapyridine; Sulfasalazine; | 1985 |
Advances in the drug management of rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Methotrexate; Sulfasalazine | 1988 |
[Basic and clinical study on combined immunomodulator therapy in rheumatoid arthritis].
Topics: Adult; Aged; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Gold Sodium Thiomalate; Human | 1988 |
[Evaluation of salazosulfapyridine enteric-coated capsules in therapy of rheumatoid arthritis].
Topics: Arthritis, Rheumatoid; Capsules; Drug Evaluation; Humans; Sulfasalazine | 1988 |
[Regional enteritis Crohn (author's transl)].
Topics: Adult; Arthritis, Rheumatoid; Azathioprine; Colitis, Ulcerative; Crohn Disease; Diagnosis, Different | 1973 |